WorldWideScience
 
 
1

Ten cases of metastatic cervical cancer with the treatment of permanent 125I seeds interstitial implants  

International Nuclear Information System (INIS)

Objective: To investigate the clinical effect of permanent 125I seeds interstitial implants for metastatic cervical cancer. Methods: Under the guidance of the B-sonography, 125I seeds were implanted into the eleven cervical lymph nodes of ten patients who had been given tumor resection. The pain relief and tumor size were observed in regular follow-up after one-month treatment. Results: All the patients were followed up for 6-14 months,and the postoperative recovery was good with no complication. One month after the implantation, the pain symptom was alleviated entirely in two nodes and partly in nine nodes. The tumor size shrank in ten nodes while there was no change in one node after one month. Conclusion: Permanent 125I seeds interstitial implants for metastatic cervical cancer is a safe, minimally invasive and effective treatment. (authors)

2011-09-01

2

A Comparison of Acute and Chronic Toxicity for Men With Low-Risk Prostate Cancer Treated With Intensity-Modulated Radiation Therapy or 125I Permanent Implant  

International Nuclear Information System (INIS)

Purpose: To compare the toxicity and biochemical outcomes of intensity-modulated radiation therapy (IMRT) and 125I transperineal permanent prostate seed implant (125I) for patients with low-risk prostate cancer. Methods and Materials: Between 1998 and 2004, a total of 374 low-risk patients (prostate-specific antigen 125I patients). Median follow-up was 43 months for IMRT and 48 months for 125I. The IMRT prescription dose ranged from 74-78 Gy, and 125I prescription was 145 Gy. Acute and late gastrointestinal (GI) and genitourinary (GU) toxicity was recorded by using a modified Radiation Therapy Oncology Group scale. Freedom from biochemical failure was defined by using the Phoenix definition (prostate-specific antigen nadir + 2.0 ng/ml). Results: Patients treated by using IMRT were more likely to be older and have a higher baseline American Urological Association symptom index score, history of previous transurethral resection of the prostate, and larger prostate volumes. On multivariate analysis, IMRT was an independent predictor of lower acute and late Grade 2 or higher GU toxicity and late Grade 2 or higher GI toxicity. Three-year actuarial estimates of late Grade 2 or higher toxicity were 2.4% for GI and 3.5% for GU by using IMRT compared with 7.7% for GI and 19.2% for GU for 125I, respectively. Four-year actuarial estimates of freedom from biochemical failure were 99.5% for IMRT and 93.5% for 125I (p = 0.09). Conclusions: The IMRT and 125I produce similar outcomes, although IMRT appears to have less acute and late toxicity

2008-06-01

3

Permanent implantation of 125I seeds combined with GP scheme chemotherapy for non-small cell lung carcinoma in aged patients  

International Nuclear Information System (INIS)

Objective: To assess the feasibility, safety and curative effect of permanent implantation of 125I seeds combined with GP scheme chemotherapy for the treatment of non-small cell lung carcinoma (NSCLC) in aged patients. Methods: CT-guided permanent implantation of 125I seeds combined with GP scheme chemotherapy was performed in 46 patients with NSCLC, of whom 26 received primary treatment and 20 underwent renewed treatment. During the procedure, 125I seeds were embedded into the tumor in all the patients. Three to five days after the implantation, GP scheme chemotherapy started. GEM (1000 mg/m2) was given (intravenously dripping for 30 min.) on the 1st, 8th and 15th day; DDP (30 mg/m2) was employed on the 1st, 2nd and 3rd day, and recombinant human endostatin (Endostar, 7.5 mg / m2) was administered (intravenously dripping for 3 - 4 hours) from the 1st to the 14th day. Every 28 days completed one treatment course. Two months after 125I seed implantation, at this time the patient had received two courses of treatment, the short-term effect and the toxic side-effect were evaluated. Results: Two months after the 125I particles were embedded in the tumor, all the 46 cases were able to be evaluate for the curative effect. Of 46 patients, complete relief (CR) was seen in 12, partial relief (PR) in 24, stable (SD) in 6 and progression (PD) in 4, with an effective rate of 78.26%. Of 26 patients in the primary treatment group, CR was obtained in 7, PR in 15, SD in 3 and PD in 1, with an effective rate of 84.6%. Of 20 patients in the renewed treatment group, CR was seen in 5, PR in 9, SD in 3 and PD in 3, with an effective rate of 70.0%. Conclusion: Permanent implantation of 125I seeds combined with GP scheme chemotherapy is an effective, safe and feasible treatment for NSCLC in aged patients. (authors)

2009-09-01

4

In Vivo Dosimetry Using a Linear Mosfet-Array Dosimeter to Determine the Urethra Dose In 125I Permanent Prostate Implants  

International Nuclear Information System (INIS)

Purpose: In vivo dosimetry during brachytherapy of the prostate with 125I seeds is challenging because of the high dose gradients and low photon energies involved. We present the results of a study using metal-oxide-semiconductor field-effect transistor (MOSFET) dosimeters to evaluate the dose in the urethra after a permanent prostate implantation procedure. Methods and Materials: Phantom measurements were made to validate the measurement technique, determine the measurement accuracy, and define action levels for clinical measurements. Patient measurements were performed with a MOSFET array in the urinary catheter immediately after the implantation procedure. A CT scan was performed, and dose values, calculated by the treatment planning system, were compared to in vivo dose values measured with MOSFET dosimeters. Results: Corrections for temperature dependence of the MOSFET array response and photon attenuation in the catheter on the in vivo dose values are necessary. The overall uncertainty in the measurement procedure, determined in a simulation experiment, is 8.0% (1 SD). In vivo dose values were obtained for 17 patients. In the high-dose region (> 100 Gy), calculated and measured dose values agreed within 1.7% ± 10.7% (1 SD). In the low-dose region outside the prostate (125I brachytherapy of prostate cancer. An action level of ± 16% (2 SD) for detection of errors in the implantation procedure is achievable after validation of the detector system and measurement conditions

2009-01-01

5

Edema-induced increase in tumour cell survival for 125I and 103Pd prostate permanent seed implants - a bio-mathematical model  

International Nuclear Information System (INIS)

Edema caused by the surgical procedure of prostate seed implantation expands the source-to-point distances within the prostate and hence decreases the dose coverage. The decrease of dose coverage results in an increase in tumour cell survival. To investigate the effects of edema on tumour cell survival, a bio-mathematical model of edema and the corresponding cell killing by continuous low dose rate irradiation (CLDRI) was developed so that tumour cell surviving fractions can be estimated in an edematous prostate for both 125I and 103Pd seed implants. The dynamic nature of edema and its resolution were modelled with an exponential function V(T)=Vp (1+M exp(-0.693T/Te)) where Vp is the prostate volume before implantation, M is the edema magnitude and Te is edema half-life (EHL). The dose rate of a radioactive seed was calculated according to AAPM TG43, i.e. D radical Sk?g(r) ?-baran/r2, where r is the distance between a seed and a given point. The distance r is now a function of time because of edema. The g(r) was approximated as 1/r0.4 and 1/r0.8 for 125I and 103Pd, respectively. By expanding the mathematical expression of the resultant dose rate in a Taylor series of exponential functions of time, the dose rate was made equivalent to that produced from multiple fictitious radionuclides of different decay constants and strengths. The biologically effective dose (BED) for an edematous prostate implant was then calculated using a generalized Dale equation. The cell surviving fraction was computed as exp(-?BED), where ? is the linear coefficient of the survival curve. The tumour cell survival was calculated for both 125I and 103Pd seed implants and for different tumour potential doubling time (TPDT) (from 5 days to 30 days) and for edemas of different magnitudes (from 0% to 95%) and edema half-lives (from 4 days to 30 days). Tumour cell survival increased with the increase of edema magnitude and EHL. For a typical edema of a half-life of 10 days and a magnitude of 50%, the edema increased tumour cell survival by about 1 and 2 orders of magnitude for 125I and 103Pd seed implants respectively. At the extreme (95% edema magnitude and an edema half-life of 30 days), the increase was more than 3 and 5 orders of magnitude for 125I and 103Pd seed implants respectively. The absolute increases were almost independent of TPDT and the prostate edema did not significantly change the effective treatment time. Tumour cell survival for prostate undergoing CLDRI using 125I or 103Pd seeds may be increased substantially due to the presence of edema caused by surgical trauma. This effect appears to be more pronounced for 103Pd than 125I because of the shorter half-life of 103Pd. If significant edema is observed post implantation, then a boost to the prostate using external beam radiotherapy may be considered as a part of the treatment strategy. (author)

2002-04-01

6

Dosimetric and volumetric criteria for selecting a source activity and a source type (125I or 103Pd) in the presence of irregular seed placement in permanent prostate implants  

International Nuclear Information System (INIS)

Purpose: The dosimetric merit of a permanent prostate implant relies on two factors: the quality of the plan itself, and the fidelity of its implementation. The former factor depends on source type and on source strength, while the latter is a combination of skill and experience. The purpose of this study is to offer criteria by which to select a source type (125I or 103Pd) and activity. Methods and Materials: Given a prescription dose and potential seed positions along needles, treatment plans were designed for a number of seed types and activities, specifically for 125I with activities ranging from 0.3 to 0.7 mCi, and for 103Pd with activities in the range of 0.8 to 1.6 mCi. To avoid human planner bias, an automated computerized planning system based on integer programming was used to obtain optimal seed configurations for each seed type and activity. To simulate the effect of seed-placement inaccuracies, random seed-displacement 'errors' were generated for all plans. The displacement errors were assumed to be uniformly distributed within a cube with side equal to 2no. sigmano. The resulting treatment plans were assessed using two volumetric and two dosimetric indices. Results: For 125I implants a coverage index (CI) of 98.5% or higher can be achieved for all activities (CI is the fraction of the target volume receiving the prescribed or larger dose). The external volume index (EI) (i.e., the amount of healthy tissue, as percentage of the target volume, receiving the prescribed or larger dose) increases from 13.9% to 20% as the activity increases from 0.3 to 0.7 mCi. For implants using 103Pd, the external volume index increases from 10.2% to 13.9% whenever CI exceeds 98.5%. Volumetric and dosimetric indices (coverage index, external volume index, D90, and D80) are all sensitive to seed displacement, although the activity dependence of these indices is more pronounced for 125I than for 103Pd implants. Conclusions: For both isotopes, the lower activities studied systematically result in lower EIs. If seeds can be placed within approximately 0.5 cm of their intended position 103Pd should be preferred because its EI is lower than that of 125I. For all activities the coverage indices and D90 are within the required range. If seed placement uncertainties are larger than 0.5 cm, 125I provides slightly better target coverage; however, in terms of external volume (healthy tissue) covered, 103Pd is superior to 125I

2000-06-01

7

Implant quality and acute urinary toxicity with 125I permanent seed implantation for clinically localized prostate cancer. Results of the first 30 patients treated at PMCC  

International Nuclear Information System (INIS)

It is widely recognized that a steep learning curve exists for departments initiating a prostate low-dose radiation (LDR) implant service. Appropriate team credentialing, willingness to accept mentoring and attention toward ongoing QA initiatives are required to ensure that both clinical and dosimetric endpoints consistently achieve standards deemed appropriate. The department of urological services began a prostate seed service in 4/2002. All participating staff were suitably trained in Seattle, Washington with unit protocols based on standard trans-rectal sonographic pre-planning, modified peripheral loading, prescription dose 145Gy and 4 week CT based post implant dosimetry. Patient eligibility paralleled federal medicare guidelines with men presenting with favorable risk disease, gland volumes 15ml/sec) considered potential candidates. a) Presenting Demographics: (n=30) Median age 62 (41-73), T stage 1c:2a:2b:2c = 18:10:1:1, Median PSA 6.3ng/ ml (5.1ng/ml - 11.1ng/ml), Median IPSS 5 (0-12), Mean Qmax 18ml/s (10ml/s -35ml/s).; b) Acute toxicity: No significant peri-procedural complications. One patient developed urinary retention day 3 and was successfully trialed day 10. All patients experienced some degree of sub-acute urinary irritation although three patients followed for at least 12 months have returned to their baseline level of functioning. c) Post implant Dosimetry: Median D90 139Gy (104Gy - 190Gy). 3 Patients received a D90 < 90% with one at 104Gy receiving additional 'top-up' external beam radiation (20Gy). A definable improvement in implant quality was observed over the 12 month study interval. Although acute toxicity was considered acceptable, patients do experience a sub-acute period of low grade albeit persistent urinary irritation and need to be cautioned appropriately. A high level of implant quality was achieved in the majority of patients. Despite 5 years HDR brachytherapy experience, considerable refinement in technique and approach was required in order to achieve consistent high level results

2003-08-17

8

CT-guided permanent 125I seed brachytherapy for vertebral metastatic cancer  

International Nuclear Information System (INIS)

Objective: To evaluate the functional outcome, predicting response and toxicity of CT- guided permanent implanted 125I seed brachytherapy for metastatic cancers in vertebrae. Methods: Forty three vertebrae with metastatic cancer were treated by CT-guided percutaneous permanent implanted 125I seed brachytherapy in 15 patients. There were 8 male and 7 female patients with average age of 54.6 years and 2 to 5 vertebrae involved in this group. According to the size of tumor, the optimal activity and quantity of seeds were calculated by TPS and correlative formula. 125I seeds were implanted percutaneous puncture under CT- guidance with coaxial needles to pass the normal osseous tissue for approaching the lesions including 3 routes of pedicular, lateral and anterior ways. The distance between seeds and posterior border of vertebral body was over 3 mm (3-10 mm). Permanent 125I seed implantation brachytherapy for paraspinal metastatic lesions were also taken place. Results: Mean follow-up time was 12.3 months (range 3-30 months) and outcome was evaluated clinically and radiographically in 10 of 15 procedures, with 5 only on clinical data. No new pain occurred at 11 sites with no previous complaint. The pain was completely controlled at 18/32 sites, partial control at 14/32 sites. No complications correlated to the radiotherapy damage of nerve and spinal cord were found. Conclusion: The procedure of CT-guided permanent implanted 125I seeds brachytherapy for vertebral metastatic cancers is a safe effective and minimal invasive method with few complications. It is beneficial not only for pretherapeutic metastasis but also for recurrent tumors after radiotherapy; bearing rather high tolerance and safety. (authors)

2007-12-01

9

Operation and permanent low activity 125I brachytherapy for recurrent high-grade astrocytomas  

International Nuclear Information System (INIS)

Twenty-two adult patients with recurrent high grade astrocytomas [18 glioblastoma multiforme (GBM) and 4 anaplastic astrocytoma (AA) at time of implant] underwent therapy at the University of Washington from October 1991 through March 1995, with repeat craniotomy, maximal debulking of tumor, and placement of permanent low activity 125I seeds. Median age was 41 years and median Karnofsky performance status was 90. Median survival for the entire group was 65 weeks from the time of implant. For the subgroup of GBM patients, median survival was 64 weeks from the time of implant. One-year survival from the date of implant was 57% for the entire group and 59% for those with GBM. The site of first failure after implant was local (within 2 cm of the resection cavity) in 70%, distant (noncontiguous, beyond 2 cm) in 18% and concurrently local and distant in 12%. There was one case of symptomatic radiation injury that resolved with steroid therapy, and no patient required repeat craniotomy for parenchymal necrosis. For patients with recurrent GBM, treatment with resection and permanent low activity 125I brachytherapy yielded improved survival compared to an internal historical control group treated with resection and chemotherapy (p = 0.023). Craniotomy with maximal tumor debulking and placement of low activity 125I seeds yields encouraging results with minimal morbidity in patients with recurrent high-grade astrocytomas

1996-06-01

10

Urethral dosimetry constraints in 125I permanent prostate brachytherapy used as boost to external radiotherapy  

International Nuclear Information System (INIS)

With 125I monotherapy in permanent brachytherapy implants, the recommendation is to deliver to the urethra less than 150% of the prescribed dose, 145 Gy, that is a limit of 217.5 Gy. However, there are not recommendations in the case of the brachytherapy boost. At our hospitals, permanent brachytherapy implants are used as a 108 Gy boost in intermediate risk patients with prostate carcinoma, which have undergone an external beam radiotherapy course ranging between 45 and 50.4 Gy. The purpose of this work is to present a simple radiobiologically-based analysis performed in order to obtain the urethral dose limit in permanent prostate brachytherapy boost. The linear-quadratic model has been used to determine the biologically effective dose, analysing the results for different dose/fraction, t1/2 and a/b values. Assuming 46 Gy delivered by external beam radiotherapy, it is found that a limit value of 145 Gy, corresponding to the isodose level of 135% of the prescribed dose, is adequate. The results for a ten patients sample are shown in order to illustrate the values that are obtained in clinical practice. In conclusion, we present the method employed to find the urethral dose limit in the case of the combination of external beam radiotherapy and permanent 125I seeds brachytherapy boost implants (Author).

2010-01-01

11

Sequential Comparison of Seed Loss and Prostate Dosimetry of Stranded Seeds With Loose Seeds in 125I Permanent Implant for Low-Risk Prostate Cancer  

International Nuclear Information System (INIS)

Purpose: To compare stranded seeds (SSs) with loose seeds (LSs) in terms of prostate edema, dosimetry, and seed loss after 125I brachytherapy. Methods and Materials: Two prospective cohorts of 20 men participated in an institutional review board-approved protocols to study postimplant prostate edema and its effect on dosimetry. The LS cohort underwent brachytherapy between September 2002 and July 2003 and the SS cohort between April 2006 and January 2007. Both cohorts were evaluated sequentially using computed tomography-magnetic resonance imaging fusion-based dosimetry on Days 0, 7, and 30. No hormonal therapy or supplemental beam radiotherapy was used. Results: Prostate edema was less in the SS cohort at all points (p = NS). On Day 0, all the prostate dosimetric factors were greater in the LS group than in the SS group (p = 0.003). However, by Days 7 and 30, the dosimetry was similar between the two cohorts. No seeds migrated to the lung in the SS cohort compared with a total of five seeds in 4 patients in the LS cohort. However, the overall seed loss was greater in the SS cohort (24 seeds in 6 patients; 1.1% of total vs. 0.6% for LSs), with most seeds lost through urine (22 seeds in 5 patients). Conclusion: Despite elimination of venous seed migration, greater seed loss was observed with SSs compared with LSs, with the primary site of loss being the urinary tract. Modification of the technique might be necessary to minimize this. Prostate dosimetry on Days 7 and 30 was similar between the SS and LS cohorts

2009-01-01

12

Ejaculatory Function After Permanent 125I Prostate Brachytherapy for Localized Prostate Cancer  

International Nuclear Information System (INIS)

Purpose: Ejaculatory function is an underreported aspect of male sexuality in men treated for prostate cancer. We conducted the first detailed analysis of ejaculatory function in patients treated with permanent 125I prostate brachytherapy for localized prostate cancer. Patients and Methods: Of 270 sexually active men with localized prostate cancer treated with permanent 125I prostate brachytherapy, 241 (89%), with a mean age of 65 years (range, 43-80), responded to a mailed questionnaire derived from the Male Sexual Health Questionnaire regarding ejaculatory function. Five aspects of ejaculatory function were examined: frequency, volume, dry ejaculation, pleasure, and pain. Results: Of the 241 sexually active men, 81.3% had conserved ejaculatory function after prostate brachytherapy; however, the number of patients with rare/absent ejaculatory function was double the pretreatment number (p < .0001). The latter finding was correlated with age (p < .001) and the preimplant International Index of Erectile Function score (p < .001). However, 84.9% of patients with maintained ejaculatory function after implantation reported a reduced volume of ejaculate compared with 26.9% before (p < .001), with dry ejaculation accounting for 18.7% of these cases. After treatment, 30.3% of the patients experienced painful ejaculation compared with 12.9% before (p = .0001), and this was associated with a greater number of implanted needles (p = .021) and the existence of painful ejaculation before implantation (p < .0001). After implantation, 10% of patients who continued to be sexually active experienced no orgasm compared with only 1% before treatment. in addition, more patients experienced late/difficult or weak orgasms (p = .001). Conclusion: Most men treated with brachytherapy have conserved ejaculatory function after prostate brachytherapy. However, most of these men experience a reduction in volume and a deterioration in orgasm.

2009-05-01

13

Value of CT guided 125I seeds implantation for vertebra metastasis  

International Nuclear Information System (INIS)

Objective: To evaluate the clinical value of 125I seeds implantation for vertebra metastasis. Methods: By CT guide, 125I seeds were implanted in 22 vertebra metastasis of 15 patients. 3-6 months later, pain and metastasis biggest diameter were observed to judge therapeutic effect. Results: In 22 spinal and paraspinal metastases after implantation of particles, complete remission of pain (O grade)14, partial remission (I grade) 6, a slight relief (II grade) 2, the total effective rate was 90.9% (u=5.41, P125I seed implantation in vertebra metastasis is safe, minimally invasive, and possesses a high efficacy. (authors)

2011-01-01

14

Efficacies of 125I seed implantation in advanced stage central lung cancer via fibrobronchoscope  

International Nuclear Information System (INIS)

Objective: To explore the temporal curative effect of 125I seed implantation in advanced stage central type lung cancer. Methods: 125I seed was implanted in 56 patients confirmed advanced stage central type lung cancer via fibrobronchoscope and all cases were fellow up in certain duration to explore their efficacies and the adverse reaction. Results: Total efficient rate was 76.78% in 56 patients. Lung reexpanded rate was 90.90%. Conclusion: The therapy of 125I seed implantation in advanced stage central type lung cancer is safe and available. (authors)

2009-09-01

15

Clinical application of transperineal 125I-seed implantation guided by ultrasonography in prostate cancer  

International Nuclear Information System (INIS)

Objective: To establish an optimal technological protocol, and to observe the short-term efficacy and morbidity of transperineal 125I-seed implantation guided by transrectal ultrasonography in prostate cancer. Method: Thirty-two patients were treated with transperineal 125I-seed brachytherapy guided by transrectal ultrasound. Among them 6 patients were treated with the seed implantation plus preor post-external beam radiotherapy (EBRT). Biochemical failure was defined as consecutive elevations of PSA level for three times during follow-up period and the biochemical progression-free was defined as biochemical control. Results: The pre- and post-implantation median serum PSA values of 14 patients were (52.14 ± 54.61) ng/ml and (4.26 ± 7.11) ng/ml, respectively (t=3.253, P=0.003). The biochemical control rate was 100%. The pre- and post-treatment median PSA values of 12 recurrent prostate cancer patients were (15.14 ± 20.80) ng/ml and (18.94 ± 35.25) ng/ml, respectively (t=-0.307, P=0.764). Their biochemical control rate was 75%. The pre- and post-implantation median PSA values of 5 patients with bone metastases were (120.03 ± 145.96) ng/ml and (75.53 ± 84.84) ng/ml, respectively (t=0.527, P=0.621). In 34.62% patients treated only with 125I-seed implication urinary complications were not experience and the incidences of Grade I, II, III, IV and V urinary side effects were 38.46%, 11.54%, 11.54%, 0 and 3.85%, respectively. The incidences of Grade I, II, III and IV urinary morbidity were 16.67%, 0, 0 and 16.67%, respectively for patients treated with seed implantation plus EBRT. Grade 1 rectal toxicity was noted in 3.12% patients. In 3.12% patients, one seed migration occurred. Conclusion: Transperineal permanent brachytherapy is safe, convenient, minimally invasive, with low urinary and rectal side effects. (authors)

2004-12-01

16

125I Vicryl suture implants as a surgical adjuvant in cancer of the head and neck  

International Nuclear Information System (INIS)

Sixty-four intraoperative 125I seed implants using absorbable suture (Vicryl) carriers were performed in 53 patients with head and neck cancers at Stanford between 1975 and 1980. In previously untreated patients, local control in the implanted volume or in all head and neck sites was obtained in 79 and 71%, respectively. Of 34 patients with recurrent carcinomas, local control was obtained in the implant volume in 20 (59%), while 38% had no recurrence post-implantation in any head and neck site. The incidence of complications is correlated with 125I radiation doses, total millicuries inserted, seed strength used, and tissue volume implanted for both untreated patients and those with local recurrences. Guidelines for the optimal use of the above 4 parameters are also presented. The authors conclude that 125I seed Vicryl intraoperative suture implants are an effective surgical adjuvant in the treatment of advanced, previously untreated or recurrent head and neck cancers

1985-01-01

17

Urethral dosimetry constraints in 125I permanent prostate brachytherapy used as boost to external radiotherapy; Restricciones dosimetricas de la uretra en el caso de braquiterapia permanente de prostata con 125I utilizada como complemento a radioterapia externa  

Energy Technology Data Exchange (ETDEWEB)

With 125I monotherapy in permanent brachytherapy implants, the recommendation is to deliver to the urethra less than 150% of the prescribed dose, 145 Gy, that is a limit of 217.5 Gy. However, there are not recommendations in the case of the brachytherapy boost. At our hospitals, permanent brachytherapy implants are used as a 108 Gy boost in intermediate risk patients with prostate carcinoma, which have undergone an external beam radiotherapy course ranging between 45 and 50.4 Gy. The purpose of this work is to present a simple radiobiologically-based analysis performed in order to obtain the urethral dose limit in permanent prostate brachytherapy boost. The linear-quadratic model has been used to determine the biologically effective dose, analysing the results for different dose/fraction, t1/2 and a/b values. Assuming 46 Gy delivered by external beam radiotherapy, it is found that a limit value of 145 Gy, corresponding to the isodose level of 135% of the prescribed dose, is adequate. The results for a ten patients sample are shown in order to illustrate the values that are obtained in clinical practice. In conclusion, we present the method employed to find the urethral dose limit in the case of the combination of external beam radiotherapy and permanent 125I seeds brachytherapy boost implants (Author).

Lliso, F.; Perez-Calatayud, J.; Carmona, V.; Guirado, D.; Munoz, M.; Richart, J.; Ballester, F.; Granero, D.; Rodriguez, S.; Tormo, A.; Santos, M.

2010-07-01

18

CT-guided radioactive seed 125I implantation for the treatment of malignant adrenal neoplasms  

International Nuclear Information System (INIS)

Objective: To evaluate CT-guided radioactive seed 125I implantation in treating malignant adrenal neoplasms. Methods: CT-guided radioactive seed 125I implantation was performed in 9 cases of malignant adrenal neoplasms with a total of 9 lesions. The clinical data were retrospectively analyzed. Treatment plan system was used to design the distribution of 125I seeds for treatment. Under CT guidance, the 125I seeds of 29.6 MBq were implanted into the malignant adrenal neoplasms with an interval distance of 1.0-1.5 cm. A follow-up of 1-15 months was conducted. The postoperative efficacy was evaluated with enhanced CT scanning. Results: After the treatment, complete remission (CR) was obtained in 5 patients, partial remission (PR) in 3 patients and no change (NC) in 1 patients, with an overall effective rate of 88.9%. The main complication was slight bleeding (n=1). Conclusion: For the treatment of malignant adrenal neoplasms, CT-guided radioactive seed 125I implantation carries reliable short-term effectiveness, therefore, it is a safe, effective and minimally-invasive therapy. (authors)

2011-04-01

19

Effectiveness and security of CT-guided percutaneous implantation of (125)I seeds in pancreatic carcinoma.  

Science.gov (United States)

Objective: To assess the effectiveness and security of CT-guided percutaneous implantation of iodine-125 ((125)I)-labelled seeds in pancreatic carcinoma. Methods: A total of 36 patients (25 males and 11 females) with an average age of 57 years (range, 39-84 years) were enrolled and categorized into Stage III (27 cases) and Stage IV (9 cases) of pancreatic cancer. There were 3 tumours in the pancreatic head and 33 tumours in the pancreatic body or tail. The average diameter of the tumours was 37.1?mm (range, 15-65?mm). The implantation of (125)I seeds was performed by using 18-G needles (length, 150-200?mm) through the anterior, lateral and posterior approaches. Then, (125)I seeds were loaded and released into the lesions. Results: Implantations were performed via the anterior (23 patients), lateral (9 patients) and posterior (4 patients) approaches. During implantation, 3-14 punctures were performed for each patient, and a total of 164 punctures were recorded. Meanwhile, a total of 657 seeds were implanted with an average of 25.27 (range, 12-50) seeds per patient, and the success rate was 100%. The activity of each seed ranged from 0.55 to 0.65?mCi. A main adverse event occurred in one puncture and minor events in seven punctures. No significant relationship between the punctures or adverse events was identified. No serious complication was detected after the implantations during follow-up visits. Conclusion: This study suggested that CT-guided percutaneous implantation of (125)I seeds in a pancreatic carcinoma was relatively safe and effective for treating unresectable pancreatic cancer. Advances in knowledge: The CT-guided percutaneous implantation of (125)I seeds in unresectable pancreatic cancer showed highly successful rates without serious complications. PMID:24734936

Yu, Y-P; Yu, Q; Guo, J-M; Jiang, H-T; Di, X-Y; Zhu, Y

2014-07-01

20

Clinical efficacy of CT-guided 125I seed implantation therapy for advanced pancreatic cancer  

International Nuclear Information System (INIS)

Objective: To discuss the clinical efficacy of CT-guided radioactive 125I seed implantation treatment for unresectable pancreatic cancer. Methods: Forty patients with inoperable pancreatic cancer were enrolled in this study, including 25 males and 15 females with an median age of 69 years (38-89 years). Treatment planning system (TPS) was used to reconstruct 3-dimensional images of pancreatic tumor and to define the quantity and distribution of 125I seeds. The radioactivity of 125I seeds was 0.5 - 0.8 mCi / seed. The seeds were implanted into pancreatic tumor under CT guidance at intervals of 1 cm and were kept away from vessels, pancreatic duct and other adjacent important organs. The tumor matched peripheral dose (MPD) was 60-140 Gy. The median amount of implanted 125I seeds was 36 (18-68) in number. CT scan was performed immediately after the procedure to check the quality of the seeds. In addition, 10 patients received concurrent chemotherapy with arterial infusion of gemcitabin and 5-fluororacil (5-Fu) for 3 to 4 therapeutic courses. Results: The median diameter of the tumors was 4.9 cm. The follow-up period was 2 to 28 months. After the treatment the refractory pain was significantly relieved (P 125I seed implantation is a safe, effective and minimally-invasive brachytherapy for unresectable pancreatic cancer with reliable short-term efficacy. It has an excellent anti-pain effect. The curative results can be further improved when chemotherapy is employed together. However, its long-term efficacy needs to be observed. (authors)

2009-09-01

 
 
 
 
21

Treatment-related symptoms during the first year following transperineal [sup 125]I prostate implantation  

Energy Technology Data Exchange (ETDEWEB)

The purpose was to summarize the urinary, rectal, and sexual symptoms occurring during the first 12 months following [sup 125]I prostatic implantation. Thirty-one patients with Stage T[sub 1] or T[sub 2] prostatic carcinoma were evaluate for morbidity following computed tomography-guided transperineal [sup 125]I implants from 1988 to 1991. The median total activity used was 47 mCi (range 35-37 mCi). Toxicity was evaluated using a modification of the Radiation Therapy Oncology Group grading system. Nocturia was the most common treatment-related symptom, reported by 80% of patients within 2 months after implantation, and persisted at 12 months in 45% of the patients. Mild dysuria developed in 48% of patients within 2 months of implantation; two patients needed analgesics for their dysuria. Terazosin hydrochloride (2-10 mg qd) provided subjective improvement of urinary symptoms in seven of eight patients in whom it was tried. Rectal urgency, soft stools, and increased frequency of bowel movements was reported by 25% of the patients within 1-2 months after implantation. The incidence of assymptomatic rectal bleeding or ulceration occurring at any time after implantation was 47%, but resolved in all patients with expectant treatment. Self-limiting ulceration of the rectal mucosal occurred in 16%, but only one patient developed a prostato-rectal fistula, managed with an ileal conduit. Five of the 18 potent patients experienced discomfort on erection or ejaculation, beginning within several weeks of their implant. The discomfort resolved within 6 months in three of the patients, but persisted for 18 and 24 months in the other two. [sup 125]I implantation, as performed in this series, is generally associated with only mild-moderate genitourinary and rectal symptoms that may persist 6 months or more after implantation. 16 refs., 6 figs., 2 tabs.

Kleinberg, L.; Wallner, K.; Roy, J.; Zelefsky, M.; Arterbery, V.E.; Fuks, Z.; Harrison, L. (Memorial Sloan-Kettering Cancer Center, New York, NY (United States))

1994-03-01

22

Surgery and permanent 125I seed paraspinal brachytherapy for malignant tumors with spinal cord compression  

International Nuclear Information System (INIS)

Purpose: To evaluate the functional outcome, predictors of response, and toxicity from spinal surgery and 125I brachytherapy in patients with malignant tumors resulting in spinal cord compression. Methods and Materials: Between July 1985 and September 2001, after surgical resection, 30 patients underwent 31 intraoperative paraspinal brachytherapy procedures at Barrow Neurological Institute. Twenty-four (with 25 procedures) had follow-up at our clinic and form the basis for this report. Surgical procedures were based on the location of the impinging lesion: corpectomy or spondylectomy in 13 cases and laminectomy in 12. Permanent 125I seeds in absorbable suture were placed with open exposure after resection. Results: Spinal cord compression was cervical in 4 (16%), thoracic in 14 (56%), and lumbar in 7 (28%) of the 25 cases. One patient underwent two separate procedures at different spinal sites. Of the 25 brachytherapy sites, 22 also received external beam radiotherapy (EBRT): 5, EBRT with a planned brachytherapy boost; 4, brachytherapy and prompt EBRT after recovery; and 13, brachytherapy as salvage for local failure after prior EBRT. Three had no EBRT: 1 had lymphoma treated with chemotherapy, 1 had remote previous EBRT for a childhood tumor, and 1 refused EBRT. The mean follow-up was 19.8 months. The 2- and 3-year actuarial local control rate was 87.4% and 72.9%, respectively. Four sites (16.0%) experienced local failure. The mean time to recurrence for these 4 patients was 20.3 months. Three of the four had failed prior EBRT, with surgery and brachytherapy used for salvage. The 2- and 3-year actuarial overall survival rates were 24.0% and 16.0%, mean 19.2 months. An ambulatory function score was assigned pre- and postoperatively: I, normal ambulation; II, abnormal not requiring assistance; III, abnormal requiring assistance; and IV, unable to ambulate. All patients with score I, 91% of those with score II, 67% of those with score III, and 67% of those with score IV were ambulatory after the procedure; 84% had either normal or improved ambulation postoperatively. Morbidity was restricted to four postoperative events: one cerebrospinal fluid leak, two wound infections treated in situ without removal of seeds or instrumentation, and one pulmonary embolus. No myelopathies or other neurologic sequelae were encountered. Conclusion: This is the largest series in the literature exploring surgery and 125I brachytherapy in the treatment of malignant spinal cord compression. We found this to be well tolerated and to result in durable local control and ambulatory function. Our results suggest a benefit to aggressive local therapy in selected patients with spinal cord compression

2002-10-01

23

Pathological impairments induced by interstitial implantation of 125I Seeds in spinal canal of banna mini-pigs  

Directory of Open Access Journals (Sweden)

Full Text Available Abstract Background Use a banna mini-pig to set up 125I implantation model, and investigate the consequence of radiation-related impairments. Methods In present study, 125I seeds were implanted into spinal canal of T13 level of spine in banna mini-pigs. After operation, the pigs were raised up to 8 months, behavior changes were recorded within this period. After 8 months, spinal cords were collected for pathological analysis. Results In this study, a 125I brachytherapy animal model had been successfully established, in the model group, the banna pigs' Tarlov scale decreased from 5 to 2.57 ± 0.36, significant cellular impairments were noted by pathological analysis. Conclusions Without any protection and operation improvement, 125I implantation can cause serious histological impairments and moving difficulty for banna mini-pigs; this present research provides an alternative tool to study spinal 125I brachytherapy.

Yang Zuozhang

2012-03-01

24

Clinical results of early stage prostatic cancer treated by pelvic lymphadenectomy and 125I implants  

International Nuclear Information System (INIS)

Eighty patients with clinically early stage adenocarcinoma of the prostate were treated with pelvic lymphadenectomy and interstitial implantation of 125I seeds. A new applicator that permits greater accuracy in spacing the seeds has been developed. Postoperative complications were minimal, with urinary irritability being the most common. Multiple transrectal needle biopsies were performed 12 and 18 months after treatment in 46 patients. The prostatic biopsies were negative for carcinoma in 61 per cent and positive in 39 per cent of the patients. Long-term followup is needed to correlate post-treatment biopsies with survival and to determine if patients with positive biopsies should receive further treatment

1982-01-01

25

Optimum timing for image-based dose evaluation of 125I and 103Pd prostate seed implants  

International Nuclear Information System (INIS)

Purpose/Objective: Image-based dose evaluation of permanent brachytherapy implants for prostate cancer is important for optimal patient management after implantation. Because of edema caused by the surgical procedure in the implantation, if the dose evaluation is based on the images obtained too early after implantation, dose coverage will usually be underestimated. Conversely, if the images are obtained too late, the dose coverage will be overestimated. This study uses a biomathematical model to simulate edema and its resolution on 29 patients, so that the optimum time to obtain image scans and perform dose evaluation can be investigated and estimated. Methods and Materials: Edema of a prostate and its resolution has been shown to follow an exponential function V(t) = V(0)(1 + ?V[e-0.693t/Te- 1]) where ?V is the initial relative increase in the prostate volume due to edema (and is related to edema magnitude), and Te (edema half-life) is the time for the edema to decrease by half in volume. In this study, edema was simulated by increasing the volume of preimplant prostate (obtained from ultrasound volume study) to a given magnitude of edema. Similarly, the locations of planned seeds were changed to their corresponding locations in the edematous prostate proportionally. The edema was then allowed to resolve according to the exponential function. The correct dose distribution was calculated by taking into account the dynamic variations of the prostate volume, seed locations, and source strengths with respect to time. Dose volume histograms (DVHs) were then generated from this dose distribution. The conventional postimplant DVHs, which assume the prostate volume and seed locations are as in the image scans and constant in time, were also calculated based on the simulated image scans for various days postimplantation. The conventional DVHs of prostate on various days after implantation were compared to the DVH calculated assuming dynamic conditions. The optimum timing for conventional postimplant dose evaluation was identified as the time at which a minimum difference between the conventional DVH and the dynamic model DVH was achieved. The analysis was done on 29 prostate seed implant patients for both 125I and 103Pd. The edema magnitude was assumed to be 30%, 40%, 50%, 75%, and 100% of original prostate volume, and the half-life of edema was assumed to be 4, 7, 10, 15, 20, and 25 days. In this study, the original volume of prostate varied from 17 cm3 to 91 cm3, and number of seeds in the implants varied from 57 to 119. Results: The optimum timing was mainly dependent on the half-lives of edema and radionuclides, and varied slightly with edema magnitude, prostate volume, and number of seeds. It can be expressed as a function of edema half-life in the form of C0+ C1exp(-C2Te). However, if the dose evaluation was performed based on the image scans taken too early or too late, the error became larger, as the edema magnitude was larger. By averaging all 29 patients and various edemas, it was found that for 125I seed implants, if the postimplant dose evaluation is performed based on image scans taken between 5 and 9 weeks, the average error will be less than 5%, with a maximum possible error less than 10% in 80% coverage dose; for 103Pd seed implants, if the postimplant dose evaluation is performed based on image scans taken between 2 and 4 weeks, the average error will be less than 5%, with a maximum error less than 15% in 80% coverage dose. Because of edema, a conventional preimplant plan also overestimates dose coverage of prostate. On the average, a standard preimplant planning overestimates dose coverage by about 6% for 125I implants and 14% for 103Pd implants in our study. Conclusion: Based on the dynamic model, the optimum timing of image scans for postimplant dose evaluation of prostate seed implantation is 7 weeks postimplantation for 125I implants and about 3 weeks for 103Pd implants. The time-window for reasonable accuracy (± 5%) is ± 2 weeks for 125I a nd ± 1 week for 103Pd around the optimum timing. During preim

1999-11-01

26

Radiochemotherapy with interstitial implantation of 125I seeds and 5-FU slow-released seeds for recurrent colorectal adenocarcinoma  

International Nuclear Information System (INIS)

Objective: To investigate the feasibility, security, and short-term efficacy of combined treatment of interstitial implantation of 125I seeds and 5-FU slow-released seeds for recurrent colorectal adenocarcinoma. Methods: From December 2001 to December 2005, 26 eases of recurrent colorectal adenocarcinoma underwent Mile's procedure were treated with the radiochemotherapy. We implanted alternately 125I seeds and 5-FU slow-released seeds following the treatment planning system. The matched peripheral dose (MPD) of 125I seed implantation was 90-130 Gy. Twelve granules of 125I seeds and 600 mg of 5-FU were administered in every patient on average. Results: No operation-related complication was occurred during the implantations for all the cases. No displacement of 125I seed was found by pelvic X-ray examination. Lenitive rate of the pain was 88.9% (16/18) .The relief has lasted for 5-10 days on average. CT scanning showed that the size of tumor reduced in various degree at 3-6 months after the implantation. The complete recovery rate was 7.7 % (2/26), the partial recovery rate was 73.1% (19/26). The PD was 15.4% (4/26).The median survival time was 29 months estimated by following these cases for 6-42 months. One case died of bone and lung metastases at 6 months after the implantation. Conclusion: Combined radiochemotherapy with interstitial implantation of 125I seeds and 5-FU slow-released seeds was a safe and effective microinvasive treatment for recurrent colorectal carcinoma. (authors)

2006-08-01

27

Dose verification with Monte Carlo technique for prostate brachytherapy implants with 125I sources  

International Nuclear Information System (INIS)

The Monte Carlo technique has been implemented to generate the dose distributions in a model prostate patient, implanted with iodine-125 (125I) brachytherapy sources. The results of these calculations are also compared with the dose distributions calculated by a commercially available treatment planning system. The comparison shows that with the source strength suggested by the Monte Carlo technique, the current clinical planning system is found to provide 100% coverage of the prostate with the prescription dose for the same implant pattern. However, the dose-volume histogram of this investigation shows that the VariSeedTM treatment planning system has a 29% and 136% larger dose coverage for the 150% and 200% isodose lines, respectively, than the Monte Carlo simulation. These differences are attributed to the oversimplification of the current planning system using the point source approximation, and also to the interseed effects from multisources that are neglected in the conventional planning systems. The results of this study provide evidence that supports the use of the Monte Carlo technique in treatment planning systems to provide accurate dose calculations in brachytherapy implants

2005-01-01

28

Preparation of 125I seed sources for implantation therapy of prostate cancer  

International Nuclear Information System (INIS)

The scope of the research was to optimize the adsorption of 125I on core seeds using radiochemical techniques. The encapsulation, the Ag bar uniformity adsorption and self-shielding of 125I seed source were investigated. The chemical processing and TIG (tungsten inert gas) welding technology of 125I seed source bar were studied. Silver bar chlorination, iodination and self absorption of 125I were quantified; for example, reagent selection of chlorination and iodination, reagent quantity, reaction time, processing bar, reaction medium, reaction rate and temperature were measured. The quality control of 125I seed source was performed. The adsorption efficiency of 125I in a large batch production was found very high. The homogeneity and reproducibility of 125I seed source between batch and intra-batch was considered optimal. (author)

2006-06-01

29

Postimplant dosimetry for 125I prostate implants: definitions and factors affecting outcome  

International Nuclear Information System (INIS)

Objective: An analysis of CT-based dosimetry was performed to assess the efficacy of the real time method of prostate implantation, explore the relationship of various dose descriptions and determine implant factors affecting outcome. Methods and Materials: Between 7/95 and 8/99, 297 patients underwent 125I implants for T1-T2 prostate cancer and had CT-based dosimetry performed (TG43 formalism). Dosimetry was performed 1 month postimplant. Using a dose-volume histogram, doses delivered to 100%, 95%, 90%, and 80% of the prostate (D100, D95, D90, D80, respectively) as well as percentages of the gland receiving 240 Gy, 160 Gy, 140 Gy (V240, V160, V140, respectively) were reported. Correlations between the various dose parameters and D90 were generated. The effect of the number of seeds implanted, seeds/volume, prostate volume, experience as assessed by time (8/01/99--date of implant), ultrasound probe (mechanical sector vs. dual phased electronic), and the ratio of the CT dosimetry prostate volume/ultrasound implant volume (CT/US vol) were analyzed. Results: The median D100, D95, D90, and D80 values were 10,200 cGy, 15,655 cGy, 17,578 cGy, and 19,873 cGy, respectively. The median V240, V160, and V140 were 56%, 94%, and 98%, respectively. Correlations of dose descriptions found a close relationship of D95, D80, V240, V160, and V140 with D90 with r values of 0.928, 0.973, 0.911, 0.816, and 0.733, respectively. D100 correlated poorly with D90 (r = 0.099). Using a stepwise regression analysis, CT/US vol ratio, prostate volume, and seed number were the only significant factors affecting D90 with CT/US vol ratio having the greatest effect. The dual-phased electronic probe was associated with fewer D90 values of less than 140 Gy (2%) compared to the mechanical sector probe (14%) (p = 0.02). Conclusion: CT-based dosimetry results reveal the real-time implant technique to be an effective method of prostate implantation. Factors associated with more precise implantation, such as decreased postimplant edema, new technology, and increased number of seeds will lead to higher D90 values

2000-10-01

30

From manual to 3-D computerized treatment planning for /sup 125/I stereotactic brain implants  

Energy Technology Data Exchange (ETDEWEB)

Aspects of planning for the treatment of high grade primary or recurrent brain tumors with stereotactically placed catheters afterloaded with high activity /sup 125/I seeds are discussed. At our institution, planning has evolved from a simple manual process, which assumed geometric symmetry, through a more advanced manual process, that took advantage of certain mechanical properties of the stereotactic frame used, into a sophisticated, computerized planning approach that includes optimization of the source distribution and 3-D displays. Use of the simple manual method is limited to the rare situations where target volumes are quite regular in shape. The advanced manual method provides some customization for irregularly shaped volumes, but is slow and tedious to implement. The interactive, computerized approach permits identification of target volumes directly on CT slices, reconstructions in arbitrary planes, and optimization of catheter placement, source separation along each catheter, and selection of source strengths from an available inventory. A multi-format display feature which includes a probe's eye view perspective is provided to aid in planning. Integral dose-volume histograms for the target volume point out the advantages in using sophisticated, 3-D, computerized planning systems for these implants.

Ten Haken, R.K.; Diaz, R.F.; McShan, D.L.; Fraass, B.A.; Taren, J.A.; Hood, T.W.

1988-08-01

31

From manual to 3-D computerized treatment planning for 125I stereotactic brain implants  

International Nuclear Information System (INIS)

Aspects of planning for the treatment of high grade primary or recurrent brain tumors with stereotactically placed catheters afterloaded with high activity 125I seeds are discussed. At our institution, planning has evolved from a simple manual process, which assumed geometric symmetry, through a more advanced manual process, that took advantage of certain mechanical properties of the stereotactic frame used, into a sophisticated, computerized planning approach that includes optimization of the source distribution and 3-D displays. Use of the simple manual method is limited to the rare situations where target volumes are quite regular in shape. The advanced manual method provides some customization for irregularly shaped volumes, but is slow and tedious to implement. The interactive, computerized approach permits identification of target volumes directly on CT slices, reconstructions in arbitrary planes, and optimization of catheter placement, source separation along each catheter, and selection of source strengths from an available inventory. A multi-format display feature which includes a probe's eye view perspective is provided to aid in planning. Integral dose-volume histograms for the target volume point out the advantages in using sophisticated, 3-D, computerized planning systems for these implants

1988-01-01

32

Results of biopsy after early stage prostatic cancer treatment by implantation of 125I seeds  

International Nuclear Information System (INIS)

Seventy-seven patients have been treated for clinically early stage carcinoma of the prostate, 9 stage A2, 63 stage B and 5 stage C, with direct implantation of 125I seeds into the prostate and pelvic lymphadenectomy. It is estimated that a minimum dose of 15,000 rad but a maximum dose of 35,000 rad is delivered to the prostate over several months. Of the 77 patients, 14 (18%) had metastatic disease in the pelvic lymph nodes. In 22 cases perineal needle biopsy was done 12 to 18 months after treatment and in 3 cases a second biopsy was performed after 2 to 3 years. Persistent tumor was present in 11 biopsies. Cytological changes were observed in 8 of these, primarily cytoplasmic vacuolation and nuclear pyknosis. There seemed to be no relationship between grade and stage of disease and histological evidence of persistence of tumor after radiation. One patient with persistent tumor in the postoperative biopsy has shown progression of disease after 2 years and another with a negative biopsy has a bony metastasis. The remaining 10 patients with persistent tumor have shown no sign of progression of disease during a 2 to 4-year interval

1979-01-01

33

Treatment-related symptoms during the first year following transperineal "1"2"5I prostate implantation  

International Nuclear Information System (INIS)

The purpose was to summarize the urinary, rectal, and sexual symptoms occurring during the first 12 months following "1"2"5I prostatic implantation. Thirty-one patients with Stage T_1 or T_2 prostatic carcinoma were evaluate for morbidity following computed tomography-guided transperineal "1"2"5I implants from 1988 to 1991. The median total activity used was 47 mCi (range 35-37 mCi). Toxicity was evaluated using a modification of the Radiation Therapy Oncology Group grading system. Nocturia was the most common treatment-related symptom, reported by 80% of patients within 2 months after implantation, and persisted at 12 months in 45% of the patients. Mild dysuria developed in 48% of patients within 2 months of implantation; two patients needed analgesics for their dysuria. Terazosin hydrochloride (2-10 mg qd) provided subjective improvement of urinary symptoms in seven of eight patients in whom it was tried. Rectal urgency, soft stools, and increased frequency of bowel movements was reported by 25% of the patients within 1-2 months after implantation. The incidence of assymptomatic rectal bleeding or ulceration occurring at any time after implantation was 47%, but resolved in all patients with expectant treatment. Self-limiting ulceration of the rectal mucosal occurred in 16%, but only one patient developed a prostato-rectal fistula, managed with an ileal conduit. Five of the 18 potent patients experienced discomfort on erection or ejaculation, beginning within several weeks of their implant. The discomfort resolved within 6 months in three of the patients, but persisted for 18 and 24 months in the other two. "1"2"5I implantation, as performed in this series, is generally associated with only mild-moderate genitourinary and rectal symptoms that may persist 6 months or more after implantation. 16 refs., 6 figs., 2 tabs

1994-03-01

34

125I seed implantation combined with bronchial arteries infusion chemotherapy for non-small cell lung cancer  

International Nuclear Information System (INIS)

Objective: To evaluate the clinical efficacy of 125I seed implantation combined with bronchial arterial infusion chemotherapy in the treatment of non-small cell lung carcinoma (NSCLC). Methods: A total of 34 patients with NSCLC were enrolled in this study between September 2007 and September 2009, and were allocated to Group A and Group B according to the self-imposed treatment. Group A were treated with BAI, and Group B were treated with the combination treatment of 125I seed implantation plus BAI. Clinical effects and survival rate were estimated. Results: 16 patients were in Group A and 18 in Group B. Complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD) were 0, 12, 3 and 1 in Group A and 2, 13, 3 and 0 in Group B, respectively. The effective rates (CR + PR %) were 75% in Group A and 83.3% in Group B. The median survival time were 7.4 months in Group A and 12.6 months in Group B respectively. Conclusion: 125I seed implantation combined with BAI + BAE is an effective and safe treatment for NSCLC. It can significantly prolong the patient's survival time. (authors)

2011-10-01

35

CT-guided percutaneous interstitial implantation of 125I for recurrent patients of postoperative non-small cell lung carcinoma  

International Nuclear Information System (INIS)

Objective: To evaluate the efficacy of percutaneous interstitial implantation with 125I seeds for recurrent patients of postoperative non-small cell lung carcinoma (NSCLC) guided by CT. Methods: Thirty-two NLCLC patients were verified by biopsy pathology. Prescribed dose was 90 Gy. The percutaneous interstitial implantation of 125I seeds treatment was guided by CT. The carcinoma were scanned by CT and compared before and 6 months after treatment. Then judge the curative effect according to the curative standard put forward by World Health Organization. All the patients were followed-up for 6 to 72 months, mean 24 months. Results: The mean radioactive dose of therapy group was 153.7 Gy, D90 was 93.5 Gy. Among the 32 follow-up cases, the complete and partial remission rate was 90.6%, and no major complications. One and two year survival rate were 87% and 73%, mean survival was 35 months. Conclusion: Percutaneous interstitial implantation with 125I seeds for recurrent patients of postoperative NSCLC guided by CT is a valid, minimally invasive and efficient method. (authors)

2011-05-01

36

{sup 125}I seed implant brachytherapy for the treatment of parotid gland cancers in children and adolescents  

Energy Technology Data Exchange (ETDEWEB)

Background and purpose: There is a lack of optimal treatment strategies for managing salivary gland cancers in children and adolescents. This study is aimed at assessing the effect of {sup 125}I seed implantation for the treatment of parotid cancers in children and adolescents. Patients and methods: A total of 12 patients younger than 16 years with parotid gland malignant tumors underwent {sup 125}I seed implant brachytherapy between October 2003 and November 2008. All patients were assessed after treatment and at the local tumor control appointments. Facial nerve function, maxillofacial development, and radioactive side-effects were assessed. Results: The follow-up period ranged from 41-104 months. One patient with T4b died of pulmonary metastasis. The other patients were alive during the follow-up period. There were no serious radiation-related complications. The treatment did not affect facial nerve function and dentofacial growth in any of the children. Conclusion: For parotid gland cancers in children, {sup 125}I seed implant brachytherapy may be an acceptable treatment without serious complications and with satisfactory short-term effects. (orig.)

Zheng, L.; Zhang, J.; Song, T.; Zhang, J.; Yu, G.; Zhang, Y. [Peking University School and Hospital of Stomatology, Beijing (China). Dept. of Oral and Maxillofacial Surgery

2013-05-15

37

Radioimmunoassay of tumor markers for monitoring the effect of TPS directed implantation of radioactive seeds 125I into tumor tissue  

International Nuclear Information System (INIS)

Objective: To assess the therapeutic effect of TPS directed implantation of radioseeds 125I into tumor tissue with Radioimmunoassay of tumor markers. Methods: Radio-active seeds 125I was implanted intra-operatively into 78 patients with malignancy (brain 8, lung 15, liver 12, prostate 7, rectum 10, pancreas 8, bileduct 6, breast 10 and malignant teratoma 2). The organ absorption dose was 90-120 Gy and radio activity was 370-925 MBq. Patients were followed up for 6-12 months and Radioimmunoassays of virions tumor markers serum levels (CYFRA21-1, AFP, CEA, PSA, CA119, CA153) were performed as suitable for the specific disease entity. Results: Reduction of tumor mass was very remarkable (9.0% complete regression, 41.0% regression>1/2 and 50% regression>1/3). Correspondingly, the tested serum tumor marker levels were all significantly lowered. Conclusion: For assessing the therapeutic effect of radioactive seeds 125I implantation, determination of tumor marker levels could be a very sensitive and reliable means

2003-08-01

38

Comparison between preoperative and real-time intraoperative planning 125I permanent prostate brachytherapy: long-term clinical biochemical outcome  

Science.gov (United States)

Background The purpose of the study is to evaluate the long-term clinical outcome through biochemical no evidence of disease (bNED) rates among men with low to intermediate risk prostate cancer treated with two different brachytherapy implant techniques: preoperative planning (PP) and real-time planning (IoP). Methods From June 1998 to July 2011, 1176 men with median age of 67 years and median follow-up of 47 months underwent transperineal ultrasound-guided prostate 125I-brachytherapy using either PP (132) or IoP (1044) for clinical T1c-T2b prostate adenocarcinoma Gleason brachytherapy, external beam radiation and 6-month androgen deprivation therapy (ADT). Biological effective dose (BED) was calculated using computerized tomography (CT)-based dosimetry 1-month postimplant. Failure was determined according to the Phoenix definition. Results The 5- and 7-year actuarial bNED rate was 95% and 90% respectively. The 7-year actuarial bNED was 67% for the PP group and 95% for the IoP group (P?implant technique or BED, ADT and PSA as independent prognostic factors for biochemical failure. Conclusions Following our previous published results addressing the limited and disappointing outcomes of PP method when compared to IoP based on CT dosimetry and PSA kinetics, we now confirm the long-term clinical, bNED rates clear cut superiority of IoP implant methodology.

2013-01-01

39

Effect of preoperative channel transurethral prostatectomy on complications of "1"2"5I implantation in carcinoma of prostate  

International Nuclear Information System (INIS)

Patients receiving "1"2"5I implantation and pelvic lymphadenectomy for clinically localized prostatic carcinoma were divided into two groups, with one group receiving a preoperative channel transurethral prostatectomy. The groups were matched according to clinical stage and histologic grade. Complications were classified as operative, short-term, and long-term. Although preoperative channel transurethral prostatectomy was associated with a greater incidence of surgical procedures after implantation, the overall complication rate did not differ between the two groups. The overall mortality rate and the incidence of progression of Stage C tumors did not differ between the two groups

1985-01-01

40

Effect of preoperative channel transurethral prostatectomy on complications of /sup 125/I implantation in carcinoma of prostate  

Energy Technology Data Exchange (ETDEWEB)

Patients receiving /sup 125/I implantation and pelvic lymphadenectomy for clinically localized prostatic carcinoma were divided into two groups, with one group receiving a preoperative channel transurethral prostatectomy. The groups were matched according to clinical stage and histologic grade. Complications were classified as operative, short-term, and long-term. Although preoperative channel transurethral prostatectomy was associated with a greater incidence of surgical procedures after implantation, the overall complication rate did not differ between the two groups. The overall mortality rate and the incidence of progression of Stage C tumors did not differ between the two groups.

Lizza, E.F.; Kandzari, S.J.; Belis, J.A.; Jain, P.

1985-11-01

 
 
 
 
41

Computed tomography fluoroscopy-guided percutaneous 125I seed implantation for safe, effective and real-time monitoring radiotherapy of inoperable stage T1-3N0M0 non-small-cell lung cancer  

Science.gov (United States)

The management of inoperable lung cancer remains a challenge. It has been proven that computed tomography (CT)-guided iodine-125 (125I) seed implantation is a safe and efficient method for treating lung cancer. Computed tomographic fluoroscopy (CTF) is superior to traditional CT for percutaneous management of lung lesions, due to the real-time guidance and accurate localization of the lesions. The aim of the present prospective study was to evaluate the feasibility, safety and efficacy of CTF-guided percutaneous permanent implantation of 125I seeds for the treatment of selected patients with inoperable stage T1-3N0M0 non-small-cell lung cancer (NSCLC). A total of 24 patients with resectable but inoperable stage T1-3N0 NSCLC, with a total of 28 lesions, underwent CTF-guided percutaneous implantation of radioactive 125I seeds. A prescription dose of 100–120 Gy was delivered to each lesion. The complications and local tumor control rates were documented. Survival was estimated using the Kaplan-Meier method. All the patients successfully completed the procedure, with a mean procedure duration of 45.7 min (range, 30–75 min). No severe complications occurred. Small asymptomatic pneumothorax with lung volume compression of brachytherapy with implantation of 125I seeds is a safe, feasible and effective modality for the treatment of inoperable early-stage NSCLC and may be considered an alternative option in selected patients with medically inoperable NSCLC.

LI, JIAKAI; YU, MIAO; XIAO, YUEYONG; YANG, LI; ZHANG, JINSHAN; RAY, ERIK; YANG, XIAOMING

2013-01-01

42

Implantation of 125I seeds for recurrence cervical node of head and neck tumor after external beam radiotherapy  

International Nuclear Information System (INIS)

Objective: To summarize the efficacy and the feasibility of 125I seed implantation for recurrence cervical lymph node of head and neck tumor after radiotherapy or radiotherapy plus neck dissection. Methods: Thirty-six patients with the recurrence cervical lymphnode of head and neck tumor after radiotherapy (17 patients) or radiotherapy plus neck dissection (19 patients) were treated with 125I seed implantation guided by ultrasound or CT under local anesthesia. The median number of seeds was 27( range from 3 to 78). Postoperative quality evaluation were routinely obtained for all patients. The actuarial D90 ranged from 90-160 Gy (median, 130 Gy). Results: The follow-up rate was 100%. The number of the patients who were followed up over 1-and 2-year were 11 and 3. The overall response rate was 81%. The 1-and 2-year over local control rates, over survival rates were 69% and 35%, 50% and 22%, respectively. The 1-and 2-year local control rates in patients with recurrence node after radiotherapy plus neck dissection were 72% and 54%, while those were 67% and 50% in patients with recurrence node after radiotherapy,respectively (?2=00, P=0.965). The 1-and 2-year survival rates in two groups were 48%, 13% , and 51%, 39%, respectively (?2=0.17, P=0.676). Conclusions: 125I seed implantation is a safe,minimal invasive with low morbidity and high efficacy salvage treatment method for cervical lymph node recurrence of head and neck tumor after radiotherapy with or without neck dissection. (authors)

2011-03-01

43

Efficacy of 125I seed implantation as an adjunctive therapy for extrahepatic metastasis of primary hepatocellular carcinoma  

International Nuclear Information System (INIS)

Objective: To evaluate the efficacy of 125I seed implantation for extra-hepatic metastasis of primary hepatocellular carcinoma (HCC) treatment. Methods: The clinical records of 26 patients with primary HCC and extrahepatic metastasis were reviewed. Twenty six patients had 31 primary hepatic lesions, 14 patients had 32 lung metastasis, 6 had 8 bone metastasis and 6 had 8 hepatohilar or retroperitoneal lymphatic metastasis. The hepatic lesions were treated by combination of transcatheter arterial chemo- embolization(TACE) and radiofrequency ablation(RFA) or percutaneous ethanol injection (PEI) and were followed up by contrast-enhanced CT (CECT) after 1 month. The extra-hepatic lesions were treated by 125I seeds implantation and were followed up by CECT 3 months after treatment. The treatments were evaluated by imaging examinations. The patients were followed up every 1 month during the first half year, including CT examinations of chest, abdomen and lesions and chest films. Telephone follow-up were performed every 3 months after the 6th month till they were lost and the survival time were calculated. Results: Of the extra-hepatic lesions, 16 cases were complete response (CR), 3 cases were partial response (PR), 4 cases were stable disease (SD) and 3 were progressive diseases (PD). Of the hepatic lesions, 11 were CR, 4 were PR, 6 were SD and 5 PD. The 26 patients are survived at the time of end of follow-up (7.0 to 24.0 months). The median survival duration was 14.5 months. Conclusions: 125I seed implantation integrated interventional and minimally invasive therapy could improve the life and survival and it is an effective adjunctive therapy for primary hepatocellular carcinoma with metastasis outside the liver. (authors)

2009-08-01

44

Induction of lung tumours in the rat by radiation emitted from implanted 192Ir wires or 125I seeds  

International Nuclear Information System (INIS)

In the observation period of 15 months, 30 of the 40 WAG/Rij rats implanted with 192Ir wires developed tumours in or close to the thoracic cavity. Lung tumours were observed only in the implanted lung. Malignant hemangioendotheliomas occurred with a frequency of 50 per cent. In 12 lungs, a squamous cell carcinoma was found. Several other types of tumours were found. In 8 lungs, two types of tumours and in one three different types of tumours were identified. The frequency of tumours derived from bronchial epithelial tissue was 42.5 per cent. Four animals were lost due to massive bleeding in the implanted lung without signs of tumour development and 6 others due to other causes. The frequency of the tumours induced as a function of time after implantation is shown. In the observation period of 18 months, only one of 20 animals implanted with a 125I seed developed a lung tumour, a squamous cell carcinoma in the implanted lung and two others with a tumour that could not be identified. Six animals were lost due to other causes, with no macroscopic signs of neoplasms in the lungs. Of these, one animal had a massive bleeding in the lung. Eleven animals were still alive at the end of this observation period. (Auth.)

1983-01-01

45

A nomograph for permanent implants of Palladium-103 seeds  

International Nuclear Information System (INIS)

103Pd is being substituted for 125I in permanent implants for which it is desired to deliver a higher initial dose rate while maintaining readily achieved radiation protection. The authors have constructed a nomograph to assist in determining both the total seed strength required and the appropriate needle spacing for 103Pd implants. They have calculated the open-quotes matched peripheral doseclose quotes (MPD), that is, the dose for which the isodose contour volume is equal to the target volume, for 64 125I and 13 103Pd actual implants as if 103Pd had been used for all of them, employing a computer lookup table based on single-seed dose distribution measurements in solid water. The calculated data were used to obtain a least-squares fit to a linear relationship between the logarithm of the total seed strength for a given MPD and the logarithm of the average dimension, da (cm). They found that, for a nominal MPD of 11,500 cGy, total seed strength (in mCi) is given by 3.2 da2.56. A 103Pd nomograph has been constructed on the basis of this power function relationship. The nomographic guide for planning 103Pd implants calls for total seed strength to increase significantly faster as a function of target volume average dimension than is the case for 125I. This nomograph will facilitate the application of 103Pd seeds in permanent implants

1993-09-01

46

Transnasal permanent interstitial implantation for carcinoma of the nasopharynx  

International Nuclear Information System (INIS)

A technique for transnasal permanent interstitial implantation of the nasopharynx with 125I seeds is described. This technique allows the precise placement of radioactive sources into mucosal and submucosal tumors, without the need for palatal fenestration. Preliminary results in 10 patients treated by this technique for recurrent nasopharyngeal carcinoma are presented. In the future the authors also hope to employ this technique for delivering ''boost'' irradiation to the primary site, in the initial definitive management of carcinoma of the nasopharynx

1984-01-01

47

The clinical application of 125I seeds implantation together with bronchial arterial infusion chemotherapy for the treatment of advanced lung cancer  

International Nuclear Information System (INIS)

Objective: To assess the clinical value of 125I seeds implantation combined with the bronchial arterial infusion chemotherapy in treating advanced lung cancer. Methods: 125I seeds implantation combined with the bronchial arterial infusion chemotherapy was performed in 30 patients with advanced lung cancer. About 3 -70 seeds of 125I (6711 type, 0.7 mCi / seed) were delivered in each patient. In all patients bronchial arterial infusion chemotherapy was carried out at the time of 7 days before the implantation and 30 and 60 days after the implantation. The results and complications were observed. The clinical data were retrospectively analyzed. The therapeutic efficacy was evaluated according to RECIST standards. Results: A total of 40 lesions were detected in all 30 patients and 125I seeds were successfully embedded in all lesions. No procedure-related complications occurred. All patients were followed up for 2 -24 months. The two-year survival rate was 86.6% (26 / 30). Therapeutic evaluation made at four months after the treatment showed that CR, PR, NC and PD was seen in 26, 10, 2 and 2 lesions respectively,with a total effective rate of 90%. Conclusion: 125I seeds implantation combined with the bronchial arterial infusion chemotherapy is a safe and effective therapy for advanced lung cancer with excellent clinical results. (authors)

2010-08-01

48

Clinical efficacy of interstitial implantation of 125I seeds combined with chemotherapy in patients with non-small cell Lung carcinoma  

International Nuclear Information System (INIS)

To evaluate the clinical efficacy of 125I seed implantation combined with chemotherapy in the treatment of patients with non-small cell lung carcinoma(NSCLC). The patients with NSCLC (n=64) were received interstitially 125I seed implantation by CT-guided, and then were treated with NVB and DDP after three days. In control group (n=70), the patients were only treated with NVB and DDP. The therapeutic efficacy was observed after two,four and six months. The results showed that the effective rates (CR + PR) after two, four and six months of the treatment were 82.8%, 90.6%, 93.7%, respectively. The effective rates in the control group were 4.4%, 48.6%, 52.9%, respectively. The therapeutic effects had significant difference between two groups (P125I seed implantation and chemotherapy in patients with NSCLC to reduce tumor load in a short period and improve the therapeutic efficacy. (authors)

2011-06-01

49

125I implantation for carcinoma of prostate. Further follow-up of first 100 cases  

International Nuclear Information System (INIS)

Analysis of the first 100 patients at the Memorial Sloan-Kettering Cancer Center with Stage B or C prostatic cancer treated by pelvic lymph node dissection and Iodine-125 implantation and endocrine therapy when specifically indicated revealed five-year survival rates of 87 and 77 per cent, respectively. Tumor stage, tumor grade, and lymph node metastasis each correlated with survival, but the latter was the most significant factor. Although routine follow-up biopsies were not performed, local tumor control as judged by serial digital rectal examination defined a prognostically favored group of patients. In the absence of controls, however, whether the latter response indicates a salutary effect of the treatment which produces an improved survival or merely identifies a group of patients who were predetermined to have a more favorable survival is undetermined

1982-01-01

50

Multi-species prostate implant treatment plans incorporating 192Ir and 125I using a Greedy Heuristic based 3D optimization algorithm  

International Nuclear Information System (INIS)

The goals of interstitial implant brachytherapy include delivery of the target dose in a uniform manner while sparing sensitive structures, and minimizing the number of needles and sources. We investigated the use of a multi-species source arrangement (192Ir with 125I) for treatment in interstitial prostate brachytherapy. The algorithm utilizes an 'adjoint ratio', which provides a means of ranking source positions and is the criterion for the Greedy Heuristic optimization. Three cases were compared, each using 0.4 mCi 125I seeds: case I is the base case using 125I alone, case II uses 0.12 mCi 192Ir seeds mixed with 125I, and case III uses 0.25 mCi 192Ir mixed with 125I. Both multi-species cases result in lower exposure of the urethra and central prostate region. Compared with the base case, the exposure to the rectum and normal tissue increases by a significant amount for case III as compared with the increase in case II, signifying the effect of slower dose falloff rate of higher energy gammas of 192Ir in the tissue. The number of seeds and needles decreases in both multi-species cases, with case III requiring fewer seeds and needles than case II. Further, the effect of 192Ir on uniformity was investigated using the 0.12 mCi 192Ir seeds in multi-species implants. An increase in uniformity was observed with an increase in the number of 0.12 mCi 192Ir seeds implanted. The effects of prostate size on the evaluation parameters for multi-species implants were investigated using 0.12 mCi 192Ir and 0.4 mCi 125I, and an acceptable treatment plan with increased uniformity was obtained

2007-02-01

51

Comparison of therapeutic effects between CT-guided 125I seed implantation and chemotherapy with Gemcitabine for the treatment of unresectable pancreatic carcinoma  

International Nuclear Information System (INIS)

Objective: To compare the therapeutic effects of CT-guided 125I seed implantation with simple Gemcitabine chemotherapy for the treatment of unresectable pancreatic carcinoma. Methods: Forty-six untreated patients with unresectable advanced pancreatic carcinoma were randomly divided into two groups: group A (n=22), treated with 125I seed implantation and group B (n=24), treated with intravenous chemotherapy using Gemcitabine only. The clinical benefit response (CBR), objective tumor response (OTR), safety and the improvement of living quality were evaluated and analyzed. Results: Three months after the treatment, the OTR rate of group A and group B was 45.5% and 8.33% respectively (P 0.05). And also, the incidence of hematological toxicity and complication between two groups were of no significant difference. Conclusion: For the treatment of advanced unresectable pancreatic carcinoma, both simple Gemcitabine chemotherapy and 125I seed implantation are able to obtain a moderate objective response, although 125I seed implantation seems to be more effective than Gemcitabine in improving the living quality and survival rate. (authors)

2009-09-01

52

Intro-operative dosimetry of trans-rectal ultrasound guided 125I prostate implants using C-arm fluoroscopic images  

International Nuclear Information System (INIS)

Permanent implantation of radioactive seeds is a viable and effective therapeutic option widely used today for early-stage prostate cancer. The implant technique has improved considerably during the recent years due to the use of image guidance; however, real-time dose distributions would allow potential cold spots to be assessed and additional seeds added. In this study, we investigate the use of a conventional C-arm fluoroscopy unit for image acquisition and evaluation of dose distribution immediately after the implant. The phantom study indicates that it is possible to obtain seed positions within ±2 mm. A pilot study carried out with three patients indicated that it is possible to obtain seeds and calculate the dose distribution with C-arm fluoroscopy and about 95% of the seeds were reconstructed within ±2 mm. The results could be further improved with better digital imaging. (author)

2006-01-01

53

Effect of Foley catheters on seed positions and urethral dose in 125I and 103Pd prostate implants  

International Nuclear Information System (INIS)

Purpose: To estimate the perturbation of seed position and urethral dose, subsequent to withdrawal of urethral catheters. Methods and Materials: A mathematical model based on the volume incompressibility of tissues was used to compute seed positions and doses following removal of the Foley. The model assumed that the central axis of the urethra remains stationary, and that prostate tissue and seeds move radially toward the center of the urethra to fill the void left by the catheter. Seed motion has also been measured using transrectal ultrasound. Results: Based on the computations, seeds located originally close to the urethra travel relatively large distances toward the urethra upon Foley removal, whereas seeds located further away move substantially less. This seed motion leads to higher urethral doses than shown in a standard treatment plan. Dose enhancements increase with catheter size, decrease with increasing prostate volume, are more pronounced for 103Pd than for 125I, and range between 3.5% and 32.4%. Postimplant dosimetry is equally affected if images are taken with urethral catheters in place, showing lower urethral doses than actually delivered. Preliminary ultrasound based measurements of seed motion agree with the theory. Conclusion: During the implantation procedure, 12 fr or smaller urethral catheters are preferable to larger diameter catheters if urine drainage is sufficient. Treatment planners should avoid planning seeds at 5 mm or closer from the urethra. Special caution is indicated in prostates having about 20 cm3 or smaller volumes, and when 103Pd is used. Postimplant dosimetry is susceptible to the same errors

2001-04-01

54

Linear 125I seed strand implantation combined with portal vein stenting and TACE for the treatment of hepatocellular carcinoma with portal vein tumor thrombus  

International Nuclear Information System (INIS)

Objective: To evaluate the therapeutic efficacy of linear 125I seed strand implantation combined with portal vein stenting and transcatheter hepatic arterial chemoembolization (TACE) in treating hepatocellular carcinoma (HCC) with portal vein tumor thrombus. Methods: Seventeen HCC patients with tumor thrombus in the main branch of the portal vein received a combination therapy of linear 125I seed strand implantation with TACE. A total of 17 - 23 seeds of 125I (model 6711, 0.7 mCi) with a dosage of (73.51 ? 76.22) Gy on the first half-decay period was delivered to each patient. The postoperative complications, tumor response, stent patency rate and the successful rate of the procedure were all recorded, and the Kaplan-Meier method was used for analyzing the survival rate. Results: Stents and 125I seed strands were successfully placed in the portal veins in all patients. No serious complications occurred. The 60-, 180-and 360-day cumulative stent patency rates were 94%, 94% and 94% respectively, and the overall survival (OS) rates were 87%, 65% and 53% respectively. During a follow-up period of (2 - 13) months, twelve patients remained alive and five patients died of hepatic dysfunction (n = 4) or metastasis (n = 1). Conclusion: For the treatment of hepatocellular carcinoma with portal vein tumor thrombus, a combination of linear 125I seed strand implantation with portal vein stenting and TACE can increase the stent patency rate, elongate the survival span, although its long-term efficacy needs to be further studied. (authors)

2009-08-01

55

_1_2_5I implants as an adjuvant to surgery and external beam radiotherapy in the management of locally advanced head and neck cancer  

International Nuclear Information System (INIS)

_1_2_5I seeds either individually placed or inserted into absorbable Vicryl suture carriers were utilized in conjunction with surgery and external beam radiotherapy in an attempt to increase local control rates in patients with advanced oropharyngeal and laryngopharyngeal cancers (T3-T4, N2-N3), massive cervical lymphadenopathy (N3) and an unknown primary site and locally recurrent head and neck cancers. Forty-eight patients were treated with 55 implants. The carotid artery was implanted in 15 patients, while seven patients had seeds inserted into the base of the skull region, and another three patients had implants near cranial nerves. Eighteen of the 48 patients were treated for cure. The actuarial survival at five years in this subgroup was 50%. The overall local control in the head and neck area was 58%. In this group no patients to date have had a local failure in the implanted volume. Seventeen patients with comparable stage of disease treated prior to 1974 with curative intent without _1_2_5I implants were analyzed retrospectively for comparison with the implanted patients. The actuarial survival of these patients was 18% and the overall head and neck control was 21%. These differences are statistically significant at a P value of 0.01 and 0.007, respectively. Seventeen patients received implants for local recurrence. The local control in the head and neck area was 50%; however, the 2.5 year actuarial survival was only 17%. The complication rate was 11% (six of 55 implants). The improved survival, the high local control, and the minimal complication rates in this series makes the intraoperative implantation of _1_2_5I seeds and effective adjunctive treatment to surgery and external beam irradiation

1983-03-15

56

A digital model individual template and CT-guided 125I seed implants for malignant tumors of the head and neck  

International Nuclear Information System (INIS)

The purpose of this study was to enhance the accuracy of radioactive seed implants in the head and neck, a digital model individual template, containing information simultaneously on needle pathway and facial features, was designed to guide implantation with CT imaging. Thirty-one patients with recurrent and local advanced malignant tumors of head and neck after prior surgery and radiotherapy were involved in this study. Before 125I implants, patients received CT scans based on 0.75 mm thickness. And the brachytherapy treatment planning system (BTPS) software was used to make the implantation plan based on the CT images. Mimics software and Geomagic software were used to read the data containing CT images and implantation plan, and to design the individual template. Then the individual template containing the information of needle pathway and face features simultaneously was made through rapid prototyping (RP) technique. All patients received 125I seeds interstitial implantation under the guide of the individual template and CT. The individual templates were positioned easily and accurately, and were stable. After implants, treatment quality evaluation was made by CT and TPS. The seeds and dosages distribution (D90, V100, V150) were well meet the treatment requirement. Clinical practice confirms that this approach can facilitate easier and more accurate implantation. (author)

2012-11-01

57

The evaluation of short term effect of CT guided radioactive seed 125I implantation in treating pulmonary metastases from gastrointestinal tumor  

International Nuclear Information System (INIS)

Objective: To investigate the short term effect of CT guided radioactive seed 125I implantation in treating pulmonary metastases from gastrointestinal tumor. Methods: 20 patients (male 13, female 7, the age range of 25 to 73, mean age 49±24) with pulmonary metastases from gastrointestinal tumor accepting CT guided radioactive seed 125I implantation were enrolled in this study. Among these patients, no more than 5 pulmonary metastases lesions occurred in any one case, diameters of all lesions were from 0.5 to 3.0 cm with. average 2.8 lesions per case, and the mean diameter of pulmonary metastases was 2.1 cm. 13 cases presented pulmonary metastases only unilaterally, and 7 others were found bilaterally. All primary tumors were confirmed by pathology, and pulmonary metastases were identified by CT or MRI and confirmed through pathology. Under CT guidance, 125I seeds were implanted into pulmonary metastases according to CT based computerized treatment planning in radio-oncology of the treatment planning system (TPS). All cases were observed two months after the treatment. Results: Among 56 pulmonary metastases in 20 patients, 32 obtained CR, 19 PR, 5 NC. The responsive rate was 91.1%. During follow up, no mortality occurred, but with complications of pneumothorax in 2 cases, bloody sputum in 2 cases, hemothorax in 1 case. Conclusions: CT guided radioactive seed 125I implantation procedure possesses satisfied clinical effects in treating pulmonary metastases from gastrointestinal tumor with minimal damage and few complications, especially in these patients with no more than 5 pulmonary metastases, and less than 3.0 cm in diameter. (authors)

2006-04-01

58

Dynamic observation on changes of serum tumor markers levels after implantation of 125I radioactive seeds as treatment for several malignancies  

International Nuclear Information System (INIS)

Objective: To study the dynamic changes of serum levels of several tumor markers after implantation of 125I seeds as treatment for breast, prostate and lung malignancies. Methods: Serum CA15-3 (in 48 cases of breast cancer), PSA (in 59 cases of prostate cancer) and CYFRA21-1 (in 59 cases of lung cancer) levels were measured with RIA both before and after implantation of 125I seeds as treatment. Furthermore, dynamic observation on the serum markers levels was carried out every 3 months in ten patients in each category. Results: After treatment, levels of these markers dropped significantly. Dynamic observation revealed that in the 10 cases of breast cancer, the levels of CA15-3 dropped continually. However, in the 10 cases of prostatic cancer, the disease got worse and the PSA levels kept increasing. In the lung cancer group, the CYFRA21-1 levels rose markedly and all patients expired before 9 months. Conclusion: Dynamic observation on changes of serum tumor markers (CA15-3, PSA, CYFRA21-1) levels after 125I seed implantation treatment was of definite prognostic value. (authors)

2005-12-01

59

American brachytherapy society recommends no change for prostate permanent implant dose prescriptions using iodine-125 or palladium-103  

International Nuclear Information System (INIS)

Purpose - In 2004, the American Association of Physicists in Medicine (AAPM) issued a report outlining recommended 125I and 103Pd datasets for consistency in calculating brachytherapy dose distributions. In 2005, to aid evaluating the clinical impact of implementing these datasets, the AAPM assessed the historical dependence of how prescribed doses differed from administered doses for 125I and 103Pd for permanent implantation of the prostate. Consequently, the American Brachytherapy Society (ABS) considered the nature of these changes towards issuing recommended dose prescriptions for 125I and 103Pd interstitial brachytherapy implants for mono-therapy and standard boosts. Methods and materials - An investigation was performed of the 2005 AAPM analysis to determine changes in administered dose while affixing prescribed dose using 2004 AAPM 125I and 103Pd brachytherapy dosimetry datasets for prostate implants. For 125I and 103Pd, administered dose would change by +1.4% and +4.2%, respectively. The biological and societal impact of changing prescribed dose was considered. Results - Based on the need for clinical constancy and in recognition of overall uncertainties, the ABS recommends immediate implementation of the 2004 AAPM consensus brachytherapy dosimetry datasets and no changes to 125I and 103Pd dose prescriptions at this time. Conclusions - Radiation oncologists should continue to prescribe mono-therapy doses of 145 Gy and 125 Gy for 125I and 105Pd, respectively, and standard boost doses of 100-110 Gy and 90-100 Gy for 125I and 103Pd, respectively. (authors)

2008-01-01

60

CT-guided 125I seeds implantation combined with NP chemotherapy for the treatment of intractable central airway stenosis caused by NSCLC  

International Nuclear Information System (INIS)

Objective: To explore the clinical value of radioactive 125I seeds implantation combined with NP in treating intractable central airway stenosis caused by non-small cell cancer (NSCLC). Methods: A prospective cohort study of 80 patients, who were admitted to Beichen hospital (Tianjin, China) during the period from January 2004 to March 2010, were enrolled in this study. The patients were randomly divided into study group (n=42) and control group (n=38). Percutaneous CT-guided intratumoral implantation of 125I seeds was carried out in the patients of the study group. Treatment plan system (TPS) was used to design the distribution and the number of 125I seeds with PD=80-100 CY, and the source intensity was 0.8 mCi. Three days after operation the NP chemotherapy started and it was performed for 2 cycles. Only two cycles of NP chemotherapy was used for the patients in the control group. After the treatment, the cross area of the airway at its narrowest level was measured and the dyspnea index was evaluated. Results: All the patients were followed up for two months. The preoperative and postoperative stenosis rate of the airway in study group was 47.82%±17.55% and 15.76%±4.65%, respectively. The trachea was unobstructed and the dyspnea was markedly improved. The postoperative cross area of the airway at its narrowest level was significantly bigger than the preoperative one (P0.05). Conclusion: Radioactive 125I seeds implantation combined with NP chemotherapy is a safe and effective treatment for NSCLC. (authors)

2012-03-01

 
 
 
 
61

Evaluation of CT-guided 125I seed implantation combined with transcatheter arterial chemoembolization in treating portal vein tumor thrombus associated with hepatocellular carcinoma  

International Nuclear Information System (INIS)

Objective: To discuss the therapeutic effect of CT-guided 125I seed implantation combined with transcatheter arterial chemo embolization (TACE) for the treatment of portal vein tumor thrombus (PVTT) associated with hepatocellular carcinoma (HCC). Methods: A total of 58 patients with confirmed HCC accompanied by PVTT were enrolled in this study. Of the 58 patients, CT-guided 125I seed implantation together with TACE was performed in 26 (group A), while only TACE was employed in 32 (group B). The clinical data were retrospectively analyzed and the therapeutic results were compared between two groups. Results: For group A, the one-year and two-year survival rate was 42.3% and 23.0% respectively, with a mean survival time of 15.5 months. Of the 26 patients in group A, the complete remission (CR) was obtained in 3, partial remission (PR) in 9, with a total effective rate (CR + PR) of 46.2% (12 /26). While in group B, the one-year and two-year survival rate was 21.9% and 6.3% respectively, with a mean survival time of 7.5 months. And CR was obtained in 2 cases, PR in 6 cases,with a total effective rate (CR + PR) of 25% (8/32). Both the survival rate and the total effectiveness of group A were significant higher than that of group B (P 125I seed implantation combined with transcatheter arterial chemo embolization can markedly improve the therapeutic effect for portal vein tumor thrombus associated with hepatocellular carcinoma. (authors)

2010-07-01

62

Bioevaluation of 125I Ocu-Prosta seeds for application in prostate cancer brachytherapy  

Science.gov (United States)

Background & objectives: In recent years, brachytherapy involving permanent radioactive seed implantation has emerged as an effective modality for the management of cancer of prostate. 125I-Ocu-Prosta seeds were indigenously developed and studies were carried out to assess the safety of the indigenously developed 125I-Ocu-Prosta seeds for treatment of prostate cancer. Methods: Animal experiments were performed to assess the likelihood of in vivo release of 125I from radioactive seeds and migration of seeds implanted in the prostate gland of the rabbit. In vivo release of 125I activity was monitored by serial blood sampling from the auricular vein and subsequent measurement of 125I activity. Serial computed tomography (CT) scans were done at regular intervals till 6 months post implant to assess the physical migration of the seeds. Results: The laser welded seeds maintained their hermeticity and prevented the in vivo release of 125I activity into the blood as no radioactivity was detected during follow up blood measurements. Our study showed that the miniature 125I seeds were clearly resolved in CT images. Seeds remained within the prostate gland during the entire study period. Moreover, the seed displacement was minimal even within the prostate gland. Interpretation & conclusions: Our findings have demonstrated that indigenously developed 125I-Ocu-Prosta seeds may be suitable for application in treatment of prostate cancer.

Mukherjee, Archana; Sarma, Haladhar Dev; Saxena, Sanjay; Kumar, Yogendra; Chaudhari, Pradip; Goda, Jayant Sastri; Adurkar, Pranjal; Dash, Ashutosh; Samuel, Grace

2014-01-01

63

"1"2"5I implantation for carcinoma of the prostate: 5-year survival free of disease and incidence of local failure  

International Nuclear Information System (INIS)

Interstitial implantation with the iodine isotope, "1"2"5I has been used as definitive treatment in 115 patients with localized carcinoma of the prostate. The disease was staged surgically by bilateral pelvic lymphadenectomy in all of the patients. Followup has been for a minimum of 1 year and 64 patients have been followed for a minimum of 5 years. There has been no operative mortality in this series. Mean patient age at implantation was 63 years. Potency has been maintained in 31 of 46 patients (78 per cent) followed for a minimum of 5 years and 15 of 26 (58 per cent) followed for a minimum of 7 years. At 5 years the actuarial survival free of disease by surgical stage was 100, 81, 49 and 41 per cent for patients with stages A2, B, C and D1 disease, respectively. Local failure was defined as palpable evidence of prostatic enlargement or irregularity with biopsy confirmation of neoplasm. The actuarial probability of local failure at 5 years was 0, 13, 27 and 44 per cent for patients with surgical stages A2, B, C and D1 disease, respectively, and 5, 23 and 43 per cent for those with well, moderately and poorly differentiated tumors, respectively. Based on our experience, interstitial implantation with "1"2"5I is reserved for patients with well or moderately differentiated stage B lesions. The ultimate success of this treatment modality awaits 10 and 15 years of followup

1985-01-01

64

Preparation and deployment of indigenous 125I- seeds for the treatment of prostate cancer: dawn of prostate brachytherapy in India  

International Nuclear Information System (INIS)

'Permanent seed implantation' using 125I- seeds represents an effective treatment modality for prostate cancer. An innovative strategy to prepare and deploy 125I- seeds for treatment of prostate cancer has been evolved. Seeds prepared by chemisorptions of 125I on palladium coated silver wires were characterized and encased in titanium tubes by ND:YAG laser. Several batches of critically evaluated seeds exhibiting release of 125I were supplied to P.D. Hinduja Hospital, Mumbai for treatment of prostate cancer patients. Successful deployment of indigenous seeds in prostate brachytherapy has opened a new window for making prostate brachytherapy affordable to needy cancer patients. (author)

2014-01-20

65

"1"2"5I interstitial implants in the RIF-1 murine flank tumor: an animal model for brachytherapy  

International Nuclear Information System (INIS)

The development of a model for interstitial brachytherapy that uses high-activity, removable "1"2"5I sources in the RIF-1 murine flank tumor is reported. Experimental end points are clonogenic cell and tumor regrowth delay assays. For the clonogenic cell assay, interestitial radiation is delivered at total doses of 500-10,000 rad at dose rates of 0.9-2.7 rad/min to cells in annuli of tissue in the tumor. Dose-survival curves are characterized by an initial shoulder followed by a straight (exponential) portion, with D_0 similar to that of the curve obtained by external irradiation of the RIF-1 tumor in a self-contained cesium irradiator at similar dose rates. Tumor regrowth curves have been obtained for minimum tumor doses of 500-5000 rad; marked tumor regression has been observed with minimum tumor doses as low as 2000 rad, but results are not as reproducible as the results obtained with the clonogenic cell assay

1982-01-01

66

A clinical method for real-time dosimetric guidance of transperineal 125i prostate implants using interventional magnetic resonance imaging  

International Nuclear Information System (INIS)

Purpose: The clinical utility of an interventional magnetic resonance (IMR)-guided implant technique with real-time dosimetric feedback is presented. Methods and Materials: The work was carried out at a IMR unit at Brigham and Women's Hospital. Planning and dosimetric feedback were provided by a software system that provides an interface to the IMR images, anatomy demarcation, template registration, dose calculation engine for planning, and evaluating the implant. Planning during the procedure permits the incorporation of actual needle trajectories in the dose calculations. Results: Fifteen patients were planned in the treatment position. During source placement, actual needle locations were incorporated into the dose calculations. After accounting for the observed needle trajectories of the planned needles, 14 of 15 patients (93%) required additional sources to achieve the desired coverage of the target volume. Conclusion: A brachytherapy implant procedure which provides clinically significant advances has been implemented. Specifically, the planning system allows dosimetric validation of the needle placement. This procedure is effective in delivering brachytherapy to the target volume and assuring that the implant is delivered in accordance with the preplan. The dosimetric feedback could be incorporated in ultrasound-guided implants

2000-01-01

67

The effect of voxel size on the accuracy of dose-volume histograms of prostate 125I seed implants  

International Nuclear Information System (INIS)

Cumulative dose-volume histograms (DVH) are crucial in evaluating the quality of radioactive seed prostate implants. When calculating DVHs, the choice of voxel size is a compromise between computational speed (larger voxels) and accuracy (smaller voxels). We quantified the effect of voxel size on the accuracy of DVHs using an in-house computer program. The program was validated by comparison with a hand-calculated DVH for a single 0.4-U iodine-125 model 6711 seed. We used the program to find the voxel size required to obtain accurate DVHs of five iodine-125 prostate implant patients at our institution. One-millimeter cubes were sufficient to obtain DVHs that are accurate within 5% up to 200% of the prescription dose. For the five patient plans, we obtained good agreement with the VariSeed (version 6.7, Varian, USA) treatment planning software's DVH algorithm by using voxels with a sup-inf dimension equal to the spacing between successive transverse seed implant planes (5 mm). The volume that receives at least 200% of the target dose, V200, calculated by VariSeed was 30% to 43% larger than that calculated by our program with small voxels. The single-seed DVH calculated by VariSeed fell below the hand calculation by up to 50% at low doses (30 Gy), and above it by over 50% at high doses (>250 Gy)

2002-06-01

68

Clinical application of permanent implantation of iodine 125 seeds for osseous metastases  

International Nuclear Information System (INIS)

Objective: To evaluate the clinical efficacy of permanent implantation of iodine 125 seeds in the treatment of osseous metastases. Methods: Radioactive iodine 125 seeds were implanted permanently in 32 lesions of 25 patients with osseous metastases of different origins. The ostalgia-relieving degree and the imaging alterations of the osseous metastasis lesions were observed. Results: The effective pain-relieving rate was 92% caused by permanent implantation of iodine 125 seeds. Of al 1 the patients, 15 patients achieved complete response, 8 patients obtained partial response (PR), and 2 patients had no change. The pain grade was decreased significantly after the treatment (P125I seeds has a definite effect on tumor metastasis and caused minimal damage and few complications. It is worthy of popularization in clinic. (authors)

2010-02-01

69

American brachytherapy society recommends no change for prostate permanent implant dose prescriptions using iodine-125 or palladium-103  

Energy Technology Data Exchange (ETDEWEB)

Purpose - In 2004, the American Association of Physicists in Medicine (AAPM) issued a report outlining recommended {sup 125}I and {sup 103}Pd datasets for consistency in calculating brachytherapy dose distributions. In 2005, to aid evaluating the clinical impact of implementing these datasets, the AAPM assessed the historical dependence of how prescribed doses differed from administered doses for {sup 125}I and {sup 103}Pd for permanent implantation of the prostate. Consequently, the American Brachytherapy Society (ABS) considered the nature of these changes towards issuing recommended dose prescriptions for {sup 125}I and {sup 103}Pd interstitial brachytherapy implants for mono-therapy and standard boosts. Methods and materials - An investigation was performed of the 2005 AAPM analysis to determine changes in administered dose while affixing prescribed dose using 2004 AAPM {sup 125}I and {sup 103}Pd brachytherapy dosimetry datasets for prostate implants. For {sup 125}I and {sup 103}Pd, administered dose would change by +1.4% and +4.2%, respectively. The biological and societal impact of changing prescribed dose was considered. Results - Based on the need for clinical constancy and in recognition of overall uncertainties, the ABS recommends immediate implementation of the 2004 AAPM consensus brachytherapy dosimetry datasets and no changes to {sup 125}I and {sup 103}Pd dose prescriptions at this time. Conclusions - Radiation oncologists should continue to prescribe mono-therapy doses of 145 Gy and 125 Gy for {sup 125}I and {sup 105}Pd, respectively, and standard boost doses of 100-110 Gy and 90-100 Gy for {sup 125}I and {sup 103}Pd, respectively. (authors)

Rivard, M.J. [Tufts-New England Medical Center, Dept. of Radiation Oncology and Medical Physics, Boston, MA (United States); Butler, W.M.; Merrick, G.S. [Wheeling Jesuit Univ., Schiffler Cancer Center, WV (United States); Devlin, P.M. [Brigham and Women' s Hospital, Dept. of Radiation Oncology, Boston, MA (United States); Hayes, J.K. [Brigham and Women' s Hospital, Dept. of Radiation Oncology, Boston, MA (United States); Hearn, R.A. [Gamma West Brachytherapy, Salt Lake City, UT (United States); Lief, E.P. [Mount Sinai Medical Center, Dept. of Radiation Oncology, New York, NY (United States); Meigooni, A.S. [Kentucky Univ., Dept. of Radiation Medicine, Lexington, KY (United States); Williamson, J.F. [Medical College of Virginia, Dept. of Radiation Oncology, Richmond, VA (United States)

2008-01-15

70

Methodology of quality control for brachytherapy {sup 125}I seeds  

Energy Technology Data Exchange (ETDEWEB)

This paper presents the methodology of quality control of {sup 125}I seeds used for brachytherapy. The {sup 125}I seeds are millimeter titanium capsules widely used in permanent implants of prostate cancer, allowing a high dose within the tumour and a low dose on the surrounding tissues, with very low harm to the other tissues. Besides, with this procedure, the patients have a low impotence rate and a small incidence of urinary incontinence. To meet the medical standards, an efficient quality control is necessary, showing values with the minimum uncertainness possible, concerning the seeds dimensions and their respective activities. The medical needles are used to insert the seeds inside the prostate. The needles used in brachytherapy have an internal diameter of 1.0 mm, so it is necessary {sup 125}I seeds with an external maximum diameter of 0.85 mm. For the seeds and the spacer positioning on the planning sheet, the seeds must have a length between 4.5 and 5.0 mm. The activities must not vary more than 5% in each batch of {sup 125}I seeds. For this methodology, we used two ionization chamber detectors and one caliper. In this paper, the methodology using one control batch with 75 seeds manufactured by GE Health care Ltd is presented. (author)

Moura, Eduardo S.; Zeituni, Carlos A.; Manzoli, Jose E.; Rostelato, Maria Elisa C.M. [Instituto de Pesquisas Energeticas e Nucleares (IPEN/CNEN-SP), Sao Paulo, SP (Brazil)]. E-mail: esmoura@ipen.br

2007-07-01

71

The effect of local control on metastatic dissemination in carcinoma of the prostate: Long-term results in patients treated with 125I implantation  

International Nuclear Information System (INIS)

The study evaluates the effect of the locally recurring tumor on the incidence of metastatic disease in early stage carcinoma of the prostate. The probability of distant metastases was studied in 679 patients with Stage B-C/N0 carcinoma of the prostate treated at MSKCC between 1970 and 1985 (median follow-up of 97 months). Patients were staged with pelvic lymph node dissection and treated with retropubic 125I implantation. The actuarial distant metastases free survival (DMFS) for patients at risk at 15 years after initial therapy was 37%. Cox proportional hazard regression analysis of covariates affecting the metastatic outcome showed that local failure, used in the model as a time dependent variable, was the most significant covariate, although stage, grade, and implant volume were also found to be independent variables. The relative risk of metastatic spread subsequent to local failure was 4-fold increased compared to the risk without evidence of local relapse. The 15-year actuarial DMFS in 351 patients with local control was 77% compared to 24% in 328 patients who developed local relapses (p less than 0.00001). The relation of distant spread to the local outcome was observed regardless of stage, grade, or implant dose. Even stage B1/N0-Grade I patient with local control showed a 15-year actuarial DMFS of 82%, compared to 22% in patients with local relapse (p less than 0.00001). The median local relapse-free survival (LRFS) in the 268 patients with local recurrences who did not receive hormonal therapy before distant metastases were detected was 51 months, compared to a median of 71 months for DMFS in the same patients (p less than 0.001), consistent with the possibility that distant dissemination may develop secondary to local failure

1991-01-01

72

The effect of local control on metastatic dissemination in carcinoma of the prostate: Long-term results in patients treated with 125I implantation  

Energy Technology Data Exchange (ETDEWEB)

The study evaluates the effect of the locally recurring tumor on the incidence of metastatic disease in early stage carcinoma of the prostate. The probability of distant metastases was studied in 679 patients with Stage B-C/N0 carcinoma of the prostate treated at MSKCC between 1970 and 1985 (median follow-up of 97 months). Patients were staged with pelvic lymph node dissection and treated with retropubic 125I implantation. The actuarial distant metastases free survival (DMFS) for patients at risk at 15 years after initial therapy was 37%. Cox proportional hazard regression analysis of covariates affecting the metastatic outcome showed that local failure, used in the model as a time dependent variable, was the most significant covariate, although stage, grade, and implant volume were also found to be independent variables. The relative risk of metastatic spread subsequent to local failure was 4-fold increased compared to the risk without evidence of local relapse. The 15-year actuarial DMFS in 351 patients with local control was 77% compared to 24% in 328 patients who developed local relapses (p less than 0.00001). The relation of distant spread to the local outcome was observed regardless of stage, grade, or implant dose. Even stage B1/N0-Grade I patient with local control showed a 15-year actuarial DMFS of 82%, compared to 22% in patients with local relapse (p less than 0.00001). The median local relapse-free survival (LRFS) in the 268 patients with local recurrences who did not receive hormonal therapy before distant metastases were detected was 51 months, compared to a median of 71 months for DMFS in the same patients (p less than 0.001), consistent with the possibility that distant dissemination may develop secondary to local failure.

Fuks, Z.; Leibel, S.A.; Wallner, K.E.; Begg, C.B.; Fair, W.R.; Anderson, L.L.; Hilaris, B.S.; Whitmore, W.F. (Memorial Sloan-Kettering Cancer Center, New York, NY (USA))

1991-08-01

73

Monte Carlo calculated doses to treatment volumes and organs at risk for permanent implant lung brachytherapy  

Science.gov (United States)

Iodine-125 (125I) and Caesium-131 (131Cs) brachytherapy have been used with sublobar resection to treat stage I non-small cell lung cancer and other radionuclides, 169Yb and 103Pd, are considered for these treatments. This work investigates the dosimetry of permanent implant lung brachytherapy for a range of source energies and various implant sites in the lung. Monte Carlo calculated doses are calculated in a patient CT-derived computational phantom using the EGsnrc user-code BrachyDose. Calculations are performed for 103Pd, 125I, 131Cs seeds and 50 and 100 keV point sources for 17 implant positions. Doses to treatment volumes, ipsilateral lung, aorta, and heart are determined and compared to those determined using the TG-43 approach. Considerable variation with source energy and differences between model-based and TG-43 doses are found for both treatment volumes and organs. Doses to the heart and aorta generally increase with increasing source energy. TG-43 underestimates the dose to the heart and aorta for all implants except those nearest to these organs where the dose is overestimated. Results suggest that model-based dose calculations are crucial for selecting prescription doses, comparing clinical endpoints, and studying radiobiological effects for permanent implant lung brachytherapy.

Sutherland, J. G. H.; Furutani, K. M.; Thomson, R. M.

2013-10-01

74

[125I]Iodopride  

International Nuclear Information System (INIS)

Substituted benzamides are currently among the most selective antagonists at dopamine D-2 receptors, and high affinity ligands have been developed by substituting halogens into the aromatic ring of the benzamides. The authors report the high affinity, stereoselective, reversible, and sodium dependent binding of a new iodine-substituted benzamide, called [125I]iodopride, to a membrane preparation from rat corpus striatum. 5 refs.; 1 figure

1988-05-20

75

Tumor interventional therapy using 125I seed  

International Nuclear Information System (INIS)

Objective: To explore the feasibility, safety, and effect of interventional technology for inserting 125I seeds into tumor focus and to study the advantage or shortcome of different image equipment used in seed implantation. Methods: Fifteen cases of advanced stage tumor with metastasis and another 15 cases of advanced unresectable esophageal cancer were enrolled. Method of seed implantation was carried out by inserting 125I seeds into tumor foci through percutaneous puncture under ultrasound or CT guidance, and placed the esophageal stent binding with 125I seed to the diseased esophageal segment under DSA. Results: All 125I seeds were successfully released to the target places under ultrasound, CT and DSA guidance, except one seed was found to be lost from one esophageal 125I seed irradiated stent due to misoperation. A follow-up showed obvious improvement of clinical symptom, no significant changes of hemogram, immunity markers, and no complications including esophageal perforation, hemorrhage, and skin necrosis. No radiation seeds shedded during the releasing processes by ECT. One month follow-up by CT showed the target places were thinned in 13 cases, thickened in 2 cases. 3 cases had been followed-up for 13 months, CT revealed the obvious thinning of the foci. Three-month follow up with gastroendoscopy and biopsy demonstrated that the foci within the 125I seede binding stent placement segment resolved markedly, with no tumor cells found in biopsy for 3 of 5 cases. 15 cases by percutaneous puncture implantation had been followed-up for two months, showed the foci becoming obviously small under diagnostic imaging. Conclusions: It is feasible and safe to insert 125I seeds into tumor foci by interventional technology and the confirmed effect is favorable. (authors)

2005-12-01

76

Conformal prostate brachytherapy guided by realtime dynamic dose calculations using permanent 125iodine implants: technical description and preliminary experience  

Digital Repository Infrastructure Vision for European Research (DRIVER)

Objetive: Low dose rate (LDR) prostate brachytherapy (permanent 125I or 103Pd seeds) is an accepted treatment option for low risk prostate cancer patients. However, differences in prostate spatial location, volume and gland deformation between the images obtained during pre-planning and later on during the implant procedure prevent the pre-planned intended dose to be accurately delivered. We are reporting on a new technique based on interactive real-time dynamic intra-operative dose calculati...

2006-01-01

77

Urethral alarm probe for permanent prostate implants  

International Nuclear Information System (INIS)

We have developed a urethral dosimetry system for real time dose verification along the urethra during permanent implant prostate brachytherapy. The urethral alarm uses 'spectroscopic dosimetry' to calculate the dose rate along the urethra in real time. The application of spectroscopic dosimetry for the urethral alarm probe was verified using Monte Carlo calculations. In phantom depth dose measurements as well as isotropy measurements were performed to verify the usefulness of the urethra alarm probe as an in vivo real time dosimeter. (author)

2008-06-01

78

Quality of life after permanent prostate implant  

International Nuclear Information System (INIS)

Purpose: To report on the quality of life in patients who have received a permanent transperineal ultrasound guide prostate implant. There is increasing recognition that prostate cancer therapy impacts significantly on the patients ability to pursue relational, occupational and social interests. With the substantially expanded patient role in directing treatment for prostate cancer, the importance of examining quality of life outcomes in addition to survival has been underscored. Materials and Methods: 51 sequential patients with clinically localized prostate cancer who underwent permanent prostate implantation from September 1995 to October 1996 were evaluated. All patients were clinically staged as T1c or T2a and received implant with Iodine 125 or Palladium 103 as definitive treatment. Data was collected using the EORTC genitourinary group questionnaire and supplemental questions during an interview. Results: Urinary symptoms such as nocturia, frequency and dysuria were the most pronounced in the first two months after implant and then decreased in the majority of patients. The EORTC questionnaire was administered at 6 months and examined urinary quality, sexual quality and perception of symptoms. With regard to urinary quality, 17% had mild dysuria at 6 months and 40% noted that they urinated more frequently than pre implant. No patient had hematuria and 0 % were incontinent. 3% stated that they had occasional loss of minimal urine with severe urgency. Only 2% required intermittent self catheterization after implant secondary to obstructive symptoms. Over 90% were on an alpha blocker post implant for a minimum of 6 weeks. 0% reported psychological distress and 3% noted a disruption in social or family life. 15% experienced some fatigue and 10% noted a decreased functional status but only 1% a decreased role function. Additional questions addressed lifestyle and work issues. 100% would have an implant again as definitive treatment and 98% would recommend the procedure to a friend. Of the patients who had full time employment (38), 96% returned to work after the implant and the majority returned within 5 days. Sexual quality was high in this short follow up after seed implant. 89% of potent patients retained sexual function after implant. 3% noted some discomfort with ejaculation. 12% noticed some decrease in sexual desire. Interestingly, 14% experienced an increase in sexual desire. 79% reported an excellent overall quality of life. Conclusions: While survival is clearly a central goal of treatment for prostate cancer, the nature of this malignancy compels clinical attention to the qualitative content of the patients life after treatment. Permanent prostate implant has a high degree of patient tolerance and patient acceptance. Sexual quality and function are maintained in the majority of patients and they have minimal interruption in their social and economic function. The low morbidity and high quality of life associated with implantation make it a viable treatment option

1997-01-01

79

Study of photon angular distribution from a new Best 2300 series 125I source for interstitial brachytherapy  

International Nuclear Information System (INIS)

125I seeds employed for permanent and temporary interstitial implants exhibit significant radiation fluence anisotropy due to self absorption in the marker and oblique filtration through the encapsulation jacket. A silver wire 125I seed (Model 6711), introduced in 1983 by 3M Company, failed to improve the photon distribution anisotropy. In addition to the known 125I photon spectrum, the new seed emitted two silver characteristic x-rays, lowering the mean photon energy from 28.4 to 27.4 keV. A double wall uniform thickness encapsulated 125I source, laser welded at one end, has been developed for clinical use. The source uses a carbon coated thin tungsten filament for enhanced radiographic visualization. Measurements made by NaI and intrinsic Ge detectors indicate that the 2300 series 125I source emits a pure 125I spectrum. The angular dependence of individual photon peaks and total photon spectrum as well as the corresponding anisotropy factors were measured. The 4? averaged anisotropy factor for the total radiation fluence is 0.92 compared to 0.87 for model 6711 seed. The dose distribution around the new 125I source in water is very isotropic. (author). 11 refs., 8 figs., 2 tabs

1993-01-01

80

Model 3500 125I brachytherapy source dosimetric characterization  

International Nuclear Information System (INIS)

Low-energy gamma-emitting isotopes encapsulated for permanent implant are routinely applied in brachytherapy, most notably for prostate cancer. Before clinical use of a new source design, a full dosimetric analysis and standardized calibration are essential. Results of experimental measurement and analysis are reported here for the I-PlantTM (Implant Sciences Corporation) 125I source, model 3500. Dose measurements were made using standard methods employing thermoluminscent dosimeters in a water equivalent plastic phantom. Precision machined bores in the phantom located dosimeters and source(s) in a reproducible fixed geometry providing for transverse-axis and angular dose profiles over a range of distances from 0.17 to 10 cm. The data were analyzed in terms of parameters recommended by AAPM TG-43. The dose-rate constant, ?=1.01 cGy/h U (±6%) (1 U=1 cGy cm2 h-1), was evaluated with reference to a TG-51 calibrated 60Co standard, accounting for dosimeter response differences between 60Co and 125I photons. The radial dose function, g(r), the anisotropy function, F(r,?), the anisotropy factor, phian(r), and the point-source approximation anisotropy constant, phi-baran, were derived from one- and two-dimensional dose distribution data measured in the phantom, accounting for finite dosimeter volume and with attention to inter-chip effects. The results confirm prior dosimetric characterization of the model 3500, and indicate that the new source is comparable to the MED3631-A/M and 6702 source designs and may substitute for model 6711 in permanent implants for the treatment of prostate cancer

2002-04-01

 
 
 
 
81

Radiation protection procedures and dose to the staff in brachytherapy with permanent implant of the sources  

International Nuclear Information System (INIS)

The treatment of intra capsular prostate cancers with the permanent implantation of low energy sealed radioactive sources (''103 Pd-''125I) offers the same probability of curing the tumours as surgery and external-beam radiotherapy with a minimum incidence of unwanted side-effects. The first attempts of using sealed sources for treating prostate cancers go back to 1917, when Barringer reported the results obtained with the implant of ''236Ra needles. Beginning from that period the interest for prostate brachytherapy has shown a fluctuating trend, due especially to the technological possibilities and to the status of the alternative treatment modalities (surgery, external radiotherapy). The main reason of the substantial failure of brachytherapy as compared to the two other treatment modalities had two main causes: the energy, too high ( E? 840 keV), of ?-radiation emitted by ''226 Ra in equilibrium with its decay products and the lack of imaging techniques able to visualize with sufficient accuracy both the prostate and the arrangement, inside it, of the radioactive sources. The employ of low energy ?-emitting radionuclides began in 1974, when Whitmore et al. working at the Sloan Kettering Memorial Cancer Hospital of New York suggested the use of ''125 I sealed sources for the realisation of interstitial permanent implants. Also this attempt, though reducing the side effects typical of the surgical intervention (incontinence, impotence), did non give the expected results in terms of local control of the disease and, as a consequence, of the survival's length. This partial failure was attributed to the fact that, in most cases the dose distribution inside the target volume was not homogeneous, due to the inadequacy of the available imaging techniques used for checking the real position of the sources, during their manual insertion in the tissues. In the last ten years,however, great progresses have been made in the USimaging techniques, in the manufacture of suitable sealed sources of ''103 Pd and ''125 I, in the development of computer programs able both to acquire US-images and to calculate and display in real time the dose distribution. In selected cases, the permanent implant of such sources has demonstrated of being alternative to the surgical intervention and even to external conformal radiotherapy. (Author)

2002-01-01

82

Permanent Breast Seed Implant Dosimetry Quality Assurance  

Energy Technology Data Exchange (ETDEWEB)

Purpose: A permanent breast seed implant is a novel method of accelerated partial breast irradiation for women with early-stage breast cancer. This article presents pre- and post-implant dosimetric data, relates these data to clinical outcomes, and makes recommendations for those interested in starting a program. Methods and Materials: A total of 95 consecutive patients were accrued into one of three clinical trials after breast-conserving surgery: a Phase I/II trial (67 patients with infiltrating ductal carcinoma); a Phase II registry trial (25 patients with infiltrating ductal carcinoma); or a multi-center Phase II trial for patients with ductal carcinoma in situ (3 patients). Contouring of the planning target volume (PTV) was done on a Pinnacle workstation and dosimetry calculations, including dose-volume histograms, were done using a Variseed planning computer. Results: The mean pre-implant PTV coverage for the V{sub 90}, V{sub 100}, V{sub 150}, and V{sub 200} were as follows: 98.8% {+-} 1.2% (range, 94.5-100%); 97.3% {+-} 2.1% (range, 90.3-99.9%), 68.8% {+-} 14.3% (range, 32.7-91.5%); and 27.8% {+-} 8.6% (range, 15.1-62.3%). The effect of seed motion was characterized by post-implant dosimetry performed immediately after the implantation (same day) and at 2 months after the implantation. The mean V{sub 100} changed from 85.6% to 88.4% (p = 0.004) and the mean V{sub 200} changed from 36.2% to 48.3% (p < 0.001). Skin toxicity was associated with maximum skin dose (p = 0.014). Conclusions: Preplanning dosimetry should aim for a V{sub 90} of approximately 100%, a V{sub 100} between 95% and 100%, and a V{sub 200} between 20% and 30%, as these numbers are associated with no local recurrences to date and good patient tolerance. In general, the target volume coverage improved over the duration of the seed therapy. The maximum skin dose, defined as the average dose over the hottest 1 Multiplication-Sign 1-cm{sup 2} surface area, should be limited to 90% of the prescription dose to minimize delayed skin toxicity.

Keller, Brian M., E-mail: Brian.Keller@sunnybrook.ca [Department of Medical Physics, Sunnybrook Health Sciences Center, Toronto, ON (Canada); Department of Radiation Oncology, University of Toronto, Sunnybrook Health Sciences Center, Toronto, ON (Canada); Ravi, Ananth [Department of Medical Physics, Sunnybrook Health Sciences Center, Toronto, ON (Canada); Sankreacha, Raxa [Carlo Fidani Regional Cancer Center, Mississauga, ON (Canada); Pignol, Jean-Philippe [Department of Radiation Oncology, University of Toronto, Sunnybrook Health Sciences Center, Toronto, ON (Canada)

2012-05-01

83

Permanent implants in treatment of prostate cancer  

International Nuclear Information System (INIS)

Low-dose rate brachytherapy (LDR - BT) is one of the radiation methods that is known for several years in treatment of localized prostate cancer. The main idea of this method is to implant small radioactive seeds as a source of radiation, directly into the prostate gland. LDR brachytherapy is applied as a monotherapy and also used along with external beam radiation therapy (EBRT) as a boost. In most cases it is used as a sole radical treatment modality, however not as a palliative treatment. The application of permanent seeds implants is a curative treatment alternative in patients with organ-confined cancer, without extracapsular extension of the tumour. Nowadays three kinds of radionuclide (I-125, Pd-103, Cs-131) are in use worldwide. This technique is particular favorite in United States, in Europe however, high-dose rate brachytherapy method (HDR BT) is more popular in early staged prostate cancer treatment ( as a boost). HDR-BT monotherapy for early stage prostate cancer is still an investigational treatment. As monotherapy LDR-BT seems to be a reliable choice for early stage prostate cancer, according to low morbidity rate good results and short hospitalization. It is curative alternative of radical prostatectomy or external beam radiation (i.e. 3D CRT, IMRT) with comparable long-term survival and biochemical control and most favorable toxicity. The aim of this publication is to describe methods, indications, complications and selected results of prostate cancer LDR brachytherapy. (author)

2008-01-01

84

Image fusion techniques in permanent seed implantation  

Directory of Open Access Journals (Sweden)

Full Text Available Over the last twenty years major software and hardware developments in brachytherapy treatment planning, intraoperative navigation and dose delivery have been made. Image-guided brachytherapy has emerged as the ultimate conformal radiation therapy, allowing precise dose deposition on small volumes under direct image visualization. In thisprocess imaging plays a central role and novel imaging techniques are being developed (PET, MRI-MRS and power Doppler US imaging are among them, creating a new paradigm (dose-guided brachytherapy, where imaging is used to map the exact coordinates of the tumour cells, and to guide applicator insertion to the correct position. Each of these modalities has limitations providing all of the physical and geometric information required for the brachytherapy workflow.Therefore, image fusion can be used as a solution in order to take full advantage of the information from each modality in treatment planning, intraoperative navigation, dose delivery, verification and follow-up of interstitial irradiation.Image fusion, understood as the visualization of any morphological volume (i.e. US, CT, MRI together with an additional second morpholo gical volume (i.e. CT, MRI or functional dataset (functional MRI, SPECT, PET, is a well known method for treatment planning, verification and follow-up of interstitial irradiation. The term image fusion is used when multiple patient image datasets are registered and overlaid or merged to provide additional information. Fused images may be created from multiple images from the same imaging modality taken at different moments (multi-temporalapproach, or by combining information from multiple modalities. Quality means that the fused images should provide additional information to the brachythe rapy process (diagnosis and staging, treatment planning, intraoperative imaging, treatment delivery and follow-up that cannot be obtained in other ways. In this review I will focus on the role of image fusion for permanent seed implantation.

Alfredo Polo

2010-10-01

85

Antibiotic prophylaxis in permanent pacemaker implantation: a prospective randomised trial.  

Digital Repository Infrastructure Vision for European Research (DRIVER)

BACKGROUND--Pacemaker pocket infection is a potentially serious problem after permanent pacemaker implantation. Antibiotic prophylaxis is commonly prescribed to reduce the incidence of this complication, but current trial evidence of its efficacy is conflicting. A large prospective randomised trial was therefore performed of antibiotic prophylaxis in permanent pacemaker implantation. The intention was firstly to determine whether antibiotic prophylaxis is efficacious in these patients and sec...

Mounsey, J. P.; Griffith, M. J.; Tynan, M.; Gould, F. K.; Macdermott, A. F.; Gold, R. G.; Bexton, R. S.

1994-01-01

86

Measurment of activity of 125I seed source  

International Nuclear Information System (INIS)

For controlling the quality of the radiotherapy in which seed sources are implanted in the tissue to treat the cancer and avoiding the medical accident of exposure. 10% (5 seeds) of 50 seeds are checked and it is required that the relative deviation of apparent activity of seed sources between measured value and vendor's is within the range of 5%. The paper introduces the calibration method of 125I sources used in clinic of our hospital. The Air Kenna Rate of 125I sources is determined by the well-type ionization chamber. Thereafter the apparent activity of 125I sources is calculated and measured results are analyzed. The results show that 80% of 125I sources are up to grade. (authors)

2007-05-01

87

PSA nadir after 125I prostate brachytherapy  

International Nuclear Information System (INIS)

The purpose of this study was to evaluate the prostate-specific antigen (PSA) kinetics and nadir of PSA failure after permanent 125I prostate brachytherapy. The study included 660 patients with a potential minimum follow-up of 5 years. Patients who met the Phoenix definition of PSA failure were identified. The PSA decreased gradually to less than 0.2 ng/mL even after 5 years for many patients. The median PSA nadir was 0.09 ng/mL. Neoadjuvant hormone therapy had little effect on PSA nadir. The PSA nadir <=0.2 ng/mL or current nadir <=0.4 ng/mL seemed to be a good marker as a successful treatment. (author)

2012-06-01

88

192Ir or 125I prostate brachytherapy as a boost to external beam radiotherapy in locally advanced prostatic cancer: A dosimetric point of view  

International Nuclear Information System (INIS)

Purpose: This work aims at comparing the dosimetric possibilities of 125I or 192Ir prostate brachytherapy (Bt) as a boost to external beam radiotherapy in the treatment of locally advanced adenocarcinoma. Methods and materials: From 1/1997 to 12/2002, 260 patients were treated. Until 12/2001 a low dose rate (LDR) treatment with 192Ir wires was used, later replaced by a high dose rate (HDR) delivered with an 192Ir stepping source technology. For the present work, we selected 40 patients including the last 20 treated, respectively, by LDR and HDR. The planning CT Scans of all these 40 patients were transferred into the 3D ProwessR system for 125I permanent implants design according to the Seattle method. The reference data for dosimetric comparisons were the V100 and the prescribed dose for 192Ir as well as the dose delivered with 125I techniques to the 192Ir V100. We compared V100-150 data as well as doses to the organs at risks (OR) and cold spots (CS). Results: The V100 is 85.3±8% for 192Ir LDR and 96±2% for HDR techniques (P125I, the 192Ir LDR mode induces higher hyperdosage volumes inside the CTV but also more CS, while maximal doses to urethra and rectum are, respectively, 17 and 39% less with 125I (P192Ir HDR mode, 125I Bt induces higher hyperdosage volumes and slightly more CS deliberately planned around the bladder neck. If delivered doses to urethra are identical, those to the 20% anterior part of the rectum are 33% less with 125I (P125I Bt technique was only possible in 24 out of the 40 patients studied due to pelvic bone arch interference. Conclusions: At the present time, there is no evident dosimetric superiority of one Bt method when all the criteria are taken into account. However, improving Bt techniques to implant any prostatic size could found the superiority of the 125I or permanent implants. 125I indeed allows large hyperdosage volumes inside the CTV in comparison with 192Ir HDR techniques while lowering doses to OR and minimizing CS

2006-01-01

89

Permanent and temporary pacemaker implantation after orthotopic heart transplantation  

Scientific Electronic Library Online (English)

Full Text Available SciELO Brazil | Language: English Abstract in english PURPOSE:To determine the indication for and incidence and evolution of temporary and permanent pacemaker implantation in cardiac transplant recipients. METHODS: A retrospective review of 114 patients who underwent orthotopic heart transplantation InCor (Heart Institute USP BR) between March 1985 and [...] May 1993. We studied the incidence of and indication for temporary pacing, the relationship between pacing and rejection, the need for pemanent pacing and the clinical follow-up. RESULTS: Fourteen of 114 (12%)heart transplant recipients required temporary pacing and 4 of 114 (3.5%) patients required permanent pacing. The indication for temporary pacing was sinus node dysfunction in 11 patients (78.5%) and atrioventricular (AV) block in 3 patients (21.4%). The indication for permanent pacemaker implantation was sinus node dysfunction in 3 patients (75%) and atrioventricular (AV) block in 1 patient (25%). We observed rejection in 3 patients (21.4%) who required temporary pacing and in 2 patients (50%) who required permanent pacing. The previous use of amiodarone was observed in 10 patients (71.4%) with temporary pacing. Seven of the 14 patients (50%) died during follow-up. CONCLUSION: Sinus node dysfunction was the principal indication for temporary and permanent pacemaker implantation in cardiac transplant recipients. The need for pacing was related to worse prognosis after cardiac transplantation.

Fernando, Bacal; Edimar A., Bocchi; Marcelo L. C., Vieira; Neusa, Lopes; Luiz Felipe, Moreira; Alfredo, Fiorelli; Roberto, Costa; Martino, Martinelli; Noedir A. G., Stolf; Giovanni, Bellotti; José Antonio F., Ramires.

90

The effect of the radial function on I-125 seeds used for permanent prostate implantation  

International Nuclear Information System (INIS)

The purpose of this study was to evaluate the integrity of eight commercially-available low-activity Iodine-125 (125I) seeds for their radial function g(r) and its effect on the dose delivered to the adjacent critical structures when used in permanent prostate implants (PPI). Ten previously treated patients were retrospectively used in this comparison. The Amersham Health Oncura seed was used to peripherally design an isodose distribution with urethral and anterior rectal wall sparing. Plan criteria included minimum coverage of 144 Gy to the planning target volume (PTV), ? 70% dose to 150% of the PTV volume (V150-PTV), and the quantity of needles ? 70% of the size of the PTV, in cc. Upon completion of the Oncura plan, the seed type was changed and the activity was adjusted until the V100-PTV for each of the other 7 seed types matched the V100-PTV defined by the Oncura seed. Computed tomography (CT)-based postimplant dosimetry was used to determine the dose to 40% (D40) of the bulb of the penis (in Gy). Dose-volume histograms (DVH) were used to evaluate the differences to V100 (in %) and D40 (in Gy) of the anterior rectal wall and bulb of the penis, and V100 (in %) of the urethra. The data was tabulated. Radioactive 125I sources included in this study were 125I Source 2301 (Best); I-Plant (MedTech), IoGold (Mentor), Oncura (Amersham Health), ProstaSeed (UroCor), SelectSeed (Nucletron), SourceTech (Bard), and Symmetra (UroMed). The sizes of the PTV for the 10 patients ranged from 18.82 cc to 48.99 cc. The Oncura seed was used as the reference seed and all other seed types were normalized to it for data comparison. It was determined that the dose rate constant (xwedge) and anisotropy factor (phi) contribute to the activity needed to achieve comparable V100-PTV doses, but a strong dependence on the radial function g(r) was found to effect the doses to the critical structures studied. Values of g(r) at 4 cm were calculated and the IoGold and SourceTech seeds were determined to have the highest g(r) values, with ProstaSeed and SelectSeed having the lowest values. 125I Source 2301 and IoGold required less activity per seed to achieve the same dose to the V100-PTV due to the higher dose rate and anisotrophy constants (xwedge.phi). The seed types with silver were less penetrating and resulted in the production of characteristic x-rays that modified the energy spectrum and influenced the radial function. The seeds requiring the lowest activity showed the highest dose to the anterior rectal wall, a posterior adjacent structure; the urethra, an interior structure; and the bulb, an inferior structure. This study was designed to investigate the integrity of eight different commercially-available seed types, and their dependence on the g(r) in seed choice. It was determined that the dose rate constant and anisotropy factor determine the activity needed for implantation but a strong dependence on the radial function was found to effect the doses to the adjacent structures

2004-01-01

91

Preparation of 125I-lipiodol  

International Nuclear Information System (INIS)

An isotopic exchange method has been used to label lipiodol with 125I. The labelling efficiency is more than 92% in the optimum condition (using ethanol as reaction medium, 100 degree C, 20 min) and the radiochemical purity of 125I-lipiodol is above 98% as determined by TLC and HPLC. The labelling process does not change the chemical structure of lipiodol. The 125I-lipiodol is stable at least in one month at room temperature

1995-05-01

92

Permanent and temporary pacemaker implantation after orthotopic heart transplantation  

Digital Repository Infrastructure Vision for European Research (DRIVER)

PURPOSE:To determine the indication for and incidence and evolution of temporary and permanent pacemaker implantation in cardiac transplant recipients. METHODS: A retrospective review of 114 patients who underwent orthotopic heart transplantation InCor (Heart Institute USP BR) between March 1985 and May 1993. We studied the incidence of and indication for temporary pacing, the relationship between pacing and rejection, the need for pemanent pacing and the clinical follow-up. RESULTS: Fourteen...

2000-01-01

93

PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure  

International Nuclear Information System (INIS)

Purpose. To assess the frequency of the PSA 'bouncing' phenomenon after a significant follow-up in a series of patients treated by j permanent implant brachytherapy for a prostate cancer. To look for the clinical and dosimetric parameters possibly linked to this transitory secondary PSA increase. To evaluate in which percentage of cases this bouncing could have mimicked a biochemical relapse according to the ASTRO consensus criteria. Patients and methods. From January 1999, to December 2001, 295 patients were treated by a permanent prostate implantation (real-time technique, with free 125I seeds- Isoseed Bebig-) by the Institut Curie-Hopital Cochin-Hopital Necker Paris group. The mean follow-up is 40.3 months (9--66 months). The PSA level was regularly checked, at least every 6 months. We defined as a 'bouncing' all increase in PSA, starting at 0.1 ng/ml, subsequently followed by a spontaneous (without any treatment) decrease, with return to the previous level or lower. We particularly focused on the patients fulfilling the criteria for a biochemical relapse according to the ASTRO consensus (Three successive increases in PSA). A multivariate analysis tried to identify independent factors among the usual clinical and dosimetric parameters. Results. In our series, 161 patients (55%) showed a transitory PSA increase (bouncing) of at least 0.1 ng/ml; 145 patients (49%) a bouncing of 0.2 ng/ml, 93 patients (32%) a bouncing of 0.4 ng/ml and 43 patients (15%) a bouncing of at least 1 ng/ml. Mean PSA bounce was 0.8 ng/ml (0.1 .1), and mean time to bounce was 19 months. Thirty-two patients (11% of the total number) presented three successive PSA increases with a significant (3 months) interval between the dosages, and therefore were to be considered as being in biochemical relapse according to the ASTRO consensus criteria. Actually, among those 32 patients, 18 (56%) subsequently showed a complete normalization of their PSA, without any treatment. Ten patients went on increasing their PSA, and were considered to be really in biochemical relapse. For the last 4 patients, the situation still remains ambiguous. In multivariate analysis, age 200 Gy (P 200 Gy were found to be independent factors predicting for such a secondary transitory increase in PSA. Interestingly, among 32 patients fulfilling the classical criteria of the ASTRO for a biochemical relapse, 18 (560/0) subsequently showed a spontaneous PSA decrease, demonstrating that the ASTRO consensus is not well adapted to the biochemical follow-up of our patients undergoing permanent implant prostate Brachytherapy. (authors)

2007-05-01

94

The determination of radiobiologically optimized half-lives for radionuclides used in permanent brachytherapy implants  

International Nuclear Information System (INIS)

Purpose: To use tumor growth kinetics and other biologic parameters in an extended version of the linear-quadratic (LQ) formulation to determine radiobiologically optimized half-lives of radionuclides which might be used in permanent brachytherapy implants. Methods and Materials: A version of the LQ model suitable for the analysis of permanent brachytherapy implants has been modified to investigate the radionuclide half-lives that will maximize the biologically effective dose (BED) delivered to tumors with repopulation rates (K values) in the range 0.01-1.1 Gyday-1. The method assumes that part of the physical dose delivered to the tumor may be radiobiologically wasted because of the repopulation phenomenon, whereas adjacent normal tissues will exhibit little or no wastage. To perform the analysis, it is necessary to stipulate ?/? ratios and sublethal damage recovery rates together with the normal tissue tolerance BED. The analysis also takes into account a range of likely relative biological effectiveness (RBE) values. Results: Rapidly growing tumors require the shortest radionuclide half-lives, but even slow-growing tumors such as prostate adenocarcinomas can be satisfactorily treated with radionuclides possessing half-lives substantially less than that associated with I125. The likelihood that prostate tumors possess an ?/? value which is comparable with, or lower than, that associated with late-responding normal tissues would also mitigate against the use of long-lived radionuclides. Although a number of parameter assumptions are involved, the results suggest that, for a wide range of tumor types, shorter-lived radionuclides are more versatile for achieving reasonable clinical results. The theoretically derived optimum half-lives typically range from around 0-5 days for fast-repopulating tumors (K 1.1 Gyday-1) to approximately 14-50 days for slow-growing tumors (K ? 0.1 Gyday-1 or less). For prostate implantation, 103Pd is overall a better choice than 125I. Conclusion: With so many variables and parameter uncertainties, it is not appropriate to attempt to define optimum radionuclide half-lives too closely. However, this study suggests that half-lives in the approximate range 4-17 days are likely to be significantly better for a wide range of tumor types for which the radiobiologic characteristics may not be precisely known in advance

2003-02-01

95

Local nuclear orientation of 125I in tin and graphite using defect induced electric field gradients  

International Nuclear Information System (INIS)

Defect-induced field electric field gradients, generated by ion implantation of 125I in ?- and ?-Sn and in graphite, were used to obtain local nuclear orientation at low temperatures. The resulting nuclear orientation at the parent 125I state was detected by 125Te Moessbauer spectroscopy. From the measured nuclear quadrupole interaction strengths at the parent state, the electric field gradient and the cooling behavior of implanted atoms were studied. (orig.)

1990-08-01

96

Tumor therapy with 125I-octreotide and 125I-UdR  

International Nuclear Information System (INIS)

Purpose: To determine the tumor cell damage effect with Auger-electron emitter 125I in different chemical states. Methods: (1) [Tyr3] octreotide (TOC) and UdR are labeled with 125I,respectively. (2) Receptor analysis of 125I-TOC on small cell lung cancer (SCLC) NCI-H446 cell lines is performed comparing with normal lymph cells. NCI-H446 cells added various dose of 125I-TOC are incubated for different time with 125I-Nal and non-labeled TOC as control. The capacity of NCI-H446 cell lines bound and internalization of 125I TOC are determined. The radiation damage of tumor cells is measured by MTF methods. (3) The killing effects of 125I-UdR in human pancreatic cancer cell line Bax-Pc and Sca-BER bladder carcinoma cells are evaluated with the similar methods. I-UdR penetrating into the Sca-BER cell nucleus is observed with confocal microscope. The grow suppression and clonogenic formation of Sca-BER cells after incubation with 125I-UdR are analyzed. Proliferation fraction and S phase cell fraction of Sca-BER cell added 125I-UdR is measured with flow cytometric analysis. Results: (1) Kd=(0.56?2.0) x 10-11 mol/L and Bmax=(1.17?2.0) x 105 cell site are obtained by receptor analysis of 125I-TOC on NCI-H446 cells. Comparatively, the difference between total binding and non-specific binding is low and there is no saturation of specific binding for normal lymphocyte. About 50% of 125I-TOC is internalized into the NCI-H446 cell nucleus at 24h after incubation. The damige of NCI-H446 cells by 125I-TOC is clearly observed. (2) The penetration amount of 125I-UdR into cell nucleus increases with the incubate time when the concentration of 125I-UdR is in the range of 10?500 kBq/mL and reaches the peak fraction of 94% at 36 h after incubation. The radioactivity of 125I-UdR is then achieved equelibration and no more increased with time. The linear correlation with ?=0.867?0.978 between the concentration of 125I-UdR in cell nucleus and the incubation time is observed before reaching peak value. As a control, very low radioactivities in cells and in neucleus are measured in Na 125I case. Incubating for 36 h, the amount of 125I-UdR entering into the cells and nucleus are 1000 times more than that with Na 125I. The 125I-UdR killing effect of 100 kBq to Bax-Pc cells is 60 times more than Na 125I after 36 h incubation. The Sca-BER bladder carcinoma cells growth cycle in the treatment group with 125I-UdR is suppressed and clonogenic formation is lower in experimental group than in control group. Proliferation fraction and S phase cell fraction decrease and apoptosis fraction increase with 125I-UdR treatment time. The results of confocal microscope shows the Sca-BER cells of treatment group at 48h after administration are entirely broken. Conclusion: 125I-TOC has a better specificity to the somatostatin positive tumors. 125I-UdR is a cell cycle dependent agent. It can be incorporated into DNA of Bax-Pc cells and can selectively kill tumor cells in S phase. Both 125I-TOC and 125I-UdR are more effective for killing tumor cells than Na 125I.

2005-10-17

97

The effect of seed anisotropy on brachytherapy dose distributions using 125I and 103Pd  

International Nuclear Information System (INIS)

We have evaluated the effect of the anisotropy of individual seeds on dose distributions for permanent prostate implants using 125I and 103Pd. The dose distributions were calculated for various implants using both the line source and point source calculational formalisms, for two different models of 125I and 103Pd seeds. The dose distributions were compared using cumulative dose volume histograms (DVH) and cumulative difference dose volume histograms (?DVH) for the prostate target volume and for the rectum surface. The DVHs could not distinguish between the dose distributions from isotropic and non-isotropic seeds. However, the ?DVHs were useful in determining the fraction of the target volume for which the difference between the dose distribution for line sources and for point sources exceeded a threshold value. The dose distributions were calculated (1) for all the seeds oriented co-linearly, along either the x-, y-, or z-axis, and (2) for the seeds at randomized orientations, more closely resembling the clinical situation. For all cases, there was a significant difference in the effect of seed anisotropy from the different seed types. For the geometrically simpler test cases with a small number of seeds, the effect of anisotropy on the dose distribution was too large to ignore for any of the seed types investigated. For the idealized pre-plan case, the effect was much smaller. For clinical prostate implants, the calculations done with seeds oriented co-linearly along the z-axis (needle implant axis) were a reasonable approximation for those from simulations of seeds with randomized orientations. Again, the effect of anisotropy varied drastically between different seed models, and also between different clinical cases. However, the effect of anisotropy must be considered in the context of all the other uncertainties in clinical brachytherapy treatments

2001-03-01

98

Routine chest radiography after permanent pacemaker implantation: Is it necessary?  

Directory of Open Access Journals (Sweden)

Full Text Available Background and Aims: Chest radiographs (CXRs are performed routinely after permanent pacemaker implantation to identify pacemaker lead position and exclude pneumothorax. We assessed the clinical value and need for this procedure. Design: Retrospective analysis of pacemaker data and CXRs following permanent pacemaker insertion between December 2002 and February 2004. Materials and Methods: Post-procedural CXRs were available in 125/126 consecutive patients after either first endocardial pacemaker implantation or insertion of at least one new lead. Subclavian vein puncture was used for venous access in all cases. CXRs were examined to establish the incidence of pneumothorax and assess pacing lead positions. The clinical records were examined in all patients who had subsequent CXRs or a further pacemaker procedure to identify the indication for these and to establish whether CXR had influenced patient management. Results: In total, 192 post-procedural CXRs were performed, either postero-anterior (PA and/or lateral views. Ventricular and/or atrial pacing lead contour and electrode position was considered radiographically appropriate in 86% CXRs. Fourteen per cent of post-procedural radiographs were considered to have radiologically sub-optimal pacemaker lead positioning. None of the patients with these "abnormal" radiographs experienced subsequent pacemaker complications or had further radiographs recorded at a later date. Later repeat CXRs were performed in 16 patients (13% but only 3 patients (2% had pacing abnormalities as the primary indication. All three had satisfactory pacing lead position on initial post-implantation and later radiographs, but required further procedures for lead re-positioning. Iatrogenic pneumothorax occurred in one patient (incidence 0.8% in our series. CXR confirmed the clinical diagnosis and allowed an assessment of size to guide treatment. Conclusion: Routine CXR after permanent pacemaker insertion is not necessary in uncomplicated cases with adequate pacing characteristics.

Edwards N

2005-01-01

99

Inverse planning optimization for hybrid prostate permanent-seed implant brachytherapy plans using two source strengths.  

Science.gov (United States)

The purpose is to demonstrate the ability to generate clinically acceptable prostate permanent seed implant plans using two seed types which are identical except for their activity. The IPSA inverse planning algorithms were modified to include multiple dose matrices for the calculation of dose from different sources, and a selection algorithm was implemented to allow for the swapping of source type at any given source position. Five previously treated patients with a range of prostate volumes from 20-48 cm3 were re-optimized under two hybrid scenarios: (1) using 0.32 and 0.51 mGy m2 / h 125I, and (2) using 0.64 and 0.76 mGy m2 / h 125I. Isodose lines were generated and dosimetric indices , V150Prostate, D90Prostate, V150Urethra, V125Urethra, V120Urethra,V100Urethra, and D10Urethra were calculated. The algorithm allows for the generation of single-isotope, multi-activity hybrid brachytherapy plans. By dealing with only one radionuclide, but of different activity, the biology is unchanged from a standard plan. All V100Prostate were within 2.3 percentage points for every plan and always above the clinically desirable 95%. All V150Urethra were identically zero, and V120Urethra is always below the clinically acceptable value of 1.0 cm3. Clinical optimization times for the hybrid plans are still under one minute, for most cases. It is possible to generate clinically advantageous brachytherapy plans (i.e. obtain the same quality dose distribution as a standard single-activity plan) while incorporating leftover seeds from a previous patient treatment. This method will allow a clinic to continue to provide excellent patient care, but at a reduced cost. Multi-activity hybrid plans were equal in quality (as measured by the standard dosimetric indices) to plans with seeds of a single activity. Despite the expanded search space, optimization times for these studies were still under two minutes on a modern day laptop and can be reduced to below one minute in a clinical setting. With the typical cost of a set of PPI seeds on the order of thousands of dollars, it is possible to reduce the cost of brachytherapy treatments by allowing for easier use of seeds left over from a previous patient or unused due to a cancelled treatment. PMID:20717078

Cunha, J Adam M; Pickett, Barby; Pouliot, Jean

2010-01-01

100

Urethral dose and increment of international prostate symptom score (IPSS) in transperineal permanent interstitial implant (TPI) of prostate cancer  

Energy Technology Data Exchange (ETDEWEB)

Purpose: to find the factors which influence the acute increment of international prostate symptom score (IPSS) after transperineal permanent interstitial implant (TPI) using {sup 125}I seeds. Patients and methods: from April 2004 through September 2006, 104 patients with nonmetastatic prostate cancer underwent TPI without external-beam irradiation. Median patient age was 70 years with a median follow-up of 13.0 months. 73 patients (70%) received neoadjuvant hormone therapy. The increment of IPSS was defined as the difference between pre- and postimplant maximal IPSS. Clinical, treatment, and dosimetric parameters evaluated included age, initial prostate-specific antigen, Gleason Score, neoadjuvant hormone therapy, initial IPSS, post-TPI prostatic volume, number of implanted seeds, prostate V{sub 100}, V{sub 150}, D{sub 90}, urethral D{sub max}, and urethral D{sub 90}. In order to further evaluate detailed urethral doses, the base and apical urethra were defined and the dosimetric parameters were calculated. Results: the IPSS peaked 3 months after TPI and returned to baseline at 12-15 months. Multivariate analysis demonstrated a statistically significant correlation of post-TPI prostatic volume, number of implanted seeds, and the dosimetric parameters of the base urethra with IPSS increment. Conclusion: the base urethra appears to be susceptible to radiation and the increased dose to this region deteriorates IPSS. It remains unclear whether the base urethral dose relates to the incidence of late urinary morbidities. (orig.)

Murakami, N.; Itami, J. [Dept. of Radiation Therapy and Oncology, International Medical Center of Japan, Tokyo (Japan); Div. of Radiation Therapy, National Cancer Center Hospital, Tokyo (Japan); Okuma, K.; Marino, H.; Ban, T.; Nakazato, M.; Kanai, K.; Naoi, K.; Fuse, M. [Dept. of Radiation Therapy and Oncology, International Medical Center of Japan, Tokyo (Japan); Nakagawa, K. [Dept. of Radiology, School of Medicine, Tokyo Univ. (Japan)

2008-10-15

 
 
 
 
101

Urethral dose and increment of international prostate symptom score (IPSS) in transperineal permanent interstitial implant (TPI) of prostate cancer  

International Nuclear Information System (INIS)

Purpose: to find the factors which influence the acute increment of international prostate symptom score (IPSS) after transperineal permanent interstitial implant (TPI) using 125I seeds. Patients and methods: from April 2004 through September 2006, 104 patients with nonmetastatic prostate cancer underwent TPI without external-beam irradiation. Median patient age was 70 years with a median follow-up of 13.0 months. 73 patients (70%) received neoadjuvant hormone therapy. The increment of IPSS was defined as the difference between pre- and postimplant maximal IPSS. Clinical, treatment, and dosimetric parameters evaluated included age, initial prostate-specific antigen, Gleason Score, neoadjuvant hormone therapy, initial IPSS, post-TPI prostatic volume, number of implanted seeds, prostate V100, V150, D90, urethral Dmax, and urethral D90. In order to further evaluate detailed urethral doses, the base and apical urethra were defined and the dosimetric parameters were calculated. Results: the IPSS peaked 3 months after TPI and returned to baseline at 12-15 months. Multivariate analysis demonstrated a statistically significant correlation of post-TPI prostatic volume, number of implanted seeds, and the dosimetric parameters of the base urethra with IPSS increment. Conclusion: the base urethra appears to be susceptible to radiation and the increased dose to this region deteriorates IPSS. It remains unclear whether the base urethral dose relates to the incidence of late urinary morbidities. (orig.)

2008-10-01

102

Temporary and Permanent Inferior Vena Cava Filter Combination in a Young Patient: To Implant or Not to Implant?  

International Nuclear Information System (INIS)

The decision to implant vena cava filters, either temporary or permanent, is difficult in young patients. We present the case of a young man with pulmonary embolism in whom temporary and permanent inferior vena cava filters were implanted. The decision process is discussed in relation to the current literature

2003-09-01

103

Rectal injury during permanent seed implantation for prostate brachytherapy  

International Nuclear Information System (INIS)

Serious complications have not been previously reported during seed implantation for prostate brachytherapy. We present an unreported case of rectal injury caused by an ultrasound probe. A 67-year-old male presented with a serum prostate-specific antigen level of 5.50 ng/ml, a Gleason score of 7 (3+4) and clinical T2a adenocarcinoma of the prostate. A transperineal permanent prostate brachytherapy implantation was performed. The patient subsequently complained of abdominal pain postoperatively. A gastrointestinal perforation was suspected based on an abdominal X-ray obtained on the day after the brachytherapy. Rectal injury was recognized during an exploratory laparotomy, and a primary closure and temporary diversion ileostomy were performed. The healing of the injury was confirmed by colonoscopy and an ileostomy closure was performed 2 months after the temporary diversion. The investigating committee for this accident concluded that the ultrasound probe had perforated the rectum. This is the first case of a rectal injury during seed implantation for prostate brachytherapy. (author)

2012-12-01

104

Impact of interseed attenuation and tissue composition for permanent prostate implants  

International Nuclear Information System (INIS)

The purpose is to evaluate the impact of interseed attenuation and prostate composition for prostate treatment plans with 125I permanent seed implants using the Monte Carlo (MC) method. The effect of seed density (number of seeds per prostate unit volume) is specifically investigated. The study focuses on treatment plans that were generated for clinical cases. For each plan, four different dose calculation techniques are compared: TG-43 based calculation, superposition MC, full MC with water prostate, and full MC with realistic prostate tissue. The prostate tissue description is from the ICRP report 23 (W. S. Snyer, M. J. Cook, E. S. Nasset, L. R. Karkhausen, G. P. Howells, and I. H. Tipton, ''Report of the task group on reference man,'' Technical Report 23, International Commission on Radiological Protection, 1974). According to the comparisons, the seed density has an influence on interseed attenuation. A plan with a typical low seed density (42 0.6 mCi seeds in a 26 cm3 prostate) suffers a 1.2% drop in the CTV D90 value due to interseed attenuation. A drop of 3.0% is calculated for a higher seed density (75 0.3 mCi seeds, same prostate). The influence of the prostate composition is similar for all seed densities and prostate sizes. The difference between MC simulations in water and MC simulations in prostate tissue is between 4.4% and 4.8% for the D90 parameter. Overall, the effect on D90 is ranging from 5.8% to 12.8% when comparing clinically approved TG-43 and MC simulations in prostate tissue. The impact varies from one patient to the other and depends on the prostate size and the number of seeds. This effect can reach a significant level when reporting correlations between clinical effect and deposited dose

2006-03-01

105

Two-dimensional dose distribution of 125I seeds  

International Nuclear Information System (INIS)

Two-dimensional dose distribution has been measured for the new (model 6711) 125I seeds used in interstitial implants. Two independent methods, using a silicon diode or thermoluminescent dosimeters, yielded identical results. At any given distance r from the seed center, the dose varies with theta, the angle relative to the seed's axis. Similarly, the r dependence of the dose distribution is different at various theta values. These observations can be qualitatively understood in terms of several factors, namely, source encapsulation, geometrical relationship, and attenuation and scatter. Empirical expressions which approximate the measured results have been developed to facilitate clinical dose distribution calculations

1985-01-01

106

125I in Britain's drinking water supply  

International Nuclear Information System (INIS)

125I has been measured in Britain's fresh water environment using a rapid ion exchange method with X-ray fluorescence to estimate yield. Non-detectable or low levels were found in most rivers throughout England with persistent amounts in the Trent, Cam and Thames (range 1-100 mBq litre-1). The Thames Valley has been particularly studied as the river supplies much of the drinking water in the London and Oxford areas. The activity originates in waste discharged by product manufacturers and users of 125I into the sewage system, mainly in the south-east of England. Occasionally a coherent 125I peak has been followed from discharge through the waterways to tap water. Activity has been found wherever the Thames or the Lee is used in drinking water, values found range from 1 to 86 mBq litre-1 with a mean of 5-10 mBq litre-1. Low levels of 125I occur in the thyroid glands of people drinking this water but the consequent radiation dose is very low and only a very tiny fraction of that due to natural background. (author)

1992-01-01

107

The absolute counting of {sup 125}I  

Energy Technology Data Exchange (ETDEWEB)

The Institute of Nuclear Energy Research (INER) participated in a comparison of activity organized by the Electrotechnical Laboratory (ETL, Japan). At this occasion, {sup 125}I was measured. Seven laboratories of the Asia Pacific region carried out measurements and ETL, at the same time, took part in BIPM SIR measurements. Two measurement methods developed by INER, the sum-peak coincidence counting with two 76x76 mm NaI(Tl) detectors and the 4{pi}e-X coincidence counting technique with efficiency extrapolation, were used to standardize the activity of {sup 125}I. The results from the two methods are 2.6% different. INER's results agree with the results of the regional comparison and the BIPM SIR.

Yuan, M.-C. E-mail: mcyuan@iner.gov.tw; Hwang, W.-C

2000-03-01

108

Combination of multi-disciplinary techniques with 125I seeds in treating malignant obstructive jaundice  

International Nuclear Information System (INIS)

Objective: To explore the effectiveness and safety of the combined multi-disciplinary techniques with 125I seeds to treat the malignant obstructive jaundice. Methods: 18 cases:of malignant obstructive jaundice were divided into 2 groups. A group with ERBD technique followed by CT-guided interstitial 125I seeds implantation, B group with 125I seeds implantation during the operation and gallbladder-intestine anastomosis later on. After 2 months amelioration (CR, PR,SD, PD) of the obstructive jaundice was observed with inspection of liver functions. Results: All cases were ameliorated with 44% patients in group A and 56% patients in group B, showing no significant statistical difference (P>0.05); and the liver functions were also relieved in both groups with no statistical significance (P>0.05). Conclusion: Multi-disciplinary techniques combined with 125I seeds implantation is effective in the management of the malignant obstructive jaundice. No significant difference for relief and liver function were found between CT-guided and during operation interstitial 125I seeds implantations, but it seems more quickly relief or recovery was achieved in the latter. (authors)

2008-05-01

109

Edema-induced changes in tumor cell surviving fraction and tumor control probability in 131Cs permanent prostate brachytherapy implant patients.  

Science.gov (United States)

The study is designed to investigate the effect of edema on the delivered dose, tumor cell surviving fraction (SF), and tumor control probability (TCP) in the patients of prostate cancer who underwent (131)Cs permanent seed implantation. The dose reduction, the SF, and the TCP for edematous prostate implants were calculated for 31 patients who underwent real-time (131)Cs permanent seed implantation for edema half-lives (EHL), ranging from 4 days to 34 days and for edema magnitudes (M0) varying from 5% to 60% of the actual prostate volume. A dose reduction in (131)Cs implants varied from 1.1% (for EHL = 4 days and M(0) = 5%) to 32.3% (for EHL = 34 days and M(0) = 60%). These are higher than the dose reduction in 125I implants, which vary from 0.3% (for EHL = 4 days and M(0) = 5%) to 17.5% (for EHL = 34 days and M(0) = 60%). As EHL increased from 4 days to 34 days and edema magnitude increased from 5% to 60%, the natural logarithmic value of SF increased by 4.57 and the TCP decreased by 0.80. Edema induced increase in the SF and decrease in the TCP in (131)Cs seed implants, is significantly more pronounced in a combination of higher edema magnitude and larger edema half-lives than for less edema magnitude and lower edema half-lives, as compared for M(0) = 60% and EHL = 34, and M(0) = 5% and EHL = 4 days. PMID:23318378

Kehwar, Than S; Jones, Heather A; Huq, M Saiful; Smith, Ryan P

2013-01-01

110

Quality indicators for permanent I-125 prostate seed implants : seven years post implant dosimetry evaluation  

International Nuclear Information System (INIS)

Full text: The aim of the current work is to assess the progress of prostate implant quality via post implant dosimetry over a 7-year time period. The roles of post implant dosimetry (PID) after permanent 1-125 implant are to: identify suboptimal implants; assess the dosimetric quality indicators and evaluate dose to organs at risk. The 7-years PID learning-curve shows clear changes in dosimetric trend. Beside the expected improvement in technique the following factors were investigated: the replacement of the computed tomography (CT)-delineation based PID with ultrasound (US)-CT fusion based, and the evolution and influence of parameters such as 090 and V I 00. The correlation between dosimetric parameters and clinical outcome was also evaluated. Results A study on 30 patients showed manual target contouring on CT tends to overestimate the prostate volume when compared to ultrasound data (mean difference 38.3%), translating to CT based D90 values being lower than US-CT D90 by an average of 6%. There was 4.7% patient relapse and urinary retention was reported in 2.7% of the patients. CT-based PID was found less reliable than US-CT fusion due to target overestimation. This result shows the biased interpretation of low D90 based on CT targeting and may not relate to patient relapse data. The low urinary retention statistics are in accordance with the PID data for the organ, as only 5.2% of patients had their PID D I 0 >218 Gy, i.e. above recommended GEC-ESTRO guidelines. Besides the 'learning' component, the 7-years PID D90 curve is influenced by PID technique.

2011-08-14

111

Current prospects for 125I in tumour therapy  

International Nuclear Information System (INIS)

To evaluate 125I as a tool in tumour therapy, microdosimetric data, results from animal experiments and information obtained from clinical applications are presented. Numbers and energies of electrons and photons emitted were calculated to determine the energy deposition in critical biological targets (spheres of 20 nm diameter) after incorporation of 125IUdR. The total energy deposited per decay includes the energy imparted to Auger electrons (0.96 keV) and the ionization potential (1.07 keV) which is built up in consequence of the electron cascade. The latter will be locally absorbed. Thus, 125I acts like a high-LET radiator. In animal experiments tumour bearing mice were continuously injected intravenously with cold IUdR and 125IUdR. Tumour regression improved from 10% for the controls to 25% after infusion of 2x10-4mol/L IUdR and to 31% after infusion of 200 ?Ci of 125IUdR per mouse, respectively. In clinical applications two patients with advanced squamous carcinomas of the tongue and buccal cavity were locally intra-arterially perfused with 125IUdR. To the first patient 50 ?Ci 125IUdR were administered via the arteria lingualis every 12 h followed at day 12 by 500 ?Ci 125IUdR per 12 h period. In the second patient 'interport' catheters were implanted in the arteria carotis externa. Twenty-five ?Ci were infused 10-18 h daily for 44 days, to a total of 1080 ?Ci. Retained activities remained below the expected levels in both patients and the treatments were discontinued. To render more promising the application of 125I in tumour therapy it appears necessary to specifically augment 125IUdR uptake in tumour DNA. (author)

1986-09-01

112

78 FR 41125 - Interim Enforcement Policy for Permanent Implant Brachytherapy Medical Event Reporting  

Science.gov (United States)

...Policy for Permanent Implant Brachytherapy Medical Event Reporting AGENCY: Nuclear Regulatory...violations of regulations for reporting medical events occurring under an NRC licensee's...In SECY-05-0234, ``Adequacy of Medical Event Definitions in 10 CFR [Title...

2013-07-09

113

Sexual function after permanent seed implant prostate brachytherapy  

International Nuclear Information System (INIS)

The aim of this study was to evaluate the long-term effects of permanent seed implant prostate brachytherapy (BT) on sexual function (SF). From September 2003 to July 2005, 56 patients underwent radical retropubic prostatectomy (RRP) without any hormone therapy, while 353 patients had undergone BT without any adjuvant hormone therapy in a single institute. Out of these 353 patients in the BT group, 305 patients received neoadjuvant hormone therapy (BT NHT + group), while 48 did not (BT NHT - group). SF was prospectively evaluated using the UCLA Prostate Cancer Index (UCLA-PCI). Potency was defined as the UCLA-PCI Q26 point of ?3. The preimplant UCLA-PCI scores of SF for BT NHT - and BT NHT + groups were 50.9 and 13.4, respectively. The SF score of the NHT - group post operatively decreased to 38.9 within 6 months, but was maintained at the same level after that. With the recovery of the androgen, SF score of the NHT + group improved after BT: however, it did not reach up to that of the NHT - group. In the univariate analysis, patient's age was the only predictive factor for SF after BT. Thirty-four out of 48 patients in the BT NHT - group and 23 out of 56 patients in the RRP group showed adequate potency before surgery. Their 5-year potency preservation rate was 73.6% in the BT NHT - group and 4.3% in the RRP group. SF slightly decreased immediately after BT but was usually maintained during the course observation for 5 years. The 5-year SF preservation rate after BT was 73.6%. (author)

2012-07-01

114

Radioimmunoassay for motilin. [/sup 125/I  

Energy Technology Data Exchange (ETDEWEB)

A specific radioimmunoassay for motilin has been developed with the use of antisera to porcine motilin raised in guinea pigs. Highly purified /sup 125/I-motilin was used as the tracer and the sensitivity range was 10 to 320 pg. No cross-reactivity was demonstrated with gastric inhibitory polypeptide, secretin, glucagon, gastrin, cholecystokininpancreozymin, or vasoactive intestinal peptide. In dogs with denervated pouches of the fundus of the stomach and Mann-Bollman fistulae, duodenal alkalinization resulted in an increase in gastric motor activity in the fundic pouch with a corresponding increase in serum motilin.

Dryburgh, J.R.; Brown, J.C.

1975-01-01

115

Electrophoretic purification of 125I-gliadin  

International Nuclear Information System (INIS)

A sensitive RIA technique is introduced for the estimation of gliadins in foodstuffs allowing the detection of less than 1 mg gliadin per kg of food. 125I-gliadin succinylated is used as a tracer after purification by electrophoresis in polyacrylamide gel. The method can be used for an effective control of gluten-free foods. False positive results cannot be excluded completely, since interfering factors are extracted together with the gliadins from the sample material. Vegetable lectins are discussed as the most probable interfering factors. (author)

1988-01-01

116

Radiotoxicity of intranuclear 125I atoms not bound to DNA  

International Nuclear Information System (INIS)

The radiotoxicity of 125I covalently bound to DNA is unusually high. This has been attributed both to the Auger electrons which result from the electron capture process accompanying 125I decay and to local transmutation effects which cause extensive damage to nearby structures. 125I was introduced into cell nuclei in the form of iodoantipyrine, a molecule which diffuses freely through cells, compared the survival of these cells to those exposed to radiation from extracellular 125I-labelled albumin or 55Fe-labelled transferrin. A value for D0 of 34 rad for 125I decays occurring within the cell nucleus was found compared to 362 rad for extracellular 125I and 277 rad for extracellular 55Fe. Since transmutation effects are very short range and 125I was distributed uniformly throughout the nucleus rather than bound to DNA, most of the radiotoxicity of intranuclear 125I-labelled iodoantipyrine must be due to Auger electrons. (author)

1980-01-01

117

Permanent cardiac pacemakers implanted in the pleural space.  

Science.gov (United States)

Intrapleural implantation is recommended for children, active adolescents and adults, psychiatric patients, and infection-prone patients because of the protection afforded by the pleural space. The implantation technique is briefly described. Complications include diaphragmatic muscle stimulation (with a unipolar unit) and continuous migration of the pulse generator. The advantages of this implantation site include the following (1) reduced risk of lead fracture, (2) protection from physical trauma, (3) reduced risk of infection and erosion. (4) improved cosmetic appearance, and (5) minimized child/generator size disproportion. In one groups of patients undergoing both standard and intrapleural implantation, the number of pacing months per surgical procedure was increased from 5.1 months (standard implant) to 26.2 months (intrapleural implant). Intrapleural implantation may be considered the generator position of choice for the small percentage of patients who require special pacing system protection. PMID:661358

Lynch, M F; Jensen, N K; Urdaneta, L

1978-07-01

118

Continuous and low-energy 125I seed irradiation changes DNA methyltransferases expression patterns and inhibits pancreatic cancer tumor growth  

Directory of Open Access Journals (Sweden)

Full Text Available Abstract Background Iodine 125 (125I seed irradiation is an effective treatment for unresectable pancreatic cancers. However, the radiobiological mechanisms underlying brachytherapy remain unclear. Therefore, we investigated the influence of continuous and low-energy 125I irradiation on apoptosis, expression of DNA methyltransferases (DNMTs and cell growth in pancreatic cancers. Materials and methods For in vitro 125I seed irradiation, SW-1990 cells were divided into three groups: control (0 Gy, 2 Gy, and 4 Gy. To create an animal model of pancreatic cancer, the SW 1990 cells were surgically implanted into the mouse pancreas. At 10 d post-implantation, the 30 mice with pancreatic cancer underwent 125I seed implantation and were separated into three groups: 0 Gy, 2 Gy, and 4 Gy group. At 48 or 72 h after irradiation, apoptosis was detected by flow cytometry; changes in DNMTs mRNA and protein expression were assessed by real-time PCR and western blotting analysis, respectively. At 28 d after 125I seed implantation, in vivo apoptosis was evaluated with TUNEL staining, while DNMTs protein expression was detected with immunohistochemical staining. The tumor volume was measured 0 and 28 d after 125I seed implantation. Results 125I seed irradiation induced significant apoptosis, especially at 4 Gy. DNMT1 and DNMT3b mRNA and protein expression were substantially higher in the 2 Gy group than in the control group. Conversely, the 4 Gy cell group exhibited significantly decreased DNMT3b mRNA and protein expression relative to the control group. There were substantially more TUNEL positive in the 125I seed implantation treatment group than in the control group, especially at 4 Gy. The 4 Gy seed implantation group showed weaker staining for DNMT1 and DNMT3b protein relative to the control group. Consequently, 125I seed implantation inhibited cancer growth and reduced cancer volume. Conclusion 125I seed implantation kills pancreatic cancer cells, especially at 4 Gy. 125I-induced apoptosis and changes in DNMT1 and DNMT3b expression suggest potential mechanisms underlying effective brachytherapy.

Gong Yan-fang

2011-04-01

119

Adjuvant stereotactic permanent seed breast implant: A boost series in view of partial breast irradiation  

Digital Repository Infrastructure Vision for European Research (DRIVER)

Purpose: The aim of this study was to use permanent seed implants in the breast and describe our experience with 15 cases, using iodine seed implants as a tumor bed boost. Methods and Materials: Breasts were fixed with a thermoplastic sheet, a template bridge applied, the thorax scanned and the images rotated to be perpendicular to the implant axis. Skin, heart, and lung were delineated. A preplan was made, prescribing 50 Gy to the clinical target volume (CTV), consisting in this boost series...

Jansen, Nicolas; Deneufbourg, Jean-marie; Nickers, Philippe

2007-01-01

120

Superior immunoreactivity of 125I-(Des-Tyr-?Ala)-secretin with rabbit anti-secretin sera compared to 125I-secretin and 125I-6-tyrosyl secretin  

International Nuclear Information System (INIS)

A secretin analogue in which the normal amino acid sequence had been elongated by a (Des-Tyr-?Ala)-residue was studied as tracer for secretin radioimmunoassay. 125I-(DATA)-secretin exhibited superior immunoreactivity with several rabbit anti-secretin sera compared to 125I-6-Tyr-secretin and also to secretin iodinated at its N-terminal histidyl residue. This may be due, at least in part, to higher conformational integrity of the secretin moiety in the 125I-(DATA)-secretin molecule. Thus, at present, 125I-(DATA)-secretin appears to be most suitable as tracer for sensitive secretin radioimmunoassay. (orig.)

1976-11-01

 
 
 
 
121

Self-expandable stent loaded with 125I seeds: Feasibility and safety in a rabbit model  

International Nuclear Information System (INIS)

Objective: To evaluate technical feasibility and acute and subacute radiotolerance of a self-expandable stent loaded with 125I seeds in the rabbit esophagus. Methods: A self-expandable stent designed for esophageal application was made of 0.16 mm nitinol wire and loaded with 125I seeds (CIAE-6711). Twenty-seven stents with three different radioactive dosages (n = 9 in each dosage group) were implanted in the esophagus of healthy rabbits, while nine stents alone were used as controls. The stents were perorally deployed into the esophagus under fluoroscopic guidance. Radiological follow-up included plain chest film, CT scan, and barium esophagography which were undertaken in all rabbits of each group at 2, 4, and 8 weeks, respectively, which were correlated to histopathological findings. The stented esophageal segments along with their adjacent tissues were harvested for histopathological examinations. Results: The stent was successfully deployed into the targeted esophageal segment in all rabbits. Neither 125I seeds dislodged from the stent during the deployment, nor they did during the follow-up period. The greatest (16.2 Gy) absorbed dose was found in the tissue 10 mm from 125I seeds at 8 weeks. Slight epithelial hyperplasia on the stent surface and submucosal inflammatory process developed at 2 weeks, which reached the peak at 8 weeks after the procedure. Significant thickness of the esophageal muscular layer was found at 8 weeks only in the groups with 125I seeds. On radiologic follow-up, moderate strictures on both ends of the stents developed at 4 weeks and became severe at 8 weeks after the procedure in all groups. Conclusion: Deployment of a self-expandable stent loaded with 125I seeds is technically feasible and safe within the first 8 weeks. Acute and subacute radiotolerance of the treated esophagus and its adjacent tissues by 125I seeds is well preserved in a healthy rabbit model

2007-02-01

122

DNA damage induction by 125I-estrogen  

International Nuclear Information System (INIS)

DNA damage induced by the radioactive decay of 125I-estrogen (125I-VME2) in an estrogen receptor expressing CHO cell line, CHO-ER, was measured. 125I-VME2 targeted 125I atoms proximal to DNA estrogen response elements (EREs). 125I decays were accumulated at -135 C, and thereafter assayed by alkaline and neutral filter elution techniques to measure DNA single strand break (ssb) and double strand break (dsb) induction respectively. Increasing DNA damage (both ssbs and dsbs) was detected after exposure of cells to increasing concentrations of 125I-VME2. DNA ssb and dsb dose-response curves for 125I-VME2 were multiphasic. The rates of DNA damage induction by the decay of 125I-VME2 was determined by comparing slopes of all data or by comparing initial slopes. DNA ssb induction per 125I-VME2 decay was approximately 2 times greater compared with DNA dsb induction. 125I-VME2 decay induced approximately 4-8 times more DNA dsbs than 125IUdR decay. (orig.)

1996-01-01

123

Decontamination of 125I in Medical Laboratory  

International Nuclear Information System (INIS)

A radiological laboratory for diagnoses was contaminated by 125I. A large-scale survey of gamma-radiation has been made in different locations of the floors and walls of the lab to determine the contaminated area and its activity. The activity level before decontamination for the wall and floor was 1400 and 2000 Bq/cm2 respectively. Decontamination was carried out by using ethyl alcohol, potassium permanganate, ethylene diamine tetracetic acid and tissue papers. Decontamination factor has been calculated and it was 175 and 200 for the wall and floor respectively. D and D computer code has been used to calculate Total Effective Dose Equivalent (TEDE). TEDE from the wall and floor before decontamination were 3.05 and 4.35 ( mSv/yr ) while after decontamination were 18 and 23?Sv/yr respectively. These results are lower than the Egyptian and the international regulations (10 mSv/y for the public ) according to International Atomic Energy agency, IAEA, Safety Series, SS, no. 115 (1994).

2008-02-19

124

Optimization of 125I ophthalmic plaque brachytherapy  

International Nuclear Information System (INIS)

Episcleral plaques containing 125I sources are often used in the treatment of ocular melanoma. Within four years post-treatment, however, the majority of patients experience some visual loss due to radiation retinopathy. The high incidence of late complications suggests that careful treatment optimization may lead to improved outcome. The goal of optimization would be to reduce the magnitude of vision-limiting complications without compromising tumor control. We have developed a three-dimensional computer model for ophthalmic plaque therapy which permits us to explore the potential of various optimization strategies. One simple strategy which shows promise is to maximize the ratio of dose to the tumor apex (T) compared to dose to the macula (M). By modifying the parameters of source location, activity distribution, source orientation, and shielding we find that the calculated T:M ratio can be varied by a factor of 2 for a common plaque design and posterior tumor location. Margins and dose to the tumor volume remain essentially unchanged

1990-01-01

125

Radiolabeling of paclitaxel with 125I  

International Nuclear Information System (INIS)

The modified Ch-T labeling method has been investigated. Firstly, the paclitaxel was reacted with non-radioactive Nal. Then the mixture was radiolabeled with 125I by modified Ch-T method. The radiolabeling yield was analyzed by thin paper chromatography and HPLC. After purified, the radiochemical purity and stability of the radiolabeled compounds were tested in vitro under different conditions, such as temperature or solvent and the final labeled compound was identified by infrared spectra. The radiolabeled yield of the com- pound produced by the modified Ch-T method was compared with those produced by the nitric acid oxidization method and the common Ch-T method. The radiolabeling yield of the labeled compound produced by the modified Ch-T method was about 63.1% ±5.7% and the radiochemieal purity was about 96.3% ± 1.3% . After 24 hours stored in NS or alcohol sys- tem at 4 degree C, the radioehemical purity of the product was above 95%, and 90% after 120 h. The labeled product was also stable in serum, after 24 h stored at 4 degree C and 37 degree C, the radiochemical purities were 92.3%±0.4% and 89.5%±0.6% respectively. The modified Ch-T method was simple and convenient. The radiolabeling yield was high and the labeled compound was stable. It was qualified for the isotopic tracing experiment in vivo. (authors)

2008-05-01

126

Determination of radiochemical purity of 125I-TOC and 125I-F-PGA  

International Nuclear Information System (INIS)

To explore whether there is accordance among three determination methods of the radiochemical purity of [Tyr3] octreotide (TOC) and folate-penicillin G amidase conjugate (F-PGA), which are both labeled with 125I by Iodogen method, the RCP of the labelings are determined by high performance liquid chromatography (HPLC), paper chromatography and trichloroacetic acid (TCA) precipitation, in which four different concentrations of proteins are used to investigate the effect of them on the determination of RCP. It is shown that both HPLC and paper chromatography can separate the labelings from free iodine efficiently, though HPLC is the most precise and reliable method to determinate RCP of such labelings. In TCA precipitation, the RCP measured with 0.2%BSA is the lowest, but those with three other concentrations of the BSA are similar (P>0.05). When RCP0.05), whereas higher than that with HPLC (P10%, the RCP of 125I-TOC obtained by TCA precipitation is a bit lower than those by two other methods (P0.05), and there are no significant differences to determinate the RCP of 125I-F-PGA (P>0.05). The three methods are correlated each other (r=0.0996-0.999, P<0.001). (authors)

2006-05-01

127

Absorption of 125I and 3H in aquatic plants  

International Nuclear Information System (INIS)

The absorption of 125I and 3H in four aquatic plants was studied by solution cultivation. The results showed that arrowhead (Sagittaria pygmaea Miq.) was the fastest in absorbing 125I among the four tested aquatic plants and its concentration factor for 125I was the highest (85.79). The alligator alternanthera (Alternanthera philoxeroides) was the slowest in absorbing 125I and its concentration factor was the lowest. However, the absorption of 3H in alligator alternanthera was the fastest among the four aquatic plants. After being absorbed by aquatic plants, the 125I could be transferred to the shoot. In arrowhead, about 75% of 125I remained in the root, 25% being transferred to the shoot

1998-12-01

128

Relation of QRS Width in Healthy Persons to Risk of Future Permanent Pacemaker Implantation  

Digital Repository Infrastructure Vision for European Research (DRIVER)

In the setting of acute myocardial infarction, prolongation of the QRS interval on an electrocardiogram identifies patients at risk of needing permanent pacemaker implantation. However, the implications of a prolonged QRS in healthy individuals are unclear, especially since the QRS prolongation encountered in this setting is typically mild. We studied the relation between QRS duration and incident pacemaker implantation in a community-based cohort of 8,311 individuals (mean age 54 years, 55% ...

Cheng, Susan; Larson, Martin G.; Keyes, Michelle J.; Mccabe, Elizabeth L.; Newton-cheh, Christopher; Levy, Daniel; Benjamin, Emelia J.; Vasan, Ramachandran S.; Wang, Thomas J.

2010-01-01

129

Interstitial implantation with radioisotopes  

International Nuclear Information System (INIS)

This classic paper published in 1956, clearly demonstrated that higher doses could be delivered to the tumor by interstitial implant with better sparing of the surrounding normal tissues than with any other method of radiation therapy. The author discussed both temporary and permanent implant techniques, specifically using /sup 60/Co and /sup 198/Au. He discussed the superiority of /sup 60/Co with only two gamma photons of 1170 kev and 1330 kev and beta energy of 310 kev compared with a complex gamma spectrum as well as several beta spectra of various energies emitted by radium. This method is still used today in permanent implants for various sites. He initially used /sup 198/Au, /sup 222/Rn, and /sup 192/Ir but later recommended /sup 125/I seeds to be most suitable for permanent implants

1984-01-01

130

Effectiveness of Permanent Implantable Catheter (Polysite in Children with Cancer  

Directory of Open Access Journals (Sweden)

Full Text Available AbstractBackground Totally implantable central venous access devices (ports have been available for over 10 years, but have not been achieved widespread use in pediatric oncology patients. Ports facilitate the administration of chemotherapy in children with cancer. Materials and Methods In this study, we investigated early complications of implantable central venous access devices in children who suffered from different type of cancer. All of the complications were recorded by staff nurses by checklist for one week. This study included 68 patients with different cancer (lymphoma-leukemia-sarcoma and wilms’ tumor who were treated between April 2007 and November 2011 in oncology department of Dr Sheikh hospital, Mashhad University of medical science. ResultsVenous ports were placed in 26 (38.2% girls and 42 (61.8% boys aged between 2 and 12 years (mean: 6 years.We implanted all of the venous ports in patients for chemotherapy, and port implantation procedures were performed by one experienced Pediatric Surgery. 3 cases (4.4% have needle access site infections which were controlled with starting of antibiotics. Catheter leakage in 3 cases (4.4%, port-catheter disconnection in 4(5.8% cases, Occlusion of the system in 5 cases (7.4%. In this period, there were no major complications.Conclusion With proper placement technique and adequate nursing care, they represent a definite improvement in child cancer therapy. Ports can provide satisfactory for the majority of pediatric oncology patients, with a low risk of line-related complications and a high degree of acceptability to children and their parents.

Hashemizadeh Hayede

2012-03-01

131

AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: Report of Task Group 137  

Digital Repository Infrastructure Vision for European Research (DRIVER)

During the past decade, permanent radioactive source implantation of the prostate has become the standard of care for selected prostate cancer patients, and the techniques for implantation have evolved in many different forms. Although most implants use 125I or 103Pd sources, clinical use of 131Cs sources has also recently been introduced. These sources produce different dose distributions and irradiate the tumors at different dose rates. Ultrasound was used originally to guide the planning a...

Nath, Ravinder; Bice, William S.; Butler, Wayne M.; Chen, Zhe; Meigooni, Ali S.; Narayana, Vrinda; Rivard, Mark J.; Yu, Yan

2009-01-01

132

Synthesis and binding of [125I2]philanthotoxin-343, [125I2]philanthotoxin-343-lysine, and [125I2]philanthotoxin-343-arginine to rat brain membranes  

International Nuclear Information System (INIS)

125I2-iodinated philanthotoxin-343 (PhTX-343), [125I2]PhTX-343-arginine, and [125I2]PhTX-343-lysine were synthesized and evaluated as probes for glutamate receptors in rat brain synaptic membranes. It was found that these probes were not specific for the glutamate receptors but may be useful for investigating the polyamine binding site. Filtration assays with Whatman GF/B fiber glass filters were unsuitable because the iodinated PhTX-343 analogues exhibited high nonspecific binding to the filters, thus hindering detection of specific binding to membranes. When binding was measured by a centrifugal assay, [125I2]PhTX-343-lysine bound with low affinity (KD = 11.4 ± 2 microM) to a large number of sites (37.2 ± 9.1 nmol/mg of protein). The binding of [125I2]PhTX-343-lysine was sensitive only to the polyamines spermine and spermidine, which displaced [125I2]PhTX-343-lysine with Ki values of (3.77 ± 1.4) x 10(-5) M and (7.51 ± 0.77) x 10(-5) M, respectively. The binding was insensitive to glutamate receptor agonists and antagonists. Binding results with [125I2]PhTX-343-arginine were similar to those of [125I2]-PhTX-343-lysine. Considering the high number of toxin binding sites (10000-fold more than glutamate) in these membranes and the insensitivity of the binding to almost all drugs that bind to glutamate receptors, it is evident that most of the binding observed is not to glutamate receptors. On the other hand, PhTX analogues with photoaffinity labels may be useful in the isolation/purification of various glutamate and nicotinic acetylcholine receptors; they could also be useful in structural studies of receptors and their binding sites

1991-01-01

133

Installation of radiochromatography for testosterone-3-carboxymethyloxime-tyramine-125 I (T-3-CMO-Ty-125 I)  

International Nuclear Information System (INIS)

The paper presents a device for radiochromatography of testosterone-3-carboxymethyloxime-tyramine-125 I (T-3-CMO-Ty-125 I), a reagent used as marker in radioimmunoassays (RIA) of steroid hormones. One of the most adequate technique of analyzing the steroid hormones is RIA (radioimmunoassay) due to its sensitivity and specificity. This technique requires advanced purification of the sample. In the view of developing a sensitive RIA technique for assaying the steroid hormones an installation for radiochromatography of testosterone-3-carboxymethyloxime-tyramine-125 I (T-3-CMO-Ty-125 I) is necessary. (authors)

2002-09-26

134

Scattering of gaseous 125I from a bottle containing Na125I solution for iodination in a calm condition  

International Nuclear Information System (INIS)

Scattering of gaseous 125I from a bottle containing Na125I solution for iodination has been measured by distributing active charcoal granule at various heights on the inner surface of a plastic cylinder surrounding the bottle and counting the activities of granule samples. The result shows that about 70% of total scattered 125I exist below the level of mouth of the bottle. By drawing the air from the bottle of the cylinder through a tube filled with active charcoal, about 90% of scattered 125I collected. (author)

1997-05-01

135

I-123 metaiodobenzylguanidine cardiac scintigraphy in patients with an implanted permanent pacemaker  

International Nuclear Information System (INIS)

Tl scintigraphic abnormalities have been reported in patients with an implanted permanent pacemaker, but little is known about the MIBG scintigraphic findings in such patients. This study was performed to assess the MIBG scintigraphic findings in patients with an implanted permanent pacemaker, and to test the hypothesis that imaging characteristics of MIBG scintigraphy differ according to its mode. Twelve patients (4 men and 8 women, mean age: 72.4±9.5 years), who had undergone the implantation of a permanent pacemaker for bradyarrhythmias, underwent MIBG scintigraphy. The patients were divided into VVI pacemaker and DDD pacemaker groups. The tomograms were divided into nine segments and the MIBG defect in each segment scored on a scale ranging from 0 (normal uptake) to 3 (no uptake). Total MIBG defect scores were generated by summing the scores for the nine segments in each patient. MIBG scintigraphic abnormalities were found in ten of the twelve patients. The six patients with the VVI pacemaker manifested MIBG scintigraphic abnormalities. These MIBG scintigraphic abnormalities were observed in all segments, particularly in the posterior segments. The mean total defect score of the VVI group was higher than that of the DDD group (14.8±9.8 vs 3.0±3.5, respectively p<0.05). Therefore, we conclude that despite several limitations of the study, MIBG scintigraphic abnormalities occur in patients with implanted permanent pacemakers, and that such abnormalities are more prominent with the VVI than DDD pacemaker. (author)

1995-09-01

136

Quality asurance of iodinated (125 I) human fibrinogen  

International Nuclear Information System (INIS)

The radiopharmaceutical iodinated (125 I) human fibrinogen is currently used for the detection of deep vein thrombosis in the legs, a fairly common post-surgical complication. A comprehensive quality assurance programme for (125 I) - human fibrinogen has been determined for routine use at the Australian Radiation Laboratory, with adaptions necessary for hospital quality control testing

1980-01-01

137

Monitoring of /sup 125/I in saliva of workers internally contaminated with /sup 125/I  

Energy Technology Data Exchange (ETDEWEB)

Monitoring of workers who did iodination of protein was performed for 5 months on 10 persons. The activity in saliva was evaluated following the sum peak method by using a NaI(Tl) detector and a 400-channel analyzer. The concentration of /sup 125/I in saliva ranged 4.65 +- 2.1cBq (1.26 +- 0.57 pCi)/ml to 135 +- 2.7 cBq (36.45 +- 0.73 pCi)/ml and the average was 20.8 +- 1.9cBq (5.62 +- 0.51pCi)/ml. The ratio of concentration in saliva to used activity ranged (2.2 +- 0.64) x 10/sup -9/ to (3.6 +- 0.073) x 10/sup -8/ and the average was (8.1 +- 1.1) x 10/sup -9/. The thyroidal uptake per iodination ranged 146 Bq (3.94nCi) to 2700 Bq (72.9nCi). The ratio of the uptake to the used activity ranged from 7.3 x 10/sup -5/ to 5.4 x 10/sup -6/. The thyroidal absorbed dose ranged from 378 ..mu..Gy (37.8 mrad) to 4740 ..mu..Gy (474mrad). Monitoring of /sup 125/I in saliva was proved to be a useful method to investigate the internal contamination of workers doing iodination.

Nishizawa, Kunihide; Hamada, Nobuyoshi; Sakuma, Sadayuki (Nagoya Univ. (Japan))

1983-08-01

138

Brachytherapy dosimetry of 125I and 103Pd sources using an updated cross section library for the MCNP Monte Carlo transport code  

International Nuclear Information System (INIS)

Permanent implantation of low energy (20-40 keV) photon emitting radioactive seeds to treat prostate cancer is an important treatment option for patients. In order to produce accurate implant brachytherapy treatment plans, the dosimetry of a single source must be well characterized. Monte Carlo based transport calculations can be used for source characterization, but must have up to date cross section libraries to produce accurate dosimetry results. This work benchmarks the MCNP code and its photon cross section library for low energy photon brachytherapy applications. In particular, we calculate the emitted photon spectrum, air kerma, depth dose in water, and radial dose function for both 125I and 103Pd based seeds and compare to other published results. Our results show that MCNP's cross section library differs from recent data primarily in the photoelectric cross section for low energies and low atomic number materials. In water, differences as large as 10% in the photoelectric cross section and 6% in the total cross section occur at 125I and 103Pd photon energies. This leads to differences in the dose rate constant of 3% and 5%, and differences as large as 18% and 20% in the radial dose function for the 125I and 103Pd based seeds, respectively. Using a partially updated photon library, calculations of the dose rate constant and radial dose function agree with other published results. Further, the use of the updated photon library allows us to verify air kerma and depth dose in water calculations performed using MCNP's perturbation feature to simulate updated cross sections. We conclude that in order to most effectively use MCNP for low energy photon brachytherapy applications, we must update its cross section library. Following this update, the MCNP code system will be a very effective tool for low energy photon brachytherapy dosimetry applications

2003-04-01

139

The effect of 125I seed in comprehensive therapy of the head and neck adenoid cystic carcinoma  

International Nuclear Information System (INIS)

Adenoid cystic carcinoma (ACC) often occurs in head and neck, many patients are treated with surgical operation combined radiation treatment method in clinic. Surgery combined radiation therapy can achieve good local control, especially for those late-stage cancer undlgo patients who cannot undergo surgical resection. Radiation therapy can alleviate local symptoms, retards the growth of tumor. 125I seed interstitial brachytherapy is an effective treatment method which has the characteristics of minimal damage in normal tissue, accurate positioning in target area and simple operation, and it can be one-time completed. 125I seed can be implanted in tumors through the CT. B ultrasonic and image navigation equipment. Application of 125I seed interstitial brachytherapy treatment in head and neck ACC has achieved good short-term curative effect. Preoperative establishing treatment plan and intraoperative or postoperative quality verification can guarantee the quality of treatment and make 125I seed interstitial brachytherapy work better. (authors)

2011-01-01

140

Obtainment and radioimmunological characterization of 2,4 D-tyramine -125 I and Dicamba -tyramine -125 I  

International Nuclear Information System (INIS)

The paper presents the synthesis and radioimmunological characterization of two radioactive microconjugates: 2,4 dichlorophenoxyacetyl-tyramine-125 I (2,4 D-tyramine-125 I) and 3,5 dichloro-2-metoxybenzoic-tyramine-125 I (Dicamba-tyramine-125 I), reagents used as markers in radioimmunoassays (RIA) of the pesticides 2,4 D and Dicamba from the environmental factors. The pesticides were activated with ethylchloroformate and tributylamine in dioxan and coupled to tyramine (or tyramine-125 I ). Tyramine was labelled by chloramine method. Markers were purified by thin layer chromatography and extracted in methyl alcohol. Radioimmunological characterization of the pesticide markers was carried out with the help of the anti 2,4 D and anti Dicamba antisera also obtained in the laboratory. (authors)

2003-01-01

 
 
 
 
141

Comparison of /sup 125/I-angiotensin III and /sup 125/I-angiotensin II binding to rat brain membranes  

Energy Technology Data Exchange (ETDEWEB)

The binding of /sup 125/I-angiotensin III (/sup 125/I-ANG III) to rat brain membranes was examined and compared with that of /sup 125/I-angiotensin II (/sup 125/I-ANG II). Degradation of each ligand, as monitored by HPLC, was effectively inhibited using fragments of ANG III and ANG II known to have little affinity for angiotensin binding sites. Three classes of /sup 125/I-ANG III-binding sites were observed based on affinity (KD = 0.13, 1.83, and 10.16 nM) and capacity (Bmax = 1.30, 18.41, and 67.2 fmol/mg protein, respectively). Two classes of /sup 125/I-ANG II-binding sites of high affinity (KD = 0.11 and 1.76 nM) and low capacity (Bmax = 1.03 and 18.86 fmol/mg protein, respectively) were also identified. Cross-displacement studies confirmed that the two highest-affinity /sup 125/I-ANG III-binding sites and the /sup 125/I-ANG II-binding sites were the same. On the other hand, the binding of /sup 125/I-ANG III to the low-affinity /sup 125/I-ANG III-binding site could not be inhibited with ANG II. These data imply that previously measured differences in the biological potency of cerebroventricularly applied ANG III and ANG II probably do not result from differential binding of these peptides to central angiotensin receptors.

Abhold, R.H.; Hanesworth, J.M.; Harding, J.W.

1988-03-01

142

Quality control of 125I-brachytherapy seeds  

International Nuclear Information System (INIS)

An indigenous technology for the production of 125I brachytherapy sources has been developed for the management of intraocular cancer. This indigenous method of producing 125I seeds represents a new paradigm, and a thorough quality evaluation of the seeds in accordance with Atomic Energy Regulatory Board (AERB) of India was carried to ensure their safety during therapy. In this current work, we describe an overview of our experience, the efforts made in establishing enviable quality analysis of 125I seeds to ensure their safety in episcleral plaque brachytherapy. (author)

2012-11-01

143

Online gamma-camera imaging of {sup 103}Pd seeds (OGIPS) for permanent breast seed implantation  

Energy Technology Data Exchange (ETDEWEB)

Permanent brachytherapy seed implantation is being investigated as a mode of accelerated partial breast irradiation for early stage breast cancer patients. Currently, the seeds are poorly visualized during the procedure making it difficult to perform a real-time correction of the implantation if required. The objective was to determine if a customized gamma-camera can accurately localize the seeds during implantation. Monte Carlo simulations of a CZT based gamma-camera were used to assess whether images of suitable quality could be derived by detecting the 21 keV photons emitted from 74 MBq {sup 103}Pd brachytherapy seeds. A hexagonal parallel hole collimator with a hole length of 38 mm, hole diameter of 1.2 mm and 0.2 mm septa, was modeled. The design of the gamma-camera was evaluated on a realistic model of the breast and three layers of the seed distribution (55 seeds) based on a pre-implantation CT treatment plan. The Monte Carlo simulations showed that the gamma-camera was able to localize the seeds with a maximum error of 2.0 mm, using only two views and 20 s of imaging. A gamma-camera can potentially be used as an intra-procedural image guidance system for quality assurance for permanent breast seed implantation.

Ravi, Ananth [Department of Medical Biophysics, University of Toronto (Canada); Caldwell, Curtis B [Department of Medical Biophysics, University of Toronto (Canada); Keller, Brian M [Medical Physics, Sunnybrook Health Sciences Centre (Canada); Reznik, Alla [Department of Medical Biophysics, University of Toronto (Canada); Pignol, Jean-Philippe [Department of Medical Biophysics, University of Toronto (Canada)

2007-09-21

144

Online gamma-camera imaging of 103Pd seeds (OGIPS) for permanent breast seed implantation  

Science.gov (United States)

Permanent brachytherapy seed implantation is being investigated as a mode of accelerated partial breast irradiation for early stage breast cancer patients. Currently, the seeds are poorly visualized during the procedure making it difficult to perform a real-time correction of the implantation if required. The objective was to determine if a customized gamma-camera can accurately localize the seeds during implantation. Monte Carlo simulations of a CZT based gamma-camera were used to assess whether images of suitable quality could be derived by detecting the 21 keV photons emitted from 74 MBq 103Pd brachytherapy seeds. A hexagonal parallel hole collimator with a hole length of 38 mm, hole diameter of 1.2 mm and 0.2 mm septa, was modeled. The design of the gamma-camera was evaluated on a realistic model of the breast and three layers of the seed distribution (55 seeds) based on a pre-implantation CT treatment plan. The Monte Carlo simulations showed that the gamma-camera was able to localize the seeds with a maximum error of 2.0 mm, using only two views and 20 s of imaging. A gamma-camera can potentially be used as an intra-procedural image guidance system for quality assurance for permanent breast seed implantation.

Ravi, Ananth; Caldwell, Curtis B.; Keller, Brian M.; Reznik, Alla; Pignol, Jean-Philippe

2007-09-01

145

Systemic administration of kainic acid induces selective time dependent decrease in [125I]insulin-like growth factor I, [125I]insulin-like growth factor II and [125I]insulin receptor binding sites in adult rat hippocampal formation  

International Nuclear Information System (INIS)

Administration of kainic acid evokes acute seizure in hippocampal pathways that results in a complex sequence of functional and structural alterations resembling human temporal lobe epilepsy. The structural alterations induced by kainic acid include selective loss of neurones in CA1-CA3 subfields and the hilar region of the dentate gyrus followed by sprouting and permanent reorganization of the synaptic connections of the mossy fibre pathways. Although the neuronal degeneration and process of reactive synaptogenesis have been extensively studied, at present little is known about means to prevent pathological conditions leading to kainate-induced cell death. In the present study, to address the role of insulin-like growth factors I and II, and insulin in neuronal survival as well as synaptic reorganization following kainate-induced seizure, the time course alterations of the corresponding receptors were evaluated. Additionally, using histological preparations, the temporal profile of neuronal degeneration and hypertrophy of resident astroglial cells were also studied. [125I]Insulin-like growth factor I binding was found to be decreased transiently in almost all regions of the hippocampal formation at 12 h following treatment with kainic acid. The dentate hilar region however, exhibited protracted decreases in [125I]insulin-like growth factor I receptor sites throughout (i.e. 30 days) the study. [125I]Insulin-like growth factor II receptor binding sites in the hippocampal formation were found to be differentially altered following systemic administration of kainic acid. A significant decrease in [125I]insulin-like growth factor II receptor sites was observed in CA1 subfield and the pyramidal cell layer of the Ammon's horn at all time points studied whereas the hilar region and the stratum radiatum did not exhibit alteration at any time. A kainate-induced decrease in [125I]insulin receptor binding was noted at all time points in the molecular layer of the dentate gyrus whereas binding in CA1-CA3 subfields and discrete layers of the Ammon's horn was found to be affected only after 12 h of treatment. These results, when analysed with reference to the observed histological changes and established neurotrophic/protective roles of insulin-like growth factors and insulin, suggest possible involvement of these growth factors in the cascade of neurotrophic events that is associated with the reorganization of the hippocampal formation observed following kainate-induced seizures. (Copyright (c) 1997 Elsevier Science B.V., Amsterdam. All rights reserved.)

1997-08-11

146

Procedures for RIA "1"2"5I waste disposal  

International Nuclear Information System (INIS)

"1"2"5I can be effectively removed from coated tubes and plastic beads used as solid-phase separators by a 50% household bleach solution. This technique enables the user to dispose of these separators into common trash

1982-01-01

147

Procedures for RIA /sup 125/I waste disposal  

Energy Technology Data Exchange (ETDEWEB)

/sup 125/I can be effectively removed from coated tubes and plastic beads used as solid-phase separators by a 50% household bleach solution. This technique enables the user to dispose of these separators into common trash.

Hidalgo, J.U.; Shepard, E.S.; Ball, J.M.; Colomb, K.D.

1982-04-01

148

Preparation of "1"2"5I FSH hormone  

International Nuclear Information System (INIS)

Labelling of human FSH of pituitary origin with "1"2"5I and its purification are described. Suitable parameters are selected for the use of radioimmunologic technique for FSH dosage in human serum. (author)

1976-01-01

149

Case report on extensive left atrial myxoma removal with permanent pacemaker implantation  

Digital Repository Infrastructure Vision for European Research (DRIVER)

Aim: To represent a case report of extensive left atrial myxoma removal with permanent pacemaker implantation. Methods: A 56-year old female patient admitted to the Bakulev Center of Cardiovascular Surgery with cardiac evaluation. She noted progressive chest pain associated with dyspnea and fatigue. After physical examination, transthoracic echocardiography and other methods of evolution confirmed the diagnosis: Tumor of the left atrium. Left atrial dilatation. Left ventricle hypertrophy. Art...

2013-01-01

150

Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (Radiation Therapy Oncology Group 98-05)  

International Nuclear Information System (INIS)

Purpose: To evaluate the effectiveness of transrectal ultrasound-guided permanent radioactive 125I implantation of the prostate for organ-confined adenocarcinoma of the prostate compared with historical data of prostatectomy and external beam radiotherapy within a cooperative group setting. Methods and Materials: Patients accrued to this study had histologically confirmed, locally confined, adenocarcinoma of the prostate with clinical Stage T1b, T1c, or T2a, no nodal or metastatic disease, prostate-specific antigen level of ?10 ng/mL, and Gleason score of ?6. All patients underwent transrectal ultrasound-guided radioactive 125I permanent seed implantation into the prostate. The prescribed dose was 145 Gy to the prostate planning target volume. Results: A total of 27 institutions accrued a total of 101 patients to this protocol, with no institution accruing >8 patients. Six patients were ineligible, leaving 95 properly entered as eligible in the study. The median follow-up was 5.3 years (range, 0.4-6.5 years). At 5 years, 5 patients had local failure, 1 had evidence of distant failure, and 6 (6%) had biochemical failure. The overall survival rate at 5 years was 96.7%. At last follow-up, no patient had died of prostate cancer or related toxicities. Eight patients had a maximal acute toxicity level of 3, and no patient had Grade 4 or 5 acute toxicity. During follow-up, 2 patients had maximal Grade 3 toxicity, both related to bladder issues, and no patient experienced Grade 4 or 5 toxicity. Conclusion: The results of this clinical protocol (a multi-institutional trial of brachytherapy for localized adenocarcinoma of the prostate) have demonstrated that this type of trial can be successfully completed through Radiation Therapy Oncology Group. Biochemical disease-free survival was comparable with other brachytherapy published series and with the results after surgery and external beam radiotherapy

2007-01-01

151

Chromosomal abnormalities induced by 125I in mouse germ cells  

International Nuclear Information System (INIS)

In this experiments, male mice of the ICR strain were used and were injected intraperitoneally with different dose of 125I. The rate of chromosomal abnormalities in mouse germ cells, and its changes with time were studied. The results showed that: (1) From 1 to 28 days after injection of 555 kBq of 125I, the rate of chromosomal abnormalities of germ cells reached a peak at 1 day. During that time, the abnormal rate in spermatogonia is 1.8%, which is equal to that in spermatocytes. After that, the abnormal percentages in those cells were quickly dropped down; (2) The rates of chromosomal aberrations spermatogonias in males treated with 0, 175, 555 and 1665 kBq of 125I at 1 day after injection were 0.14%, 0.45%, 1.80% and 2.65% respectively. Similarly, the chromosomal abnormal rates in spermatocytes were 0.13%, 0.60%, 1.80% and 2.20% accordingly. These results indicate 125I can induce a significant increase in the percentage of chromosomal aberrations of germ cells in male treated with 1'2'5I. The results also provide further evidence of the cytogenetic effects to mammalian germ cells of 125I

1992-05-01

152

Study on preparation of 125I iodination labelling of leptin  

International Nuclear Information System (INIS)

125I-LEP was prepareded by 125I with indirect iodination and direct iodination respectively, to develop RIA for method comparison. For indirect iodination, BH agent was iodinated by ch-T , then conjugated with leptin. Specific radioactivity of 125I-LEP was 1.43 MBq/?g, to- tal labelling rate of 125I -37.8%. The Bmax of 125I-LEP-97.5%, NSB-6.7% and B0-43.7%. The sensitivity was 0.25 ?g/L , CV of within and between assay-7.8% and 12.90%, respectively. The recovery rate was 96.4%-103.2%, there was no cross-reaction with TSH, LH,FSH, PRL,GH and Ins, the correlation coefficient between results of indirect iodination method and that of Linco Kit was 0.951. Standard curve stability of 125I-LEP prepared by indirect iodination was much better than that by the direct iodination in 45 days, which can satisfy the needs in clinic use. (authors)

2006-12-01

153

Preparation of 5-Iodo-2'- deoxyuridine labelled with 125 I  

International Nuclear Information System (INIS)

5-Iodo-2'-deoxyuridine (IUdR), an analogue of thymidine is taken up by the proliferating cells during DNA synthesis. When IUdR is labelled with 125 I, due to Auger electrons from 125 I, this analogue of thymidine is very effective in cell destruction when is internalized. Recently, radioiodinated (125 I and 123 I) IUdR is considered a potential therapeutic agent, for treatment of cancer.125 I-IUdR was prepared by direct radioiodination of 2'-deoxyuridine (UdR), using chloramine T method. The radioiodination reaction was studied by varying the reaction parameters such as temperature and reaction time. The yield was improved by heating the reaction mixture to 65 deg. C for 10 min. Purification of 125 I-IUdR was carried out by gel filtration over a Sephadex G 25 column using 0.05 M citrate buffer (pH = 6). The yield of the reaction as well as the radiochemical purity were determined by paper electrophoresis using Whatman chromatography paper No.1, 0.05 M phosphate buffer at 13 V/cm. The analyse time was 1 h. The yield of radioiodination reaction was ?70% and the radiochemical purity of 125 I-IUdR prepared by this method was: 91-92%. (authors)

2000-01-01

154

Determination of prescription dose for Cs-131 permanent implants using the BED formalism including resensitization correction  

International Nuclear Information System (INIS)

Purpose: The current widely used biological equivalent dose (BED) formalism for permanent implants is based on the linear-quadratic model that includes cell repair and repopulation but not resensitization (redistribution and reoxygenation). The authors propose a BED formalism that includes all the four biological effects (4Rs), and the authors propose how it can be used to calculate appropriate prescription doses for permanent implants with Cs-131. Methods: A resensitization correction was added to the BED calculation for permanent implants to account for 4Rs. Using the same BED, the prescription doses with Au-198, I-125, and Pd-103 were converted to the isoeffective Cs-131 prescription doses. The conversion factor F, ratio of the Cs-131 dose to the equivalent dose with the other reference isotope (Fr: with resensitization, Fn: without resensitization), was thus derived and used for actual prescription. Different values of biological parameters such as ?, ?, and relative biological effectiveness for different types of tumors were used for the calculation. Results: Prescription doses with I-125, Pd-103, and Au-198 ranging from 10 to 160 Gy were converted into prescription doses with Cs-131. The difference in dose conversion factors with (Fr) and without (Fn) resensitization was significant but varied with different isotopes and different types of tumors. The conversion factors also varied with different doses. For I-125, the average values of Fr/Fn were 0.51/0.46, for fast growing tumors, and 0.88/0.77 for slow growing tumors. For Pd-103, the average values of Fr/Fn were 1.25/1.15 for fast growing tumors, and 1.28/1.22 for slow growing tumors. For Au-198, the average values of Fr/Fn were 1.08/1.25 for fast growing tumors, and 1.00/1.06 for slow growing tumors. Using the biological parameters for the HeLa/C4-I cells, the averaged value of Fr was 1.07/1.11 (rounded to 1.1), and the averaged value of Fn was 1.75/1.18. Fr of 1.1 has been applied to gynecological cancer implants with expected acute reactions and outcomes as expected based on extensive experience with permanent implants. The calculation also gave the average Cs-131 dose of 126 Gy converted from the I-125 dose of 144 Gy for prostate implants. Conclusions: Inclusion of an allowance for resensitization led to significant dose corrections for Cs-131 permanent implants, and should be applied to prescription dose calculation. The adjustment of the Cs-131 prescription doses with resensitization correction for gynecological permanent implants was consistent with clinical experience and observations. However, the Cs-131 prescription doses converted from other implant doses can be further adjusted based on new experimental results, clinical observations, and clinical outcomes

2014-02-01

155

Determination of prescription dose for Cs-131 permanent implants using the BED formalism including resensitization correction  

Energy Technology Data Exchange (ETDEWEB)

Purpose: The current widely used biological equivalent dose (BED) formalism for permanent implants is based on the linear-quadratic model that includes cell repair and repopulation but not resensitization (redistribution and reoxygenation). The authors propose a BED formalism that includes all the four biological effects (4Rs), and the authors propose how it can be used to calculate appropriate prescription doses for permanent implants with Cs-131. Methods: A resensitization correction was added to the BED calculation for permanent implants to account for 4Rs. Using the same BED, the prescription doses with Au-198, I-125, and Pd-103 were converted to the isoeffective Cs-131 prescription doses. The conversion factor F, ratio of the Cs-131 dose to the equivalent dose with the other reference isotope (F{sub r}: with resensitization, F{sub n}: without resensitization), was thus derived and used for actual prescription. Different values of biological parameters such as ?, ?, and relative biological effectiveness for different types of tumors were used for the calculation. Results: Prescription doses with I-125, Pd-103, and Au-198 ranging from 10 to 160 Gy were converted into prescription doses with Cs-131. The difference in dose conversion factors with (F{sub r}) and without (F{sub n}) resensitization was significant but varied with different isotopes and different types of tumors. The conversion factors also varied with different doses. For I-125, the average values of F{sub r}/F{sub n} were 0.51/0.46, for fast growing tumors, and 0.88/0.77 for slow growing tumors. For Pd-103, the average values of F{sub r}/F{sub n} were 1.25/1.15 for fast growing tumors, and 1.28/1.22 for slow growing tumors. For Au-198, the average values of F{sub r}/F{sub n} were 1.08/1.25 for fast growing tumors, and 1.00/1.06 for slow growing tumors. Using the biological parameters for the HeLa/C4-I cells, the averaged value of F{sub r} was 1.07/1.11 (rounded to 1.1), and the averaged value of F{sub n} was 1.75/1.18. F{sub r} of 1.1 has been applied to gynecological cancer implants with expected acute reactions and outcomes as expected based on extensive experience with permanent implants. The calculation also gave the average Cs-131 dose of 126 Gy converted from the I-125 dose of 144 Gy for prostate implants. Conclusions: Inclusion of an allowance for resensitization led to significant dose corrections for Cs-131 permanent implants, and should be applied to prescription dose calculation. The adjustment of the Cs-131 prescription doses with resensitization correction for gynecological permanent implants was consistent with clinical experience and observations. However, the Cs-131 prescription doses converted from other implant doses can be further adjusted based on new experimental results, clinical observations, and clinical outcomes.

Luo, Wei, E-mail: wei.luo@uky.edu; Molloy, Janelle; Aryal, Prakash; Feddock, Jonathan; Randall, Marcus [Department of Radiation Medicine, University of Kentucky, Lexington, Kentucky 40536 (United States)

2014-02-15

156

Adverse reactions after cosmetic lip augmentation with permanent biologically inert implant materials.  

Science.gov (United States)

Augmentation of lips is a common aesthetic procedure that is mostly performed with alloplastic materials or autologous tissue. Various alloplastic injectable implants have been developed for soft tissue augmentation without surgery. Most biologic materials are resorbed within a few months, fluid silicone may migrate, and autologous fat is not ideal for fine contouring of the lips. The search for a biocompatible, permanent, nontoxic, and biologically inert filler material led to the development of some new materials for subdermal or intradermal implantation. Recently Bioplastique, Artecoll, and Gore-Tex have been well established and recommended by many authors. Although these materials meet most of the characteristics that constitute an ideal injectable prosthetic material, we describe 3 examples of adverse reactions after their implantation into lips. PMID:9922021

Hoffmann, C; Schuller-Petrovic, S; Soyer, H P; Kerl, H

1999-01-01

157

Research on the inhibitory effect of interstitial brachytherapy with 125I seeds in treatment of solid tumors in mice  

International Nuclear Information System (INIS)

Objective: To study the inhibitory effect of interstitial brachytherapy with 125I seeds in treatment of solid tumors in mice. Methods: Solid tumor-bearing mice were produced with Ehrlich ascites tumor cells (EAC) and were divided into a treatment group (n=12) and a control group (n=10). In each mouse of the treatment group, four BT-125-I Model 125I seeds with apparent activity of 8.14 MBq were implanted into the tumor; whereas in each mouse of the control group four dummy seeds were implanted. The mice survival rates of both groups were recorded after 28 days. The tumor weights and dimensions of survived mice were measured; tumor volume inhibition rate was calculated. T-test was performed to compare differences of tumor weights and volumes between these two groups. Routine pathological slides of tumor tissue were observed under light microscope to evaluate the range of tumor tissues damaged by 125I seeds. Results: The survival rate of the treatment group was 75% and that of control group was 50%; the average weights of tumors of these two groups were (0.347±0.249) g and (5.162±1.749) g, respectively(t=6.164, P3 and (3974.1±1507.7) mm3, respectively (t=5.618, P125I seeds. No pathological changes but slight edema and fibroplasia were observed at the periphery of dummy seeds. Conclusion: The visible effective radius of 125I seeds used in this study was about 3 mm on pathological slides of tumor tissue. The interstitial brachytherapy with 125I seeds could significantly inhibit the growth of EAC solid tumor of mice

2003-10-01

158

Antithrombotic or Anti-Platelet Agents in Patients Undergoing Permanent Pacemaker Implantation  

Science.gov (United States)

Background and Objectives The growing implantations of electrophysiological devices in the context of increasing rates of chronic antithrombotic therapy in cardiovascular disease patients underscore the importance of an effective periprocedural prophylactic strategy for prevention of bleeding complications. We assessed the risk of significant bleeding complications in patients receiving anti-platelet agents or anticoagulants at the time of permanent pacemaker (PPM) implantation. Subjects and Methods We reviewed bleeding complications in patients undergoing PPM implantation. The use of aspirin or clopidogrel was defined as having taking drugs within 5 days of the procedure and warfarin was changed to heparin before the procedure. A significant bleeding complication was defined as a bleeding incident requiring pocket exploration or blood transfusion. Results Permanent pacemaker implantations were performed in 164 men and 96 women. The mean patient age was 73±11 years old. Among the 260 patients, 14 patients took warfarin (in all of them, warfarin was changed to heparin at least 3 days before procedure), 54 patients took aspirin, 4 patients took clopidogrel, and 25 patients took both. Significant bleeding complications occurred in 8 patients (3.1%), all of them were patients with heparin bridging (p<0.0001). Heparin bridging markedly increased the length of required hospital stay when compare with other groups and the 4 patients (1.5%) that underwent the pocket revision for treatment of hematoma. Conclusion This study suggests that hematoma formation after PPM implantation was rare, even among those who had taken the anti-platelet agents. The significant bleeding complications frequently occurred in patients with heparin bridging therapy. Therefore, heparin bridging therapy was deemed as high risk for significant bleeding complication in PPM implantation.

Lee, Chang Kun; Yoo, Sang Yong; Hong, Man Yong

2012-01-01

159

Self-expandable medical memorial metallic stent with 125I seeds for the treatment of esophageal carcinoma: a retrospective analysis  

International Nuclear Information System (INIS)

Objective: To discuss the curative effect and safety of the implantation of self-expandable medical memorial metallic stent with 125I seeds for the treatment of advanced esophageal carcinomas. Methods: Implantation of self-expandable medical memorial metallic stent with 125I seeds was performed in 32 patients with advanced esophageal canner. The clinical data were retrospectively analyzed. The technical success rate, the operation time, the immediate and mid-term effectiveness, the survival time, the complications, the body weight, the blood picture, the immune indexes, the average hospitalization days and hospitalization expenses were analyzed. Results: The average operation time was (18±5) minutes. Successful stent implantation was achieved in all 32 patients (100%). No 125I seeds fell off during the procedure. The remission rate of dysphagia was 100%. Esophageal restenosis occurred in four patients, and displacement of the stent was seed in one patient. One month after the treatment, 90% of patients had a Karnofsky performance score over 60. The mean survival time was (8.7±6.6) months. The average hospitalization time was (7.8±3.7) days and the mean hospitalization cost was (12±3) thousand Chinese Yuan. Conclusion: For the treatment of esophageal carcinomas, the implantation of self-expandable medical memorial metallic stent with 125I seeds is safe, effective and simple. This treatment can markedly improve the symptom of dysphagia and significantly prolong the patient's survival time. (authors)

2011-06-01

160

Prostate brachytherapy: Pre-plan and real-time transperineal ultrasound guided Iodine-125 permanent seed implants at Södersjukhuset, Karolinska University Hospital.  

Digital Repository Infrastructure Vision for European Research (DRIVER)

Purpose: The aim of this thesis is to study the European (ESTRO/EAU/EORTC) and American (ABS) guidelines how to report the permanent seed implant and the most significant dosimetric parameters. It will also report on the permanent seed implant at Södersjukhuset, Karolinska University Hospital according to the guidelines. A large number of studies on pre- and post-implant dosimetry on permanent seed implants have recently been published but none is considered a standard. This makes it difficu...

Kramar, Johanna

2008-01-01

 
 
 
 
161

Dose rate effect of 125I irradiation on normal rabbit eyes and experimental choroidal melanoma  

International Nuclear Information System (INIS)

The dose rate effect of radiation by 125I plaque on choroidal melanoma and normal intraocular tissue was studied. In the first part of the experiment, high activity plaques (HAP) and low activity plagues (LAP) were implanted on rabbit eyes with experimental Greene choroidal melanoma to deliver a total dose of 10 000 cGy to the tumor apex. The mean dose rate calculated at 0.5 mm from the inner sclera in eight eyes with high activity plaques was 3341.5 cGy hr-1 while that in ten eyes with low activity plaques was 239.9 cGy hr-1. For tumors less than 1.0 mm in height, both groups showed complete tumor regression at the tumor implantation site after plaque treatment. For tumours more than 1.0 mm in height, two out of two eyes in the low activity plaque group and one of four eyes in the high activity plaque group failed to show complete tumor regression. In the second part of the experiment, 125I plaques were implanted on the sclera of 12 normal rabbits' eyes. Six received high dose rate plaque treatment, while the other six received low dose rate plaque treatment. Clinical and histologic examinations demonstrated more damaging effects to the normal chorioretinal tissues at the plaque implantation site in the high dose rate plaque group. These results suggest that high dose rate plaques are more effective than low dose rate plaques when tumor height is statistically controlled. (Author)

1993-11-01

162

Permanent biventricular ICD-implantation in a heart failure second re-do-CABG patient : a case report  

Digital Repository Infrastructure Vision for European Research (DRIVER)

Biventricular pacing has been suggested in end-stage heart failure. We present a 59-year-old patient undergoing second re-do CABG (coronary artery bypass graft) and carotid artery endarterectomy. Ejection fraction was 15%, QRS-width 175 ms. Following the carotid and CABG procedure, an implanted single-chamber ICD (implantable cardioverter defibrillator) was upgraded to permanent biventricular DDD pacing by implantation of one epicardial left ventricular and one epicardial atrial electrode. At...

2009-01-01

163

Permanent biventricular ICD-implantation in a heart failure second re-do-CABG patient: a case report  

Digital Repository Infrastructure Vision for European Research (DRIVER)

Biventricular pacing has been suggested in end-stage heart failure. We present a 59-year-old patient undergoing second re-do CABG (coronary artery bypass graft) and carotid artery endarterectomy. Ejection fraction was 15%, QRS-width 175 ms. Following the carotid and CABG procedure, an implanted single-chamber ICD (implantable cardioverter defibrillator) was upgraded to permanent biventricular DDD pacing by implantation of one epicardial left ventricular and one epicardial atrial electrode. At...

2009-01-01

164

Dosimetry of ophthalmic applications using 125I seed sources  

International Nuclear Information System (INIS)

Intraocular melanoma is the most common primary malignancy of the eye and radiation therapy using ophthalmic plaque has proved successful for its management. The dose prescription point recommended for 125I eye plaque therapy is usually 5 mm from tumour base centre for tumours with 5 mm or less height and tumour apex, otherwise. A computational programme was written to generate data for the dosimetry of eye plaque therapy using 125I seeds. Variation of central axis depth dose and isodose distributions at reference depth have been studied for different diameter plaques. The reference dose rate chosen for a clinical application, based on treatment planning software, was compared with that derived from the data generated in the present study. The dosimetry data generated and presented in this paper will help pre-planning of ophthalmic applications, using 125I seeds. (author)

2005-01-01

165

Computer assisted treatment planning for 125I ophthalmic plaque radiotherapy  

International Nuclear Information System (INIS)

This paper describes a computer program for planning the treatment of ocular tumors with 125I plaques. The program permits the input of the tumor configuration into a model eye and facilitates the viewing of the relative geometry of the tumor and various eye structures in different perspectives. Custom-designed 125I plaques can be localized onto the globe, and dose distributions can be calculated and superimposed on the eye structures in any plane or on the inner eye surface. The program allows efficient evaluation of the plaque design in terms of radiation dose distribution relative to the tumor and critical structures

1989-01-01

166

"1"2"5I therapy of hyperthyroidism  

International Nuclear Information System (INIS)

In recent years increasing interest is shown in the use of "1"2"5I for the therapy of hyperthyroidism, instead of the traditional "1"3"1I, based on the postulate that there is a relative sparing of the reproductive integrity of the thyroid follicular cell and a consequent possibility of smaller incidence of hypothyroidism after therapy. Dosimetric and radiobiological bases of this postulate are first described in this paper and then a brief review of the results of the pilot clinical trials conducted at different centers using "1"2"5I for the management of hyperthyroidism is given. (orig./MG)

1976-05-05

167

False positive "1"2"5I fibrinogen test  

International Nuclear Information System (INIS)

"1"2"5I fibrinogen test was performed in 20 selected patients who presented with symptoms suggestive of deep venous thrombosis. The incidence of a false positive study was found to be very high: 90%. An increased accumulation of fibrinogen was noted over recent, well-healed surgical incisions, diffuse or focal inflammatory sites, hematoma and also, following a venogram or arthrogram test. The large number of coincidental circumstances that result in an abnormal accumulation of "1"2"5I fibrinogen lead us to believe that venogram is the procedure of choice in patients with symptoms simulating thrombophlebitis

1976-01-01

168

[Permanent implant prostate cancer brachytherapy: 2013 state-of-the art].  

Science.gov (United States)

With an experience of more than 25 years for the pioneers (and more than 14 years in France), permanent implant brachytherapy using iodine 125 seeds (essentially) is now recognized as a valuable alternative therapy for localized low-risk prostate cancer patients. The possible extension of the indications of exclusive brachytherapy towards selected patients in the intermediate-risk group has now been confirmed by several studies. Moreover, for the other patients in the intermediate-risk group and for the patients in the high-risk group, brachytherapy, as an addition to external radiotherapy, could represent one of the best ways to escalate the dose. Different permanent implant brachytherapy techniques have been proposed; preplanning or real-time procedure, loose or stranded seeds (or both), manual or automatic injection of the seeds. The main point here is the ability to perfectly master the procedure and to comply with the dosimetric constraints, which have been recently redefined by the international societies, such as the GEC-ESTRO group. Mid- and long-term results, which are now available in the literature, indicate relapse-free survival rates of about 90% at 5-10 years, the best results being obtained with satisfactory dosimetric data. Comparative data have shown that the incontinence and impotence rates after brachytherapy seemed to be significantly inferior to what is currently observed after surgery. However, a risk of about 3 to 5% of urinary retention is usually reported after brachytherapy, as well as an irritative urinary syndrome, which may significantly alter the quality of life of the patients, and last several months. In spite of those drawbacks, with excellent long-term results, low rates of incontinence and impotence, and emerging new indications (focal brachytherapy, salvage brachytherapy after localized failure of an external irradiation), permanent implant prostate brachytherapy can be expected to be proposed to an increasing number of patients in the next future. PMID:23478488

Cosset, J-M; Hannoun-Lévi, J-M; Peiffert, D; Delannes, M; Pommier, P; Pierrat, N; Nickers, P; Thomas, L; Chauveinc, L

2013-04-01

169

Self-expandable stent loaded with {sup 125}I seeds: Feasibility and safety in a rabbit model  

Energy Technology Data Exchange (ETDEWEB)

Objective: To evaluate technical feasibility and acute and subacute radiotolerance of a self-expandable stent loaded with {sup 125}I seeds in the rabbit esophagus. Methods: A self-expandable stent designed for esophageal application was made of 0.16 mm nitinol wire and loaded with {sup 125}I seeds (CIAE-6711). Twenty-seven stents with three different radioactive dosages (n = 9 in each dosage group) were implanted in the esophagus of healthy rabbits, while nine stents alone were used as controls. The stents were perorally deployed into the esophagus under fluoroscopic guidance. Radiological follow-up included plain chest film, CT scan, and barium esophagography which were undertaken in all rabbits of each group at 2, 4, and 8 weeks, respectively, which were correlated to histopathological findings. The stented esophageal segments along with their adjacent tissues were harvested for histopathological examinations. Results: The stent was successfully deployed into the targeted esophageal segment in all rabbits. Neither {sup 125}I seeds dislodged from the stent during the deployment, nor they did during the follow-up period. The greatest (16.2 Gy) absorbed dose was found in the tissue 10 mm from {sup 125}I seeds at 8 weeks. Slight epithelial hyperplasia on the stent surface and submucosal inflammatory process developed at 2 weeks, which reached the peak at 8 weeks after the procedure. Significant thickness of the esophageal muscular layer was found at 8 weeks only in the groups with {sup 125}I seeds. On radiologic follow-up, moderate strictures on both ends of the stents developed at 4 weeks and became severe at 8 weeks after the procedure in all groups. Conclusion: Deployment of a self-expandable stent loaded with {sup 125}I seeds is technically feasible and safe within the first 8 weeks. Acute and subacute radiotolerance of the treated esophagus and its adjacent tissues by {sup 125}I seeds is well preserved in a healthy rabbit model.

Guo Jinhe [Department of Radiology, Zhong-Da Hospital, Southeast University, 87 Dingjiaqiao Road, Nanjing 210009 (China); Teng Gaojun [Department of Radiology, Zhong-Da Hospital, Southeast University, 87 Dingjiaqiao Road, Nanjing 210009 (China)]. E-mail: gjteng@vip.sina.com; Zhu Guangyu [Department of Radiology, Zhong-Da Hospital, Southeast University, 87 Dingjiaqiao Road, Nanjing 210009 (China); He Shicheng [Department of Radiology, Zhong-Da Hospital, Southeast University, 87 Dingjiaqiao Road, Nanjing 210009 (China); Deng Gang [Department of Radiology, Zhong-Da Hospital, Southeast University, 87 Dingjiaqiao Road, Nanjing 210009 (China); He Jie [Department of Radiology, Zhong-Da Hospital, Southeast University, 87 Dingjiaqiao Road, Nanjing 210009 (China)

2007-02-15

170

Permanent-magnet type electron cyclotron resonance (ECR) ion source for heavy ion implanter  

International Nuclear Information System (INIS)

A new ECR ion-source has been designed to have a mirror field produced by permanent magnet for heavy ion implanter. A similar plasma-chamber size as normal-conducting ECR ion source was designed. Design aim of magnetic field is to in start a plasma chamber of 50 mm inner diameter and a hexapole magnet of 150 mm length with 12-14 GHz operation. We could to design near magnetic field of design aim for ECR ion source with 12-14 GHz operation. The new ECR ion source was first operated by 12-14 GHz. (author)

2004-06-01

171

Stereotactic iodine-125 brachytherapy for brain tumors: temporary versus permanent implantation  

Directory of Open Access Journals (Sweden)

Full Text Available Abstract Stereotactic brachytherapy (SBT has been described in several publications as an effective, minimal invasive and safe highly focal treatment option in selected patients with well circumscribed brain tumors 40?cGy/h in combination with adjuvant external beam radiation and/or chemotherapy for the treatment of malignant gliomas and metastases resulted in increased rates of radiation induced adverse tissue changes requiring surgical intervention. Vice versa, such effects have been only minimally observed in numerous studies applying low dose rate (LDR regiments (3–8?cGy/h for low grade gliomas, metastases and other rare indications. Besides these observations, there are, however, no data available directly comparing the long term incidences of tissue changes after HDR and LDR and there is, furthermore, no evidence regarding a difference between temporary or permanent LDR implantation schemes. Thus, recommendations for effective and safe implantation schemes have to be investigated and compared in future studies.

Ruge Maximilian I

2012-06-01

172

A comparative study of 19-iodo cholesterol-125I 3-acetate and Na 125I in liquid scintillation measurements  

International Nuclear Information System (INIS)

A comparative study of performance of 19-iodo cholesterol 125I 3-acetate and sodium iodide samples labeled with 125I is presented for liquid scintillation counting measurements. Quench effect, count rate stability and spectral evolution of samples have been followed for several weeks in Toluene, Hisafe II, Instagel, Dioxane-naphthalene and Toluene-alcohol scintillators. Organic samples have negligible quench effect in the interval of I concentration of 0-90 ?g and inorganic samples only show a very small variation, lower than 12%, for Dioxane-naphthalene, in the same range of concentration. Satisfactory stability is obtained in general for both, organic and inorganic samples, but small counting losses, 0.03% for 19-iodocholesterol 1 I 3-acetate samples in Tolue ne-alcohol and 0 .04% for Na 125I samples in Dioxane-naphthalene and Toluene-alcohol, have been reported. (Author) 8 refs

1994-01-01

173

Pulmonary embolization of permanently implanted radioactive palladium-103 seeds for carcinoma of the prostate  

International Nuclear Information System (INIS)

Purpose: It has been reported that permanently implanted iodine-125 seeds can embolize to the lungs. There is little data on the embolization of palladium-103 seeds. The purpose of this study is to collect and evaluate data on the embolization of Pd-103 seeds. Methods and Materials: The records of 112 patients implanted with Pd-103 for carcinoma of the prostate were reviewed to systemically study the incidence and dynamics of pulmonary embolism of Pd-103 seeds. Five patients had no postoperative chest radiograph and were thus excluded, leaving 107 patients for review. Results: Chest radiographs of 19 of the 107 patients showed embolized seeds in the lungs (18%). Two patients had three seeds each, nine patients had two seeds each; and in the remaining eight patients, a single seed migrated to the lungs. The seeds migrated mainly (84%) to the lower lobes. None of the eight patients who had their first postoperative chest radiograph on the day of the implant showed any embolized seeds. The embolized seed appeared only on subsequent chest radiographs taken 27 to 40 days later. Ten of the other 11 patients who had their first radiograph 1 to 97 days after brachytherapy had embolized seeds on their first chest radiograph. In the other patient, the embolized seed appeared only on a subsequent chest radiograph taken after 127 days. There were no clinical pulmonary or cardiac effects evident on routine follow-up of these patients with pulmonary embolized seeds. Conclusion: Embolization of Pd-103 seeds to the lungs after implantation for carcinoma of the prostate is an unusual event. In this study only 0.3% of the seeds implanted migrated to the lungs. Although it was previously thought that pulmonary seed migration mainly occurred on the day of brachytherapy, our experience shows that seeds usually migrated to the lungs after the day of the implant. There were no clinical pulmonary or cardiac effects attributable to embolized seeds in the lungs on routine follow-up

1997-10-01

174

Evaluation of physician eye lens doses during permanent seed implant brachytherapy for prostate cancer.  

Science.gov (United States)

Treatment of low grade prostate cancer with permanent implant of radioactive seeds has become one of the most common brachytherapy procedures in use today. The implant procedure is usually performed with fluoroscopy image guidance to ensure that the seeds are deployed in the planned locations. In this situation the physician performing the transperineal implant is required to be close to the fluoroscopy unit and dose to the eye lens may be of concern. In 1991 the International Commission on Radiological Protection (ICRP) provided a recommended dose limit of 150 mSv yr(-1) for occupational exposures to the lens of the eye. With more long term follow-up data, this limit was revised in 2011 to 20 mSv yr(-1). With this revised limit in mind, we have investigated the dose to the lens of the eye received by physicians during prostate brachytherapy seed implantation. By making an approximation of annual workload, we have related the dose received to the annual background dose. Through clinical and phantom measurements with thermoluminescent dosimeters, it was found that the excess dose to the physician's eye lens received for a conservative estimate of annual workload was never greater than 100% of the annual background dose. PMID:22854245

Penfold, S N; Marcu, L; Lawson, J M; Asp, J

2012-09-01

175

Chemical influence on the decay constant of 125I  

International Nuclear Information System (INIS)

The chemical influence on the electron capture decay of 125I has been studied. The decay constant difference between NaIO3 and Na2H3IO6 has been assessed and measured. The results obtained are discussed in terms of the isomer shift of Moessbauer iodine isotopes

1984-01-01

176

Case report on extensive left atrial myxoma removal with permanent pacemaker implantation  

Directory of Open Access Journals (Sweden)

Full Text Available Aim: To represent a case report of extensive left atrial myxoma removal with permanent pacemaker implantation. Methods: A 56-year old female patient admitted to the Bakulev Center of Cardiovascular Surgery with cardiac evaluation. She noted progressive chest pain associated with dyspnea and fatigue. After physical examination, transthoracic echocardiography and other methods of evolution confirmed the diagnosis: Tumor of the left atrium. Left atrial dilatation. Left ventricle hypertrophy. Arterial hypertension 2 stage of high risk. Circulatory failure 2 stage (by Strazhesko-Vasilenko, functional class II by NYHA. The huge tumor was successfully excised with closure of atrial septal defect by patch. Results: Transthoracic echocardiography in postoperative period showed a normal left and right ventricular function and no residual shunts. The presence of conduction abnormalities in early postoperative period predicted the need for permanent pacemaker implantation. Conclusions: It must be noted rare occurrence of a huge tumor (myxoma filling left atrium. Large left atrial tumor is approached by biatrial incision with further excision. It is believed that the case can be beneficial in huge cardiac tumors management. Early detection and surgical treatment of heart tumors can reduce the risk of heart failure, systemic embolization, syncope and sudden cardiac death.

Bokeria L.A.

2013-06-01

177

Intraoperative modification method in the transperineal permanent implant of I-125 seed in prostate cancer  

International Nuclear Information System (INIS)

In the Department of Radiation Therapy and Oncology, International Medical Center of JAPAN, transperineal permanent implant (TPI) of I-125 seeds have been performed since April 2004. In April the planning method was changed from the preplanning to the intraoperative modification method in April 2006. Various dose parameters were compared between the 106 patients treated by preplanning and the 42 patients undergoing the intraoperative modification. The mean operation time was 84 minutes in the preplanned method and 92 minutes in the intraoperative modification. The prostatic volume reduced at the postplanning, compared to the preplanning. Dosimetric parameters of prostate (V100, V150, and D90%) diminished at the time of postplanning with a statistical significance, while the degree of the reductions was greater in the patients treated by the preplanned method. The mean prostate V100 of the preplanning and the intraoperative modification was 89% and 93.3%, respectively, and the mean prostate D90% was 100% and 111%, respectively, both with a statistically significant difference. In contrast, urethral and rectal dose parameters were the same in both methods. The intraoperative modification method was useful to attain the high quality permanent implant of I-125 seeds. (author)

2007-12-01

178

Biologically effective dose (BED) for interstitial seed implants containing a mixture of radionuclides with different half-lives  

International Nuclear Information System (INIS)

Purpose: To develop a tool for evaluating interstitial seed implants that contain a mixture of radionuclides with different half-lives and to demonstrate its utility by examining the clinical implications of prescribing to an isodose surface for such an implant. Methods and Materials: A linear-quadratic model for continuous low dose rate irradiation was developed for permanent implants containing a mixture of radionuclides. Using a generalized equation for the biologically effective dose (BED), the effects of cell proliferation and sublethal damage repair were examined systematically for implants containing a mixture of radionuclides. A head-and-neck permanent seed implant that contained a mixture of 125I and 103Pd seeds was used to demonstrate the utility of the generalized BED. Results: An equation of BED for implants containing a mixture of radionuclides with different half-lives was obtained. In such an implant, the effective cell kill was shown to depend strongly on the relative dose contributions from each radionuclide type; dose delivered by radionuclides with shorter half-life always resulted in more cell kill for any given sublethal damage repair and cell proliferation rates. Application of the BED formula to an implant containing a mixture of 125I and 103Pd seeds demonstrates that the conventional dose prescription to an isodose surface is not unique for such an implant. When the prescription dose was based on existing clinical experience of using 125I seeds alone, mixing 103Pd seeds with 125I seeds would increase the cell kill. On the other hand, if the prescription dose were based on existing clinical experience of using 103Pd seeds alone, mixing 125I seeds with 103Pd seeds in the same implant would create radiobiologically 'cold' spots (i.e., an increase in cell survival) at locations where a major portion of the prescription dose is contributed by the 125I seeds. For fast-growing tumors, these 'cold' spots can become significant. Conclusions: Total dose alone is no longer sufficient for a complete characterization of a permanent seed implant containing a mixture of radionuclides with different half-lives due to the presence of cell proliferation and sublethal damage repair in the protracted dose delivery. BED provides a tool for evaluating the radiobiologic effects of mixing different type of radionuclides in the same implant. When radionuclides of different half-lives are mixed in a permanent implant, using the dose prescription established from existing clinical experience of implants with the longer half-life radionuclide would help to avoid radiobiologic 'cold' spots

2003-03-01

179

Preparation and evaluation of 125I-aflatoxin B1  

International Nuclear Information System (INIS)

Aflatoxin B1 (AfB1), present in fungus infested crops is highly carcinogenic and is measured by immunoassays. 125I labeled aflatoxin B1 is a key reagent for development of radioimmunoassay (RIA) which exhibits less interference and better sensitivity than other immunoassays. Since AfB1 lacks suitable functional groups for radiolabeling, an oxime derivative of AfB1 was synthesised and evaluated by UV-spectrophotometry and 1H NMR spectroscopy. 125I-histamine was conjugated to AfB1 oxime by mixed anhydride method and purified by solvent extraction followed by TLC. The tracer obtained was immunoreactive, stable as ethanolic solution and could be used in RIA. (author)

2001-11-01

180

The metabolism of 125I-gelatin in rabbits  

International Nuclear Information System (INIS)

125I-labeled gelatin sponge was made by special technique. Healthy adult rabbits were anesthetized by amytal. Then the thigh-bone was exposed and drilled a hole. The bone marrow and bone substance were taken out and the bone-cave was planted with 125I-gelatin sponge. At 14 or 30 days after planting, the radioactivities of the liver, lung, kidney, genitals as well as the blood (obtained from ear-vein every two days after planting) were measured. The results showed that the radioactivity remained high in all of these tissues and blood from the sixth day to the eighteenth day after planting. The biological half-life in abdominal cavity and bone were 8.5 days and 9.2 days respectively. At 14 days after planting, liver spleen and kidney exhibited high level of radioactivity, while low radioactivity was found in other organs

1992-08-01

 
 
 
 
181

Amino acid tolerance test using L-?-phenylalanine-125I  

International Nuclear Information System (INIS)

An amino acid tolerance test is described. L-?-phenylalanine-125I was used as representative of L-amino acids. The change in radioactivity of the blood after giving a test dose of tagged L-?-phenylalanine was also investigated. L-?-phenylalanine-125I tolerance curves were found to be irreproducible when the test dose was given without a carrier. The addition of 2.5 g untagged phenylalanine as a carrier to the test dose allowed a reproducible and precise type of tolerance curves. Metformin in a dose of 0.5 g t.d.s. for three days induced an inhibitory effect on amino acid absorption in normal persons. (author)

1978-01-01

182

Preparation of 19-iodocholesterol labelled with 125 I  

International Nuclear Information System (INIS)

In this paper a new method of synthesis of 19-iodo cholesterol labelled with ''125 I, from commercial cholesterol, is described. Its high chemical (96%) and radiochemical (99.9%) purities high yield and short time of preparation permit us to dispose or a more accessible labelled compound, which results appropriates for clinical investigations and in the diagnosis of disturbances of the suprarenal glands. (Author) 9 refs

1986-01-01

183

Production of 125I seed sources for brachytherapy uses  

International Nuclear Information System (INIS)

The production of radioactive sources of 125I, used mainly for the brachytherapy of prostate and ocular cancer, is a work that is being carried out in the plant of production of radioisotopes (PPR) of the Nuclear Center Racso of the IPEN. The employed methodology is based on the 125I physical-chemistry adsorption at silver wires coated with palladium. In the realization of the tests, it has been considered the procedure used by India and Iran participants of this CRP. In the execution of this work, the 131I radioisotope is been used simulating the 125I, because in the PPR-IPEN we produce the 131I. In total 50 samples were used, they were divided in ten groups. In first place with nine working groups, the optimum conditions for work for the coating of the silver wires with palladium were obtained, these being the following: simple method, employing PdCl2 0.1 m, pH of 5.5 to 6.5 and a temperature of 100 deg. C. Later on, a series of tests were carried out to determine the appropriate parameters for the adsorption of 131I in the previously treated wires, these being the following: carrier concentration of Ki 0.03 m, time of adsorption of 6 hours, and temperature of 70 deg. C. Finally, the percentage of 131I adsorption was obtained in the silver wires tried previously with palladium chloride solution of 98.24%. The control of leachability was made, having very good results. To confirm these previously mentioned parameters, a test was made with ten pieces of silver wires, corresponding to the group 10, giving the confirmation as a result of these. Also, samples of the titanium tube have been sent for test with microplasma welding to a French company: air welding liquidates export. With these results obtained, subsequently the production of these radioactive sources will be carried out employing 125I as a radioisotope. (author)

2006-06-01

184

Comparative biological efficacy of 125I and 131I  

International Nuclear Information System (INIS)

An experimental study of comparative biological efficacy of 125I and 131I at equal absorbed doses (2.3 and 13 Gy) in the thyroid of rats showed that the blastomogenic effect of both radionuclides was almost the same. Sex differences were found in the development of delayed conseguences (20 mos. after drug administration): breast tumors developed in female rats and thyroid tumors in male rats

1987-01-01

185

Renal catabolism of "1"2"5I-glicentin  

International Nuclear Information System (INIS)

The renal catabolism of "1"2"5I-glicentin has been studied in vivo by the disappearance of this peptide from the plasma of bilaterally nephrectomized, ureteral-ligated, or normal rats and by using tubular microinfusion techniques. In addition the catabolism of glicentin by the isolated, perfused kidney has been studied. Results from in vivo studies demonstrated that half-disappearance time was lower in control (59.5 +/- 1.8 min) than in bilaterally nephrectomized rats (97.2 +/- 2.6 min), and this value was significantly higher than that of ureteral-ligated animals (83.2 +/- 1.1 min, P less than 0.005). Microinfusion experiments revealed that when "1"2"5I-glicentin was injected into the proximal tubule, no trichloroacetic-precipitable radioactivity was recovered in the urine, whereas most of inulin injected was recovered. By contrast most of the "1"2"5I-glicentin injected into the distal tubule was recovered in the urine. In isolated kidney experiments, organ clearance rate of "1"2"5I-glicentin averaged 0.88 +/- 0.10 ml/min, a value significantly higher than that of glomerular filtration rate (0.72 +/- 0.06 ml/min, P less than 0.005, paired data), and both parameters showed a close linear relationship (r = 0.90). Urinary clearance of glicentin was negligible. These results demonstrate that the kidney plays a major role in the catabolism of glicentin, mainly by glomerular filtration and tubular catabolism. The site of tubular catabolism appears to be the proximal tubule. Peritubular uptake was minimal

1986-01-01

186

Labeling Lanreotide with 125I and 188Re  

International Nuclear Information System (INIS)

Lanreotide is a new somatostatin analogue. It can bind to human somatostatin receptor (hSSTR) subtype 2 through 5 with high affinity and to hSSTR subtype I with low affinity. We investigate labeling condition, quality control and stability in vitro of 125I-Lanreotide and 188Re-lanreotide respectively. (A) Lanreotide is labeled with 125I using Chloramine T. The effect of reaction condition (such as reaction time, pH value, Lanreotide amount, quantity of Chloramine T and reaction volume) on labeling yield is investigated in detail. (B) The labeling yield and radiochemical purity (RP) is measured with paper chromatography (PC) and Sep-Pak C18 Cartridge. (C) The stability of 125I-Lanreotide in vitro is investigated by labeling compound incubating for 48 hours at 37 deg C in the 0.9% sodium chloride solution and RP is tested by PC at specific time intervals. (D) Lanreotide is labeled directly with 188Re via the mixture of citrate and tartate using stannous chloride as reduced agent. The influence of reaction conditions such as pH, temperature, amount of stannous chloride, amount of Lanreotide and reaction time on labeling yield is investigated in detail. At the time, the stability in vitro quality control and animal test are evaluated

2000-02-04

187

125I-neuropeptide Y and 125I-peptide YY bind to multiple receptor sites in rat brain  

International Nuclear Information System (INIS)

We describe the preparation of monoiodinated neuropeptide Y (Tyr1-125I-NPY) and monoiodinated peptide YY (Tyr36-125I-PYY). Using these ligands, we detected high, moderate, and low affinity receptor populations in rat brain. Only high and moderate affinity binding sites were suggested by saturation binding studies. Tyr1-125I-NPY bound to 8 +/- 3% of the sites with a Kd of 54 pM (Bmax = 19.4 fmol/mg of protein) and to 92 +/- 3% of the sites with a Kd of 0.92 nM (Bmax = 220.0 fmol/mg of protein). Tyr36-125I-PYY bound to 14 +/- 3% of the sites with a Kd of 23.5 pM (Bmax = 36.4 fmol/mg of protein) and to 86 +/- 3% of the sites with a Kd of 1.9 nM (Bmax = 220.1 fmol/mg of protein). The fragments NPY 13-36 and PYY 13-36 were able to compete with 10 pM Tyr1-125I-NPY for essentially all the binding sites. The fragments were 1 to 2 orders of magnitude less potent than the native peptides. Approximately 50% of the moderate affinity sites, but not the high affinity sites, were reversibly lost in the presence of 5'-guanylyl imidophosphate [Gpp(NH)p], a nonhydrolyzable analog of GTP. Kinetic studies revealed that Tyr1-125I-NPY dissociation could be best described by three dissociation rates. The proportions of slow and intermediate dissociation matched the proportions of moderate and high affinity binding sites, respectively, as suggested by equilibrium studies. There also existed a phase of fast dissociation. When Gpp(NH)p was added during dissociation, the proportion of slow dissociation decreased to the same extent that the fast dissociation was increased. However, the proportion of intermediate dissociation did not change. We propose that rat brain contains a minor population of high affinity NPY binding sites with an intermediate dissociation rate and no sensitivity to Gpp(NH)p

1988-01-01

188

Bypassing the learning curve in permanent seed implants using state-of-the-art technology  

International Nuclear Information System (INIS)

Purpose: The aim of this study was to demonstrate, based on clinical postplan dose distributions, that technology can be used efficiently to eliminate the learning curve associated with permanent seed implant planning and delivery. Methods and Materials: Dose distributions evaluated 30 days after the implant of the initial 22 consecutive patients treated with permanent seed implants at two institutions were studied. Institution 1 (I1) consisted of a new team, whereas institution 2 (I2) had performed more than 740 preplanned implantations over a 9-year period before the study. Both teams had adopted similar integrated systems based on three-dimensional (3D) transrectal ultrasonography, intraoperative dosimetry, and an automated seed delivery and needle retraction system (FIRST, Nucletron). Procedure time and dose volume histogram parameters such as D90, V100, V150, V200, and others were collected in the operating room and at 30 days postplan. Results: The average target coverage from the intraoperative plan (V100) was 99.4% for I1 and 99.9% for I2. D90, V150, and V200 were 191.4 Gy (196.3 Gy), 75.3% (73.0%), and 37.5% (34.1%) for I1 (I2) respectively. None of these parameters shows a significant difference between institutions. The postplan D90 was 151.2 Gy for I1 and 167.3 Gy for I2, well above the 140 Gy from the Stock et al. analysis, taking into account differences at planning, results in a p value of 0.0676. The procedure time required on average 174.4 min for I1 and 89 min for I2. The time was found to decrease with the increasing number of patients. Conclusion: State-of-the-art technology enables a new brachytherapy team to obtain excellent postplan dose distributions, similar to those achieved by an experienced team with proven long-term clinical results. The cost for bypassing the usual dosimetry learning curve is time, with increasing team experience resulting in shorter treatment times

2007-01-01

189

Evaluation of permanent I-125 prostate implants using radiography and magnetic resonance imaging  

International Nuclear Information System (INIS)

Purpose: The aim of this study is the evaluation of permanent I-125 prostate implants using radiography and magnetic resonance imaging (MRI). Methods and Materials: Twenty-one patients underwent radiography on the simulator and MRI within 3 days after implantation of the I-125 seeds. Isocentric radiographs were used for reconstruction of the seed distribution, after which registration with the seed-induced signal voids on MRI provided the seed positions in relation to the prostate. The prostate was contoured on the transversal magnetic resonance images, and dose-volume histograms were computed to evaluate the implants. The validity of the ellipsoidal prostate volume approximation, as applied in preimplant dose calculation, was assessed by comparison of ellipsoidal volumes given by prostate width, height, and length and prostate volumes obtained by a slice-by-slice contouring method, both on postimplant MRI. Prostate volume changes due to postimplant prostate swelling were assessed from radiographs taken at 3 days and 1 month after the implantation. Results: The seeds were readily identified on T1-weighted spin-echo images and matched with the seed distribution reconstructed from the isocentric radiographs. The matching error, averaged over 21 patients, amounted to 1.8 ± 0.4 mm (mean ± standard deviation). The fractions of the prostate volumes receiving the prescribed matched peripheral dose (MPD) ranged from 32 to 71% (mean ± standard deviation: 60 ± 10%). Prostate volumes, obtained by the contouring method on postimplant MRI, were a factor 1.5 ± 0.3 larger than the ellipsoidal volumes given by the prostate dimensions on postimplant MRI. Prostate volumes 3 days after the implantation were a factor 1.3 ± 0.2 larger than the prostate volumes 1 month after the implantation. Registration of the reconstructed seed distribution and the MR images showed inaccuracies in seed placement, for example, two or more seeds clustering together or seeds outside the prostate. Conclusions: Registration of the reconstructed seed distribution and the MR images enabled evaluation of target coverage, which amounted to 60 ± 10%. The discrepancy between prescribed dose and realized dose was caused by underestimation of the preimplant prostate volume due to the ellipsoidal approximation, postimplant prostate swelling at the time of evaluation, and inaccuracies in seed placement

1997-03-01

190

Comparison of [125I]somatomedin A and [125I]somatomedin C radioreceptor assays for somatomedin peptide content in whole and acid-chromatographed plasma  

International Nuclear Information System (INIS)

The placental membrane radioreceptor assay was used to measure the levels of somatomedin (SM) peptides in plasma. Displacement of both [125I]somatomedin A ([125I]SM-A) and [125I]somatomedin C ([125I]SM-C) by normal whole plasma, the peptide fraction of acid-chromatographed plasma, and a partially purified, insulin-free SM preparation were compared. The peptide fraction of plasma was isolated by acid chromatography over Sephadex G-50 in 0.25 M formic acid with a yield of greater than or equal to 90%, as determined by bioassay and [125I]SM. In the case of [125I]SM-A, the dose-response curves for whole plasma, acid-chromatographed plasma, and the standard SM preparation were parallel (P > 0.2). In contrast, for [125I]SM-C, the dose-response curves for acid-chromatographed plasma and the purified SM preparation were parallel (P > 0.2), but both differed significantly from that of whole plasma (P 125I]SM-A is a valid measure of SM peptide concentration, while radioreceptor assay of unextracted normal plasma using [125I]SM-C, in our hands, is not. Acid chromatography of plasma before its assay is an uncomplicated procedure which allows valid and precise measurement of SM peptide content using either [125I]SM-A or [125I]SM-C

1978-01-01

191

Labeling Lanreotide with 125I and 188Re. China  

International Nuclear Information System (INIS)

Lanreotide (D-?-Nal-Cys-Try-D-Trp-Lys-Val-Cys-Thr-NH2) is a new somatostatin analogue. It can bind to human somatostatin receptor (hSSTR) subtype 2 through 5 with high affinity and to hSSTR subtype 1 with low affinity. We investigate labeling condition, quality control and stability in vitro of 125I-Lanreotide and 188Re-lanreotide respectively. (A) Lanreotide is labeled with 125I using Chloramine T. The effect of reaction condition (such as reaction time, pH value, Lanreotide amount, quantity of Chloramine T and reaction volume) on labeling yield is investigated in detail. (B) The labeling yield and radiochemical purity (RP) is measured with paper chromatography (PC) and Sep-Pak C18 Cartridge. For PC method, 125I-Lanreotide is spotted on the Whatman No.1 paper and developed in the mixture of CH3CH2CH2CH2OH and CH3CH2OH and NH4OH (v/v/v=5:2:1), the Rf value of every component in the mobile phase is given in table 1. For Sep-Pak C18 Cartridge methods each cartridge is washed with 10 ml of ethanol followed by 10 ml of iso-CH3CH2CH2OH solution. Aliquots of 0.1 mI sample is loaded onto the cartridge, unbound peptide (sodium iodine-125) is eluted with 5 ml of 0.5mol/L sodium acetate solution, 125I-Lanreotide is eluted with 5 mI of 95% aqueous ethanol solution. (C) The stability of 125I-Lanreotide in vitro is investigated by labeling compound incubating for 48 hours at 37 deg. C in the 0.9% sodium chloride solution and RP is tested by PC at specific time intervals. (D) Lanreotide is labeled directly with 188Re via the mixture of citrate and tartate using stannous chloride as reduced agent. The influence of reaction conditions such as pH, temperature, amount of stannous chloride, amount of Lanreotide and reaction time on labeling yield is investigated in detail. At the time, the stability in vitro quality control and animal test are evaluated

2000-02-04

192

The use of new GAFCHROMIC EBT film for 125I seed dosimetry in Solid Water phantom  

International Nuclear Information System (INIS)

Radiochromic film dosimetry has been extensively used for intravascular brachytherapy applications for near field within 1 cm from the sources. With the recent introduction of new model of radiochromic films, GAFCHROMIC EBT, with higher sensitivity than earlier models, it is promising to extend the distances out to 5 cm for low dose rate (LDR) source dosimetry. In this study, the use of new model GAFCHROMIC EBT film for 125I seed dosimetry in Solid Water was evaluated for radial distances from 0.06 cm out to 5 cm. A multiple film technique was employed for four 125I seeds (Implant Sciences model 3500) with NIST traceable air kerma strengths. Each experimental film was positioned in contact with a 125I seed in a Solid Water phantom. The products of the air kerma strength and exposure time ranged from 8 to 3158 U-h, with the initial air kerma strength of 6 U in a series of 25 experiments. A set of 25 calibration films each was sequentially exposed to one 125I seed at about 0.58 cm distance for doses from 0.1 to 33 Gy. A CCD camera based microdensitometer, with interchangeable green (520 nm) and red (665 nm) light boxes, was used to scan all the films with 0.2 mm pixel resolution. The dose to each 125I calibration film center was calculated using the air kerma strength of the seed (incorporating decay), exposure time, distance from seed center to film center, and TG43U1S1 recommended dosimetric parameters. Based on the established calibration curve, dose conversion from net optical density was achieved for each light source. The dose rate constant was determined as 0.991 cGy U-1 h-1 (±6.9%) and 1.014 cGy U-1 h-1 (±6.8%) from films scanned using green and red light sources, respectively. The difference between these two values was within the uncertainty of the measurement. Radial dose function and 2D anisotropy function were also determined. The results obtained using the two light sources corroborated each other. We found good agreement with the TG43U1S1 recommended values of radial dose function and 2D anisotropy function, to within the uncertainty of the measurement. We also verified the dosimetric parameters in the near field calculated by Rivard using Monte Carlo method. The radial dose function values in Solid Water were lower than those in water recommended by TG43U1S1, by about 2%, 3%, 7%, and 14% at 2, 3, 4, and 5 cm, respectively, partially due to the difference in the phantom material composition. Radiochromic film dosimetry using GAFCHROMIC EBT model is feasible in determining 2D dose distributions around low dose rate 125I seed. It is a viable alternative to TLD dosimetry for 125I seed dose characterization

2008-08-01

193

Retrospective analysis of 1650 permanent pacemaker implantations experience over two different consecutive time periods in a single cardiology clinic  

Directory of Open Access Journals (Sweden)

Full Text Available Objective: Indications for pacing, pacing modes, and demographics of patients who underwent pacemaker implantation between two different time periods were compared in this study.Methods: Pacemaker registry of our cardiology department was used to evaluate these changes from 1986 to 2007 (First period: 1986-1996, second period: 1997-2007 retrospectively. Results: Registry revealed 776 implantations in the first and 874 implantations in the second period. The percentages of first implantation were 89% and 70.1% respectively. Nearly 50% of the patients in both periods were female. Main indications for pacing were atrioventricular (AV block, sick sinus syndrome (SSS and slow ventricular rate during atrial fibrillation in both periods. Implantation of VVI-AAI pacemakers have decreased (77.8%/1.5% to 51%/0.3%, p<0.05 and implantation of DDD-VDD pacemakers have increased (19.3%/1.3% to 42.3%/6.3%, p<0.05 during the second period compared to the first period. Permanent pacemaker implantation for SSS has decreased significantly from 31.1% in the first period to 12.0% (p<0.05 in the second period. Implantation for AV block has increased significantly from 63.3% to 79.7% (p<0.05 in the second period.Conclusion: Our data revealed temporal changes in pacemaker implantation practice during last twenty years in the cardiology department of a teaching hospital. Implantation of VVI-AAI pacemakers have decreased significantly during the second period. Permanent pacemaker implantation for AV block has also decreased during the last period.

Serdar Bayata

2010-04-01

194

Synthesis and radioimmunological characterization of testosterone-3-carboxymethyloxime-tyramine-125 I (T-3-Cmo-Ty-125 I)  

International Nuclear Information System (INIS)

The paper presents the synthesis and radioimmunological characterization of testosterone-3-carboxymethyloxime-tyramine-15 I (T-3-CMO-Ty-125 I), a reagent used as marker in radioimmunoassay (RIA) of steroid hormones. Some of the most adequate techniques of analyzing the steroid hormones are RIA and ELISA (enzyme linked immunosorbent assay) due to their sensitivity and specificity. These techniques do not require advanced purification of the sample. In the view of developing a sensitive RIA technique for assaying the testosterone-3-carboxymethyloxime-tyramine-125 I it is necessary to obtain the reagents as anti-testosterone antibody and radioactive labeled testosterone. The carboxy derivative of the steroid hormone was activated with ethylchloroformiate and tributylamine in dioxan and coupled with tyramine-125 I. Tyramine was labelled by chloramine method. The marker was purified by thin layer chromatography and extracted in methylic alcohol. Radioimmunological characterization of the marker was carried out with the help of the anti testosterone antibody obtained in our laboratory. (authors)

2002-09-26

195

Study on agroecology contamination from 125I gas and control measures in a simulated ecosystem  

International Nuclear Information System (INIS)

The study was made in an air-tight space in which a simulated agricultural ecosystem was contaminated from 125I gas. The contents of the study were summarized as follows: The space and time distribution of 125I gas, contamination of foliage of the plants, accumulation and transfer of 125I fallen on the soil and entered into the plants from the roots of crops and vegetables, the time distribution of 125I in crops in water contaminated from 125I fallout, distribution, accumulation and transfer of 125I in chickens and rabbits which inhaled 125I gas or fed the fodder contaminated from 125I. The control measures of contamination in agroenvironment from 125I were discussed. (7 refs., 20 figs., 29 tabs.)

1995-01-01

196

Relationship between temperature change and the requirement for a permanent pacemaker implantation in bradyarrhythmias  

Science.gov (United States)

Some cardiovascular diseases are associated with seasonal or meteorological factors. We tried to identify the relationship between meteorological parameters and the requirement for a permanent pacemaker (PPM) implantation for advanced sinus node dysfunction (SND) and atrioventricular block (AVB). This study enrolled 656 patients (67% male, age = 76 ± 11 years) who underwent a PPM implantation due to SND or AVB from January 2004 to December 2008. Using daily temperature, barometric pressure, humidity, and daylight hour records from Taipei, we evaluated the effect of these meteorological parameters within different time periods on the occurrence of SND and AVB. There were 355 patients in the SND group and 301 in the AVB group. In the AVB group, more patients presented in the spring than in other seasons ( P = 0.003). In the SND group, there was no relationship with the seasons ( P = 0.137). The proportion of patients with AVB did not depend on the average temperature, barometric pressure, humidity, or daylight hours within 3, 7, and 14 days prior to admission ( P = NS). A temperature change of greater than 11°C within 30 days prior to admission was associated with a significantly higher proportion of patients with advanced AVB compared to those with advanced SND ( P = 0.009). Extreme change in temperature was the most independent predictor of the development of advanced AVB. The peak occurrence of advanced AVB was in the spring. The occurrence of advanced AVB was associated with extreme temperature changes within 30 days, especially in the spring.

Liu, I.-Fan; Chang, Shih-Lin; Lo, Li-Wei; Hu, Yu-Feng; Tuan, Ta-Chuan; Kong, Chi-Woon; Wu, Tsu-Juey; Chiang, Chern-En; Chen, Shih-Ann; Lin, Yenn-Jiang

2011-09-01

197

Killing effect of 125I-UdR on human lymphoma Raji and Daudi cell lines  

International Nuclear Information System (INIS)

Objective: To evaluate the killing effect and the uptake of 125I-UdR on human lymphoma Raji and Daudi cell lines. Methods: The amount of 125I-UdR in the cells and cell nuclei were determined after incubation of different time in RPMI 1640 culturing medium containing different concentrations of 125I-UdR. The killing effects of 125I-UdR on Raji and Daudi cell lines were estimated through MTT assay and cell cycle was analyzed by propidium iodide (PI) staining. Results: The amounts of 125I-UdR in Raji and Daudi cells and cell nuclei were much higher than that of Na125I( P125I-UdR in Raji and Daudi cells were 14 414 ± 95 and (6916 ± 53.69) Bq/106 cell when the concentration was 100 kBq/ml. The amounts of Na125I were 68±3.8 and (324±32.8) Bq/106 cell. The uptake of 125I-UdR in Raji and Daudi cells and cell nuclei increased with the 125I-UdR concentration and incubated time. The cell surviving fractions of 125I-UdR groups was much lower than that of Na125I groups (P125I-UdR groups were (19.78±1.39)% and (43.17±2.69)%; those of Na125I groups were(79.10±1.79)% and (80.36±6.12)%. The surviving fi:actions of 125I-UdR groups reduced with the 125I-UdR concentration. Conclusions: 125I-UdR can Be specially ingested by Raji and Daudi cells and incorporated into DNA, then the cells will be killed. The uptake of 125I-UdR is dose and time dependent. (authors)

2009-02-01

198

Development of procedure using plasma welding process to produce 125I seeds  

International Nuclear Information System (INIS)

The prostate cancer, which is the second cause of death by cancer in men, overcome only by lung cancer, is a problem of public health in Brazil. Brachytherapy is among the possible available treatments for prostate cancer, in which small seeds containing 125I radioisotope are implanted in the prostate. The seed consists of a titanium sealed capsule with 0.8 mm external diameter and 4.5 mm length, containing a central silver wire with adsorbed 125I. The plasma arc welding is one of the viable techniques for the sealing process. The equipment used in this technique is less costly than in other processes. The main objective of this work was the development and the validation of the welding procedure using plasma welding process and the elaboration of a sealing routine according to Good Manufacturing Practices. The development of this work has presented the following phases: cut and cleaning of the titanium material, determination of the welding parameters, development of a device for holding the titanium tube during the welding process, validation of sealed sources according to ISO 2919 Sealed Radioactive Sources - General Requirements and Classification, leakage test according to ISO 9978 Sealed Radioactive Sources - Leakage Test Methods and metallographic assays. The developed procedure, to seal 125I seeds using plasma welding process, has shown to be efficient, satisfying all the established requirements of ISO 2919. The results obtained in this work have given the possibility to establish a routine production process according to the orientations presented in resolution RDC number 59 - Good Manufacturing Practices do Medical Products of the ANVISA - Brazilian Nacional Agency of Sanitary Surveillance. (author)

2006-01-01

199

Superior immunoreactivity of 125I (Des-Tyr-betaAla)-secretin with rabbit anti-secretin sera compared to 125I-secretin and 125 I-6-Tyrosyl secretin.  

Science.gov (United States)

A secretin analogue in which the normal amino acid sequence had been elongated by a (Des-Tyr-betaAla)-residue was studied as tracer for secretin radioimmunoassay. 125I-(DATA)-secretin exhibited superior immunoreactivity with several rabbit anti-secretin sera compared to 125I-6-Tyr-secretin and also to secretin iodinated at its N-terminal histidyl residue. This may be due, at least in part, to higher conformational integrity of the secretin moiety in the 125I-(DATA)-secretin molecule. Thus, at present, 125I-(DATA)-secretin appears to be most suitable as tracer for sensitive secretin radioimmunoassay. PMID:1002105

Urbach, J H; Domschke, W; Reiss, M; Domschke, S; Rosselin, G; Wünsch, E; Jaeger, E; Moroder, L; Demling, L

1976-11-01

200

Distribution of progesterone receptor in the 20-day-old fetal mouse: an autoradiographic study with [125I]progestin  

International Nuclear Information System (INIS)

The distribution of progestin target sites in 20-day-old fetuses of estrogen-primed pregnant mice was investigated by thaw-mount autoradiography. Pregnant mice received a Silastic estradiol implant on day 17 and were ovariectomized on day 19 of pregnancy. Twenty-four hours after ovariectomy 10 prematurely delivered fetuses were each injected with 0.33 microgram/100 g BW [125I]progestin (SA, 2200 Ci/mM). To show specificity of progestin localization two additional fetuses were each injected sc with 20 micrograms R5020, a synthetic progestin, 1 h before the injection of [125I]progestin. The fetuses were frozen 2 h after injection of [125I]progestin, sectioned, and processed for thaw-mount autoradiography. Cells with nuclear uptake and retention of radioactivity were observed in numerous tissues, including certain regions of the oral mucosa and developing teeth, esophagus, larynx, skin, mammary gland, skeletal muscle, kidney, and reproductive glands and ducts. Injection of unlabeled R5020 1 h before [125I]progestin prevented nuclear concentration of radioactivity in all target tissues. The results indicate that progesterone receptors are expressed with a regional, cellular, and subcellular distribution in term fetal mouse tissues and suggest that progesterone is important to the growth and development of certain fetal tissues

1988-01-01

 
 
 
 
201

Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation  

International Nuclear Information System (INIS)

Purpose: To look for factors predictive of acute urinary retention (AUR) after permanent seed prostate brachytherapy. Methods and Materials: From March 1999 to February 2001, 150 permanent seed prostate implants were performed at Princess Margaret Hospital (Stage T1c, n = 113; T2a, n = 37; mean prostate-specific antigen level 5.9 ng/mL, prescription dose 145 Gy per Task Group No. 43). ?-Blockers were used routinely after implantation. Dosimetry was based on the 1-month postimplant CT scan. The International Prostate Symptom Score (IPSS) and catheterization were recorded at 1 month and 3 months and then every 3 months. The following variables were examined: age, baseline IPSS, prior androgen ablation, prostate transrectal ultrasound volume, number of seeds, D90, V100, V200, and urethral dose. Results: Twenty patients (13%) experienced AUR. No difference was seen in the mean D90 (149 Gy vs. 152 Gy, p=0.6), V100 (90% vs. 91%, p=0.6), V200 (23% vs. 25% p=0.4), IPSS (6.4 vs. 5.9, p=0.8), or maximal urethral dose (204 Gy vs. 210 Gy, p=0.5). The prostate volume was significantly larger in men with AUR (39.8 cm3 vs. 34.3 cm3, p=0.003), and the mean number of seeds was higher (112 vs. 103, p=0.006). Of the 20 patients experiencing AUR, 11 (55%) had received prior antiandrogen therapy to downsize their prostates vs. 35 (27%) of the 130 who did not have AUR (p=0.02). Multivariate analysis showed prostate volume and prior hormone use to be independent predictors of AUR. Conclusions: Implant quality as determined by D90, V100, V200, and urethral dose did not predict AUR. Prostate size was the major determinant of AUR. For any given prostate size, prior androgen ablation increased the risk of AUR. Men with larger prostates should be aware of the increased risk when contemplating brachytherapy

2002-02-01

202

Evaluating the Phoenix Definition of Biochemical Failure After 125I Prostate Brachytherapy: Can PSA Kinetics Distinguish PSA Failures From PSA Bounces?  

International Nuclear Information System (INIS)

Purpose: To evaluate the prostate-specific antigen (PSA) kinetics of PSA failure (PSAf) and PSA bounce (PSAb) after permanent 125I prostate brachytherapy (PB). Methods and Materials: The study included 1,006 consecutive low and 'low tier' intermediate-risk patients treated with 125I PB, with a potential minimum follow-up of 4 years. Patients who met the Phoenix definition of biochemical failure (nadir + 2 ng/mL-1) were identified. If the PSA subsequently fell to ?0.5 ng/mL-1without intervention, this was considered a PSAb. All others were scored as true PSAf. Patient, tumor and dosimetric characteristics were compared between groups using the chi-square test and analysis of variance to evaluate factors associated with PSAf or PSAb. Results: Median follow-up was 54 months. Of the 1,006 men, 57 patients triggered the Phoenix definition of PSA failure, 32 (56%) were true PSAf, and 25 PSAb (44%). The median time to trigger nadir + 2 was 20.6 months (range, 6-36) vs. 49 mo (range, 12-83) for PSAb vs. PSAf groups (p < 0.001). The PSAb patients were significantly younger (p < 0.0001), had shorter time to reach the nadir (median 6 vs. 11.5 months, p = 0.001) and had a shorter PSA doubling time (p = 0.05). Men younger than age 70 who trigger nadir +2 PSA failure within 38 months of implant have an 80% likelihood of having PSAb and 20% chance of PSAf. Conclusions: With adequate follow-up, 44% of PSA failures by the Phoenix definition in our cohort were found to be benign PSA bounces. Our study reinforces the need for adequate follow-up when reporting PB PSA outcomes, to ensure accurate estimates of treatment efficacy and to avoid unnecessary secondary interventions.

2010-10-01

203

125I-progesterone radioimmunoassay for fertility control in cows  

International Nuclear Information System (INIS)

A 125I RIA has been developed for progesterone determination in full-cream milk, skimmed milk and blood plasma. Because of its specificity, accuracy and practicability it is particularly suitable for routine work. First experience has been gained in field studies on fertility control of cows. As early as one estrous cycle after insemination, non-pregnant cows can be distinguished from presumably pregnant ones with a high degree of certainty, so that a timely re-insemination of those animals is rendered possible. Insemination outside the estrous cycle was found to be one reason for supposed fertility disorders

1985-01-01

204

Studies on characteristics of dosimetry for 125I ophthalmic applicator  

International Nuclear Information System (INIS)

Isodose curves for 125I ophthalmic application in different geometry and activity can be obtained using the empirical formula based on suitable geometric model. The results of surface dose rate determined with lithium fluoride (LiF) thermoluminescent dosimeter (TLD's) chips in water-organic glass phantom and air had no obvious difference and the surface dose rate and its uniformity, (3.46 +- 0.011) and (0.178 +- 0.15) nGy/h·107Bq were obtained. Count measurements and dose determinations for the front and back etc. of the ophthalmic applicator with BaF2 scintillation detector and LiF TLD's had revealed the space distribution of dose for 125I ophthalmic applicator in which dose on the back was less than 0.1% of that on the front. The distribution of the absorbed dose rate along the eye axis had been measured using LiF TLD's in water-organic glass phantom. The measured and calculated dose data indicated that when measuring distances were larger than about 5 mm the experimental results agreed with those from calculation within the range of error, otherwise the measured values were lower, still it could be explained by experimental conditions

2001-05-01

205

Practical application of 125I-fibrinogen leg scanning  

International Nuclear Information System (INIS)

The diagnosis of venous thrombosis by radioiodine-labeled fibrinogen scanning depends upon the incorporation of circulating labeled fibrinogen into a developing or established thrombus which is then detected by measuring the increase of overlying surface radioactivity with an isotope detector. The scanning procedure is simple and rapid, and one technician can screen 15 to 20 patients daily. A single intravenous injection of 100 ?Ci of 125I-fibrinogen enables scanning to be performed for approximately 7 days. leg scanning has been a valuable research tool and is also useful for the clinical management of patients with venous thrombosis. Its limitations are its insensitivity to iliac vein thrombosis and relative insensitivity to thrombi in the upper thigh, and when used diagnostically in patients with clinically suspected venous thrombosis there is a delay of up to 2 days before a positive result is obtained. For these reasons leg scanning should not be used alone in patients with clinically suspected venous thrombosis. The practical indications for using 125I-fibrinogen leg scanning are (1) for diagnosis of clinically suspected venous thrombosis when used in combination with impedance plethysmography; (2) detection of acute venous thrombosis in patients with chronic venous insufficiency; (3) screening patients who develop calf vein thrombosis when there is contraindication to anticoagulant therapy; and (4) screening certain high-risk patients and patient groups in whom the prophylaxis is either contraindicated or ineffective

1981-01-01

206

Scattering of gaseous {sup 125}I from a bottle containing Na{sup 125}I solution for iodination in a calm condition  

Energy Technology Data Exchange (ETDEWEB)

Scattering of gaseous {sup 125}I from a bottle containing Na{sup 125}I solution for iodination has been measured by distributing active charcoal granule at various heights on the inner surface of a plastic cylinder surrounding the bottle and counting the activities of granule samples. The result shows that about 70% of total scattered {sup 125}I exist below the level of mouth of the bottle. By drawing the air from the bottle of the cylinder through a tube filled with active charcoal, about 90% of scattered {sup 125}I collected. (author)

Aoki, Katsumi; Furuse, Yuko; Nishimaki, Toshiyuki; Shinozuka, Akiko [Kitasato Univ., Sagamihara, Kanagawa (Japan). School of Medicine

1997-05-01

207

PSA bounce after brachytherapy with permanent seed implantation for prostate cancer  

International Nuclear Information System (INIS)

The purpose of this study was to evaluate prostate specific antigen (PSA) bounce that may occur as a time PSA rise phenomenon during follow up period after brachytherapy (BT) with permanent seed implantation for prostate cancer. Seven hundred and forty-six patients had undergone BT from November 2003 to April 2007 in a single institute, and of 130 patients who did not receive hormone therapy and had minimal 3-year follow up are analyzed. PSA bounce was defined as a rise of at least 0.4 ng/ml with spontaneous return to pre-bounce level or lower. Among the 130 patients, 40 patients (30.8%) developed PSA bounce, and median time to PSA bounce was 18 months after the BT. With univariate analysis, younger patients (P=0.027) and larger prostate (P=0.030) had statistically significant correlation with PSA bounce. With multivariate analysis, younger patients were identified as only independent factor for predicting PSA bounce. Eight patients out of 130 patients (6.2%) triggered the Phoenix definition (nadir +2 ng/ml) of PSA failure, however, clinical failure was seen only in 3 patients, and other 5 patients were considered as PSA bounce. PSA bounce is likely to occur in younger patients within 3 years after BT. It is clinically important to distinguish PSA bounce from PSA failure during following period after BT. (author)

2011-09-01

208

Standardisation of 125I using seven techniques for radioactivity measurement  

International Nuclear Information System (INIS)

Seven methods of radioactivity measurement were used to standardise an 125I solution within the frame of an international key comparison organised by BIPM: photon-photon coincidence counting with two NaI detectors, photon sum-peak counting in a NaI well detector and in a 4? CsI(Tl) sandwich spectrometer, total emission counting in a windowless 4? CsI(Tl) sandwich spectrometer, electron-X,? coincidence counting and electron-X,? sum counting in a pressurised proportional counter inside a NaI well detector and liquid scintillation counting with the CIEMAT/NIST method. The solid sources were prepared by quantitative drop deposition with addition of AgNO3. The measurement methods, the results and the applied corrections are described and discussed

2005-06-01

209

Potential errors in the radioassay of 125I  

International Nuclear Information System (INIS)

The radioassay of very small 125I samples in both conventional and side-hole well crystal scintillation counters was investigated. Using a multichannel analyzer, the source was counted at various positions within these well crystals. The effect of using a single-channel pulse-height analyzer was simulated by summing the counts over a 24-keV range across the primary peak, over a 30-keV range across the sum-coincidence peak, and over a 56-keV range across both peaks. In all crystals the primary peak was independent of sample position within the well over a range of several centimeters. The contribution of the sum-coincidence peak varied significantly with sample position in the conventional well crystals. With the side-hole crystal the counts contributed by the sum-coincidence peak exhibited a 2-cm plateau. (auth)

1975-01-01

210

Potential errors in the radioassay of 125I.  

Science.gov (United States)

The radioassay of very small 125I samples in both conventional and side-hole well crystals has been investigated. Using a multichannel analyzer, the source was counted at various positions within these well crystals. The effect of using a single-channel pulse-height analyzer was simulated by summing the counts over a 24-keV range across the primary peak, over a 30-keV range across the sum-coincidence peak, and over a 56-keV range across both peaks. In all crystals the primary peak was independent of sample position within the well over a range of several centimeters. The contribution of the sum-coincidence peak varied significantly with sample position in the conventional well crystals. With the side-hole crystal the counts contributed by the sum-coincidence peak exhibited a 2-cm plateau. PMID:1177028

Hunter, D; Dratz, A F; Rohrer, R H; Coberly, J C

1975-10-01

211

Permanent pacemaker implantation for late atrioventricular block in patients receiving catheter ablation for atrioventricular nodal reentrant tachycardia.  

Science.gov (United States)

The present study investigated the incidence and predictors of permanent pacemaker (PPM) implantation for late atrioventricular block (AVB) in patients with atrioventricular nodal reentrant tachycardia (AVNRT) who received ablation. The data from 3,442 patients with AVNRT who received ablation were analyzed. Those who developed late AVB (>1 month after ablation) and received a PPM were identified. The incidence of PPM implantation in 1,148 matched patients with Wolff-Parkinson-White syndrome and in the whole population of Taiwan were compared. Of the patients with AVNRT receiving ablation (mean follow-up duration 128.3 ± 62.5 months), 15 (0.4%) received PPM implantation for late AVB (mean interval after catheter ablation 95.4 ± 55.0 months). Only age (odds ratio 1.05, p = 0.02) and transient AVB (odds ratio 8.55, p = 0.01) during the procedure were independently associated with PPM implantation for late AVB. The patients with AVNRT had a greater incidence of PPM implantation due to late AVB compared to the matched patients with Wolff-Parkinson-White syndrome. The annual incidence of PPM implantation for AVB was also greater in the patients with AVNRT than in the general population. In conclusion, the incidence of PPM implantation for late AVB in patients with AVNRT who received catheter ablation was low but still greater than that in patients with Wolff-Parkinson-White syndrome and the general population in Taiwan. PMID:23219174

Liao, Jo-Nan; Hu, Yu-Feng; Wu, Tsu-Juey; Fong, Ann-Ning; Lin, Wei-Shiang; Lin, Yenn-Jiang; Chang, Shih-Lin; Lo, Li-Wei; Tuan, Ta-Chuan; Chang, Hung-Yu; Li, Cheng-Hung; Chao, Tze-Fan; Chung, Fa-Po; Hanafy, Dicky Armein; Lin, Wen-Yu; Huang, Jin-Long; Huang, Chin-Chou; Leu, Hsin-Bang; Lee, Pi-Chang; Chiang, Chern-En; Chen, Shih-Ann

2013-02-15

212

Sensitive radioimmunoassay for somatostatin using N-[125I]-tyr-somatostatin as labelled antigen  

International Nuclear Information System (INIS)

A sensitive radioimmunoassay for somatostatin using N-(125I]-Tyr-somatostatin is described and compared with using [125I]-Tyr1-somatostatin. The minimum detectable amount of somatostatin using N-[125I]-Tyr-somatostatin as tracer was 0.1 to 0.5 pg, which is approximately 10-fold lower detection limit of the RIA using [125I]-Tyr1-somatostatin. Moreover, it was found that the shelf-life of N-[125I]-Tyr-somatostatin was prolonged in comparison with labelled Tyr1-somatostatin. Human pancreatic and gastric extracts displayed immunological similarity to synthetic somatostatin tetradecapeptide. (author)

1979-01-01

213

Activation of 125I-Factor IX and 125I-Factor X: Effect of tissue factor and Factor VII, Factor Xsub(a) and thrombin  

International Nuclear Information System (INIS)

Activation of Factor IX and Factor X was studied by adding 125I-Factor IX or 125I-Factor X to reaction mixtures and quantitating cleavage products by reduced sodium dodecylsulfate gel electrophoresis. Thrombin failed to activate Factors IX or X; Factor Xsub(a) produced insignificant amounts of cleavage products of both factors. In contrast, the reaction product of tissue factor and Factor VII cleaved large amounts of both Factor IX and Factor X in purified systems and in plasma. In incubation mixtures of plasma containing added 125I-Factor IX or 125I-Factor X, tissue factor and Ca2+ions, the percentage of total radioactivity in the heavy chain peak of 125I-IXsub(a) and the heavy chain of 125I-Xsub(a) increased at a similar rate. When the tissue factor was diluted, similar curves were obtained for percent cleavage of 125I-Factor IX and percent cleavage of 125I-Factor X plotted against tissue factor concentration. These findings support the hypothesis that activation of Factor IX by the tissue factor-Factor VII reaction product represents a physiologically significant step in normal haemostasis. (author)

214

Metabolism and placental transfer of /sup 125/I-proinsulin and /sup 125/I-tyrosylated C-peptide in the pregnant rhesus monkey  

Energy Technology Data Exchange (ETDEWEB)

/sup 125/I-Proinsulin or /sup 125/I-tyrosylated-C-peptide (/sup 125/I-tyr-CP) was administered to pregnant Rhesus monkeys by bolus followed by constant infusion to examine placental transfer of these peptides. At the end of each infusion, fetuses were exsanguinated in situ via the umbilical vein. The bolus-constant infusion technique produced a steady state in maternal plasma of immunoprecipitable label, measured using excess insulin or C-peptide antiserum. In animals infused with /sup 125/I-proinsulin, analysis of umbilical venous plasma revealed no apparent transfer to the fetus of immunoprecipitable label. In animals infused with /sup 125/I-tyr-CP, 3-13% of the umbilical venous plasma radioactivity was immunoprecipitable, representing 1.4-5.8% of the immunoprecipitable radioactivity in maternal plasma at delivery. Gel filtration chromatography of umbilical venous plasma revealed that the immunoprecipitated moiety was a fragment of /sup 125/I-tyr-CP. Analysis of maternal plasma showed that the predominant peak of radioactivity represented intact C-peptide. A peak corresponding to the fetal immunoprecipitable peak was also present. Analysis of simultaneous maternal arterial and uterine vein plasma samples showed that degradation of /sup 125/I-tyr-CP occurred across the uterus. Studies in one nonpregnant and three postpartum animals indicated that pregnancy increased the rate of metabolism of /sup 125/I-tyr-CP. When /sup 125/I-tyr-CP was incubated with trophoblastic cells in culture, degradation to a species corresponding on gel filtration to the immunoprecipitable fetal metabolite was found. We conclude that proinsulin, like insulin, does not traverse the placenta. Immunoreactive fragments of C-peptide do cross, however, and pregnancy alters the metabolism of /sup 125/I-tyr-CP, probably owing to placental degradation.

Gruppuso, P.A.; Susa, J.B.; Sehgal, P.; Frank, B.; Schwartz, R.

1987-10-01

215

Metabolism and placental transfer of 125I-proinsulin and 125I-tyrosylated C-peptide in the pregnant rhesus monkey  

International Nuclear Information System (INIS)

125I-Proinsulin or 125I-tyrosylated-C-peptide (125I-tyr-CP) was administered to pregnant Rhesus monkeys by bolus followed by constant infusion to examine placental transfer of these peptides. At the end of each infusion, fetuses were exsanguinated in situ via the umbilical vein. The bolus-constant infusion technique produced a steady state in maternal plasma of immunoprecipitable label, measured using excess insulin or C-peptide antiserum. In animals infused with 125I-proinsulin, analysis of umbilical venous plasma revealed no apparent transfer to the fetus of immunoprecipitable label. In animals infused with 125I-tyr-CP, 3-13% of the umbilical venous plasma radioactivity was immunoprecipitable, representing 1.4-5.8% of the immunoprecipitable radioactivity in maternal plasma at delivery. Gel filtration chromatography of umbilical venous plasma revealed that the immunoprecipitated moiety was a fragment of 125I-tyr-CP. Analysis of maternal plasma showed that the predominant peak of radioactivity represented intact C-peptide. A peak corresponding to the fetal immunoprecipitable peak was also present. Analysis of simultaneous maternal arterial and uterine vein plasma samples showed that degradation of 125I-tyr-CP occurred across the uterus. Studies in one nonpregnant and three postpartum animals indicated that pregnancy increased the rate of metabolism of 125I-tyr-CP. When 125I-tyr-CP was incubated with trophoblastic cells in culture, degradation to a species corresponding on gel filtration to the immunoprecipitable fetal metabolite was found. We conclude that proinsulin, like insulin, does not traverse the placenta. Immunoreactive fragments of C-peptide do cross, however, and pregnancy alters the metabolism of 125I-tyr-CP, probably owing to placental degradation

1987-01-01

216

Dosimetric characterization of the GammaClip™{sup 169}Yb low dose rate permanent implant brachytherapy source for the treatment of nonsmall cell lung cancer postwedge resection  

Energy Technology Data Exchange (ETDEWEB)

Purpose: A novel {sup 169}Yb low dose rate permanent implant brachytherapy source, the GammaClip™, was developed by Source Production and Equipment Co. (New Orleans, LA) which is designed similar to a surgical staple while delivering therapeutic radiation. In this report, the brachytherapy source was characterized in terms of “Dose calculation for photon-emitting brachytherapy sources with average energy higher than 50 keV: Report of the AAPM and ESTRO” by Perez-Calatayud et al. [Med. Phys. 39, 2904–2929 (2012)] using the updated AAPM Task Group Report No. 43 formalism.Methods: Monte Carlo calculations were performed using Monte Carlo N-Particle 5, version 1.6 in water and air, the in-air photon spectrum filtered to remove photon energies below 10 keV in accordance with TG-43U1 recommendations and previously reviewed {sup 169}Yb energy cutoff levels [D. C. Medich, M. A. Tries, and J. M. Munro, “Monte Carlo characterization of an Ytterbium-169 high dose rate brachytherapy source with analysis of statistical uncertainty,” Med. Phys. 33, 163–172 (2006)]. TG-43U1 dosimetric data, including S{sub K}, D-dot (r,?), ?, g{sub L}(r), F(r, ?), ?{sub an}(r), and ?{sub an} were calculated along with their statistical uncertainties. Since the source is not axially symmetric, an additional set of calculations were performed to assess the resulting axial anisotropy.Results: The brachytherapy source's dose rate constant was calculated to be (1.22 ± 0.03) cGy h{sup ?1} U{sup ?1}. The uncertainty in the dose to water calculations, D-dot (r,?), was determined to be 2.5%, dominated by the uncertainties in the cross sections. The anisotropy constant, ?{sub an}, was calculated to be 0.960 ± 0.011 and was obtained by integrating the anisotropy factor between 1 and 10 cm using a weighting factor proportional to r{sup ?2}. The radial dose function was calculated at distances between 0.5 and 12 cm, with a maximum value of 1.20 at 5.15 ± 0.03 cm. Radial dose values were fit to a fifth order polynomial and dual exponential regression. Since the source is not axially symmetric, angular Monte Carlo calculations were performed at 1 cm which determined that the maximum azimuthal anisotropy was less than 8%.Conclusions: With a higher photon energy, shorter half-life and higher initial dose rate {sup 169}Yb is an interesting alternative to {sup 125}I for the treatment of nonsmall cell lung cancer.

Currier, Blake [Medical Physics, University of Massachusetts Lowell, 1 University Avenue, Lowell, Massachusetts 01854 (United States); Munro, John J. III [Source Production and Equipment Co., Inc., 113 Teal Street, St. Rose, Louisiana 70087 (United States); Medich, David C. [Department of Physics, Worcester Polytechnic Institute, 100 Institute Road, Worcester, Massachusetts 01609 (United States)

2013-08-15

217

Dosimetric characterization of the GammaClip™169Yb low dose rate permanent implant brachytherapy source for the treatment of nonsmall cell lung cancer postwedge resection  

International Nuclear Information System (INIS)

Purpose: A novel 169Yb low dose rate permanent implant brachytherapy source, the GammaClip™, was developed by Source Production and Equipment Co. (New Orleans, LA) which is designed similar to a surgical staple while delivering therapeutic radiation. In this report, the brachytherapy source was characterized in terms of “Dose calculation for photon-emitting brachytherapy sources with average energy higher than 50 keV: Report of the AAPM and ESTRO” by Perez-Calatayud et al. [Med. Phys. 39, 2904–2929 (2012)] using the updated AAPM Task Group Report No. 43 formalism.Methods: Monte Carlo calculations were performed using Monte Carlo N-Particle 5, version 1.6 in water and air, the in-air photon spectrum filtered to remove photon energies below 10 keV in accordance with TG-43U1 recommendations and previously reviewed 169Yb energy cutoff levels [D. C. Medich, M. A. Tries, and J. M. Munro, “Monte Carlo characterization of an Ytterbium-169 high dose rate brachytherapy source with analysis of statistical uncertainty,” Med. Phys. 33, 163–172 (2006)]. TG-43U1 dosimetric data, including SK, D-dot (r,?), ?, gL(r), F(r, ?), ?an(r), and ?an were calculated along with their statistical uncertainties. Since the source is not axially symmetric, an additional set of calculations were performed to assess the resulting axial anisotropy.Results: The brachytherapy source's dose rate constant was calculated to be (1.22 ± 0.03) cGy h?1 U?1. The uncertainty in the dose to water calculations, D-dot (r,?), was determined to be 2.5%, dominated by the uncertainties in the cross sections. The anisotropy constant, ?an, was calculated to be 0.960 ± 0.011 and was obtained by integrating the anisotropy factor between 1 and 10 cm using a weighting factor proportional to r?2. The radial dose function was calculated at distances between 0.5 and 12 cm, with a maximum value of 1.20 at 5.15 ± 0.03 cm. Radial dose values were fit to a fifth order polynomial and dual exponential regression. Since the source is not axially symmetric, angular Monte Carlo calculations were performed at 1 cm which determined that the maximum azimuthal anisotropy was less than 8%.Conclusions: With a higher photon energy, shorter half-life and higher initial dose rate 169Yb is an interesting alternative to 125I for the treatment of nonsmall cell lung cancer

2013-08-01

218

New material for low-dose brachytherapy seeds: Xe-doped amorphous carbon films with post-growth neutron activated 125I  

International Nuclear Information System (INIS)

We report a novel material for use in 125I brachytherapy that consists of amorphous carbon films grown by ion-beam-assisted deposition and doped with Xe (5 at%) by implantation. Samples of these films grown on Si substrates were irradiated with neutrons in a TRIGA-I nuclear reactor for the production 125Xe, and latter characterized by gamma spectroscopy. The results indicate that the 124Xe was efficiently converted into 125Xe, the precursor of 125I, and support the activity calculations for a model brachytherapy seed.

2011-01-01

219

New material for low-dose brachytherapy seeds: Xe-doped amorphous carbon films with post-growth neutron activated 125I.  

Science.gov (United States)

We report a novel material for use in (125)I brachytherapy that consists of amorphous carbon films grown by ion-beam-assisted deposition and doped with Xe (5 at%) by implantation. Samples of these films grown on Si substrates were irradiated with neutrons in a TRIGA-I nuclear reactor for the production (125)Xe, and latter characterized by gamma spectroscopy. The results indicate that the (124)Xe was efficiently converted into (125)Xe, the precursor of (125)I, and support the activity calculations for a model brachytherapy seed. PMID:20729094

Gonçalves, R G F; Pinheiro, M V B; Lacerda, R G; Ferlauto, A S; Ladeira, L O; Krambrock, K; Leal, A S; Viana, G A; Marques, F C

2011-01-01

220

Dose escalation in permanent brachytherapy for prostate cancer: dosimetric and biological considerations  

Science.gov (United States)

No prospective dose escalation study for prostate brachytherapy (PB) with permanent implants has been reported. In this work, we have performed a dosimetric and biological analysis to explore the implications of dose escalation in PB using 125I and 103Pd implants. The concept of equivalent uniform dose (EUD), proposed originally for external-beam radiotherapy (EBRT), is applied to low dose rate brachytherapy. For a given 125I or 103Pd PB, the EUD for tumour that corresponds to a dose distribution delivered by EBRT is calculated based on the linear quadratic model. The EUD calculation is based on the dose volume histogram (DVH) obtained retrospectively from representative actual patient data. Tumour control probabilities (TCPs) are also determined in order to compare the relative effectiveness of different dose levels. The EUD for normal tissue is computed using the Lyman model. A commercial inverse treatment planning algorithm is used to investigate the feasibility of escalating the dose to prostate with acceptable dose increases in the rectum and urethra. The dosimetric calculation is performed for five representative patients with different prostate sizes. A series of PB dose levels are considered for each patient using 125I and 103Pd seeds. It is found that the PB prescribed doses (minimum peripheral dose) that give an equivalent EBRT dose of 64.8, 70.2, 75.6 and 81 Gy with a fraction size of 1.8 Gy are 129, 139, 150 and 161 Gy for 125I and 103, 112, 122 and 132 Gy for 103Pd implants, respectively. Estimates of the EUD and TCP for a series of possible prescribed dose levels (e.g., 145, 160, 170 and 180 Gy for 125I and 125, 135, 145 and 155 for 103Pd implants) are tabulated. The EUD calculation was found to depend strongly on DVHs and radiobiological parameters. The dosimetric calculations suggest that the dose to prostate can be escalated without a substantial increase in both rectal and urethral dose. For example, increasing the PB prescribed dose from 145 to 180 Gy increases EUD for the rectum by only 3%. Our studies indicate that the dose to urethra can be kept within 100-120% of the prescription dose for all the dose levels studied. In conclusion, dose escalation in permanent implant for localized prostate cancer may be advantageous. It is dosimetrically possible to increase dose to prostate without a substantial increase in the dose to the rectum and urethra. Based on the results of our studies, a prospective dose escalation trial for prostate permanent implants has been initiated at our institution.

Li, X. Allen; Wang, Jian Z.; Stewart, Robert D.; Di Biase, Steven J.

2003-09-01

 
 
 
 
221

Immediate postextraction implantation with provisionalization of two primary canines and related impacted permanent canines: a case report.  

Science.gov (United States)

This study presents a case of replacing two maxillary primary canines and related impacted permanent canines with two single implants, in conjunction with grafting lost hard tissue. By using immediate postextraction implant placement and provisionalization protocols, the stability of the implant was ensured while bypassing the bony void created by the removal of the primary canines. In this respect, a minimum healing period of 1 year was originally planned to evaluate the gingival esthetics before the final step was carried out. By the time the final restorations were fitted, the graft and tissues were stable. The time involved not only placed biology on the clinician's side, but also helped the patient to spread the cost over time. In modern esthetic dentistry, harmonious results can be achieved relatively quickly when the prerequisites for esthetic success have already been met, but, as this case demonstrates, human biology often requires more time and patience for augmented hard and soft tissues to heal and mature. PMID:24600661

D'Amato, Salvatore; Redemagni, Marco

2014-01-01

222

The influence of repopulation kinetics on isoeffect doses for permanent implants  

Energy Technology Data Exchange (ETDEWEB)

To calculate the isoeffective doses a model is used which describes the number of clonogenic tumor cells as a function of time. The effective irradiation time for permanent inplants depends on the half-life T{sub 1/2} of the used isotope. During the irradiation tumor cells may repopulate, an effect which is well known in fractionated radiotherapy. The longer the radiation treatment lasts the more dose will be needed to kill these repopulating tumor cells. A differential equation has been constructed where cell kill is determined by an {alpha}-{beta} term and cell proliferation by a constant tumor cell doubling time T{sub pot}. The solution of the differential equation gives the number of clonogenic tumor cells as a function of time. For our model an analytic solution has been found. The number of repopulating tumor cells shows a minimum if the dose rate is sufficiently high. Otherwise cell kill be radiation is overcompensated by growing tumor cells. The minimum value N{sub min} of tumor cells depends on the initial cell number N{sub 0}, the total dose D{sub tot}, the half-life T{sub 1/2} of the implant, the half-life T{sub r} for repair of the sublethal damage, the {alpha} and {beta} values of the tumor cells, and the effective clonogen doubling time T{sub pot} of the tumor. Assuming that the tumor is cured if no clonogenic cell survives, the tumor control probability (TCP) is determined by the Poisson statistics TCP=exp(-N{sub min}). Isoeffective doses are doses with constant TCP. Isoeffective doses D{sub tot} have been calculated for different T{sub pot} as a function of the half-life T{sub 1/2} of the isotope. The model allows the calculation of isoeffective doses for permanent impants. Care must be taken to use the results in clinical practice unless all of the radiobiological parameters are known for a specific tumor. [Deutsch] Zur Berechnung der Isoeffektdosen wurde ein Modell entwickelt, das die Zahl der Tumorzellen als Funktion der Zeit beschreibt. Bei Permanentimplantaten haengt die effektive Bestrahlungszeit von der Halbwertszeit des Isotopes ab. Waehrend der Bestrahlung koennen die Tumorzellen sich weiter teilen, ein Effekt, der aus der perkutanen Strahlentherapie gut bekannt ist. Je laenger die effektive Bestrahlungszeit ist, um so mehr zusaetzliche Dosis wird gebraucht, um die in dieser Zeit repopulierten Zellen abzutoeten. Es wurde eine Differentialgleichung aufgestellt, in der die Zelltoetung durch einen {alpha}-{beta}-Term und das Zellwachstum durch eine konstante Zellverdoppelungszeit beschrieben werden. Die Loesung dieser Differentialgleichung ergibt die Zahl der klonogenen Tumorzellen als Funktion der Zeit. Fuer die Differentialgleichung konnte eine analytische Loesung gefunden werden. Die Zahl der Tumorzellen zeigt ein Minimum, falls die initiale Dosisleistung genuegend hoch ist. Andernfalls wird die Zelltoetung durch das Zellwachstum ueberkompensiert. Die minimale Zellzahl haengt von der Anfangszellzahl, der Gesamtdosis, der Halbwertszeit des Implantates, der Kinetik der Reparatur subletaler Schaeden, dem {alpha}- und {beta}-Wert der Tumorzellen und der Wachstumsgeschwindigkeit der Tumorzellen ab. Unter der Annahme, dass der Tumor vernichtet wird, falls alle Tumorzellen abgetoetet werden, ist die Tumorkontrollwahrscheinlichkeit durch die Poisson-Verteilung bestimmt. Isoeffektive Dosen sind diejenigen Werte, bei denen die Tumorkontrollwahrscheinlichkeit konstant ist. Diese Werte wurden fuer verschiedene Tumorverdopplungszeiten als Funktion der Halbwertszeit des Isotops bestimmt. Das Modell erlaubt die Berechnung von Isoeffektdosen fuer Permanentimplantate. Bei einer klinischen Anwendung muss allerdings beruecksichtigt werden, dass alle erforderlichen radiobiologischen Parameter fuer den speziellen Tumor bekannt sein muessen, um eine ausreichende Sicherheit zu gewaehrleisten.

Kneschaurek, P. [Technische Univ. Muenchen (Germany). Klinikum rechts der Isar, Klinik fuer Strahlentheraphie und Radiologische Onkologie

1994-10-01

223

Optimization of sup 125 I ophthalmic plaque brachytherapy  

Energy Technology Data Exchange (ETDEWEB)

Episcleral plaques containing {sup 125}I sources are often used in the treatment of ocular melanoma. Within four years post-treatment, however, the majority of patients experience some visual loss due to radiation retinopathy. The high incidence of late complications suggests that careful treatment optimization may lead to improved outcome. The goal of optimization would be to reduce the magnitude of vision-limiting complications without compromising tumor control. We have developed a three-dimensional computer model for ophthalmic plaque therapy which permits us to explore the potential of various optimization strategies. One simple strategy which shows promise is to maximize the ratio of dose to the tumor apex (T) compared to dose to the macula (M). By modifying the parameters of source location, activity distribution, source orientation, and shielding we find that the calculated T:M ratio can be varied by a factor of 2 for a common plaque design and posterior tumor location. Margins and dose to the tumor volume remain essentially unchanged.

Astrahan, M.A.; Luxton, G.; Jozsef, G.; Liggett, P.E.; Petrovich, Z. (Univ. of Southern California School of Medicine, Los Angeles (USA))

1990-11-01

224

/sup 125/I-LSD: a high sensitivity ligand for serotonin receptors  

Energy Technology Data Exchange (ETDEWEB)

/sup 125/I-labeled receptor ligands offer unique advantages over their /sup 3/H-labeled counterparts. Carrier-free /sup 125/I-labeled ligands can be synthesized with specific activities of up to 2170 Ci/mmol while (mono) tritium labeled ligands are limited to 29 Ci/mmol. Therefore, /sup 125/I-labeled ligands can be approximately 70-fold more sensitive than /sup 3/H-labeled ligands in detecting receptor sites. In addition, /sup 125/I-labeled ligands emit relatively energetic X-rays and ..gamma..-rays which are readily detected by gamma counting equipment. The authors report here the serotonergic binding properties of /sup 125/I-LSD the first reported /sup 125/I-labeled ligand for serotonin receptors.

Hartig, P.R.; Kadan, M.J.; Evans, M.J.; Krohn, A.M. (Johns Hopkins Univ., Baltimore, MD (USA). Dept. of Biology)

1983-05-06

225

Synthesis of [125I]iodoDPA-713: A new probe for imaging inflammation  

International Nuclear Information System (INIS)

[125I]IodoDPA-713 [125I]1, which targets the translocator protein (TSPO, 18 kDa), was synthesized in seven steps from methyl-4-methoxybenzoate as a tool for quantification of inflammation in preclinical models. Preliminary in vitro autoradiography and in vivo small animal imaging were performed using [125I]1 in a neurotoxicant-treated rat and in a murine model of lung inflammation, respectively. The radiochemical yield of [125I]1 was 44 ± 6% with a specific radioactivity of 51.8 GBq/?mol (1400 mCi/?mol) and >99% radiochemical purity. Preliminary studies showed that [125I]1 demonstrated increased specific binding to TSPO in a neurotoxicant-treated rat and increased radiopharmaceutical uptake in the lungs of an experimental inflammation model of lung inflammation. Compound [125I]1 is a new, convenient probe for preclinical studies of TSPO activity.

2009-11-06

226

Binding and degradation of (/sup 125/I)human growth hormone in rat adipocytes  

Energy Technology Data Exchange (ETDEWEB)

Iodinated human growth hormone (( /sup 125/I)hGH) binds to both specific and nonspecific sites on the surface of adipocytes isolated from the epididymal fat of normal rats. When adipocytes were incubated at 37 C with 1 nM (/sup 125/I)hGH, specific binding increased for 30-60 min and thereafter remained approximately constant as long as the hormone was present in the medium. About 90% of the /sup 125/I released was soluble in 5% trichloroacetic acid and was in the form of iodotyrosine. The rate of /sup 125/I release from specific binding sites decreased by a factor of 4 when the temperature was lowered from 37 to 17 C. Replacement of some of the sodium chloride in the buffer with 25 mM ammonium chloride had little or no effect on the amount on /sup 125/I that bound to cells when (/sup 125/I)hGH was present in the medium, but completely blocked the release of /sup 125/I from cells transferred to hormone-free medium. Ammonium chloride also significantly reduced both the release of /sup 125/I from nonspecific binding sites and the amount of /sup 125/I recovered in trichloroacetic acid-soluble form. Cloroquine, leupeptin, or colchicine nearly doubled the specific binding of (/sup 125/I)hGH after 180 min and markedly slowed the release of /sup 125/I when cells were transferred to hormone-free medium. All of these agents also significantly reduced the rate of release of /sup 125/I from nonspecific binding sites. Incubation of adipose tissue from hypophysectomized rats with ammonium chloride, leupeptin, or colchicine failed to alter the ability of GH to increase glucose oxidation, induce refractoriness, or promote lipolysis in the presence of theophylline.

Gorin, E.; Grichting, G.; Goodman, H.M.

1984-08-01

227

Influence of glucose and urea on {sup 125}I transport across an anion exchange paper membrane  

Energy Technology Data Exchange (ETDEWEB)

In order to study the influence of glucose and urea on the {sup 125}I transport across an anion exchange paper membrane, the transmembrane potential, the fluxes, and the concentrations of {sup 125}I, glucose and urea within the membrane were measured in the Na{sup 125}I concentration-cell system containing glucose or urea. Glucose and urea increased the membrane/solution distribution of the iodide ion, but scarcely affected the diffusion process of iodide ion within the membrane.

Inoue, Hiroyoshi E-mail: hiroin@med.kurume-u.ac.jp

2001-02-01

228

Intraperitoneal (125I) insulin absorption during intermittent and continuous peritoneal dialysis  

International Nuclear Information System (INIS)

The authors have measured intraperitoneal (125I) insulin absorption during intermittent and continuous peritoneal dialysis in order to study the following: insulin regulation of blood glucose when administered continuously via dialysate during continuous ambulatory peritoneal dialysis (CAPD) versus when given intermittently and subcutaneously before CAPD; the degree of (125I) insulin retention in plastic CAPD bags, after complete drainage of the dialysis fluid; absorption of (125I) insulin from the dialysate in the peritoneal cavity of diabetic and non-diabetic patients. (Auth.)

1981-06-19

229

Characterization of two new ETB selective radioligands, [125I]-BQ3020 and [125I]-[Ala1,3,11,15]ET-1 in human heart.  

Digital Repository Infrastructure Vision for European Research (DRIVER)

Two new endothelin receptor radioligands, [125I]-BQ3020 and [125I]-[Ala1,3,11,15]ET-1, were characterized in tissue sections of human right atrium and left ventricle. Both radioligands had high affinity ([125I]-BQ3020 right atrium: KD = 0.145 +/- 0.037 nM, left ventricle: KD = 0.107 +/- 0.004 nM; [125I]-[Ala1,3,11,15]ET-1 right atrium: KD = 0.239 +/- 0.036 nM, left ventricle: KD = 0.199 +/- 0.027 nM). Competition binding experiments were performed in the left ventricle. The selective ETA rece...

Molenaar, P.; Kuc, R. E.; Davenport, A. P.

1992-01-01

230

Pharmacokinetics of the in vivo distribution of "1"2"5I-TSH  

International Nuclear Information System (INIS)

A study of "1"2"5I-TSH pharmacokinetics in mice was performed in order to obtain more information on the peripheral tissues rich in thyrotropin receptors. By comparison with Na "1"2"5I-biodistribution, it was shown that "1"2"5I-TSH pharmacokinetics are quite different of that of free radioiodine. After "1"2"5I-TSH injection, an increased uptake is seen in thyroid, brain, eyes, pancreas and intestine and the pharmacokinetics of the radioactivity in these organs do not follow blood clearance. The results suggest thyrotropin receptors to be present in the above organs. (Author)

1986-01-01

231

Synthesis of [125I]IodoDPA-713, a New Probe for Imaging Inflammation  

Digital Repository Infrastructure Vision for European Research (DRIVER)

[125I]IodoDPA-713 [125I]1, which targets the translocator protein (TSPO, 18 KDa), was synthesized in seven steps from methyl-4-methoxybenzoate as a tool for quantification of inflammation in preclinical models. Preliminary in vitro autoradiography and in vivo small animal imaging were performed using [125I]1 in a neurotoxicant-treated rat and in a murine model of lung inflammation, respectively. The radiochemical yield of [125I]1 was 44 ± 6% with a specific radioactivity of 51.8 GBq/?mol (1...

Wang, Haofan; Pullambhatla, Mrudula; Guilarte, Tomas R.; Mease, Ronnie C.; Pomper, Martin G.

2009-01-01

232

Very late pacemaker extrusion: A rare complication of permanent pacemaker implantation  

Digital Repository Infrastructure Vision for European Research (DRIVER)

Pacemaker extrusion is an uncommon complication of device implantation. Mostly, it happens either beuse of infection or secondary to various mechanical factors. It usually occurs days to months after the implantation, however very late pacemaker extrusion has not been described in the literature. We present a case of 70 years old male, who had pacemaker extrusion 11 years after its implantation. The various management issues related with such patient is discussed in the article.

Rajesh Vijayvergiya; Ram Chitlangia; Mukesh Yadav; Asif Hasan

2012-01-01

233

Very late pacemaker extrusion: A rare complication of permanent pacemaker implantation  

Directory of Open Access Journals (Sweden)

Full Text Available Pacemaker extrusion is an uncommon complication of device implantation. Mostly, it happens either beuse of infection or secondary to various mechanical factors. It usually occurs days to months after the implantation, however very late pacemaker extrusion has not been described in the literature. We present a case of 70 years old male, who had pacemaker extrusion 11 years after its implantation. The various management issues related with such patient is discussed in the article.

Rajesh Vijayvergiya

2012-10-01

234

Permanent interstitial implantation of /sup 125/iodine in case of carcinomas of the oral cavity and the oropharynx  

Energy Technology Data Exchange (ETDEWEB)

The authors present their first experiences gained during the last year with the permanent implantation of /sup 125/iodine seeds in thirty patients suffering from carcinomas of the oral cavity and the oropharynx. The properties and advantages of /sup 125/iodine, the method of implantation, the dosimetry and the problems of radioprotection are particularly underlined. In every case, we apply pre- or postoperative external radiotherapy, i.e. we expose the primary tumor to a dose of 50 Gy fractionated in the usual manner over four or five weeks. This combined treatment is intended to overcome the resistance to therapy of ORL malignomas and to obtain a high local rate of tumor control and a low rate of functional and cosmetic troubles.

Weidenbecher, M.; Jaumann, M.P.; Mueller, R.; Thiel, H.J.; Herbst, M.

1982-10-01

235

Feasibility study of using MOSFET detectors for in vivo dosimetry during permanent low-dose-rate prostate implants  

International Nuclear Information System (INIS)

Purpose: To investigate the feasibility of using new micro-MOSFET detectors for QA and in vivo dosimetry of the urethra during transperineal interstitial permanent prostate implants (TIPPB). Methods and materials: This study involves measurements for several patients who have undergone the implant procedure with iodine-125 seeds. A new micro-MOSFET detector is used as a tool for in vivo measurement of the initial dose rate within the urethra. MOSFETs are calibrated using a single special order calibration seed. The angular response is investigated in a 100 kVp X-ray beam. Results: micro-MOSFETs are found to have a calibration factor of 0.03 cGy/mV for low energy X-rays and a high isotropic response (within 2.5%). Prostate volume and shape changes during TIPPB due to edema caused by the trauma of needle insertion, making it difficult to achieve the planned implant geometry and hence the desired dose distribution. MOSFET measurements help us to evaluate the overall quality of the implant, by analyzing the maximum dose received by urethra, the prostate base coverage, the length of the prostatic urethra that is irradiated, and the apex coverage. Conclusions: We demonstrate that ease of use, quick calibration and the instantaneous reading of accumulated dose make micro-MOSFETs feasible for in vivo dosimetry during TIPPB

2006-09-01

236

A Monte Carlo evaluation of the dosimetric characteristics of the Best[reg] Model 2301 125I brachytherapy source  

International Nuclear Information System (INIS)

Recently a new design of a 125I brachytherapy source was introduced for interstitial seed implants, particularly for prostate seed implants. This new source is the Best[reg] Model 2301 brachytherapy source. Due to the differences in source design and manufacturing process from one new source to the next, their dosimetric parameters should be determined according to the AAPM TG-43 guidelines. As per AAPM recommendation (Med. Phys. 25 (12) (1998) 2269), it is required to perform the seed dosimetry using at least one experimental study and one Monte Carlo simulation, preferably done by two separate investigators. Other investigators have experimentally determined the dosimetric parameters of this new source. In this project, the Monte Carlo simulated dosimetric parameters of the Best[reg] Model 2301 125I source have been provided. The results of this evaluation indicate the value of dose rate constant of 1.01±3% cGy h-1 U-1 in liquid water, which is in good agreement with 1.02±8% cGy h-1 U-1 reported by Nath and Yue, 2002. The anisotropy constant was found to be 0.98 in liquid water

2002-09-01

237

Systemic administration of kainic acid induces selective time dependent decrease in [{sup 125}I]insulin-like growth factor I, [{sup 125}I]insulin-like growth factor II and [{sup 125}I]insulin receptor binding sites in adult rat hippocampal formation  

Energy Technology Data Exchange (ETDEWEB)

Administration of kainic acid evokes acute seizure in hippocampal pathways that results in a complex sequence of functional and structural alterations resembling human temporal lobe epilepsy. The structural alterations induced by kainic acid include selective loss of neurones in CA1-CA3 subfields and the hilar region of the dentate gyrus followed by sprouting and permanent reorganization of the synaptic connections of the mossy fibre pathways. Although the neuronal degeneration and process of reactive synaptogenesis have been extensively studied, at present little is known about means to prevent pathological conditions leading to kainate-induced cell death. In the present study, to address the role of insulin-like growth factors I and II, and insulin in neuronal survival as well as synaptic reorganization following kainate-induced seizure, the time course alterations of the corresponding receptors were evaluated. Additionally, using histological preparations, the temporal profile of neuronal degeneration and hypertrophy of resident astroglial cells were also studied. [{sup 125}I]Insulin-like growth factor I binding was found to be decreased transiently in almost all regions of the hippocampal formation at 12 h following treatment with kainic acid. The dentate hilar region however, exhibited protracted decreases in [{sup 125}I]insulin-like growth factor I receptor sites throughout (i.e. 30 days) the study. [{sup 125}I]Insulin-like growth factor II receptor binding sites in the hippocampal formation were found to be differentially altered following systemic administration of kainic acid. A significant decrease in [{sup 125}I]insulin-like growth factor II receptor sites was observed in CA1 subfield and the pyramidal cell layer of the Ammon's horn at all time points studied whereas the hilar region and the stratum radiatum did not exhibit alteration at any time. A kainate-induced decrease in [{sup 125}I]insulin receptor binding was noted at all time points in the molecular layer of the dentate gyrus whereas binding in CA1-CA3 subfields and discrete layers of the Ammon's horn was found to be affected only after 12 h of treatment. These results, when analysed with reference to the observed histological changes and established neurotrophic/protective roles of insulin-like growth factors and insulin, suggest possible involvement of these growth factors in the cascade of neurotrophic events that is associated with the reorganization of the hippocampal formation observed following kainate-induced seizures. (Copyright (c) 1997 Elsevier Science B.V., Amsterdam. All rights reserved.)

Quirion, R. [Department of Pharmacology and Therapeutics, McGill University, Montreal (Canada); Chabot, J.-G.; Dore, S. [Douglas Hospital Research Center, Department of Psychiatry, McGill University, Montreal (Canada); Seto, D. [Department of Pharmacology and Therapeutics, McGill University, Montreal (Canada); Kar, S. [Douglas Hospital Research Center, Department of Psychiatry, McGill University, Montreal (Canada)

1997-08-11

238

Neuropeptide Y receptor binding sites in rat brain: differential autoradiographic localizations with 125I-peptide YY and 125I-neuropeptide Y imply receptor heterogeneity  

International Nuclear Information System (INIS)

Neuropeptide Y (NPY) receptor binding sites have been localized in the rat brain by in vitro autoradiography using picomolar concentrations of both 125I-NPY and 125I-peptide YY (PYY) and new evidence provided for differentially localized receptor subtypes. Equilibrium binding studies using membranes indicate that rat brain contains a small population of high-affinity binding sites and a large population of moderate-affinity binding sites. 125I-PYY (10 pM) is selective for high-affinity binding sites (KD = 23 pM), whereas 10 pM 125I-NPY labels both high- and moderate-affinity sites (KD = 54 pM and 920 pM). The peptide specificity and affinity of these ligands in autoradiographic experiments match those seen in homogenates. Binding sites for 125I-PYY are most concentrated in the lateral septum, stratum oriens, and radiatum of the hippocampus, amygdala, piriform cortex, entorhinal cortex, several thalamic nuclei, including the reuniens and lateral posterior nuclei, and substantia nigra, pars compacta, and pars lateralis. In the brain stem, 125I-PYY sites are densest in a variety of nuclei on the floor of the fourth ventricle, including the pontine central grey, the supragenual nucleus, and the area postrema. 125I-NPY binding sites are found in similar areas, but relative levels of NPY binding and PYY binding differ regionally, suggesting differences in sites labeled by the two ligands. These receptor localizations resemble the distribution of endogenous NPY in some areas, but others, such as the hypothalamus, contain NPY immunoreactivity but few binding sites

1989-01-01

239

Soluble Antibody Affinity Chromatography Technique Investigated with Ultratrace (125I) Thyroxine.  

Science.gov (United States)

An amount of 10 pg of (125I) thyroxine was subjected to DEAE agarose chromatography and then complexed with an antibody. Recycling of the (125I) thyroxine now as a complex with the antibody through a second DEAE agarose column under the same conditions ga...

B. A. Warden R. W. Giese

1984-01-01

240

Pharmacokinetics of 125I-recombinant human thrombopoietin in rats after i.v  

International Nuclear Information System (INIS)

Purpose of this work is to establish the analytic method and investigate the pharmacokinetics of 125I-rhTPO in rats receiving single injection of vein. 125I-rhTPO was prepared with Iodogen method. The radiochemical purity of 125I-rhTPO was determined both by HPLC and SDS-PAGE. In the test, 125I-rhTPO was injected via caudal vein at the dose of 2 ?g·kg-1 in rats. Blood samples were collected at different time after i.v., then the drug concentration was determined according to the radioactivity and the pharmacokinetic parameters were calculated. It is shown that radiochemical purity of 125I-rhTPO was above 98%, and the pharmacokinetics of 125I-rhTPO following i.v. with 2 ?g·kg-1 in rats was fit to two-compartment model. The T1/2(?) was (1.32 ± 0.35) h, T)1/2(?) was (24.55 ± 1.07) h and AUC0?t was (134.26 ± 22.99) ng·h·mL-1. 125I-rhTPO prepared with Iodogen method was accordant with original rhTPO at purity and molecular weight by SDS PAGE test. The stability of 125I-rhTPO was good in vitro. Half-lives were about 25 h. (authors)

2005-01-01

 
 
 
 
241

Labelling monoclonal antibody 10D9 with 125I using the iodogen method  

International Nuclear Information System (INIS)

To establish the method radiolabeled monoclonal antibody 10D9 against human costimulatory molecules CD80 with 125I, 10D9 was labeled with 125I using the Iodogen method at room temperature. The labeling efficiency and radiochemical purity were tested with TCA, and the immune activity and stability of the labeling product were analyzed. The optimum labeling condition was 10 ?g Iodogen, 20 ?g 10D9 and 22.2 MBq Na125I. The reaction time was 8 min at room temperature. The labeled yield was (84.10±3.18)%, and the radiochemical purity was (98.49±1.14)%. The radio-activity of 125I-10D9 was 933.51 MBq/mg. The specific binding efficiency of 125I-10D9 with Daudi cell was(23.21±1.14)%. The radiochemical purity of 125I-10D9 was over 90% after three weeks of mixing with PBS. In conclusion, the method is simple and easy to perform. The labeling efficiency and radiochemical purity is high. The stability of 125I-10D9 is fine in vitro and 125I-10D9 keeps its immune activity after Iodogen labeling. (authors)

2009-05-01

242

The biodistribution of 12'5I-UdR in mice  

International Nuclear Information System (INIS)

The biodistribution of 125I-UdR in normal and tumor born nude mice (LOVO type colonic cancer, small cell lung cancer and cervix cancer) are studied. The results show that the biodistribution of 125I-UdR among these tumor models is different, and pending further study

2001-02-01

243

5-[125I]iodo-2'-deoxyuridine in the radiotherapy of pancreatic cancer in mice  

International Nuclear Information System (INIS)

Objective: To investigate the distribution, therapeutic effect and safety of 5-[125I-iodo-2'-deoxyuridine (125I-UdR) in Balb/c nude mice bearing pancreatic cancer. Methods: After 125I-UdR was intratumourally injected, the distribution of 125I-UdR was estimated by SPECT scintigrams and the radioactivity of various organs was determined by ? well counter, the antineoplastic capabilities was demonstrated through estimating the gross pathological and cellular changes of tumour, as well as analyzing the survival rate; and the pharmic safety was evaluated by using hemogram, marrow cell and flow biochemistry indexes: alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), creatinine (Cr). Results: (1) intratumourally injected 125I-UdR was retained within the tumour tissue without serious leakage. (2) 125I-UdR could damage cancerous cell and distinctly extended the survival of tumour-bearing mice. (3) The changes of hemogram and biochemistry indexes were not observed, but the proliferation of marrow cells was suppressed within a short period (30 d) after intratumoral injection of 125I-UdR. Conclusion: 125I-UdR can selectively kill proliferative tumour cells, and distinctly extend the survival of tumour-bearing mice, but the proliferation of marrow cells is suppressed within a short period

2004-05-01

244

Digital monitor of 125I in thyroid glands of human being  

International Nuclear Information System (INIS)

A new digital monitor of 125I in thyroid glands is described. This instrument is used to measure the activity of 125I in thyroid glands of human being directly, rapidly, and accurately. Furthermore, it can calculate and display the intake, committed dose equivalent and committed effective dose equivalent

1996-12-02

245

Immediate permanent implant reconstruction following mastectomy with capsule preservation in patients with prior augmentation mammoplasty.  

Science.gov (United States)

Prior breast augmentation in patients desiring post-mastectomy reconstruction provides a unique opportunity for capsular preservation and immediate, single-step implant reconstruction. We report a case series of a single-surgeon experience with immediate implant reconstruction after skin-sparing mastectomy in patients with prior subpectoral augmentation. Final implant volumes, complications, and outcomes were examined. Twenty patients (15 bilateral, total 35 breasts) were included. Eighteen (90%) patients were treated for cancer. Mean augmentation-to-reconstruction interval was 9 years (range, 3-19 years). Mean patient age was 45.1 years (range, 37-64 years). Eight patients (40%) received postoperative chemotherapy and two (10%) radiation. Mean mastectomy weight was 321 g. Mean weight of the implants removed was 346 g. Mean volume of new implants was 487 mL. All patients underwent capsulotomy (100% superior, 85% medial, 30% inferior, 5% lateral). Mean operative time was less than 1 hour for bilateral reconstruction. With average follow-up of 25.6 months, 2 patients were re-operated on for asymmetry (implant malposition, synmastia). Thirty-day complications included 1 implant loss due to infection, 1 drain placement with implant salvage, 1 hematoma requiring evacuation, and 1 cellulitis treated with antibiotics. There were no late complications and no capsular contractures. None have required further oncologic surgery. No cancer recurrences have been detected. In patients who desire prosthetic reconstruction similar to their original submuscular augmentation, capsule preservation and implant replacement with a larger prosthetic inserted within the old capsule is safe, fast, and aesthetically pleasing without compromising oncologic principles. PMID:24401813

Elliott, L Franklyn; Chu, Carrie K; Daniel, Jarrod; Harper, Garrett; Bergey, Patricia

2014-06-01

246

Comparison of radiation doses in permanent cardiac pacemaker implantation in three Greek hospitals  

International Nuclear Information System (INIS)

Full text: Permanent cardiac pacemaker implantation is a simple Interventional Cardiology (IC) procedure during which fluoroscopy is employed for aiding in the manipulations required for the successful placement of the pacemaker. However, it is also known that these procedures involve high radiation doses due to long fluoroscopy times. During the SENTINEL European project, radiation doses were measured in three major hospitals in Greece in order to: (1) investigate the levels of dose imparted to the patient, (2) explore the various factors that could have an impact on patient dose, and finally (3) compare the results of this study to corresponding values found in the recent literature. One hundred and eighty four (184) patients participated in the study, 24 of which were treated in Hospital A, 52 in Hospital B and 108 in Hospital C. The radiation dose imparted to the patient was measured in terms of dose area product (DAP) measured in Gycm2 by using DAP meters, all calibrated according to the National Protocol of the National Radiation Protection Board (NRPB) of the United Kingdom. Other patient data collected were the following: age (A), weight (W), height (H), body mass index (BMI), which is the ratio of patient weight in kilogram (kg) to square height in meters (m) (BMI = W/H2), the kilovoltage (kVp) and the fluoroscopy time (T). It was found that results did not exhibit a normal distribution in any of the hospitals and, therefore, DAP and T were calculated in terms of median values. According to our results, median values of DAP and T were: 6.7 Gycm2 and 2.6 min (Hospital A), 9.0 Gycm2 and 3.0 min (Hospital B), 7.7 Gycm2 and 6.5 min (Hospital C). It appears that Hospital A gave the lowest dose to the patient with the lowest fluoroscopy time. However, at comparable fluoroscopy time with Hospital A and even less than half the fluoroscopy time of Hospital C, Hospital B presented the highest DAP. The results show that probably its X ray equipment is calibrated in higher dose rate than the other two hospitals. The correlation between every patient clinical and technical factor collected (W, H, BMI, kVp and T) and DAP were investigated separately. No correlation was found between DAP and patient weight, height or BMI. No correlation was also found between DAP and kilovoltage. Finally, significant correlation was found in all three hospitals between DAP and T (r=0.72 Hospital A, r=0.87 Hospital B, r=0.87 Hospital C). Comparison of results with recent literature such as those reported by the National Radiation Protection Board (NRPB) (27 Gycm2 and 10.7 min) showed that radiation doses are lower for all three Greek hospitals. The results of the study showed that comparable radiation doses are given in the three hospitals participating in the study. These doses are lower than internationally established reference levels. It was found that patient dimensions do not affect patient radiation dose. The limitation of the study was that the X ray equipment dose rate was not investigated in detail to explain small differences between hospitals and this should be done in the near future. (author)

2006-11-13

247

N-(m-[125I]iodophenyl)maleimide: an agent for high yield radiolabeling of antibodies  

International Nuclear Information System (INIS)

In an effort to radiolabel antibodies, N-(m-[125I]iodophenyl)maleimide (m-[125I]IPM) was prepared by the demetallation of an N-[m-tri-(n-butyl)stannylphenyl]maleimide intermediate. The unlabeled intermediate was synthesized in ? 75% yield using a palladium catalyzed reaction of hexabutylditin with m-bromoaniline, followed by reaction with maleic anhydride and ring annulation. All products were confirmed by NMR and elemental analysis. Labeling with 125I was carried out in a biphasic mixture containing chloramine-T (radiochemical yield ? 70%). Rabbit IgG modified with the heterobifunctional crosslinking agent N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP) and bovine serum albumin were conjugated with m-[125I]IPM (yield: 40 and 80%, respectively). In addition, m-[125I]IPM was conjugated to rabbit IgG subunits (HL) in 70% yield. The in vitro stability of the radiolabeled proteins in serum showed < 1% deiodination over 24h. (author)

1992-04-01

248

Preparation and metabolism of _1_2_5I-sulfobromophthalein  

International Nuclear Information System (INIS)

Metabolism of _1_2_5I-sulfobromophthalein (BSP) prepared by the chloramine-T method was studied in rats. _1_2_5I-BSP is removed rapidly from the circulation. However, as compared to BSP, its plasma clearance and biliary excretion are delayed, and its accumulation in the liver is prolonged. Although BSP and _1_2_5I-BSP show similar binding to albumin in serum, their binding properties to liver cytosolic proteins and to the liver cell plasma membrane organic anion binding protein (OABP) differ. In contrast to the X-, Y- and Z-protein binding of BSP, _1_2_5I-BSP binds predominantly to a high molecular weight protein and only a small proportion of _1_2_5I-BSP binds to OABP. (Auth.)

1983-03-14

249

Isolation of 125I-concanavalin A-labeled plasma membrane from unfertilized mouse eggs  

International Nuclear Information System (INIS)

A procedure was developed for isolation of plasma membrane (PM) preparations from unfertilized mouse eggs. Zona-free mouse eggs prepared by the method of Boldt and Wolf (Gamete Res 13:213-222, 1986) were labeled with 125I-concanavalin A (ConA) prior to sonication and fractionation on iso-osmotic self-generated Percoll density gradients. Experiments using the ConA-specific sugar alpha-methylmannoside (alpha MM) indicated that 125I-ConA bound specifically to the egg PM. Greater than 95% of 125I-ConA binding to zona-free eggs was blocked in the presence of 0.1 M alpha MM, and incubation of eggs in alpha MM after 125I-ConA labeling caused release of 85-90% of bound label. Fractionation of 125I-ConA-labeled eggs by Percoll density gradient centrifugation yielded a single radioactive peak at density = 1.025, corresponding to egg PM material. Prolonged incubation of 125I-ConA-labeled eggs or egg sonicates prior to fractionation did not alter the location of the radioactive peak, indicating that 125I-ConA did not label other organelles. As a control, human erythrocytes were labeled with 125I-ConA and fractionated under identical experimental conditions and yielded a single radioactive peak at density (1.020) comparable to that observed for 125I-ConA-labeled eggs. These results indicate that 125I-ConA can be used as a specific marker to support PM isolation from small numbers of zona-free mouse eggs

1987-01-01

250

Isolation of /sup 125/I-concanavalin A-labeled plasma membrane from unfertilized mouse eggs  

Energy Technology Data Exchange (ETDEWEB)

A procedure was developed for isolation of plasma membrane (PM) preparations from unfertilized mouse eggs. Zona-free mouse eggs prepared by the method of Boldt and Wolf (Gamete Res 13:213-222, 1986) were labeled with 125I-concanavalin A (ConA) prior to sonication and fractionation on iso-osmotic self-generated Percoll density gradients. Experiments using the ConA-specific sugar alpha-methylmannoside (alpha MM) indicated that 125I-ConA bound specifically to the egg PM. Greater than 95% of 125I-ConA binding to zona-free eggs was blocked in the presence of 0.1 M alpha MM, and incubation of eggs in alpha MM after 125I-ConA labeling caused release of 85-90% of bound label. Fractionation of 125I-ConA-labeled eggs by Percoll density gradient centrifugation yielded a single radioactive peak at density = 1.025, corresponding to egg PM material. Prolonged incubation of 125I-ConA-labeled eggs or egg sonicates prior to fractionation did not alter the location of the radioactive peak, indicating that 125I-ConA did not label other organelles. As a control, human erythrocytes were labeled with 125I-ConA and fractionated under identical experimental conditions and yielded a single radioactive peak at density (1.020) comparable to that observed for 125I-ConA-labeled eggs. These results indicate that 125I-ConA can be used as a specific marker to support PM isolation from small numbers of zona-free mouse eggs.

Boldt, J.; Wolf, D.P.

1987-04-01

251

American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer  

International Nuclear Information System (INIS)

Purpose/Objective: To develop and disseminate the American Brachytherapy Society (ABS) recommendations for the clinical quality assurance and guidelines of permanent transperineal prostate brachytherapy with 125I or 103Pd. Methods and Materials: The ABS formed a committee of experts in prostate brachytherapy to develop consensus guidelines through a critical analysis of published data supplemented by their clinical experience. The recommendations of the panels were reviewed and approved by the Board of Directors of the ABS. Results: Patients with high probability of organ-confined disease are appropriately treated with brachytherapy alone. Brachytherapy candidates with a significant risk of extraprostatic extension should be treated with supplemental external beam radiation therapy (EBRT). Patient selection guidelines were developed. Dosimetric planning of the implant should be carried out for all patients before seed insertion. A modified peripheral loading is preferred. The AAPM TG-43 recommendations requiring a change in prescription dose for 125I sources should be universally implemented. The recommended prescription doses for monotherapy are 145 Gy for 125I and 115-120 Gy for 103Pd. The corresponding boost doses (after 40-50 Gy EBRT) are 100-110 Gy and 80-90 Gy, respectively. Clinical evidence to guide selection of radionuclide (103Pd or 125I) is lacking. Post implant dosimetry and evaluation must be performed on all patients. It is suggested that the dose that covers 90% (D90) and 100% (D100) of the prostate volume and the percentage of the prostate volume receiving the prescribed dose (V100) be obtained from a dose-volume histogram (DVH) and reported. Conclusion: Guidelines for appropriate patient selection, dose reporting, and improved quality of permanent prostate brachytherapy are presented. These broad recommendations are intended to be technical and advisory in nature, but the ultimate responsibility for the medical decisions rests with the treating physician. This is a constantly evolving field, and the recommendations are subject to modifications as new data becomes available

1999-07-01

252

Killing effect of 125I-UdR on human pancreatic cancer cell line Bax-Pc  

International Nuclear Information System (INIS)

Objective: To evaluate the killing effect of 5-iodo-2' -deoxyuridine (125I-UdR) in human pancreatic cancer cell line Bax-Pc in vitro and analyze the factors which affect the uptake of 125I-UdR. Methods: The amount of 125I-UdR in cells and caryons was determined after incubated for 0.25-84 h in RPMI1640 culturing medium containing different concentrations of 125I-UdR. The killing effects of 125I-UdR on Bax-Pc were estimated through colony-forming assay. Results: 1) The uptake of 125I-UdR by Bax-Pc cells was higher than that of Na125I control (P125I-UdR in cells and caryons increased with the increasing concentration of 125I-UdR in medium (r=0.984-0.999). 3) The amount of 125I-UdR in cells and caryons increased with increasing incubation time (r=0.867-0.978). 4) The surviving fraction of 125I-UdR groups were significantly lower than that of Na125I groups (P125I-UdR can specifically incorporated into DNA of Bax-Pc cells and kills the cells. The uptake of 125I-UdR is dose and time dependent

2004-06-01

253

Development of 125I seed source for treatment of eye and prostate cancer  

International Nuclear Information System (INIS)

The adsorption of 125I on silver bits coated with palladium was studied. The adsorbed 125I on Pd coated silver wires could be used as matrix for the preparation of interstitial source. Effective parameters on adsorption of 125I such as temperature, time and carrier volume and concentration were investigated. These experiences showed quantitative and consistent uptake (83%) of 125I and exhibited low leach ability (0.06%). The method is under optimization to obtain higher adsorption of 125I on the palladium treated silver wires. A laser welding machine used for welding of titanium capsules and welding parameters were investigated. Dosimetric parameters of solid core 125I were determined by radiochromic MD-55-2 GAFCHEROMIC film dosimetry. The results of the film dosimetry indicate that nonuniformity of activity around the core is about 8%, also the dose rate at distance of 1cm for active core was 1.133 cGy/hr/mCi. Iso-dose curves around of 125I core have been plotted for 90, 70, 50, 30 and 10 percents using simple image processing software. The results indicated that uniformity of coated activity was good. Production of 192Ir for HDR machine was carried out. 10 Ci 192Ir source with the size of 4.6 mm outer diameter and 6.5 mm length connected to flexible cable by TIG welding was fabricated and sent to hospital for further investigation. (author)

2006-06-01

254

Purification of "1"2"5I-vasoactive intestinal peptide by reverse-phase HPLC  

International Nuclear Information System (INIS)

VIP was labeled with sodium ["1"2"5I]iodide, and "1"2"5I-VIP was purified by reverse-phase high performance liquid chromatography. Optimal separations of "1"2"5I-VIP and unlabeled VIP were obtained using two C18- Novapak columns in series and a gradient of acetonitrile in triethylamine phosphate for elution. The specific activity of the "1"2"5I-VIP was 1.99 +/- 0.21 Ci/mumole, approaching the maximum specific activity of monoiodinated VIP (2.26 Ci/mumole). Radioimmunoassay and radioreceptorassay for VIP were more sensitive (2.6-fold, and 2.5-fold, respectively) using "1"2"5I-VIP purified by HPLC compared to "1"2"5I-VIP obtained from an open-end cellulose column. These results demonstrate the advantage of preparing purified "1"2"5I-VIP by HPLC for the accurate assay of VIP and VIP-receptors in tissues and biological fluids

1984-01-01

255

(125I)Iodoazidococaine, a photoaffinity label for the haloperidol-sensitive sigma receptor  

International Nuclear Information System (INIS)

A carrier-free radioiodinated cocaine photoaffinity label, (-)-3-(125I)iodo-4-azidococaine [(125I)IACoc], has been synthesized and used as a probe for cocaine-binding proteins. Photoaffinity labeling with 0.5 nM (125I)IACoc resulted in selective derivatization of a 26-kDa polypeptide with the pharmacology of a sigma receptor in membranes derived from whole rat brain, rat liver, and human placenta. (125I)IACoc labeling of the 26-kDa polypeptide was also inhibited by 10 ?M imipramine, amitriptyline, fluoxetine, benztropine, and tetrabenazine. The size of the (125I)I-ACoc-labeled proteins is consistent with the size of proteins photolabeled in guinea pig brain and liver membranes by using the sigma photolabel azido-[3H]DTG. Kinetic analysis of (125I)IACoc binding to rat liver microsomes revealed two sites with Kd values of 19 and 126 pM, respectively. The presence or absence of proteolytic inhibitors during membrane preparation did not alter the size of the photolabeled sigma receptor, indicating that the 26-kDa polypeptide was not derived from a larger protein. In summary, (125I)IACoc is a potent and highly specific photoaffinity label for the haloperidol-sensitive sigma receptor and will be useful for its biochemical and molecular characterization

1992-02-15

256

The inhabitation effect of 125I seed irradiation on prostate cancer cell  

International Nuclear Information System (INIS)

Objective: To study the effect on prostate cancer cell proliferation and cell cycle treated by continuous low dose rate 125I irradiation. Methods: PC3 cell was irradiated with 125I (2.77 cGy/h) and 60Co (2.215 Gy/min) at various doses. The cellular proliferation, vitality and cell surviving rate were evaluated by cytometric methods, typan-blue stain and the colony-forming assay after radiation. The cell cycle distribution was investigated by FCM. Results: The death rate of PC3 cell exposed to 125I was higher than that exposed to 60Co gamma rays with the increase of the irradiation dose. The parameters of radiobiology of PC3 irradiated by 125I seeds were: D0=2.243, Dq=0.87, N=1.618, SF2=0.5 whereas the parameters of 60Co were: D0=2.824, Dq=1.08, N=1.587, SF2=0.7. The RBE for 125I compared with 60Co gamma rays is 1.4. The cell cycle distribution after 4 Gy 125I or 60Co irradiation was similar, with increasing in the proportion of cells in G2 phase after 24 h. Conclusions: 125I irradiation could inhibit the proliferation of PC3 and induced G2 phase arrest. (authors)

2007-06-01

257

Exploration of dopamine transporter and D2 receptors in morphine dependent rats through 125I-?-CTT, 125I-IBZM cerebral autoradiography and the biodistribution study  

International Nuclear Information System (INIS)

Objective: To explore the variation of cerebral dopamine (DA) transmitting system in morphine dependent (MD) rats using dopamine transporter (DAT) and D2 receptors imaging agent. Methods: MD model rats were established by using a two-compartment (C1 and C2-morphine conditioned compartment) apparatus for assessing morphine conditioned place preferences in rats. 125I-2?-carbomethoxy-3?-(4-iodophenyl) tropane (125I-?-CIT) and 125I-3-iodo-2-hydroxy-6-methoxy-N[(1-ethyl-2-pyrrolidinyl) methyl] benzamide (125I-IBZM) cerebral DAT and D2 receptor autoradiography and biodistribution study were used to evaluate the variation of DAT and D2 receptors in morphine dependent rats. Results: The mean time of MD rats entering from C1 to C2 was (0.84 +- 0.50) min after 6 days' conditioned place preference training, shorter than that of the control group [(2.40 +- 1.10) min, P 125I-?-CIT uptake ratio of striatum (ST)/cerebellum (CB) and nucleus acumens (NAC)/CB in MD group were 4.76 +- 0.92 and 2.72 +- 0.96, significantly lower than that of control group (5.92 +- 0.67 and 4.16 +- 0.56, P 125I-IBZM uptake ratio in MD group were 4.11 +- 0.56 and 2.64 +- 0.25, lower than that in control group (5.43 +- 0.74 and 3.49 +- 0.65, P 125I-?-CIT, 125I-IBZM biodistribution study also showed that the DAT and D2 binding sites were reduced in ST of MD group by (21.68 +- 11.11)% and (18.69 +- 9.97)% comparing to the controls, respectively. Conclusions: The DAT and D2 receptors in both ST and NAC were all involved and reduced to some extent in morphine dependent model rats, the DAT and D2 receptor imaging agent could reflect the variation of DAT and D2receptors, this would afford the theoretical basis for D2 receptors and DAT imaging in study on preventing drug addiction and on its abstinence

2001-06-01

258

Localization of 3H-nicotine, 125I-kappa-bungarotoxin, and 125I-alpha-bungarotoxin binding to nicotinic sites in the chicken forebrain and midbrain.  

Science.gov (United States)

We have previously localized cholinergic cell bodies and fibers within the midbrain of the chicken with choline acetyltransferase immunohistochemistry. In a continuing effort to characterize the central cholinergic system, the present study examines the distribution of various nicotinic acetylcholine receptors in the forebrain and midbrain of the chicken. The binding of 3H-nicotine, 125I-kappa-bungarotoxin, and 125I-alpha-bungarotoxin was localized by film autoradiography in adjacent sections of the adult chicken brain, allowing a comparison of the distribution of different classes of nicotinic binding sites within the brain. Although all three ligands were often co-localized, there were areas that bound 3H-nicotine but not the 125I-neurotoxins, or vice versa. Very high densities of all three ligands were found in the hyperstriatum ventrale; the nucleus geniculatus lateralis, pars ventralis; the griseum tectale; the nucleus dorsolateralis anterior thalami; the nucleus lentiformis mesencephali, pars lateralis and pars medialis; the periventricular organ; and the stratum griseum et fibrosum superficiale, layer f of the optic tectum. The nucleus spiriformis lateralis had the highest levels of 3H-nicotine binding in the chicken brain, but it did not bind either of the two snake neurotoxins. On the other hand, high levels of both 125I-alpha-bungarotoxin and 125I-kappa-bungarotoxin binding were found in the nucleus semilunaris and the nucleus ovoidalis, but these areas contained little or no 3H-nicotine binding. No unique 125I-kappa-bungarotoxin sites, unrecognized by 125I-alpha-bungarotoxin, were identified by the low resolution autoradiography performed in this study. In general, nicotinic receptors were found in areas that have been reported to contain cholinergic cell bodies or fibers. Comparison of our results with the expression of neuronal nicotinic receptor subunits, as determined by in situ hybridization, suggests that many of the high affinity 3H-nicotine sites are localized presynaptically, as, for example, in the retinorecipient nuclei and the nucleus interpeduncularis. The lack of 125I-kappa-bungarotoxin binding in the presence of alpha-bungarotoxin indicates that the chicken brain has only very low levels of a unique kappa-bungarotoxin site. This is in marked contrast to chicken, frog, and rat autonomic ganglia, where a unique kappa-neurotoxin-sensitive receptor has been identified and shown to mediate nicotinic neurotransmission. PMID:1430311

Sorenson, E M; Chiappinelli, V A

1992-09-01

259

Implante de marcapasso definitivo em gestante portadora de valvopatia mitral reumática Implante de marcapaso definitivo en gestante portadora de valvulopatía mitral reumática Permanent pacemaker implantation in a pregnant woman with rheumatic mitral valve disease  

Directory of Open Access Journals (Sweden)

Full Text Available Descrevemos um caso raro de implante de marcapasso definitivo em gestante, portadora de valvopatia mitral reumática, previamente submetida à valvoplastia percutânea por cateter-balão. A paciente apresentava bloqueio atrioventricular de grau avançado, de causa não-reversível, sintomático e manifesto no 3º trimestre da gestação.Describimos un caso raro de implante de marcapaso definitivo en gestante, portadora de valvulopatía mitral reumática, previamente sometida a valvuloplastia percutánea por catéter balón La paciente presentaba bloqueo atrioventricular en grado avanzado, de causa irreversible, sintomático y manifiesto en el 3º trimestre de gestación.We describe a rare case of permanent pacemaker implantation in a pregnant woman with rheumatic mitral valve disease previously undergoing percutaneous balloon valvuloplasty. She presented symptomatic advanced atrioventricular block of non-reversible cause and manifest in the third trimester of gestation.

Rodrigo Barbosa Esper

2009-05-01

260

Implante de marcapasso definitivo em gestante portadora de valvopatia mitral reumática / Permanent pacemaker implantation in a pregnant woman with rheumatic mitral valve disease / Implante de marcapaso definitivo en gestante portadora de valvulopatía mitral reumática  

Scientific Electronic Library Online (English)

Full Text Available SciELO Brazil | Language: Portuguese Abstract in portuguese Descrevemos um caso raro de implante de marcapasso definitivo em gestante, portadora de valvopatia mitral reumática, previamente submetida à valvoplastia percutânea por cateter-balão. A paciente apresentava bloqueio atrioventricular de grau avançado, de causa não-reversível, sintomático e manifesto [...] no 3º trimestre da gestação. Abstract in spanish Describimos un caso raro de implante de marcapaso definitivo en gestante, portadora de valvulopatía mitral reumática, previamente sometida a valvuloplastia percutánea por catéter balón La paciente presentaba bloqueo atrioventricular en grado avanzado, de causa irreversible, sintomático y manifiesto [...] en el 3º trimestre de gestación. Abstract in english We describe a rare case of permanent pacemaker implantation in a pregnant woman with rheumatic mitral valve disease previously undergoing percutaneous balloon valvuloplasty. She presented symptomatic advanced atrioventricular block of non-reversible cause and manifest in the third trimester of gesta [...] tion.

Rodrigo Barbosa, Esper; Remo Holanda de Mendonça, Furtado; Flávio, Tarasoutchi; Guilherme Sobreira, Spina; Max, Grinberg; Walkiria Samuel, Ávila.

 
 
 
 
261

Progestin receptors in brain and pituitary of 20-day-old fetal mice: an autoradiographic study using (/sup 125/I)progestin  

Energy Technology Data Exchange (ETDEWEB)

The distribution of progestin target sites in the brain and pituitary of estrogen-primed 20-day-old fetal mice was investigated by thaw-mount autoradiography. Three pregnant mice were each implanted sc with a Silastic tube containing estrogen on day 17 and ovariectomized on day 19 of gestation. Twenty-four hours after ovariectomy 10 fetuses (5 males and 5 females) were collected and each injected sc with 0.33 microgram/100 g BW (/sup 125/I)progestin (SA, 2200 Ci/mM). For competition, two additional fetuses were injected with 20 micrograms R5020 1 h before (Z)-17 beta-hydroxy-17 alpha-(2(/sup 125/I)iodovinyl)4-estren-3-one ((/sup 125/I)Progestin) to demonstrate that nuclear uptake and retention of radioactivity were specific for progestin. Two hours after injection of (/sup 125/I)Progestin all fetuses were mounted, frozen, and sectioned in a cryostat. After 1-37 days of exposure, sections were developed and scanned for labeled cells. Cells with nuclear concentration were found in the male and female preoptic area, within certain nuclear groups in the basal hypothalamus, in the central gray of the midbrain, and in the pituitary. No labeling was detected in the cortex or amygdala. The results indicate that cells in certain regions of the brain and pituitary express progestin receptors at the end of gestation and suggest that progesterone is important for the normal development of these cells.

Shughrue, P.J.; Stumpf, W.E.; Sar, M.; Elger, W.; Schulze, P.E.

1989-01-01

262

Dosimetry and source design for measurement of the relative biological effectiveness of photons from 125I  

International Nuclear Information System (INIS)

This laboratory is beginning low dose rate studies of the effects of 125I photons on mammalian cells by comparing the effectiveness of the radiation with that of 137Cs gamma rays in reducing the reproductive viability of exponentially growing cells. There are a number of special problems associated with the dosimety. These arise from the low activity of available 125I sources together with the range of dose rates required and from the low energy 125I photons. A special ionization chamber, designed within the restrictions imposed by these problems, has been built and tested

1980-07-01

263

In vivo study about specific captation of 125 I-insulin by rat brain structures  

International Nuclear Information System (INIS)

The specific captation of 125 I-insulin was evaluated by brain structures, as olfactory bulbous, hypothalamus and cerebellum in rats, from in vivo experiences that including two different aspects: captation measure of 125 I-insulin after the intravenous injection of the labelled hormone, in fed rats and in rats with 48 h of fast or convulsion, procedure by the pentylene tetrazole; captation measure of 125 I-insulin after intra-cerebral-ventricular injection of the labelled hormone in fed rats. (C.G.C.)

1986-01-01

264

The contamination on farm products from "1"2"5I  

International Nuclear Information System (INIS)

The "1"2"5I contamination on 15 farm products have been investigated. The effects of 12 farm crops (wheat, bean, eggplants and other vegetables) contaminated by "1"2"5I during the growing stage on their fruits and seeds have been studied. The results show that the "1"2"5I radioactive substance is mainly concentrated on the fruit surface, and the radioactivity rapidly decreased towards its kernel. The fruits and seeds would not be contaminated when plants were contaminated in the seedling stage

1990-01-01

265

M-[[sup 125]I]iodoaniline: a useful reagent for radiolabeling biotin  

Energy Technology Data Exchange (ETDEWEB)

Biotinyl-m-[[sup 125]I]iodoanilide (BIA) was synthesized by coupling biotin to m-[[sup 125]I]iodoaniline via a mixed anhydride reaction. m-[[sup 125]I]Iodoaniline was produced from the tin precursor, which was prepared using a palladium catalyzed reaction of hexabutylditin with m-bromoaniline. The radioiodinated BIA derivative is characterized by a stable amide and/or intact ureido group on the biotin molecule, it may thus be a useful carrier for targeting radionuclides to avidin-conjugated antibodies previously localized on tumors. (author).

Khawli, L.A.; Kassis, A.I. (Harvard Medical School, Boston, MA (United States))

1992-04-01

266

m-[125I]iodoaniline: a useful reagent for radiolabeling biotin  

International Nuclear Information System (INIS)

Biotinyl-m-[125I]iodoanilide (BIA) was synthesized by coupling biotin to m-[125I]iodoaniline via a mixed anhydride reaction. m-[125I]Iodoaniline was produced from the tin precursor, which was prepared using a palladium catalyzed reaction of hexabutylditin with m-bromoaniline. The radioiodinated BIA derivative is characterized by a stable amide and/or intact ureido group on the biotin molecule, it may thus be a useful carrier for targeting radionuclides to avidin-conjugated antibodies previously localized on tumors. (author)

1992-04-01

267

Studies with encapsulated 125I sources: dosimetry for determination of relative biological effectiveness  

International Nuclear Information System (INIS)

During the past year, members of this laboratory have measured the Relative Biological Effectiveness (RBE) of photons from encapsulated 125I sources (mean energy = 28.33 keV) using 661.6 keV 137Cs gamma rays as a standard for comparison. These experiments were performed at clinically relevant dose rates and used reduction of the reproductive viability of mammalian cells as an endpoint. This section will discuss how dosimetry problems special to 125I influence the design of the apparatus and will describe the ionization chamber to be used for measuring dose rates from both 125I and 137Cs photons

1981-07-01

268

Characterization of propranolol-resistant (-)-[125I]-cyanopindolol binding sites in rat soleus muscle.  

Digital Repository Infrastructure Vision for European Research (DRIVER)

1. The characteristics of a propranolol-resistant (-)-[125I]-cyanopindolol (CYP) binding site in rat soleus muscle were determined. 2. Saturation studies performed on homogenates of rat soleus muscle showed two phases of (-)-[125I]-CYP binding, a high affinity site (KD1 30.5 +/- 16.3 pM, Bmax 9.4 +/- 1.38 fmol mg-1 protein) and a lower affinity site (KD2 522.5 +/- 29.1 pM, Bmax 62.19 +/- 11.76 fmol mg-1 protein, n = 4). 3. In rat soleus muscle homogenates labelled with (-)-[125I]-CYP (500 pM)...

1993-01-01

269

Use of an 125I-labelled DNA ligand to probe DNA structure  

International Nuclear Information System (INIS)

A simple way to endow a DNA-binding ligand with the ability to cleave DNA-labelling with 125I is described. The radiochemical damage associated with 125I decay induces a double-stranded DNA break. Using this technique it is shown that a sequence of four consecutive A.T base pairs is a necessary, but not sufficient, condition for strong binding to DNA of the bis-benzamide Hoechst 33258 and it is suggested that 125I-Hoechst 33258 may be a useful new probe of DNA structure. (U.K.)

1983-03-31

270

Labelling of ochratoxins with sup 3 H or sup 125 I  

Energy Technology Data Exchange (ETDEWEB)

Catalytic hydrogenation of ochratoxin A by carrier-free tritium was used to prepare {sup 3}H-ochratoxin B with a high specific activity. Iodination of ochratoxin B by carrier-free Na {sup 125}I using the chloramine method yielded {sup 125}I-ochratoxin with a high specific activity. Another {sup 125}I-derivative of ochratoxin A was prepared by iodination of an ochratoxin A - L-tyrosine-methylester conjugate. All three radioactive preparations were found to be useful for radioimmunoassay. (author).

Schmiedova, D.; Veres, K.; Cerny, B. (Ceskoslovenska Akademie Ved, Prague (Czechoslovakia). Ustav Nuklearni Biologie a Radiochemie); Ruprich, J. (Institut Hygieny a Epidemiologie, Prague (Czechoslovakia)); Nemecek, J. (Slovak Academy of Sciences, Prague (Czechoslovakia). Inst. of Microbiology)

1989-01-01

271

Preparation of 125I-testosterone-3-(p-hydroxyphenylacetyl) hydrazone  

International Nuclear Information System (INIS)

125I-labelled testosterone was prepared with a new kind of bridge. The product was 125I-testosterone-3-(p-hydroxyphenylacetyl) hydrazone. T0-3-HPAH was synthesized in three steps, identified by IR, NMR, MS and ultimate analysis, and then labelled with Na 125I by the chloramine-T method. The yield was higher than 85%. The radiochemical purity was higher than 95% when the product was purified by chloroform extraction and dropped slightly after a 50 days' storage at room temperature

1995-05-01

272

Use of an /sup 125/I-labelled DNA ligand to probe DNA structure  

Energy Technology Data Exchange (ETDEWEB)

A simple way to endow a DNA-binding ligand with the ability to cleave DNA-labelling with /sup 125/I is described. The radiochemical damage associated with /sup 125/I decay induces a double-stranded DNA break. Using this technique it is shown that a sequence of four consecutive AT base pairs is a necessary, but not sufficient, condition for strong binding to DNA of the bis-benzamide Hoechst 33258 and it is suggested that /sup 125/I-Hoechst 33258 may be a useful new probe of DNA structure.

Martin, R.F.; Holmes, N. (Cancer Inst., Melbourne (Australia))

1983-03-31

273

Dosimetric characterization of the GammaClip(TM) 169Yb low dose rate permanent implant brachytherapy source for the treatment of nonsmall cell lung cancer postwedge resection  

Science.gov (United States)

Purpose: A novel 169Yb low dose rate permanent implant brachytherapy source, the GammaClip™, was developed by Source Production & Equipment Co. (New Orleans, LA) which is designed similar to a surgical staple while delivering therapeutic radiation. In this report, the brachytherapy source was characterized in terms of “Dose calculation for photon-emitting brachytherapy sources with average energy higher than 50 keV: Report of the AAPM and ESTRO” by Perez-Calatayud [Med. Phys. 39, 2904–2929 (2012)]10.1118/1.3703892 using the updated AAPM Task Group Report No. 43 formalism. Methods: Monte Carlo calculations were performed using Monte Carlo N-Particle 5, version 1.6 in water and air, the in-air photon spectrum filtered to remove photon energies below 10 keV in accordance with TG-43U1 recommendations and previously reviewed 169Yb energy cutoff levels [D. C. Medich, M. A. Tries, and J. M. Munro, “Monte Carlo characterization of an Ytterbium-169 high dose rate brachytherapy source with analysis of statistical uncertainty,” Med. Phys. 33, 163–172 (2006)]10.1118/1.2147767. TG-43U1 dosimetric data, including SK, \\documentclass[12pt]{minimal} \\usepackage{amsmath} \\usepackage{wasysym} \\usepackage{amsfonts} \\usepackage{amssymb} \\usepackage{amsbsy} \\usepackage{upgreek} \\usepackage{mathrsfs} \\setlength{\\oddsidemargin}{-69pt} \\begin{document} \\dot D(r,\\theta)\\end{document}D?(r,?), ?, gL(r), F(r, ?), ?an(r), and \\documentclass[12pt]{minimal} \\usepackage{amsmath} \\usepackage{wasysym} \\usepackage{amsfonts} \\usepackage{amssymb} \\usepackage{amsbsy} \\usepackage{upgreek} \\usepackage{mathrsfs} \\setlength{\\oddsidemargin}{-69pt} \\begin{document} \\bar \\phi _{an}\\end{document}?¯an were calculated along with their statistical uncertainties. Since the source is not axially symmetric, an additional set of calculations were performed to assess the resulting axial anisotropy. Results: The brachytherapy source's dose rate constant was calculated to be (1.22 ± 0.03) cGy?h?1?U?1. The uncertainty in the dose to water calculations, \\documentclass[12pt]{minimal} \\usepackage{amsmath} \\usepackage{wasysym} \\usepackage{amsfonts} \\usepackage{amssymb} \\usepackage{amsbsy} \\usepackage{upgreek} \\usepackage{mathrsfs} \\setlength{\\oddsidemargin}{-69pt} \\begin{document} \\dot D(r,\\theta)\\end{document}D?(r,?), was determined to be 2.5%, dominated by the uncertainties in the cross sections. The anisotropy constant, \\documentclass[12pt]{minimal} \\usepackage{amsmath} \\usepackage{wasysym} \\usepackage{amsfonts} \\usepackage{amssymb} \\usepackage{amsbsy} \\usepackage{upgreek} \\usepackage{mathrsfs} \\setlength{\\oddsidemargin}{-69pt} \\begin{document} \\bar \\phi _{an}\\end{document}?¯an, was calculated to be 0.960 ± 0.011 and was obtained by integrating the anisotropy factor between 1 and 10 cm using a weighting factor proportional to r?2. The radial dose function was calculated at distances between 0.5 and 12 cm, with a maximum value of 1.20 at 5.15 ± 0.03 cm. Radial dose values were fit to a fifth order polynomial and dual exponential regression. Since the source is not axially symmetric, angular Monte Carlo calculations were performed at 1 cm which determined that the maximum azimuthal anisotropy was less than 8%. Conclusions: With a higher photon energy, shorter half-life and higher initial dose rate 169Yb is an interesting alternative to 125I for the treatment of nonsmall cell lung cancer.

Currier, Blake; Munro, John J.; Medich, David C.

2013-01-01

274

Postimplantation dosimetric analysis of permanent transperineal prostate implantation: improved dose distributions with an intraoperative computer-optimized conformal planning technique  

International Nuclear Information System (INIS)

Purpose: To compare the target coverage and dose to normal tissues after I-125 transperineal permanent implantation (TPI) of the prostate in 90 patients treated with one of three different transperineal techniques. Methods and Materials: Detailed postimplant dosimetric evaluations of permanent I-125 implantation procedures were performed on 30 consecutive patients treated between 1995-1996 who underwent TPI using a preplanning CT-based technique, on 30 consecutive patients treated in 1997-1998 who underwent an ultrasound-guided approach with intraoperative determination of seed distribution based on an I-125 nomogram, and on 30 consecutive patients in 1998-1999 who underwent TPI with intraoperative computer-based 3-dimensional conformal optimization. For all three techniques, postimplant CT scans were obtained 4-6 hours after TPI. Dosimetric parameters included V100, V90, V150, D100, D90, D80, as well as maximal and average doses to the urethra and rectal wall. These parameter outcomes are reported as a percentage of the prescription dose. Results: The intraoperative 3D-optimized technique (I-3D) provided superior target coverage with the prescription dose for all dosimetric variables evaluated compared to the other treatment techniques. The median V100, V90, and D90 values for the I-3D technique were 96%, 98%, and 116%, respectively. In contrast, the V100, V90, and D90 values for the CT preplan and ultrasound manual optimization approaches were 86%, 89%, and 88%, respectively and 88%, 92%, and 94%, respectively (I-3D versus other techniques: p < 0.001). The superior target coverage with the I-3D technique was also associated with a higher cumulative implant activity required by the optimization program. A multivariate analysis determined that the treatment technique (I-3D versus other approaches) was an independent predictor of improved target coverage for each parameter analyzed (p < 0.001). In addition, higher cumulative implant activities and smaller prostate target volumes were independent predictors of improved target coverage. The maximum and average urethral doses were significantly lower with the I-3D technique compared to the other techniques; a modest increase in the average rectal dose was also observed with this approach. Conclusion: Three-dimensional intraoperative computer optimized TPI consistently provided superior target coverage with the prescription dose and significantly lower urethral doses compared to two other techniques used. These data provide proof-of-principle that improved therapeutic ratios can be achieved with the integration of more sophisticated intraoperative planning for TPI and may potentially have a profound impact on the outcome of patients treated with this modality

2000-09-01

275

Distribution and levels of [125I]IGF-I, [125I]IGF-II and [125I]insulin receptor binding sites in the hippocampus of aged memory-unimpaired and -impaired rats  

International Nuclear Information System (INIS)

The insulin-like growth factors (IGF-I and IGF-II) and insulin are localized within distinct brain regions and their respective functions are mediated by specific membrane receptors. High densities of binding sites for these growth factors are discretely and differentially distributed throughout the brain, with prominent levels localized to the hippocampal formation. IGFs and insulin, in addition to their growth promoting actions, are considered to play important roles in the development and maintenance of normal cell functions throughout life. We compared the anatomical distribution and levels of IGF and insulin receptors in young (five month) and aged (25 month) memory-impaired and memory-unimpaired male Long-Evans rats as determined in the Morris water maze task in order to determine if alterations in IGF and insulin activity may be related to the emergence of cognitive deficits in the aged memory-impaired rat. In the hippocampus, [125I]IGF-I receptors are concentrated primarily in the dentate gyrus (DG) and the CA3 sub-field while high amounts of [125I]IGF-II binding sites are localized to the pyramidal cell layer, and the granular cell layer of the DG. [125I]insulin binding sites are mostly found in the molecular layer of the DG and the CA1 sub-field. No significant differences were found in [125I]IGF-I, [125I]IGF-II or [125I]insulin binding levels in any regions or laminae of the hippocampus of young vs aged rats, and deficits in cognitive performance did not relate to altered levels of these receptors in aged memory-impaired vs aged memory-unimpaired rats. Other regions, including various cortical areas, were also examined and failed to reveal any significant differences between the three groups studied.It thus appears that IGF-I, IGF-II and insulin receptor sites are not markedly altered during the normal ageing process in the Long-Evans rat, in spite of significant learning deficits in a sub-group (memory-impaired) of aged animals. Hence, recently reported changes in IGF-I receptor messenger RNA levels in aged memory-impaired rats [42] are apparently not reflected at the level of the translated protein. (Copyright (c) 1997 Elsevier Science B.V., Amsterdam. All rights reserved.)

1997-08-11

276

Implementation and assessment of bi-radionuclide seeds for permanent implant prostate brachytherapy  

Digital Repository Infrastructure Vision for European Research (DRIVER)

Interstitial brachytherapy using permanent seeds is a common modality for the treatment of early stage prostate cancer. It consists of inserting hundreds of radioactive seeds (size of a grain of rice) in the prostate by means of transperineal needles. In this procedure, dose delivery to healthy surrounding organs at risk (OAR) and dose homogeneity within the prostate are of prime concern. Placement errors should therefore be minimized to avoid unacceptable area underdosage or overdosage. At p...

Nuttens, Vincent

2008-01-01

277

Side effects of permanent I125 prostate seed implants in 667 patients treated in Leeds  

International Nuclear Information System (INIS)

Purpose: To report the side effects and complications after I-125 seeds prostate implant after 8.5 years experience. Methods and materials: Six hundred and sixty seven (667) patients were treated between March 1995 and December 2001. The median follow up is 31 months with a maximum of 98.2 months. Morbidity data were collected from a review of patient case-notes. Patients also provided prospective data on urinary symptoms using the International Prostate Symptom Score (IPSS) scoring chart before treatment and at regular follow up. Patients were also sent a questionnaire detailing symptoms and side effects following their brachytherapy. This enabled them to record urinary, bowel and sexual function side effects independently. Logistic regression analysis was carried out to identify the risk of catheterisation in relation to the pre-implant prostate volume and potential implant factors such as the number of seeds and needles and implant dose. Result: The urinary symptom score rises in the first few months after implantation and returns to within one or two points of the pre-treatment score within one year. Nine patients reported incontinence prior to treatment and 15, 12 and 10 patients reported incontinence 6, 12 and 24 months after treatment, respectively. Catheterisation was reported in 97 (14.5%) patients. At six months 84.9% of patients reported no change in bowel function and 78.9% at 12 months. 6.4% of patients complained of some increased bowel frequency at 6 months and 5.7% at 12 months. 402 (77.2%) patients reported being fully potent before treatment and that this fell to 32.4% after treatment. Logistic regression showed that the most significant factors which correlate with the probability of catheterisation are the pre-treatment prostate volume and the number of seeds and needles implanted. Conclusion: The side effects and complications after prostate brachytherapy as reported here and elsewhere confirm that the treatment is not only convenient but also has a low risk of serious long term side effects

2007-01-01

278

Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer  

International Nuclear Information System (INIS)

Purpose: To report the 5-year tumor control and toxicity outcomes for patients with localized prostate treated with I-125 permanent implantation using an intraoperative real-time conformal planning technique. Methods and Materials: Between January 1998 and June 2002, 367 patients with prostate cancer were treated with I-125 permanent interstitial implantation using a transrectal ultrasound-guided approach. Real-time intraoperative treatment planning which incorporated inverse planning optimization was used. The median follow-up time was 63 months. Results: The median V100 and D90 were 96% and 173 Gy, respectively. In 96% of cases a D90 of >140 Gy was achieved. The median urethral and rectal doses were 100% and 33% of the prescription doses, respectively. The 5-year PSA relapse-free survival outcomes for favorable and intermediate risk patients according to the ASTRO definition were 96% and 89%, respectively. In these patients no dosimetric parameter was identified which influenced the biochemical outcome. Of 38% who developed acute Grade 2 urinary symptoms, 63% had resolution of their symptoms within a median time of 6 months. The incidence of late rectal and urinary Grade 3 or higher toxicities were 1% and 4%, respectively. Seven percent (n = 27) developed late rectal bleeding (Grade 2) and 19% experienced late Grade 2 urinary symptoms. Conclusion: Real-time intraoperative planning consistently achieved optimal coverage of the prostate with the prescription dose with concomitant low doses delivered to the urethra and rectum. Biochemical control outcomes were excellent at 5 years and late toxicity was unusual. These data demonstrate that real-time planning methods can consistently and reliably deliver the intended dose distribution to achieve an optimal therapeutic ratio between the target and normal tissue structures

2007-01-01

279

Tolerance and Acceptance Results of a Palladium-103 Permanent Breast Seed Implant Phase I/II Study  

International Nuclear Information System (INIS)

Purpose: To test, in a prospective Phase I/II trial, a partial breast irradiation technique using a 103Pd permanent breast seed implant (PBSI) realized in a single 1-h procedure under sedation and local freezing. Methods and Materials: Eligible patients had infiltrating ductal carcinoma ?3 cm in diameter, surgical margin ?2 mm, no extensive intraductal component, no lymphovascular invasion, and negative lymph nodes. Patients received a permanent seed implant, and a minimal peripheral dose of 90 Gy was prescribed to the clinical target volume, with a margin of 1.5 cm. Results: From May 2004 to April 2007, 67 patients received the PBSI treatment. The procedure was well tolerated, with 17% of patients having significant pain after the procedure. Only 1 patient (1.5%) had an acute skin reaction (Grade 3 according to the National Cancer Institute Common Toxicity Criteria). The rates of acute moist desquamation, erythema, and indurations were 10.4%, 42%, and 27%, respectively. At 1 year the rate of Grade 1 telangiectasia was 14%. The rate of skin reaction decreased from 65% to 28% when skin received less than the 85% isodose. According to a Radiation Therapy Oncology Group questionnaire, 80-90% of patients were very satisfied with their treatment, and the remainder were satisfied. One patient (1.5%) developed an abscess, which resolved after the use of antibiotics. There was no recurrence after a median follow-up of 32 months (range, 11-49 months). Conclusions: The feasibility, safety, and tolerability of PBSI compares favorably with that of external beam and other partial breast irradiation techniques.

2009-04-01

280

In vitro cell-mediated immunity assay using 125I-iododeoxyuridine  

International Nuclear Information System (INIS)

We investigated an in vitro cell-mediated immunity assay using incorporation of 125I-iododeoxyuridine as an indicator of lymphocyte responsiveness to mitogen stimulation. The system permits the use of whole-blood cultures in rats and dogs

1979-02-01

 
 
 
 
281

Bioevaluation studies of 125I-Bakuchiol in tumor bearing animals  

International Nuclear Information System (INIS)

Bakuchiol, a meroterpene phenol is abundant in seeds and leaves of the plant Psoralea corylifolia. Bakuchiol is widely used in Indian as well as Chinese medicine to treat a variety of diseases and possesses anti-tumor, anti-bacterial, cytotoxic and anti-helmenthic properties. The cytotoxicity of bakuchiol is mainly due to its DNA polymerase 1 inhibiting activity. 125I, an auger electron emitter is an effective radiotherapeutic agent when targeted close to DNA. The incorporation of 125I in bakuchiol might augment its cytotoxic activity is envisaged and had reported the radiolabelling of bakuchiol with 125I and its in vitro evaluation in lymphosarcoma and lymphoma. The current paper describes the in vitro and in vivo evaluation of 125I-bakuchiol in fibrosarcoma cells

2006-01-23

282

Production technology of sodium "1"2"5I-iodide  

International Nuclear Information System (INIS)

A new method was developed and tested in pilot plant operation, of the production of sodium "1"2"5I-iodide from XeF_2 irradiated with neutrons in a nuclear reactor. "1"2"5I was separated from the irradiated target by sublimation at a temperature of 923 K and subsequently of 1078 K. Its absorption in 1 to 5 ml of a 10"-"2 M NaOH solution results in its transformation to sodium "1"2"5I-iodide. A minimum activity of 3.7 GBq/ml, minimum radiochemical purity of 99% in form of I"-and minimum radionuclide purity of 99% "1"2"5I were obtained. For routine production, a laboratory provided with a shielded box and the necessary single-purpose instruments was put into operation. (B.S.)

1985-06-06

283

External detection of ?-adrenoreceptors with "1"2"5I-hydroxybenzylpindolol in isolated perfused hearts  

International Nuclear Information System (INIS)

To assess the feasibility of characterizing ?-adrenoreceptors externally with ligands labeled with ?-emitting radionuclides, we infused "1"2"5I-hydroxybenzylpindolol ("1"2"5I-HYP) a potent, high affinity, ?-adrenoreceptor ligand into isolated perfused hearts and monitored uptake and release of the label externally with a gamma probe. Perfusion with specific ?-adrenergic displacing significantly increased the turnover rate constant of "1"2"5I-HYP in comparison to that obtained with non-specific displacing agents. After modifying ?-adrenoreceptor density by pretreatment of animals with thyroid hormone, an increase in "1"2"5I-HYP uptake was observed. Thus, ?-adrenoreceptor occupancy and increases in ?-adrenoreceptor density can be detected externally with an approach which may offer promise for their characterization in vivo with radiolabeled adrenergic ligands. (author)

1986-01-01

284

Proteolytic activity of beef liver determined by natural 125I-labelled substrates  

International Nuclear Information System (INIS)

The method of determining the enzymatic activity of acid proteinases is described. The method is based on the use of 125I-labelled natural protein substrates. 125I-labelled albumin, 125I-globulin and 125I-insulin were tested for the determination of activities. All the substrates were hydrolyzed with the enzymes of the supernatant fraction (106,000 g) of beef liver homogenate in the acid pH zone. Optimum enzymatic reaction conditions were tested, the dependence of the reaction on the enzyme concentration, time and temperature was determined, pH optimum was ascertained for the individual substrates, and pH stability was determined. The results show that the method is suitable for determining the enzymatic activity of proteinases of cathepsin character. (author)

1975-01-01

285

Report of a minor 125I exposure in a research laboratory  

International Nuclear Information System (INIS)

In routine thyroid scanning of personnel whose work involved the use of 125I in biological research, it was discovered that an individual who had been iodinating proteins periodically for over 6 months showed a high thyroid count rate. It was decided to monitor the individual's thyroid weekly and to curtail his work in the laboratory until the cause of the thyroid uptake could be determined. Initially the 125I concentration in his thyroid decreased as expected but a subsequent scan on the 21st day showed an 125I concentration even greater than the initial level despite his absence from the laboratory. However on monitoring his office space, it was discovered that a felt pen was grossly contaminated and that the individual habitually put the pen in his mouth during moments of cogitation. It was concluded that a contaminated glove had transferred some 125I to the pen during the course of the experiment. (U.K.)

1981-01-01

286

Simple, rapid 125I radioimmunoassay for the detection of barbiturates in biological fluids  

International Nuclear Information System (INIS)

A simple, rapid radioimmunoassay employing 125I-labeled secobarbital derivative has been developed and has been shown to be capable of detecting at the nanogram level a variety of barbiturates in urine as well as in plasma

1975-01-01

287

Measurements of the effects of 'thyroid blocking' in patients investigated with 125I-fibrinogen  

International Nuclear Information System (INIS)

The diagnosis of venous thromboses with around 4 MBq of 125I-labelled fibrinogen is a routine investigation. At the degradation of the 125I-fibrinogen, 125I is released and is available for thyroid uptake. The biological half-life of fibrinogen is around four days. In Swedish hospitals it has been found that a thyroid blocking agent using 300 mg KI daily for 10-12 days after injection of 125I-fibrinogen gives a very efficient reduction of the thyroid uptake. After cessation of the blocking, the uptake increases. Studies of the effect of longer blocking periods with smaller daily amounts of KI are in progress. (U.K.)

1980-01-01

288

Pulmonary embolization of permanently implanted radioactive iodine-125 seeds for carcinoma of the prostate  

International Nuclear Information System (INIS)

One year has passed since we started brachytherapy with radioactive iodine-125 seeds for carcinoma of the prostate. During the follow-up of patients, we have relatively frequently found migrated seeds in the lungs. Migrated seeds are reported to reach mainly the pulmonary artery and cause embolization without clinical symptoms. We counted the embolized seeds and determined the proportion of migrating seeds on chest X-ray exam. We found 47 cases of pulmonary embolization in our initial 100 cases. Less than half of the embolization were found in the chest X-ray exam performed on the next day after the implantation. We found more migrated seeds in the lower lung fields than in the upper and middle lung fields. Pulmonary embolization of implanted iodine-125 seeds is not unusual, and cases of prostate brachytherapy are likely to increase in Japan. We will have increased opportunities to observe chest X-ray films with migrated seeds in the future. (author)

2005-04-01

289

Microchemical synthesis of the serotonin receptor ligand, /sup 125/I-LSD  

Energy Technology Data Exchange (ETDEWEB)

The synthesis and properties of 2-(/sup 125/I)-lysergic acid diethylamide, the first /sup 125/I-labeled serotonin receptor ligand, are described. A novel microsynthesis apparatus was developed for this synthesis. The apparatus employs a micromanipulator and glass micro tools to handle microliter to nanoliter volumes on a microscope stage. This apparatus should be generally useful for the synthesis of radioligands and other compounds when limited amounts of material must be handled in small volumes.

Hartig, P.R.; Krohn, A.M.; Hirschman, S.A.

1985-02-01

290

Selective binding of 2-[125I]iodo-nisoxetine to norepinephrine transporters in the brain  

International Nuclear Information System (INIS)

A radioiodinated ligand, (R)-N-methyl-(2-[125I]iodo-phenoxy)-3-phenylpropylamine, [125I]2-INXT, targeting norepinephrine transporters (NET), was successfully prepared. A no-carrier-added product, [125I]2-INXT, displayed a saturable binding with a high affinity (Kd=0.06 nM) in the homogenates prepared from rat cortical tissues as well as from LLC-PK1 cells expressing NET. A relatively low number of binding sties (Bmax=55 fmol/mg protein) measured with [125I]2-INXT in rat cortical homogenates is consistent with the value reported for a known NET ligand, [3H]nisoxetine. Competition studies with various compounds on [125I]2-INXT binding clearly confirmed the pharmacological specificity and selectivity for NET binding sites. Following a tail-vein injection of [125I]2-INXT in rats, a good initial brain uptake was observed (0.56% dose at 2 min) followed by a slow washout from the brain (0.2% remained at 3 hours post-injection). The hypothalamus (a NET-rich region) to striatum (a region devoid of NET) ratio was 1.5 at 3 hours post-i.v. injection. Pretreatment of rats with nisoxetine significantly inhibited the uptake of [125I]2-INXT (70-100% inhibition) in locus coeruleus, hypothalamus and raphe nuclei, regions known to have a high density of NET; whereas escitalopram, a serotonin transporter ligand, did not show a similar effect. Ex vivo autoradiography of rat brain sections of [125I]2-INXT (at 3 hours after an i.v. injection) displayed an excellent regional brain localization pattern corroborated to the specific NET distribution in the brain. The specific brain localization was significantly reduced by a dose of nisoxetine pretreatment. Taken together, the data suggest that [123I]2-INXT may be useful for mapping NET binding sites in the brain

2004-07-01

291

Preparation and isolation of a homogeneous 125I-cortisol derivative  

International Nuclear Information System (INIS)

Tracer specificity plays an important role in the radioimmunoassay (RIA) of steroid hormones. In this paper, we describe the preparation and purification of 125I-labeled cortisol derivative with a carboxymethyloxime-histamine bridge. The investigation on the method of purification showed that HPLC could be adopted for the routine preparation of a pure, homogeneous tracer. The retention time observed in HPLC for 125I-histamine-CMO-cortisol conjugate could be used as an index for qualitative and quantitative assessments. (author)

1997-01-01

292

Inhibition effects of 125I-triplex forming oligonucleotide to hepatoma cells  

International Nuclear Information System (INIS)

Objective: Triplex forming oligonucleotide (TFO) has been reported as a new antigene strategy. The purpose of this study was to observe the inhibition effects of 125I-TFO on hepatoma cells and to investigate the possibility of using 125I-TFO as an antigene radiotherapy technique for hepatocellular carcinoma (HCC) related to HBV. Methods: TFO complementary to the initiator of S gene of HBV was synthesized and labeled with 125I. HepG2.2.15 cells, in which HBV genome was integrated, were incubated with 125I-TFO, TFO and 125I respectively. After incubation, hepatitis B e antigen (HBeAg) and hepatitis B surface antigen (HBsAg) of each group were assayed with ELISA and the survival rate of cells in each group was determined with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-trazolium bromide (MTT) reduction assay. Results: 125I-TFO showed a high stability with a radiolabeling rate of >93%. The radiochemical purity of labeled compound was 90.8%, 81.1% and 73.2% respectively after 12, 48 and 72 h at 37 degree C. The peak inhibition effect of 125I-TFO on synthesizing HBsAg and HBeAg by HepG2.2.15 cells were found at 48 h after transfection, with significantly the highest inhibition rate of 45.2% for HBsAg and 74.5% for HBeAg expression among the three groups(P125I-TFO may inhibit the antigen expression of HBV and the growth of hepatocarcinoma cells, thus it may provide a new approach to develop gene-based radiotherapeutic pharmaceuticals for anti-HBV and HCC. (authors)

2007-08-01

293

Study on 125I labelling and blood-brain barrier counteracting of calcineurin B  

International Nuclear Information System (INIS)

Calcineurin B(CNB) is labelled with 125I by iodogen method. The labelling yield is up 85%, the specific activity is 740 GBq·g-1 and the radiochemical purity is 95.7%. The blood-brain barrier counteracting of 125I-CNB is investigated in rats' brain. The results show that blood-brain barrier can counteract intact CNB into brain, but can not counteract its decomposed peptide into brain

2001-08-01

294

"1"2"5I-labelled cobalamin derivative compatible with intrinsic factor  

International Nuclear Information System (INIS)

A "1"2"5I-labelled derivative of cobalamin (vitamin B_1_2) is described which is compatible with intrinsic factor in binding assays. The derivative, ["1"2"5I]cyanocobalamin-d-iodohistamide, can be readily prepared with a specific activity of 1400 Ci/g. Used as a substitute for ["5"7Co]cyanocobalamin in binding assays, the new derivative can reduce counting times and decrease costs in such assays. (Auth.)

1982-12-23

295

(E)-[125I]-5-AOIBV: a SPECT radioligand for the vesicular acetylcholine transporter  

International Nuclear Information System (INIS)

The premise that, over the course of Alzheimer's disease (AD), changes in the levels of the vesicular acetylcholine transporter (VAChT) occur in parallel with changes to other cholinergic marker proteins provides the basis for the applicability of benzovesamicol derivatives as radioligands for AD studies by single photon emission computed tomography or positron emission tomography. We report the synthesis of enantiopure benzovesamicol derivatives: (R,R) or (S,S)-(E)-2-hydroxy-5-(3-iodoprop-2-en-1-oxy)-3- (4-phenylpiperidino)tetralin [(R,R)-AOIBV: Kd=0.45 nM or (S,S)-5-AOIBV: Kd=4.3 nM] and their corresponding tributyltin precursors for radioiodination. (R,R or S,S)-5-AOIBV was labeled with iodine-125 from their corresponding n-tributyltin precursors. Both compounds were obtained with radiochemical and optical purity greater than 97% and in radiochemical yields ranging 34-36%. To determine if these compounds could provide an advantage when compared to [125I]-iodo benzovesamicol (IBVM), IBVM was also labeled and used as the reference compound in all ex vivo experiments. Ex vivo biodistribution experiments in rats revealed that [125I]-(R,R)-5-AOIBV displayed the most suitable pharmacological profile as the radioactivity distribution corresponded well with the known VAChT brain density. Moreover, pre-injection of vesamicol prevented the uptake of [125I]-(R,R)-5-AOIBV in striatum, cortex and hippocampus, demonstrating selectivity for the VAChT. However, even if time activity curves of [125I]-(R,R)-5-AOIBV confirmed that this compound could be used to visualize the VAChT in vivo, at each point of the kinetic study, [125I]-(R,R)-5-AOIBV showed a lower specific binding compared to [125I]-IBVM. These results made [125I]-( R,R)-5-AOIBV inferior to [125I]-IBVM for the VAChT exploration in vivo

2007-11-01

296

Distribution of "1"2"5I-iodopamide-meglumine (Adipiodon) in the rat  

International Nuclear Information System (INIS)

8 minutes after injection a maximum concentration of 16% of intravenously injected "1"2"5I-Adipiodon was found in the rat liver. This amount dropped to 1/25 after 256 minutes, 58 +- 25% were found in the gastrointestinal tract 64 minutes following injection as a result of biliary excretion. The storage rates of the "1"2"5I-Adipiodon concentrations in tissues and plasma characterize the affinity of Adipiodon to the organs after distribution equilibrium has started

1981-01-01

297

Unlabelled iododeoxyuridine increases the rate of uptake of [125I]iododeoxyuridine in human xenografted glioblastomas  

International Nuclear Information System (INIS)

5-Iodo-2'-deoxyuridine (IdUrd), a thymidine (TdR) analogue, can be radiolabelled with iodine-125, an Auger radiation emitter, to provoke double-strand breaks once incorporated into DNA of cancer cells. We have previously shown that co-incubation of [125I]IdUrd with unlabelled IdUrd provided an additive cytotoxicity in two human glioblastoma cell lines. This observation was unexpectedly correlated with an increase in the rate of DNA incorporation of [125I]IdUrd. Here, we further evaluated the effects of unlabelled IdUrd on the uptake of [125I]IdUrd in vitro and in vivo in mice xenografted with three human glioblastoma lines. The results showed that, in these three glioblastoma lines, unlabelled IdUrd increased the rate of uptake of [125I]IdUrd in vitro by 2- to 4.4-fold and in vivo by 1.5- to 2.8-fold. The rate of uptake of [125I]IdUrd in normal rapidly dividing tissues was also increased by 1.3- to 2.8-fold. TdR completely blocked [125I]IdUrd uptake in tumours and tissues. Analogues of IdUrd, such as deoxyuridine and 5-iodo-1,3-dimethyuracil, did not reproduce the effect of IdUrd on the uptake of [125I]IdUrd, suggesting that it is not related to protection against [125I]IdUrd degradation. It is concluded that combined administration of unlabelled IdUrd may improve the use of radiolabelled IdUrd for cancer diagnosis or therapy. (orig.)

2002-04-01

298

Purification of monoiodinated vasointestinal peptide (M125I-VIP) by high pressure liquid chromatography (HPLC)  

International Nuclear Information System (INIS)

In our developed reverse phase high performance liquid chromatography, four forms of M125I-VIP have been isolated free from unlabeled VIP and other iodinated components. The quicker eluting M125I-VIP forms (oxidised and reduced) have a consistently and significantly low non-specific binding with specific target cells of VIP (HT-29) as compared to the late eluting forms of VIP. The retention time is considerably increased when the molecule of VIP is fully iodinated

1984-01-01

299

Radiolabeling of EGCG with 125I and its biodistribution in mice  

International Nuclear Information System (INIS)

The aim of the present study was to label EGCG with 125I and to determine its radiopharmaceutical potential in mice. EGCG was labeled with 125I using the iodogen method. The labeling yield and the radiochemical purity of 125I-EGCG were determined by radio thin-layer chromatography (RTLC). The Labeling yield was approximately 89.4 %. The radiochemical purity was approximately 96.4 %. The biodistribution studies of the labeled compound (specific activity; 0.47 TBq/?g) were performed in male Kunming mice. The uptakes of 125I-EGCG in some organs were determined at different time after injection to the mice. The radioactivity in each organ was counted and the percentage of injected activity per gram of tissue weight (%ID/g) for each organ and blood was calculated. Incorporation of radioactivity in the various tissue/organ was confirmed by microautoradiography. 125I-EGCG uptake in the stomach and salivary gland was higher than other organ/tissue. The black silver grains was concentrated in the nucleus, cytoplasm, intercellular substance and capillaries of that various organs, and its unevenly distributed. Thus, 125I-EGCG may be radiopharmaceutical for the imaging of the stomach and salivary gland. (author)

2014-07-01

300

Effects of N/sub 2//2-deoxyglucose (2-DOG) treatment on degradation of /sup 125/I-insulin, /sup 125/I-asialofetuin and /sup 125/I-epidermal growth factor by isolated rat hepatocytes  

Energy Technology Data Exchange (ETDEWEB)

/sup 125/I-insulin (INS), /sup 125/I-asialofetuin (A-FET) and /sup 125/I-epidermal growth factor (EGF) are generally believed to be internalized by an endocytotic process with subsequent degradation, some steps of which are energy-requiring. In this study they have examined the effects of ATP depletion on the degradation of these compounds. Isolated hepatocytes from male Sprague-Dawley rats (150-300 g) were prepared as previously described and maintained at 37/sup 0/C with an atmosphere of 95% O/sub 2//5% CO/sub 2/. Cells were ATP-depleted with 10 mM 2-DOG and an atmosphere of 95% N/sub 2//5% CO/sub 2/. Degradation was assessed by the change in trichloroacetic acid solubility of the labeled compounds. ATP, as measured by the luciferin-luciferase assay, was reduced to undetectable levels after 10 minutes as compared to control (O/sub 2/ + glucose) values of 9.5 +/- 0.5 nmoles ATP/10/sup 6/ cells. The time-course of INS degradation was unaffected by ATP depletion as compared to control. In contrast, ATP depletion inhibited A-FET (94-100%) and EGF (93-100%) degradation over the same time period. Assessments of ligand internalization are in progress. These results indicate that INS degradation markedly differs from degradation of A-FET and EGF in its sensitivity to lowered cellular ATP levels.

Moss, A.L.; Ward, W.F.

1986-03-05

 
 
 
 
301

Isotope and Patient Age Predict for PSA Spikes After Permanent Prostate Brachytherapy  

International Nuclear Information System (INIS)

Purpose: To evaluate prostate-specific antigen (PSA) spikes after permanent prostate brachytherapy in low-risk patients. Methods and Materials: The study population consisted of 164 prostate cancer patients who were part of a prospective randomized trial comparing 103Pd and 125I for low-risk disease. Of the 164 patients, 61 (37.2%) received short-course androgen deprivation therapy. The median follow-up was 5.4 years. On average, 11.1 post-treatment PSA measurements were obtained per patient. Biochemical disease-free survival was defined as a PSA level of ?0.40 ng/mL after nadir. A PSA spike was defined as an increase of ?0.2 ng/mL, followed by a durable decline to prespike levels. Multiple parameters were evaluated as predictors for a PSA spike. Results: Of the 164 patients, 44 (26.9%) developed a PSA spike. Of the 46 hormone-naive 125I patients and 57 hormone-naive 103Pd patients, 21 (45.7%) and 8 (14.0%) developed a PSA spike. In the hormone-naive patients, the mean time between implantation and the spike was 22.6 months and 18.7 months for 125I and 103Pd, respectively. In patients receiving neoadjuvant androgen deprivation therapy, the incidence of spikes was comparable between isotopes (125I 28.1% and 103Pd 20.7%). The incidence of spikes was substantially different in patients 125I and/or <65 years of age. Differences in isotope-related spikes are most pronounced in hormone-naive patients

2007-08-01

302

PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure; Influence sur les resultats des rebonds du PSA apres curietherapie de prostate: etude de 295 cas avec trois ans de suivi  

Energy Technology Data Exchange (ETDEWEB)

Purpose. To assess the frequency of the PSA 'bouncing' phenomenon after a significant follow-up in a series of patients treated by j permanent implant brachytherapy for a prostate cancer. To look for the clinical and dosimetric parameters possibly linked to this transitory secondary PSA increase. To evaluate in which percentage of cases this bouncing could have mimicked a biochemical relapse according to the ASTRO consensus criteria. Patients and methods. From January 1999, to December 2001, 295 patients were treated by a permanent prostate implantation (real-time technique, with free {sup 125}I seeds- Isoseed Bebig-) by the Institut Curie-Hopital Cochin-Hopital Necker Paris group. The mean follow-up is 40.3 months (9--66 months). The PSA level was regularly checked, at least every 6 months. We defined as a 'bouncing' all increase in PSA, starting at 0.1 ng/ml, subsequently followed by a spontaneous (without any treatment) decrease, with return to the previous level or lower. We particularly focused on the patients fulfilling the criteria for a biochemical relapse according to the ASTRO consensus (Three successive increases in PSA). A multivariate analysis tried to identify independent factors among the usual clinical and dosimetric parameters. Results. In our series, 161 patients (55%) showed a transitory PSA increase (bouncing) of at least 0.1 ng/ml; 145 patients (49%) a bouncing of 0.2 ng/ml, 93 patients (32%) a bouncing of 0.4 ng/ml and 43 patients (15%) a bouncing of at least 1 ng/ml. Mean PSA bounce was 0.8 ng/ml (0.1 .1), and mean time to bounce was 19 months. Thirty-two patients (11% of the total number) presented three successive PSA increases with a significant (3 months) interval between the dosages, and therefore were to be considered as being in biochemical relapse according to the ASTRO consensus criteria. Actually, among those 32 patients, 18 (56%) subsequently showed a complete normalization of their PSA, without any treatment. Ten patients went on increasing their PSA, and were considered to be really in biochemical relapse. For the last 4 patients, the situation still remains ambiguous. In multivariate analysis, age < 70 years (P < 0.00001) and D90 > 200 Gy (P < 0.003) were identified as independent factors for a PSA bouncing of at least 0.4 ng/ml. Conclusions. The observed rate of 32 of patients showing a PSA bouncing of at least 0.4 ng/ml in our series is in good agreement with what has been previously reported in the literature. Age < 70 years and D90 > 200 Gy were found to be independent factors predicting for such a secondary transitory increase in PSA. Interestingly, among 32 patients fulfilling the classical criteria of the ASTRO for a biochemical relapse, 18 (560/0) subsequently showed a spontaneous PSA decrease, demonstrating that the ASTRO consensus is not well adapted to the biochemical follow-up of our patients undergoing permanent implant prostate Brachytherapy. (authors)

Toledano, A. [Hopital Tenon, APHP, Service d' Oncologie Radiotherapie, 75 - Paris (France); Chauveinc, L. [Clinique Hartmann, 92 - Neuilly (France); Flam, T. [Hopital Cochin, Service d' Urologie, 75 - Paris (France); Thiounn, N. [Hopital Necker, Service d' Urologie, 75 - Paris (France); Solignac, S.; Timbert, M.; Rosenwald, J.C.; Cosset, J.M. [Institut Curie, Dept. de Radiotherapie et de Radiophysique, 75 - Paris (France)

2007-05-15

303

Combination of bilateral pelvic lymphadenectomy, permanent iodine-125 implantation, and percutaneous irradiation of the locally confined prostatic cancer. Pt. 1  

International Nuclear Information System (INIS)

Since the beginning of 1981, 32 patients at an age of 52 to 72 years who suffered from a locally confined adenocarcinoma of the prostate were treated by permanent implantation of I-125 seeds. 25 patients were evaluated after a median observation period of 30 months. The first group consisting of 19 patients was submitted to a combined percutaneous and interstitial treatment, the other 6 patients were initially treated only by interstitial therapy because of severe complications observed in the meantime. After bilateral pelvic staging lymphadenectomy, permanent I-125 seeds were implanted into the patients of stage T_1, T_2, early T_3 and pN_0_-_1, in case of microscopic lymph node manifestation without capsular perforation also into patients of stage pN_2 and pN_4. 8 weeks later the patients received a moving beam irradiation with 10 MV photons at the linear accelerator. The centre of the prostate was faded out by a specially constructed H absorber in such a way that the prescribed target dose of 36 Gy in 4 weeks to the 90%-isodose was only applied to a spherical surface around the implant. 1 patient died perioperatively from an embolism due to phlebothrombosis of the thigh. 22 out of the other 24 patients are in complete remission, 1 patient had a local recurrence in the right seminal vesicle which appeared 28 months after primary therapy, and 1 patient developed skeletal metastases. The objective side effects and late complications of our combined treatment are considerable with respect to their incidence as well as their severity: a slight or medium radioproctitis was found after a latent period of 1 to 2 years in 28% (5/18) of cases, after a latent time of about 1 1/2 to 2 years another 28% (5/18) developed subsequently to a proctitis an urethral stricture and an ulcer situated on the anterior rectum wall facing the prostate, and 4 patients presented finally a prostato-rectal fistula. (orig.)

1987-01-01

304

Experimental study on differential diagnosis of tumor from inflammation by using /sup 125/I labeled Pisum sativum agglutinin  

Energy Technology Data Exchange (ETDEWEB)

We have reported that Pisum sativum agglutinin (PSA), a plant lectin which recognizes mannosyl residues, accumulates markedly in Ehrlich solid tumor (EST) and suggested the possibility of applying PSA to tumor imaging radiopharmaceuticals. In the present work, an inflammation was induced by implantation of cotton thread in the left rear leg skeletal muscle of ddY mice and Ehrlich ascites tumor cells were inoculated into the right rear leg. /sup 67/Ga-citrate accumulated in the tumor tissue and the inflammatory lesion to almost equal extents. On the other hand, /sup 125/I-PSA preferentially accumulated in tumor tissues in mice bearing both tumor and inflammation. The results suggest that differential diagnosis of tumor from inflammation using radiolabeled PSA may be possible.

Kojima, Shuji; Jay, M.

1987-12-01

305

An experimental study on differential diagnosis of tumor from inflammation by using 125I labeled Pisum sativum agglutinin  

International Nuclear Information System (INIS)

We have reported that Pisum sativum agglutinin (PSA), a plant lectin which recognizes mannosyl residues, accumulates markedly in Ehrlich solid tumor (EST) and suggested the possibility of applying PSA to tumor imaging radiopharmaceuticals. In the present work, an inflammation was induced by implantation of cotton thread in the left rear leg skeletal muscle of ddY mice and Ehrlich ascites tumor cells were inoculated into the right rear leg. 67Ga-citrate accumulated in the tumor tissue and the inflammatory lesion to almost equal extents. On the other hand, 125I-PSA preferentially accumulated in tumor tissues in mice bearing both tumor and inflammation. The results suggest that differential diagnosis of tumor from inflammation using radiolabeled PSA may be possible. (orig.)

1987-01-01

306

Estado da arte do procedimento percutâneo: paciente octogenário submetido com sucesso, em apenas uma sessão, a valvotomia pulmonar, implante de stent coronário e implante de marcapasso definitivo State of the art percutaneous procedure: octogenarian patient successfully submitted, in a single session, to a pulmonary valvotomy, coronary stent implant and permanent pacemaker implant  

Directory of Open Access Journals (Sweden)

Full Text Available É relatado caso de paciente de 82 anos, portador de insuficiência renal leve, estenose valvar pulmonar (EVP severa, estenose severa de artéria descendente anterior e bloqueio atrioventricular total, submetido a angioplastia coronária com implante de stent coronário, valvotomia pulmonar e implante de marcapasso definitivo no mesmo procedimento, com sucesso.This report describes a case involving an 82 year old patient with mild renal insufficiency, severe pulmonary valve stenosis (PVS, severe anterior descending artery stenosis and complete atrioventricular block, who successfully underwent, in a single session, coronary angioplasty and a stent implant, pulmonary valvotomy and a permanent pacemaker implant.

Wilson Albino Pimentel Filho

2005-10-01

307

Plasmid DNA breakage by decay of DNA associated isotopes 123I and 125I  

International Nuclear Information System (INIS)

The biological consequences of decay of DNA-associated 125I have been extensively investigated using a variety of systems. It is well established that decay of the isotope in close proximity to DNA produces a DSB with an efficiency close to 1. Much less information is available for another iodine isotope - 123I. It is a 'weaker' Auger emitter than 125I, and has much shorter half-life; 13.2 hours compared to 60 days for 125I. Cell culture studies indicate that decay of 123I is more than two times less efficient in killing V79 cells than decay of 125I, and produces from 0.45 to 0.74 DSB per decay in the cell nucleus. The Monte Carlo simulation of 123I decay and DSB induction has generated a value of 0.4 DSB per decay of incorporated isotope. We have adapted the plasmid DNA assay to compare strand breakage by decay of DNA-associated 125I and 125I, exploiting DNA minor groove binding ligand Hoechst 33258 labelled with either of these isotopes. Application of the plasmid assay to this study highlighted a range of important factors, which were taken into account to ensure a valid outcome. These factors involve the statistical implications of the nature of the breakage events (such as multiple breaks arising from a single decay event), two different sources of damage, namely internal (from DNA-associated decay events) and external (from decays occurring anywhere in solution), and consideration of the fraction of DNA-bound ligand. In our experiments, we incubated pBR322 plasmid with [125I]-iodoHoechst 33258 or with mixture of ligands labelled with 123I and 125I. The latter approach allows measurement of the ratio of probabilities of DSB formation per decay for the two isotopes, with much higher precision than determination of the individual breakage probabilities for each isotope. We obtained for the probability (per decay) of induction of DSB by the 125I-labeled ligand a value of 0.82 ± 0.05. Inclusion of DMSO as a radical scavenger, reduces this value to 0.65 ± 0.05 DSB per decay. The ratio of DSB probability per decay of 123I to that of 125I is 0.63 ± 0.03, with little change with inclusion of DMSO; namely to 0.65 ± 0.03

2003-08-17

308

DNA strand breakage by {sup 125}I-decay in oligoDNA  

Energy Technology Data Exchange (ETDEWEB)

Full text: A double-stranded oligodeoxynucleotide containing {sup 125}I-dC in a defined location, with 5`- or 3`-{sup 32}P-end-labelling of either strand, was used to investigate DNA strand breakage resulting from {sup 125}I decay. Samples of the {sup 32}P-end-labelled and {sup 125}I-dC containing oligoDNA were incubated in 20 mM phosphate buffer (PB), or PB + 2 M dimethylsulphoxide (DMSO) at 4 deg during 18-20 days. The {sup 32}P-end-labelled DNA fragments produced by {sup 125}I decays were separated on denaturing polyacrylamide gels, and the {sup 3P} activity in each fragment was determined by scintillation counting after elution from the gel. The fragment size distribution was then converted to a distribution of single stranded break probabilities at each nucleotide position. The results indicate that each {sup 125}I decay event produces at least one break in the {sup 125}I-dC containing strand, and causes breakage of the opposite strand in 75-80% of events. Thus, the double stranded break is produced by {sup 125}I decay with probability {approx}0.8. Most of single stranded breaks (around 90%) occurred within 5-6 nucleotides of the {sup 125}I-dC, however DNA breaks were detected up to 18-20 nucleotides from the decay site. The average numbers of single stranded breaks per decay are 3.7 (PB) and 3.3 (PB+DMSO) in {sup 125}I-dC containing strand, and 1.5 (PB) and 1.3 (PB+DMSO) in the opposite strand. Deconvolution of strand break probabilities as a function of separation from the {sup 125}I, in terms of both distance (to target deoxyribosyl carbon atoms, in B-DNA) and nucleotide number, show that the latter is an important parameter for the shorter-range damage. This could indicate a role for attenuation/dissipation of damage through the stacked bases. In summary, the results represent a much more extensive set of data than available from earlier experiments on DNA breakage from {sup l25}I-decay, and may provide new mechanistic insights.

Lobachevsky, P.; Martin, R.F. [Peter McCallum Cancer Institute, Melbourne VIC (Australia)

1996-12-31

309

A novel 125I-labeled daunorubicin derivative for radionuclide-based cancer therapy  

International Nuclear Information System (INIS)

Introduction: Auger electron emitters, such as 125I, are getting increasingly wider recognition as alternatives to current anticancer treatments. The effectiveness of Auger electrons is strongly dependent on their proximity to DNA and is therefore considered as harmless outside the nucleus. Methods: 125I or 127I was conjugated with Comp1, Comp2 or Comp3 - three derivatives of the chemotherapeutic drug daunorubicin. Their capacity factors, DNA-binding constants and exclusion parameters, and the degree of DNA fragmentation after incubating isolated DNA with our 127I- or 125I-conjugated daunorubicin derivatives were determined. Human breast adenocarcinoma (SK-BR-3) cells were incubated with the derivatives; fluorescent microscopy and autoradiography images were generated; and cell growth was monitored. Results and Discussion: The capacity factor of 127I-Comp1 was similar to those of daunorubicin and doxorubicin, whereas lower capacity factors of 127I-Comp2 and 127I-Comp3 suggested reduced interactions with lipid membranes. DNA exclusion parameters and binding constants of 127I-Comp1 and 127I-Comp2, but not of 127I-Comp3, were similar to those of doxorubicin. Fluorescent microscopy and autoradiography images of SK-BR-3 cells revealed that 127I-Comp1 and 125I-Comp1 accumulated in tumor cell nuclei, whereas 127I-Comp2 and 127I-Comp3 were present predominantly in other cell compartments. The binding of 125I-Comp1 to isolated chromosomal DNA led to major fragmentation. Incubation of SK-BR-3 cells with 125I-Comp1 inhibited cell growth, whereas doxorubicin or 127I-Comp1 administered at the same concentration had no effect on cell growth. Our results thus suggest that 125I-Comp1 has the potential to become a new tool for anticancer therapy

2006-08-01

310

[(125)I]EYF: a new high affinity radioligand to neuropeptide FF receptors.  

Science.gov (United States)

[(125)I]EYF ([(125)I]EYWSLAAPQRFamide), a new radioiodinated probe derived from a peptide present in the rat Neuropeptide FF precursor (EFWSLAAPQRFamide, EFW-NPSF) was synthesized and its binding characteristics investigated on sections of the rat spinal cord and on membranes of mouse olfactory bulb. In both tissues, [(125)I]EYF binding was saturable and revealed a very high affinity interaction with a single class of binding sites in rat and mouse (K(D) = 0.041 and 0.019 nM, respectively). Competition studies showed that [(125)I]EYF bound to one class of binding sites exhibiting a high affinity for all the different peptides the precursor could generate (NPA-NPFF, SPA-NPFF, NPFF, EFW-NPSF, QFW-NPSF) with the exception of NPSF which displayed a low affinity. Autoradiographic studies demonstrated that [(125)I]EYF binding sites were fully inhibited by a synthetic Neuropeptide FF agonist (1DMe) in all areas of the rat brain. The density of [(125)I]EYF binding sites was high in the intralaminar thalamic nuclei, the parafascicular thalamic nucleus and in the superficial layers of the dorsal horn. Non specific binding reached 5-10% of the total binding in all brain areas. Similarly, in mouse brain experiments, the non-specific binding was never superior to 10%. These findings demonstrate that putative neuropeptides generated by the Neuropeptide FF precursor and containing the NPFF or NPSF sequences should bind to the same receptor. Furthermore, these data indicate that [(125)I]EYF is a useful radiolabeled probe to investigate the NPFF receptors; its major advantages being its high affinity and the very low non-specific binding it induces. PMID:11311733

Gouardères, C; Mollereau, C; Tafani, J A; Mazarguil, H; Zajac, J M

2001-04-01

311

Physical and radiobiological bases of the use of 125I in the management of thyrotoxicosis  

International Nuclear Information System (INIS)

Increasing interest is recently shown in the use of 125I as an alternative isotope to 131I for the management of thyrotoxicosis based on the postulate that there is a relative sparing of the reproductive integrity of the thyroid follicular cell and a consequent possibility of smaller incidence of hypothyroidism after therapy. A review of the dosimetric, radiobiological and clinical aspects of the use of 125I are presented here. For the same activity though 125I gives smaller mean gland dose than 131I, the dose computations at microscopic level have revealed that there is a preferential irradiation of the apical membrane compared to the nucleus of the follicular cell. The ratio of the dose to the apical membrane an that to the nucleus increases with the decrease of the percentage colloid mass of the gland. Radiobiological significance of this non-uniform dose distribution across a follicular cell, with 125I, is brought out using rat thyroid as the biological system. For the same mean gland dose the follicular cell survival is larger with 125I than with 131I. 24 h radioiodine uptake is reduced in case of 131I treatment whereas it is not affected with 125I. Pilot clinical trials using 125I for the management of thyrotoxicosis are underway in some centres. Preliminary results form centres using doses 3-4 times that of the conventional 131I dose are not very different from those with conventional 131I therapy. Centres that used doses same as or less than the conventional 131I doses, reported smaller incidence of hypothyroidism. (orig.)

1976-10-01

312

The brachytherapy by implants of iodine 125 in the localised prostate cancer; La curietherapie par implants permanents d'iode 125 dans le cancer de la prostate localise  

Energy Technology Data Exchange (ETDEWEB)

The brachytherapy by permanent iodine 125 implants is in the localised prostate cancer a clinical treatment well tolerated and characterized by a limited toxicity: the urinary flow before implantation is an important factor of evolution prediction of the acute urinary toxicity, especially with regard to acute urinary retention. The important number of gains implanted near urethra is responsible of the acute urinary toxicity. All patients were in a state of complete remission with a decrease in the concentration of serum P.S.A. to eight months. (N.C.)

Cecconi, A.; Guido, A.; Vicenzi, L.; Galuppi, A.; Barbieri, E. [U.O. Radioterapia, Policlinico S.-Orsola-Malpighi, Bologne (Italy)

2007-11-15

313

Labelling of antisense oligonucleotide with 125I and the experimental research of identification of the lymphoma cell by using 125I-FR-ASON  

International Nuclear Information System (INIS)

Objective: To establish a new method of labeling oligonucleotide with radioisotope of iodine and to investigate the possibility of using 125I-FR-ASON as imaging agent or therapeutic antisense radiopharmaceutical in lymphoma. Methods: A 18 mer oligonucleotide sequence was synthesized and grafted in 5' with a tyramine group. Radioiodination of the tyramine conjugated oligonucleotide with 125I was performed using the Chloramine T method. The Namalwa and HL-60 cell lines were transduced with DMRIE-C mediated 125I-ASON, then the transduction efficiency was calculated, authors also compared it with the transduction efficiency without DMRIE-C reagent. After incubation with serum, the tyramine-ASON was analysed by electrophoresis in 20% polyacrylamide gel. Results: The radiolabeling efficiency, radiochemical purity and specific activity were 80.7%, 98.7% and 100 kBq/?g, respectively. The transduction efficiency in Namalwa cell line reached (26.8 ±1.54)% that was as 18 times greater as that in transduction without mediation. The transduction efficiency in HL-60 cell line was only (13.6 ± 2.54)%, that was far lower than in Namalwa cell line. The gel electrophoresis showed that there wasn't any additional band at 2, 6 and 24 h post-incubation. Conclusions: The radioiodination method by conjugating the oligonucleotide with tyramine was very successful. The 125I-FR-ASON showed high specificity in Namalwa cell line and it could be used as an antisense imaging agent or antisense radiopharmaceutical in therapeutic research on lymphoma

2003-04-01

314

Clinical and physical determinants for toxicity of 125-I seed prostate brachytherapy  

International Nuclear Information System (INIS)

Background and purpose: To assess acute as well as long-term toxicity after permanent prostate seed implantation. To find predictive clinical or dosimetric factors for side effects in order to work out strategies for improvement. Patients and methods: A group of 174 patients with localised prostate cancer was treated with permanent seed implantation between 1999 and 2001, either alone (140 patients) or in combination with external radiotherapy (34 patients). For the majority (114/174, i.e. 66%) a CT was performed four weeks after implantation and analysed in the planning system VariSeed. In the postimplant analysis, dosimetric descriptors (doses, volumes) were determined for the prostate and rectum and compared with the intraoperative values. In addition, a questionnaire was sent to all patients to assess and quantify acute and chronic toxicity (urinary, rectal, sexual) and the impact on subjective acceptance and quality of life (return rate of questionnaires 83%). The derived score changes were correlated with clinical and dosimetric factors. Results: In the mono-brachytherapy group 14% (16/140) required a bladder catheter, of them 8% (9/140) with a manifest urinary obstruction. Long-term rectal toxicity (50>240 Gy), which appears to be attributed to unnecessarily high numbers of seeds (for a fixed activity per seed) and needles. The rectal toxicity is correlated with the high dose regions in the rectum (?145 Gy). Urinary toxicity is lower for combined-brachytherapy, while rectal toxicity and impairment of potency are slightly higher. Conclusions: Toxicity spectrum and quality of life after permanent seed implantation for early prostate cancer are acceptable for nearly all patients (98%). To further improve tolerance we should attempt to achieve a better dose homogeneity, i.e. by reducing D50. Therefore, special attention should be given to D50 during the real-time planning process. The necessity of more homogeneous dose distributions might imply a reduction of the activity per seed, e.g. from 0.7 mCi down to 0.6 mCi

2004-10-01

315

Cell-Based Assay System to Estimate the Effect of 125I Seeds on Cancer Cells: Effect of Osteopontin.  

Science.gov (United States)

Background and Purpose: A number of recent patents related to 125I seed and osteopontin have been awarded. In this study, we developed a new in vitro model to study the radiobiological effects of 125I seeds on cancer cells. Methods: We placed 125I seeds in a cell culture plate with cells seeded on a transwell chamber to evaluate the effects of 125I seeds on cell motility. We placed 125I seeds in a transwell chamber with cells seeded on the cell culture plate to study cell proliferation, apoptosis, and to perform western blot. Results: We used SK-Hep-1 liver cancer cells to evaluate the effectiveness of our model, and investigated the role of osteopontin in the therapeutic effects of 125I seeds. We found that 125I seeds inhibited the cell proliferation and motility in this model while osteopontin reduced these effects. We also measured the effects of 125I seeds on apoptosis. Furthermore, when treated with 125I seeds, we detected changes in several signaling pathways that are involved in the proliferation and invasion of cancer cells. Conclusions: The model can be used to assess the biological effects of 125I seeds in vitro. Osteopontin may be involved in the 125I seed-induced inhibition of SK-Hep-1 cells. PMID:24693996

Yang, Guang; Peng, Sheng; Zhang, Yanling; Liu, Zhenyin; Lu, Mingjian; Zhang, Tao; Gao, Fei; Zhang, Fujun

2014-05-01

316

Synthesis and biologic studies of iodinated (125I/127I) ethidium  

International Nuclear Information System (INIS)

An iodinated (125I/127I) ethidium derivative (3,8-diamino-5-[6'-(p-iodobenzoylamino)-4'-azahexyl]-6 -phenylphenanthridinium chloride hydrochloride) was synthesized and characterized. The labeling yield of the 125I-labeled derivative was 75% for carrier-free 125I, with a radiochemical purity of 95%. The incubation of iodoethidium with calf thymus DNA resulted in a substantial enhancement of fluorescence yield, indicating the intercalation of this compound into DNA. In the presence of iodoethidium, the nuclei of methanol-treated mammalian cells fluoresced, while those of viable cells did not (since the plasma membrane is impermeable to iodoethidium). When viable cells were incubated with the reduced form of the derivative, 125I/127I-dihydroethidium traversed the plasma membrane, was oxidized in the cytoplasm, and intercalated into nuclear DNA. Finally, we tested the hypothesis that larger malignant solid tumors, containing a relatively greater percentage of degenerating permeable cells, can be targeted with 125I-ethidium. In-vivo studies demonstrated a small but positive correlation (R = 0.72) between tumor volume and the uptake of the derivative. Because of the ubiquitous presence of abnormal permeable cells and necrosis in tumors, our results support the belief that radiolabeled DNA-intercalating or DNA-binding molecules may be of diagnostic and therapeutic value for a variety of solid tumors in humans

2001-11-01

317

Synthesis and biologic studies of iodinated ({sup 125}I/{sup 127}I) ethidium  

Energy Technology Data Exchange (ETDEWEB)

An iodinated ({sup 125}I/{sup 127}I) ethidium derivative (3,8-diamino-5-[6'-(p-iodobenzoylamino)-4'-azahexyl]-6 -phenylphenanthridinium chloride hydrochloride) was synthesized and characterized. The labeling yield of the {sup 125}I-labeled derivative was 75% for carrier-free {sup 125}I, with a radiochemical purity of 95%. The incubation of iodoethidium with calf thymus DNA resulted in a substantial enhancement of fluorescence yield, indicating the intercalation of this compound into DNA. In the presence of iodoethidium, the nuclei of methanol-treated mammalian cells fluoresced, while those of viable cells did not (since the plasma membrane is impermeable to iodoethidium). When viable cells were incubated with the reduced form of the derivative, {sup 125}I/{sup 127}I-dihydroethidium traversed the plasma membrane, was oxidized in the cytoplasm, and intercalated into nuclear DNA. Finally, we tested the hypothesis that larger malignant solid tumors, containing a relatively greater percentage of degenerating permeable cells, can be targeted with {sup 125}I-ethidium. In-vivo studies demonstrated a small but positive correlation (R = 0.72) between tumor volume and the uptake of the derivative. Because of the ubiquitous presence of abnormal permeable cells and necrosis in tumors, our results support the belief that radiolabeled DNA-intercalating or DNA-binding molecules may be of diagnostic and therapeutic value for a variety of solid tumors in humans.

Ho Nanhui; Tumeh, Paul C.; Kassis, Amin I. E-mail: amin_kassis@hms.harvard.edu

2001-11-01

318

Radioimmunoassay for etorphine in horses with a 125I analog of etorphine  

International Nuclear Information System (INIS)

To improve the sensitivity and specificity of screening for etorphine in horses, an 125I-labeled etorphine analog was synthesized and an antibody to etorphine was raised in rabbits. A radioimmunoassay (RIA) for etorphine was developed, using these reagents. Bound and free 125I-labeled etorphine was separated by a double-antibody method that reduced interference from materials associated with equine urine. The 125I-labeled etorphine binding was rarely greater than 250 pg of background etorphine equivalents/ml in raw urine and was 100 pg/ml in hydrolyzed urine. The 125I-RIA was capable of detecting etorphine equivalents in urine above these background values. Etorphine equivalents were detected in equine urine samples for about 7 days after 4 mares were dosed with 0.22 microgram of etorphine/kg of body weight, IV. The stability of etorphine in urine from these mares was evaluated. Urine from these dosed mares was held in constant -20 C storage, and aliquots were repeatedly frozen and thawed. When analyzed for etorphine equivalents using an 125I-RIA, etorphine and its metabolites in urine samples were stable for less than or equal to 38 days if continuously frozen and also were resistant to repeated freezing and thawing

1988-01-01

319

Can [125I]-iodocyanopindolol label ß3-adrenoceptors in rat urinary bladder?  

Directory of Open Access Journals (Sweden)

Full Text Available ?3-Adrenoceptors have been demonstrated to mediate urinary bladder smooth muscle relaxation but proof of their expression at the protein level has been missing because of lack of suitable antibodies or radioligands. As among various available radioligands [125I]-iodocyanopindolol ([125I]-ICYP exhibited the smallest problems in labelling cloned human ?3-adrenoceptors in previous studies, we have explored its suitability to label ?3-adrenoceptors in rat urinary bladder in saturation and competition radioligand binding experiments. Rat lung was used as an internal control and exhibited all characteristics expected from this tissue with regard to ?1/?2-adrenoceptor labelling. Saturation and competition binding studies with [125I]-ICYP in rat bladder yielded saturable binding sites with an affinity compatible with ?3-adrenoceptors. In competition experiments various agonists and antagonists largely exhibited a profile compatible with a population consisting largely of ?3-adrenoceptors. However, the binding competition properties of ICI 118,551 and SR 59,230A were not easily explained by the idea of labelling a homogeneous ?3-adrenoceptor population but interpretation of the data was limited by a high degree of non-specific binding in [125I]-ICYP concentrations required to label the receptors. We conclude that [125I]-ICYP can be used to label tissue ?3-adrenoceptors but results obtained with this ligand have to be interpreted with caution.

MartinChristianMichel

2010-10-01

320

{sup 125}I-iomazenil-benzodiazepine receptor binding during psychological stress in rats  

Energy Technology Data Exchange (ETDEWEB)

We investigated the changes in {sup 125}I-iomazenil ({sup 125}I-IMZ) benzodiazepine receptor (BZR) binding with psychological stress in a rat model. Six male Wistar rats were placed under psychological stress for 1 hour by using a communication box. No physical stress was not received. 1.85 MBq of {sup 125}I-IMZ was injected into the lateral tail vein and the rat was killed 3 hours later. Twenty-micormeter-thick sections of the brain were collected and % injected dose per body weight (% ID/BW) of eleven regions (frontal, parietal, temporal, occipital cortices, caudate putamen, accumubens nuclei, globus pallidus, amygdala, thalamus, hippocampus and hypothalamus) were calculated by autoradiography. The %ID/BW of rats which were placed under psychological stress was compared with that of 6 control rats. The %ID/BW of rats which were placed under psychological stress diffusely tended to show a reduction in {sup 125}I-IMZ-BZR binding. A significant decrease in BZR binding was observed in the hippocampus of the rats which were placed under psychological stress. {sup 125}I-IMZ-BZR binding tended to decrease throughout the brain. (author)

Fukumitsu, Nobuyoshi; Tsuchida, Daisuke; Ogi, Shigeyuki; Uchiyama, Mayuki; Mori, Yutaka [Jikei Univ., Tokyo (Japan). School of Medicine

2002-05-01

 
 
 
 
321

125I-iomazenil-benzodiazepine receptor binding during psychological stress in rats  

International Nuclear Information System (INIS)

We investigated the changes in 125I-iomazenil (125I-IMZ) benzodiazepine receptor (BZR) binding with psychological stress in a rat model. Six male Wistar rats were placed under psychological stress for 1 hour by using a communication box. No physical stress was not received. 1.85 MBq of 125I-IMZ was injected into the lateral tail vein and the rat was killed 3 hours later. Twenty-micormeter-thick sections of the brain were collected and % injected dose per body weight (% ID/BW) of eleven regions (frontal, parietal, temporal, occipital cortices, caudate putamen, accumubens nuclei, globus pallidus, amygdala, thalamus, hippocampus and hypothalamus) were calculated by autoradiography. The %ID/BW of rats which were placed under psychological stress was compared with that of 6 control rats. The %ID/BW of rats which were placed under psychological stress diffusely tended to show a reduction in 125I-IMZ-BZR binding. A significant decrease in BZR binding was observed in the hippocampus of the rats which were placed under psychological stress. 125I-IMZ-BZR binding tended to decrease throughout the brain. (author)

2002-05-01

322

Radioimmunoassay of salivary cyclosporine with use of 125I-labeled cyclosporine  

International Nuclear Information System (INIS)

We prepared 125I-labeled cyclosporine (125I-CS) by modifying the procedure of Mahoney and Orf and characterized it with regards to maximal immunoreactivity (greater than 90%), trichloroacetic acid precipitability (greater than 90%), and stability (90% immunoreactive after five half-lives of 125I). For a particular preparation of 125I-CS, we estimated its immunoreaction concentration (50 pmol/L) and the equilibrium constant for its reaction with Sandoz polyclonal antiserum (K = 3.9 X 10(9) L/mol). By substituting 125I-CS as tracer in the Sandoz radioimmunoassay and by modifying other aspects of the assay, we developed a procedure that is sufficiently sensitive (0.34 micrograms/L) to allow measurement of trough (lowest inter-dose) cyclosporine concentrations in parotid saliva. Of 38 kidney-transplant patients, 35 had measurable concentrations in saliva (mean 8.3, SD 5.2 micrograms/L), and these correlated moderately with paired serum concentrations (r = 0.68, P less than 0.001). We believe that measurement of salivary cyclosporine may offer a simple way of estimating the free fraction of the drug in serum or plasma

1988-01-01

323

Expansão rápida da maxila ancorada em implantes: uma nova proposta para expansão ortopédica na dentadura permanente Rapid maxillary expansion anchored by implants: a new proposal to orthopedic expansion in the permanent dentition  

Directory of Open Access Journals (Sweden)

Full Text Available OBJETIVO: este trabalho apresenta um método para expansão ortopédica da maxila, na dentadura permanente, utilizando implantes como ancoragem. METODOLOGIA: detalharam-se os procedimentos cirúrgicos e laboratoriais da confecção de um expansor com ancoragem dento-óssea em crânio seco humano. Dois implantes de titânio foram colocados na região anterior do palato, e o parafuso Hyrax adaptado de modo que a expansão ancorou-se nos implantes e nos primeiros molares permanentes. RESULTADOS: o experimento laboratorial em crânio seco mostrou que o procedimento apresenta-se anatômica e operacionalmente viável. Os implantes suportaram a força gerada pela ativação do parafuso expansor, redundando na separação transversal das hemimaxilas. CONCLUSÕES: vislumbra-se que a expansão rápida da maxila ancorada em implantes (ERMAI poderá potencializar a eficiência da expansão ortopédica, assim como reduzir o custo periodontal dos procedimentos convencionais de expansão. Futuros estudos clínicos são necessários para testar essas hipóteses.AIM: This study presents a method for maxillary orthopedic expansion, in the permanent dentition, using implants as anchorage. METHODS: Surgical and laboratorial procedures for the construction of a tooth-bone-borne expansor was detailed in a human dry skull. Two titanium implants were placed in the anterior region of the palate and a Hyrax screw was adapted in a way that the expansion was anchored both on the palatal implants and on permanent first molars. RESULTS: The laboratorial experiment in dry skull showed that the procedure is operationally and anatomically possible. The implants supported the force generated by the expansion screw activation and the maxilla halves were transversally split. CONCLUSIONS: Rapid maxillary expansion anchored on implants can increase the efficiency of orthopedic expansion and decrease the periodontal sequela caused by conventional RME. Further clinical studies are necessary to verify these hypotheses.

Daniela Gamba Garib

2007-06-01

324

Effect of 1. 5 tesla nuclear magnetic resonance imaging scanner on implanted permanent pacemakers  

Energy Technology Data Exchange (ETDEWEB)

Patients with a permanent pacemaker are currently restricted from diagnostic nuclear magnetic resonance (NMR) imaging because of potential adverse effects on the pacemaker by the magnet. Previous work has shown that NMR imaging will result in asynchronous pacing of the pulse generator within a given distance of the magnet. The radiofrequency signal generated by the system may also result in rapid cardiac pacing, which may have deleterious effects. This study utilized a 1.5 tesla unit in an in vivo laboratory animal to evaluate the unit's effects on eight different pulse generators from two manufacturers. All pacemakers functioned in an asynchronous mode when placed within a certain distance of the magnet. In addition, transient reed switch inhibition was observed. Seven of the eight pulse generators paced rapidly when exposed to the radiofrequency signal and there was a dramatic decrease in arterial blood pressure. Whether effective rapid cardiac pacing would occur could not be predicted before exposure to the magnetic resonance unit. Nuclear magnetic resonance imaging with high magnetic fields in patients with a pacemaker should continue to be avoided until the mechanism of the rapid cardiac pacing can be further delineated and either predicted or prevented.

Hayes, D.L.; Holmes, D.R. Jr.; Gray, J.E.

1987-10-01

325

Complicaciones del implante de marcapaso definitivo: ¿Un evento operador dependiente? Análisis de 743 pacientes consecutivos / Complications of permanent pacemaker: Event operator dependent? Analysis of 743 consecutive patients  

Scientific Electronic Library Online (English)

Full Text Available SciELO Mexico | Language: Spanish Abstract in spanish La frecuencia de complicaciones relacionadas al implante de marcapasos, es variable y se encuentra entre 6% a 9 %, y existen diferentes factores relacionados con las mismas. Objetivos: Evaluar las distintas complicaciones relacionadas con el implante de marcapasos y determinar cuáles son los factore [...] s de riesgo independientes que las predisponen. Métodos: Análisis descriptivo, tipo casos-controles, retrospectivo y prospectivo, correspondiente a 743 consecutivos, con implante de marcapasos definitivo, entre enero de 2007 y abril de 2008. Resultados: Edad de 73.83 ± 12 años, 63.9% varones. Los pacientes con algún grado de cardiopatía estructural representaron 43%. No hubo muertes relacionadas al implante de marcapasos. Tuvieron complicaciones relacionadas con el implante 57 pacientes (7.67%); 34 casos (4.57%), requirieron de una re-intervención quirúrgica. Hubo complicaciones graves: un paciente presentó endocarditis infecciosa (0.13%) que motivó la extracción del dispositivo y otro paciente, luego de la punción venosa subclavia, presentó neumotórax con necesidad de drenaje pleural (0.13%). En el análisis multivariado, las variables independientes relacionadas fueron: un operador poco experimentado y la presencia de insuficiencia cardiaca previa al implante. Conclusiones: En esta serie consecutiva de pacientes con implante de marcapasos definitivo, la incidencia de complicaciones se correlacionó con 1) operador con poca experiencia y 2) la presencia de insuficiencia cardiaca previa al implante, se relacionaron con las mismas. Abstract in english The complications of permanent pacemaker implant, are found among 6%-9% of patients. Different factors are related. Objectives: We evaluated the complications related with pacemaker implants and which are the independent risk factors associated with them. Methods: Descriptive analysis, type case-con [...] trols, retrospective and prospective, including 743 consecutive patients, between January 2007 and April 2008. Results: Age: 73.83 ± 12 years, 63.9% male. 43% of the patients had some degree of structural cardiopathy. There were no deaths related to pacemaker implants. Implant procedure-related complications were observed in 57 patients (7.67%), requiring a surgical intervention in 34 patients (4.57%). The most serious complications included one device-related infective endocarditis (0.13%), the entire device system was extracted, and one pneumothorax following subclavian vein puncture with insertion of a chest tube. In the multivariate analysis, low level of operator experience and preimplant heart failure were independent predictors for complications. Conclusions: In this consecutive series of patients with permanent pacemaker implant, there was a low rate of complications, similar to the reported international series. A low level of operator experience and preimplant heart failure were related.

Francisco J., Femenía; Mauricio, Arce; Fernando, Peñafort; Martín, Arrieta; Daniel, Gutiérrez.

326

Preparation and Evaluation of (125I) Daunorubicin as a Potential Agent for Tumor Detection and radiotherapy  

International Nuclear Information System (INIS)

In this study, the optimization of daunorubicin labeling with iodine-125 and its biological evaluation were described. Daunorubicin was labeled via direct electrophilic substitution using chloramine-T as oxidizing agent. The optimum amounts of reactants were: 40?g daunorubicin, 30?g Chloramine-T and ? 19 KBq carrier free Na125I. The labeled daunorubicin was stable for more than 24 hours. Results of the in-vivo evaluation revealed that the tracer, [125I] daunorubicin, tends to localize in tissues with high proliferation rate with preferential accumulation in cancerous tissues. Imaging should be carried at 3 hours post injection. The in-vitro cell growth inhibition assay showed that the effect of [125I] Daunorubicin was stronger than the effect of cold daunorubicin which strongly suggested that its cytotoxicity was mainly due to radiotoxicity rather than chemotherapeutic activity.

2012-11-01

327

Coincidence sum peak assay of "1"2"5I activity using solid-state detectors  

International Nuclear Information System (INIS)

The use of solid-state detectors in the coincidence sum peak technique of "1"2"5I activity assay has been studied. The improved energy resolution of these detectors allows distinct resolution of the K?, K?, and ? peaks, and four sum peaks resulting from the coincident detection of the different X and ? photons. Theoretical considerations yield three separate equations, each of which can be used, in conjunction with the experimental sum peak spectrum, to give the activity of the "1"2"5I sample in question. This method is suitable for calibration of "1"2"5I activities in the range of 0.01--0.5 ?Ci (1 Ci=3.7 x 10"1"0 Bq) with precisions of 2%--3%

1980-01-01

328

Radioiodine-labeling of proteins via the incorporation of 125I-tyrosine  

International Nuclear Information System (INIS)

125I-growth hormone (GH) was detected by electrophoretic separation of labeled protein following incubation of a rat pituitary with radio-iodinated tyrosyl tRNA. Five 125I-intermediates in GH elongation (GH-int), identified by immunoprecipitation, were present at 1 min. If the position of I-tyr in nascent GH-int was changed to phenylalanine sites with I-Tiy-tRNAphe, the resulting 125I-GH-int were altered in molecular size. The results show that radio-iodinated aminoacyl tRNA can be used to generate labeled proteins in tissue homogenates but that the iodine substituent can cause transient slowing in the rate of peptide elongation. (author). 7 refs.; 2 figs

1989-01-01

329

Changes in the tumor microenvironment during low-dose-rate permanent seed implantation iodine-125 brachytherapy  

International Nuclear Information System (INIS)

Purpose: There is a lack of data regarding how the tumor microenvironment (e.g., perfusion and oxygen partial pressure [pO2]) changes in response to low-dose-rate (LDR) brachytherapy. This may be why some clinical issues remain unresolved, such as the appropriate use of adjuvant external beam radiation therapy (EBRT). The purpose of this work was to obtain some basic preclinical data on how the tumor microenvironment evolves in response to LDR brachytherapy. Methods and Materials: In an experimental mouse tumor, pO2 (measured by electron paramagnetic resonance) and perfusion (measured by dynamic contrast-enhanced magnetic resonance imaging) were monitored as a function of time (0-6 days) and distance (0-2 mm and 2-4 mm) from an implanted 0.5 mCi iodine-125 brachytherapy seed. Results: For most of the experiments, including controls, tumors remained hypoxic at all times. At distances of 2-4 mm from radioactive seeds (?1.5 Gy/day), however, there was an early, significant increase in pO2 within 24 h. The pO2 in that region remained elevated through Day 3. Additionally, the perfusion in that region was significantly higher than for controls starting at Day 3. Conclusion: It may be advantageous to give adjuvant EBRT shortly (?1 to 2 days) after commencement of clinical LDR brachytherapy, when the pO2 in the spatial regions between seeds should be elevated. If chemotherapy is given adjuvantly, it may best be administered just a little later (?3 or 4 days) after the start of LDR brachytherapy, when perfusion should be elevated

2005-11-15

330

An instrument for measurement of "1"2"5I with automatic efficiency correction  

International Nuclear Information System (INIS)

Counting efficiencies for "1"2"5I are often uncertain because of self-absorption of the low-energy radiation. A special purpose instrument, AEP-5285, has been designed to simplify the measurement of "1"2"5I activities using a known technique in which the observed counting rate is compensated for self-absorption and any other uncertainties in the counting efficiency by making use of the coicidence properties of the radiation. The instrument contains pulse amplifiers, discriminators to define the energy regions of interest, and operational amplifier circuits to perform the necessary calculations automatically, and it displays an estimate of the source activity in becquerels. (auth)

1979-01-01

331

Selective binding of 2-[{sup 125}I]iodo-nisoxetine to norepinephrine transporters in the brain  

Energy Technology Data Exchange (ETDEWEB)

A radioiodinated ligand, (R)-N-methyl-(2-[{sup 125}I]iodo-phenoxy)-3-phenylpropylamine, [{sup 125}I]2-INXT, targeting norepinephrine transporters (NET), was successfully prepared. A no-carrier-added product, [{sup 125}I]2-INXT, displayed a saturable binding with a high affinity (K{sub d}=0.06 nM) in the homogenates prepared from rat cortical tissues as well as from LLC-PK{sub 1} cells expressing NET. A relatively low number of binding sties (B{sub max}=55 fmol/mg protein) measured with [{sup 125}I]2-INXT in rat cortical homogenates is consistent with the value reported for a known NET ligand, [{sup 3}H]nisoxetine. Competition studies with various compounds on [{sup 125}I]2-INXT binding clearly confirmed the pharmacological specificity and selectivity for NET binding sites. Following a tail-vein injection of [{sup 125}I]2-INXT in rats, a good initial brain uptake was observed (0.56% dose at 2 min) followed by a slow washout from the brain (0.2% remained at 3 hours post-injection). The hypothalamus (a NET-rich region) to striatum (a region devoid of NET) ratio was 1.5 at 3 hours post-i.v. injection. Pretreatment of rats with nisoxetine significantly inhibited the uptake of [{sup 125}I]2-INXT (70-100% inhibition) in locus coeruleus, hypothalamus and raphe nuclei, regions known to have a high density of NET; whereas escitalopram, a serotonin transporter ligand, did not show a similar effect. Ex vivo autoradiography of rat brain sections of [{sup 125}I]2-INXT (at 3 hours after an i.v. injection) displayed an excellent regional brain localization pattern corroborated to the specific NET distribution in the brain. The specific brain localization was significantly reduced by a dose of nisoxetine pretreatment. Taken together, the data suggest that [{sup 123}I]2-INXT may be useful for mapping NET binding sites in the brain.

Kung, M.-P.; Choi, Seok-Rye; Hou, Catherine; Zhuang, Z.-P.; Foulon, Catherine; Kung, Hank F. E-mail: kunghf@sunmac.spect.upenn.edu

2004-07-01

332

p-[125I]iodoclonidine is a partial agonist at the alpha 2-adrenergic receptor  

International Nuclear Information System (INIS)

The binding properties of p-[125I]iodoclonidine [( 125I]PIC) to human platelet membranes and the functional characteristics of PIC are reported. [125I]PIC bound rapidly and reversibly to platelet membranes, with a first-order association rate constant (kon) at room temperature of 8.0 +/- 2.7 x 10(6) M-1 sec-1 and a dissociation rate constant (koff) of 2.0 +/- 0.8 x 10(-3) sec-1. Scatchard plots of specific [125I]PIC binding (0.1-5 nM) were linear, with a Kd of 1.2 +/- 0.1 nM. [125I]PIC bound to the same number of high affinity sites as the alpha 2-adrenergic receptor (alpha 2-AR) full agonist [3H] bromoxidine (UK14,304), which represented approximately 40% of the sites bound by the antagonist [3H]yohimbine. Guanosine 5'-(beta, gamma-imido)triphosphate greatly reduced the amount of [125I]PIC bound (greater than 80%), without changing the Kd of the residual binding. In competition experiments, the alpha 2-AR-selective ligands yohimbine, bromoxidine, oxymetazoline, clonidine, p-aminoclonidine, (-)-epinephrine, and idazoxan all had Ki values in the low nanomolar range, whereas prazosin, propranolol, and serotonin yielded Ki values in the micromolar range. Epinephrine competition for [125I]PIC binding was stereoselective. Competition for [3H]bromoxidine binding by PIC gave a Ki of 1.0 nM (nH = 1.0), whereas competition for [3H]yohimbine could be resolved into high and low affinity components, with Ki values of 3.7 and 84 nM, respectively. PIC had minimal agonist activity in inhibiting adenylate cyclase in platelet membranes, but it potentiated platelet aggregation induced by ADP with an EC50 of 1.5 microM. PIC also inhibited epinephrine-induced aggregation, with an IC50 of 5.1 microM. Thus, PIC behaves as a partial agonist in a human platelet aggregation assay. [125I]PIC binds to the alpha 2B-AR in NG-10815 cell membranes with a Kd of 0.5 +/- 0.1 nM

1990-01-01

333

Site-specific incorporation of [125I]iododeoxyuridine into DNA  

International Nuclear Information System (INIS)

A procedure for the incorporation of [125I]IdU into specific sites in DNA is described. The approach depends upon attachment of radioiododeoxyuridine to a controlled pore glass support which is then used for automated synthesis of an oligomer. The resulting oligomer, containing a terminal 3'[125I]iododeoxyuridine, is used as a primer during DNA synthesis catalyzed by the Taq polymerase employing thermal cycling. The product formed includes the radioiodonucleotide at a single internal site determined by the length of the oligomer. (author)

1992-01-01

334

Site-specific incorporation of ( sup 125 I)iododeoxyuridine into DNA  

Energy Technology Data Exchange (ETDEWEB)

A procedure for the incorporation of ({sup 125}I)IdU into specific sites in DNA is described. The approach depends upon attachment of radioiododeoxyuridine to a controlled pore glass support which is then used for automated synthesis of an oligomer. The resulting oligomer, containing a terminal 3'({sup 125}I)iododeoxyuridine, is used as a primer during DNA synthesis catalyzed by the Taq polymerase employing thermal cycling. The product formed includes the radioiodonucleotide at a single internal site determined by the length of the oligomer. (author).

Scherberg, N.; Bloch, I.; Gardner, P. (Univ. of Chicago Hospitals and Clinics, IL (United States) Howard Hughes Research Inst., Chicago, IL (United States))

1992-07-01

335

Antibodies to 125I-glutamic acid decarboxylase in patients with stiff man syndrome.  

Digital Repository Infrastructure Vision for European Research (DRIVER)

Antibodies to glutamic acid decarboxylase (GAD) are found in about 40% of patients with stiff man syndrome. A new assay involving immunoprecipitation of (125)I-glutamic acid decarboxylase was used to measure anti-GAD antibodies in 18 patients with stiff man syndrome. Of the eight serum samples from patients with stiff man syndrome, that had previously been found positive by immunoprecipitation of (35)S-GAD, seven were strongly positive with (125)I-GAD and one gave an equivocal result. Other s...

Vincent, A.; Grimaldi, L. M.; Martino, G.; Davenport, C.; Todd, I.

1997-01-01

336

Dialyzable factors from uremic serum increase 125I-fibrinogen binding by normal blood platelets.  

Science.gov (United States)

The influence of uremic serum on 125I-fibrinogen binding by normal blood platelets after induction with adenosine diphosphate was evaluated. The study was performed on 12 hemodialyzed uremic patients. The control group included 12 healthy subjects. It has been demonstrated that the uremic serum from the patients before hemodialysis significantly augmented fibrinogen binding by normal blood platelets (33.8 +/- 11.8%) in comparison with control subjects (14.4 +/- 8.9%). After hemodialysis, fibrinogen binding was comparable with the control group (14.9 +/- 10.1%). Uremic toxins removable during hemodialysis are probably responsible for the potentiation of 125I-fibrinogen binding by platelets. PMID:2202919

Komarnicki, M; Krupa, D; Ka?mierczak, M; Drobnik, D; Zozuli?ska, M

1990-01-01

337

Dosimetry on transverse axes of 125I and 192Ir interstitial brachytherapy sources  

International Nuclear Information System (INIS)

Dose rates along the transverse axes of 125I model 6702, 125I model 6711 and 192Ir 0.2-mm steel sources for interstitial brachytherapy have been measured in a solid-water phantom for distances up to 10 cm using LiF thermoluminescent dosimeters (TLDs). Specific dose rate constants, the dose rates in water per unit source strength 1 cm along the perpendicular bisector of the source, are determined to be 0.90±0.03, 0.85±0.03, and 1.09±0.03 cGy h-1 U-1 for 125I model 6702, 125I model 6711 and 192Ir 0.2-mm steel sources, respectively (1 U=unit of air kerma strength =1 ?Gy m2 h-1=1 cGy cm2 h-1). In older and obsolete units of source strength (i.e., mCi apparent), these are 1.14±0.03, 1.08±0.03, and 4.59±0.15 cGy h-1 mCi-1 (apparent). Currently accepted values of specific dose rate constant for 125I sources are up to 20% higher than our measured values which are in good agreement with the results of our Monte Carlo simulations. But for 192Ir there is good agreement between our measured value of the specific dose rate constant and currently accepted values. The radial dose function for 125I model 6702 is found to be consistently larger than that for 125I model 6711, with an increasing difference as the distance from the source increases. Our measured values for the radial dose function for 125I sources are in good agreement with the results of our Monte Carlo simulation as well as the measured values of Schell et al. [Int. J. Radiat. Oncol. Biol. Phys. 13, 795--799 (1987)] for model 6702 and Ling et al. [Int. J. Radiat. Oncol. Biol. Phys. 9, 1747--1752 (1983)] for model 6711

1990-01-01

338

Location of [125I]-angiotensin II receptors on rat kidney cortex epithelial cells.  

Digital Repository Infrastructure Vision for European Research (DRIVER)

Angiotensin II (AII) stimulates active Na+ extrusion from Na+ loaded renal cortex slices. Specific high affinity [125I]-AII binding sites in partially purified basolateral and brush-border epithelial membranes exhibit a KD of 0.88 nM and Bmax of 321.13 fmol mg-1 protein. Separation and purification of brush-border membranes yielded high affinity [125I]-AII binding sites with KD of 1.02 nM and Bmax of 56.6 fmol mg-1 protein. Angiotensin II receptors of the same affinity are present on renal co...

Cox, H. M.; Munday, K. A.; Poat, J. A.

1984-01-01

339

3-(/sup 125/I)iodo-4-hydroxyphenobarbitone for use in radioimmunoassay  

Energy Technology Data Exchange (ETDEWEB)

A method is described for the preparation of a barbiturate derivative, 3-iodo-4-hydroxyphenobarbitone, labelled with (/sup 125/I)iodine. The structure of the compound was confirmed by synthesis and purification of the (/sup 127/I)iodine derivative followed by mass spectral studies. The (/sup 125/I)iodine labelled barbiturate has proved to be chemically stable and has been shown to bind to a barbiturate antiserum. It should, therefore, prove to be very useful for the development of a radioimmunoassay for barbiturates.

Mason, P.A.; Law, B. (Home Office Central Research Establishment, Aldermaston (UK))

1982-03-01

340

Determination of inorganic radioiodine in solutions of 125I-labelled proteins  

International Nuclear Information System (INIS)

A rapid paper chromatography procedure using 33% w/v aqueous solution of ammonium sulphate as a solvent has been applied for routine determination of the proportion of 125I present as inorganic iodine in solutions containing 125I-labelled proteins. Rsub(f) values for protein iodide and iodate correspond to 0.0, 0.5, and 0.9, respectively. The amount of inorganic iodine in the iodination mixture or in the iodinated protein preparation can be determined with good precision in less than 30 minutes. (author)

1981-01-01

 
 
 
 
341

Synthetic heparinoids labelled with /sup 125/I and /sup 35/S  

Energy Technology Data Exchange (ETDEWEB)

The labelling of a water-soluble synthetic polyelectrolyte, having anticoagulant activity, has been studied. The polyelectrolyte is derived from cis-1,4-polyisoprene and contains N-sulfate and carboxylate groups. (/sup 125/I)-Iodination of the polyelectrolyte, using the Chloramine-T method and an electrolytic method, resulted in a (/sup 125/I)-labelled polyelectrolyte from which release of the label occurred. Resulfation of a partially desulfated polyelectrolyte with a (/sup 35/S)-sulfur trioxide trimethylamine complex resulted in a (/sup 35/S)-labelled polyelectrolyte which showed no release of the label.

Sederel, L.C.; van der Does, L.; Bantjes, A. (Technische Hogeschool Twente, Enschede (Netherlands)); Kolar, Z. (Interuniversitair Reactor Inst., Delft (Netherlands))

1982-10-01

342

Preclinical evaluation on Iodine-125-b methyl iodide phenylpentadecanoic acid(125I-BMIPP)  

International Nuclear Information System (INIS)

Aim: We performed a study to investigate the biodistribution of 125I-BMIPP and the variation of myocardial uptake of 125I-BMIPP using the metabolic intervention drug. Materials and Methods: Biodistribution experiment of 125I-BMIPP was performed in fasted SD rats. The rats were killed at different interval, and the organs of interest were dissected, weighed, prepared for counting, and the uptake of each organ was expressed in fraction of injection dosage of per gram organ. Clearance of in vivo radioactivity was given in rabbits. Metabolic intervention trial(the group of glucose-insulin and sodium lactate) was determined in SD rats. Partition coefficients (logP) were measured in pH7.00 and pH7.40 PBS by counting the counts in octanol and buffer. Binding test were measured in vivo and in vitro. Results: Myocardial uptake of the 125I-BMIPP in fasted SD rats showed a peak of 5.70ID%/g and remained constant during 1h. The myocardial uptake was still 2.18ID%/g at 120min postinjection. The ratios of myocardium to blood, myocardium to liver and myocardium to lung at 30min were 3.40, 2.64 and 2.88 respectively. The liver and lung showed a lower uptake and rapid clearance of 125I-BMIPP, thus gave a quite good background of imaging. Its blood radioactivity-time curve in rabbits has a biexponential pattern. The study of metabolic intervention showed that myocardial uptake of 125I-BMIPP in the group of glucose-insulin was significantly increased(P0.05). In vivo and in vitro binding test for 125I-BMIPP to HSA showed a rather constant level of activation up to 2h. Partition coefficients (logP) were 1.93 and 1.68. Undue toxicity trial showed that the dose per kilogram administered to the mice was 500 times greater than that received by human. Conclusions: 125I-BMIPP is readily taken up by myocardium. The longer retention time, high heart/lung and heart/liver ratio, and good metabolic behavior make it an excellent myocardial imaging agent

2002-09-01

343

Synthesis of radioiodinated N-succinimidyl 3-[125I] iodobenzoate  

International Nuclear Information System (INIS)

N-Succinimidyl 3-(tri-n-butylstannyl) benzoate (ATE) was radioiodinated using Iodogen as oxidant and useful conjugate S125IB of labeling proteins was obtained. ATE and Iodogen affecting labeling proteins were successfully isolated from S125IB by Sep-Pak silica. The labeling efficiency was more than 93%. Several factors affecting labeling such as labeling time, the amount of Iodogen and the mole ratio of ATE to Na125I, were studied. The better labeling conditions were obtained as follows: mole ratio of ATE to Na125I=6:1, Iodogen=7 ?g, labeling time=5 min in room temperature

2003-03-01

344

p-( sup 125 I)iodoclonidine is a partial agonist at the alpha 2-adrenergic receptor  

Energy Technology Data Exchange (ETDEWEB)

The binding properties of p-(125I)iodoclonidine (( 125I)PIC) to human platelet membranes and the functional characteristics of PIC are reported. (125I)PIC bound rapidly and reversibly to platelet membranes, with a first-order association rate constant (kon) at room temperature of 8.0 +/- 2.7 x 10(6) M-1 sec-1 and a dissociation rate constant (koff) of 2.0 +/- 0.8 x 10(-3) sec-1. Scatchard plots of specific (125I)PIC binding (0.1-5 nM) were linear, with a Kd of 1.2 +/- 0.1 nM. (125I)PIC bound to the same number of high affinity sites as the alpha 2-adrenergic receptor (alpha 2-AR) full agonist (3H) bromoxidine (UK14,304), which represented approximately 40% of the sites bound by the antagonist (3H)yohimbine. Guanosine 5'-(beta, gamma-imido)triphosphate greatly reduced the amount of (125I)PIC bound (greater than 80%), without changing the Kd of the residual binding. In competition experiments, the alpha 2-AR-selective ligands yohimbine, bromoxidine, oxymetazoline, clonidine, p-aminoclonidine, (-)-epinephrine, and idazoxan all had Ki values in the low nanomolar range, whereas prazosin, propranolol, and serotonin yielded Ki values in the micromolar range. Epinephrine competition for (125I)PIC binding was stereoselective. Competition for (3H)bromoxidine binding by PIC gave a Ki of 1.0 nM (nH = 1.0), whereas competition for (3H)yohimbine could be resolved into high and low affinity components, with Ki values of 3.7 and 84 nM, respectively. PIC had minimal agonist activity in inhibiting adenylate cyclase in platelet membranes, but it potentiated platelet aggregation induced by ADP with an EC50 of 1.5 microM. PIC also inhibited epinephrine-induced aggregation, with an IC50 of 5.1 microM. Thus, PIC behaves as a partial agonist in a human platelet aggregation assay. (125I)PIC binds to the alpha 2B-AR in NG-10815 cell membranes with a Kd of 0.5 +/- 0.1 nM.

Gerhardt, M.A.; Wade, S.M.; Neubig, R.R. (Univ. of Michigan Medical School, Ann Arbor (USA))

1990-08-01

345

The urolume, a permanently implanted prostatic stent for patients at high risk for surgery. Results from 5 collaborative centres.  

Science.gov (United States)

Ninety-six men considered unfit for prostatic surgery underwent the insertion of a permanently implanted super alloy mesh stent (Urolume) at 5 European centres. Ninety were able to void immediately, 2 required a second stent to enable them to void and 4 voided after a period of suprapubic catheter drainage. Seven patients required the subsequent insertion of a further stent to cover the prostatic urethra completely and in 8 cases the stent was removed. Objective and symptomatic evidence of relief of bladder outflow obstruction was shown throughout the period of study. Severe irritative symptoms were seen in the majority of patients for periods of up to 3 months and resulted in removal of the stent in 3. At 12 months, 15 of 27 patients who underwent cystoscopy had complete epithelialisation of the stent and in 11 cases there was more than 70% epithelialisation. Fourteen patients developed encrustation on exposed parts of the stent during follow-up. This was associated with the development of a urinary infection in 9. The positioning of the stent in subsequent studies has been altered to overcome this problem. PMID:7693296

Williams, G; Coulange, C; Milroy, E J; Sarramon, J P; Rubben, H

1993-09-01

346

Expansão rápida da maxila ancorada em implantes: uma nova proposta para expansão ortopédica na dentadura permanente / Rapid maxillary expansion anchored by implants: a new proposal to orthopedic expansion in the permanent dentition  

Scientific Electronic Library Online (English)

Full Text Available SciELO Brazil | Language: Portuguese Abstract in portuguese OBJETIVO: este trabalho apresenta um método para expansão ortopédica da maxila, na dentadura permanente, utilizando implantes como ancoragem. METODOLOGIA: detalharam-se os procedimentos cirúrgicos e laboratoriais da confecção de um expansor com ancoragem dento-óssea em crânio seco humano. Dois impla [...] ntes de titânio foram colocados na região anterior do palato, e o parafuso Hyrax adaptado de modo que a expansão ancorou-se nos implantes e nos primeiros molares permanentes. RESULTADOS: o experimento laboratorial em crânio seco mostrou que o procedimento apresenta-se anatômica e operacionalmente viável. Os implantes suportaram a força gerada pela ativação do parafuso expansor, redundando na separação transversal das hemimaxilas. CONCLUSÕES: vislumbra-se que a expansão rápida da maxila ancorada em implantes (ERMAI) poderá potencializar a eficiência da expansão ortopédica, assim como reduzir o custo periodontal dos procedimentos convencionais de expansão. Futuros estudos clínicos são necessários para testar essas hipóteses. Abstract in english AIM: This study presents a method for maxillary orthopedic expansion, in the permanent dentition, using implants as anchorage. METHODS: Surgical and laboratorial procedures for the construction of a tooth-bone-borne expansor was detailed in a human dry skull. Two titanium implants were placed in the [...] anterior region of the palate and a Hyrax screw was adapted in a way that the expansion was anchored both on the palatal implants and on permanent first molars. RESULTS: The laboratorial experiment in dry skull showed that the procedure is operationally and anatomically possible. The implants supported the force generated by the expansion screw activation and the maxilla halves were transversally split. CONCLUSIONS: Rapid maxillary expansion anchored on implants can increase the efficiency of orthopedic expansion and decrease the periodontal sequela caused by conventional RME. Further clinical studies are necessary to verify these hypotheses.

Daniela Gamba, Garib; Ricardo de Lima, Navarro; Carlos Eduardo, Francischone; Paula Vanessa Pedron, Oltramari.

347

The experimental study of 125I seeds interstitial brachytherapy combined with external beam radiotherapy for lewis lung cancer in C57BL/6 mice  

International Nuclear Information System (INIS)

Objective: The purpose of this study was to investigate the efficacy of 125I seeds interstitial brachytherapy combined with external beam radiotherapy for lung neoplasm. Methods: Each set of six C57BL/6 mice bearing Lewis tumor was stratified into four groups on day 1:vehicle control, 125I seeds interstitial brachytherapy alone, external beam radiotherapy (15 Gy) alone, and combination of 125I seeds interstitial brachytherapy with external beam radiotherapy (8 Gy). After treatment.the volulne of the tumors was measured every 3 days. The animals were executed, the weight of tumors was measured.tumor control rate was calculated and pathological examination was performed on day 15. The intratumoral micro-vaseular density (MVD) in each group was evaluated by inmmnohistochemical methads. Tumor volume.weight and MVD were compared by one-way ANOVA, student. newlnan-keuls (SNK) -q analysis. Results: Comparing with control group, the other three groups had significant inhibiting effect on the growth of lewis tumor (q=11.06, 17.13, 16.31, all P125I seeds interstitial brachytherapy group (28.6%). while the difference of tumor weisht was not significant between the former two groups (q=0.50. P>0.05). Immunohistochemistry analysis showed that the MVD value in the four groups wag (23.33 ± 4.84). (17.50 ± 3.67), (11.83 ± 2.14) and (12.67 ± 3.39) / (high power field x 200) regpectively. The MVD value of 125I seeds interstitial brachytherapy alone group was much lower than that of control group, and higher than combination group (q=3.92 and 3.25, both P0.05). Conclusions: Radiotherapy can. significantly reduce the MVD values of tumor and inhibit tumor growth through the mechanisms of antiangiogenesis. The combined treatment of lung tumors with implanted 125I seeds and external beam irradiation can decrease the total dose of the external beam irradiation and, hence, offer the possibility of considerable dose sparing of normal tissues without compromising local tumor control rates. (authors)

2009-12-01

348

Implante de marcapaso definitivo en pacientes con vena cava superior izquierda persistente y ausencia de vena cava superior derecha: Caso clínico Permanent pacemaker implantation in patients with persistent left superior vena cava and absent right superior vena cava: Report of three cases  

Directory of Open Access Journals (Sweden)

Full Text Available Persistent left superior vena cava and absent right superior vena cava is an uncommon anatomical association. This is a challenging situation for permanent pacemaker implantation. We report three patients with this anomaly and a permanent pacemaker successfully implanted through the left superior vena cava and coronary sinus, without acute or chronic complications

Patricia Frangini S

2006-06-01

349

Development of esophageal 125I seed irradiated stent and its experiment  

International Nuclear Information System (INIS)

Objective: To investigate the feasibility of developing the esophageal irradiating esophageal stent by placing 125I seed into it, the safety of the irradiative stent esophageal in animal experiments. Methods: (1) Development of esophageal 125I seed irradiated stent: a plastic 'bullet chamber' was moulded which held only one 125I seed. Its distribution and the spot where it was stitched on outside the stents. Thus esophageal intraluminal irradiating stents were developed. (2) Animal experiment: 36 rabbits were randomly assigned to 4 groups according to different irradiated dosage, 9 rabbits in each group. Intraluminal irradiated stents each with two 125I seeds totaling 22.2 MBq (group A), 44.4 MBq (group B) and 66.6 MBq (group C) respectively were placed in the rabbits esophagus and stents without 125I seeds were placed in group D rabbits esophagus which as control group. Three rabbits of each group were killed at the 2th, 4th, or 8th week after insertion of the stents, followed by esophageal contrast exam and CT scan to observe displacement of stents and transposition of 125I seed. The damage and its degree of esophagus and the lung, bronchus and large vessels around it caused by intraluminal irradiated stents were observed macroscopically or under optical and electric microscope. Results: (1) Development of esophageal intraluminal irradiated stents: 125I seed could be stitched on outside the stents firmly. Experiments of filling and releasing seeds in vitro were feasible. Irradiated steats could be easily placed in rabbits esophagus. It was safe for no losing of radioactive source has been found after they have been placed in esophagus for a long-term. (2) Animal experiments: the esophageal wall near 125I seed thickened most distinctly in mental groups during the 8th week[ group A(4.2 ± 0.3)mm,group B(4.3 ± 0.3)mm, group C(4.5 ± 0.3)mm]. There was a significant difference between the experimental group and control group [(3.1 ± 0.1) mm (P0.05). Four weeks after the produce, no other noticeable changes of thickness occurred among the 4 groups except esophageal bore size narrowed progressively along with time, there was no significant difference between the esophageal bore size of experimental groups during the 8th [group A (5.7 ± 0.2) mm, group B (5.6 ± 0.3) mm, group C (5.6 ± 0.3) mm ] and control group (5.6 ± 0.2) mm (P>0.05). The macroscopical observation of lung, trachea and thoracic aortal wall around the stents were consistent with those under optical microscope, however the ultrastructure had mild impairment observed under electric microscope. Conclusion: The design and fabrication of binding esophageal intraluminal irradiated stents have been proven to be feasible. The radioactivity of 125I radioactive seeds commonly used in clinics only causes slight injury to the lung, trachea, large vessels around esophagus in animal experiment, 125I radioactive seed has no obvious effect of inhibition or stimulation on the hyperplastic esophageal mucosa due to the placement of stent. It is possible that 125I radioactive seeds placed in vivo for a long time stimulate esophageal smooth muscle to proliferate. (authors)

2006-05-01

350

Experimental determination of the TG-43 dosimetric characteristics of EchoSeedTM model 6733 125I brachytherapy source  

International Nuclear Information System (INIS)

Recently an improved design of a 125I brachytherapy source has been introduced for interstitial seed implants, particularly for prostate seed implants. This design improves the in situ ultrasound visualization of the source compared to the conventional seed. In this project, the TG-43 recommended dosimetric characteristics of the new brachytherapy source have been experimentally determined in Solid Water trade mark sign phantom material. The measured dosimetric characteristics of the new source have been compared with data reported in the literature for other source designs. The measured dose rate constant, ?, in Solid Water was multiplied by 1.05 to extract the dose rate constant in water. The dose rate constant of the new source in water was found to be 0.99±8% cGy h-1 U-1. The radial dose function was measured at distances between 0.5 and 10 cm using LiF TLDs in Solid Water trade mark sign phantom. The anisotropy function, F(r,?), was measured at distances of 2, 3, 5, and 7 cm

2002-06-01

351

The effectiveness of 125I seed interstitial brachytherapy for transplantation tumor of human pancreatic carcinoma in nude mice: an experiment in vivo  

International Nuclear Information System (INIS)

Objective: To discuss the effectiveness and therapeutic mechanism of 125I interstitial brachytherapy for transplantation tumor of human pancreatic carcinoma in nude mice. Methods: The human pancreatic cell line Sw1990 was subcutaneously injected into the right lower limb partially dorsal area next to the groin of the immunodeficient BABL /c nude mice. The tumor was removed and cut into small pieces after it was formed,then the tumor pieces were inoculated in nude mice. The tumor developed to 8-10 mm in size after six weeks. A total of 16 nude mice with the suitable tumor size were used in this study. The 16 experimental mice were randomly and equally divided into two groups. The mice in study group (n = 8) were implanted with 125I seeds, while the mice in control group (n = 8) were implanted with ghost seeds. After the implantation both the long and short diameter of the tumors as well as the mouse body weight were measured every 4 days. The tumor weight was measured when the mouse was sacrificed. The paraffin-embedded samples were sent for histopathological examination. Apoptotic cells were checked with terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) method. Expression of proliferating cell nuclear antigen (PCNA) was detected with immuno-histochemical staining. Results: The tumor grew slowly in the study group, but rapidly in the control group. The tumor weight in the study group and the control group was (2.68 ± 0.70)g and (4.68 ± 1.45)g, respectively, the difference between two groups was statistically significant (P = 0.021). The tumor inhibition rate was about 42.66%. No significant difference in body weight of nude mice existed between two groups both before and after the treatment (P > 0.05). Marked tumor necrosis was seen in study group, but no obvious, or only a little, tumor necrosis could be observed in the control group. The apoptotic index checked with the TUENL method in the study group and control group was (23.2 ± 1.9)% and (8.1 ± 1.5)%, respectively, and the difference between two groups was statistically significant (P 125I interstitial brachytherapy is an effective treatment for transplantation tumor of human pancreatic carcinoma in nude mice. Its mechanisms include directly killing the tumor cells, inducing tumor cell apoptosis and reducing cell proliferation. Additionally, 125I seeds impl